Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

6-30-2010

Navigating Health Sources on the Internet: A
Mixed-Methods Examination of Online Consumer
Reviews and Expert Text on Psychotropic Drugs
Shannon Hughes
Florida International University, shughes5@msn.com

DOI: 10.25148/etd.FI10080406
Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Medicine and Health Commons, Science and Technology Studies Commons, and the
Social Work Commons
Recommended Citation
Hughes, Shannon, "Navigating Health Sources on the Internet: A Mixed-Methods Examination of Online Consumer Reviews and
Expert Text on Psychotropic Drugs" (2010). FIU Electronic Theses and Dissertations. 231.
https://digitalcommons.fiu.edu/etd/231

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

NAVIGATING HEALTH SOURCES ON THE INTERNET: A MIXED-METHODS
EXAMINATION OF ONLINE CONSUMER REVIEWS AND EXPERT TEXT ON
PSYCHOTROPIC DRUGS

A dissertation submitted in partial fulfillment of the
requirements for the degree of
DOCTOR OF PHILOSOPHY
in
SOCIAL WELFARE
by
Shannon Hughes
2010

To: Dean Fernando M. Trevino
Robert Stempel College of Public Health and Social Work
This dissertation, written by Shannon Hughes, and entitled Navigating Health Sources on
the Internet: A Mixed-Methods Examination of Online Consumer Reviews and Expert
Text on Psychotropic Drugs, having been approved in respect to style and intellectual
content, is referred to you for judgment.
We have read this dissertation and recommend that it be approved.
_______________________________________
Kevin Hill
_______________________________________
Christopher Rice
______________________________________
Stephen E. Wong
______________________________________
David Cohen, Major Professor
Date of Defense: June 30, 2010
The dissertation of Shannon Hughes is approved.

_______________________________________
Dean Fernando M. Trevino
Robert Stempel College of Public Health and Social Work

_______________________________________
Interim Dean Kevin O’Shea
University Graduate School
Florida International University, 2010

ii

ACKNOWLEDGMENTS
First, I thank my advisor, David Cohen, for his continuous support in the Ph.D.
program. Every conversation with Dr. Cohen has heightened and renewed my enthusiasm
for this work, even when I felt overwhelmed and defeated by the challenges of it. I have
been constantly inspired by his thoughtfulness, creativity, and the perfection of his
writing. Without his guidance and encouragement, I could not have finished this
dissertation.
I would like to thank the rest of my committee members for their time and support
throughout this process. I thank Dr. Christopher Rice for asking hard questions that
pushed me to become a better thinker and researcher. I value Dr. Stephen Wong’s
insightful suggestions on each of my papers, and appreciate his encouragement of my
work. I thank Dr. Kevin Hill for joining the committee so quickly and eagerly, and again
appreciate the helpful comments.
During the course of this work, at Florida International University (2006-2009), I
was supported by a graduate research assistantship with the School of Social Work. In
2009-2010, I was supported by the Florida International University Dissertation Year
Fellowship. During that academic year, I was also awarded funds by the Fahs-Beck Fund
for Research and Experimentation to cover certain research related expenses.
Let me also say thank you to the following people at Florida International
University: Paul Stuart for being so attentive and responsive to doctoral student needs.
Maria Gutierrez for helping me navigate through all the red tape and confusion related to
getting enrolled, receiving paychecks, spending grant money, and so much more! Thanks
to each of my professors during the first year of the program for being so understanding

iii

of the fact that we were new (and naïve) doctoral students. Juliette Graziano for being a
remarkable cohort partner without whom I may not have made it through those first
couple years. Juliette, I am so grateful that we entered and finished this together. I am
also greatly indebted to my teacher of the past, Dr. Tomi Gomory, at Florida State
University. Dr. Gomory profoundly influenced my thinking as an undergraduate and
graduate student, and encouraged me to continue to the doctoral program. I would not be
in this position today without his guidance. Thank you to Jeffrey Lacasse, formerly of
Florida State University, for introducing me to this field as an undergraduate and for his
patient advice since then.
Last, but not least, I thank my family and loved ones. My parents have always
been unconditionally proud of me, and I thank them for allowing me to pursue my
interests in any direction they took me. I thank them too for serving as a willing audience
to listen to my frustrations and challenges throughout the program. My brother, Jason
Hughes, reminds me that this work is an important and practical contribution to the world
(just when I have seemingly forgotten). My dear friends, Kristina Obenza, Sarah Howey,
and Denise Irwin have been wonderful in their support, and always there when I needed
to relax and have fun. My partner in life, Louzonteno Johnson II, has been my rock for
the last 4 years. I thank him for his unconditional support and love, and his unrelenting
belief in me. This dissertation belongs to the both of us.

iv

ABSTRACT OF THE DISSERTATION
NAVIGATING HEALTH SOURCES ON THE INTERNET: A MIXED-METHODS
EXAMINATION OF ONLINE CONSUMER REVIEWS AND EXPERT TEXT ON
PSYCHOTROPIC DRUGS
by
Shannon Hughes
Florida International University, 2010
Miami, Florida
Professor David Cohen, Major Professor
Purpose: The Internet has provided an unprecedented opportunity for psychotropic
medication consumers, a traditionally silenced group in clinical trial research, to have
voice by contributing to the construction of drug knowledge in an immediate, direct
manner. Currently, there are no systematic appraisals of the potential of online consumer
drug reviews to contribute to drug knowledge. The purpose of this research was to
explore the content of drug information on various websites representing themselves as
consumer- and expert-constructed, and as a practical consideration, to examine how each
source may help and hinder treatment decision-making.
Methodology: A mixed-methods research strategy utilizing a grounded theory approach
was used to analyze drug information on 5 exemplar websites (3 consumer- and 2 expertconstructed) for 2 popularly prescribed psychotropic drugs (escitalopram and quetiapine).
A stratified simple random sample was used to select 1,080 consumer reviews from the
websites (N=7,114) through February 2009. Text was coded using QDA Miner 3.2
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software by Provalis Research. A combination of frequency tables, descriptive excerpts
from text, and chi-square tests for association were used throughout analyses.
Findings: The most frequently mentioned effects by consumers taking either drug were
related to psychological/behavioral symptoms and sleep. Consumers reported many of
the same effects as found on expert health sites, but provided more descriptive language
and situational examples. Expert labels of less serious on certain effects were not
congruent with the sometimes tremendous burden described by consumers. Consumers
mentioned more than double the themes mentioned in expert text, and demonstrated a
diversity and range of discourses around those themes.
Conclusions: Drug effects from each source were complete relative to the information
provided in the other, but each also offered distinct advantages. Expert health sites
provided concise summaries of medications’ effects, while consumer reviews had the
added advantage of concrete descriptions and greater context. In short, consumer reviews
better prepared potential consumers for what it’s like to take psychotropic drugs. Both
sources of information benefit clinicians and consumers in making informed treatmentrelated decisions. Social work practitioners are encouraged to thoughtfully utilize online
consumer drug reviews as a legitimate additional source for assisting clients in learning
about treatment options.

vi

TABLE OF CONTENTS
CHAPTER

PAGE

1. STATEMENT OF PROBLEM

1

2. LITERATURE REVIEW
Definitions and Concepts
Expert Drug Knowledge in the Off-line World
Consumer Drug Knowledge in the Off-line World
Expert and Consumer Knowledge in the Online World
Previous Forms of Internet Research
Grounded Theory
Summary
Conceptual Approach
Research Questions

4
4
15
28
31
46
49
51
51
56

3. METHODOLOGY
Research Strategy
The Sample
Data Collection
Data Analysis

58
58
60
70
75

4. FINDINGS
Sample Characteristics
Inter-coder Agreement Analysis
Drug Effects According to Consumers
Drug Effects According to Experts
Drug Effects by Experts versus Consumers
Drug Effects by Variables
Themes Mentioned by Consumers
Themes by Experts versus Consumers
Usability of Consumer Sites According to Typical Web Use
Preliminary Data Checking
Data Checking of the Research Sample

86
86
95
98
115
123
140
155
179
192
201
205

5. STRENGTHS AND LIMITATIONS
Research Strategy
Authenticity of the Sample
Generalizability and Applicability
Units of Analysis
Statistical Analysis and Comparisons

215
215
216
218
218
219

vii

6. DISCUSSION
222
Additional Data on Popularly Reported Drug Effects
222
Effect Classification
227
Variation among Consumers
229
How do Expert and Consumer Sources Help and Hinder Decision-Making? 231
Theoretical Explanations of Findings
237
7. CONCLUSION
Hypotheses for Future Research
Future Research: Authenticity and Credibility
Future Research: Usability
Searching for Health Information on the Internet

241
241
244
245
248

LIST OF REFERENCES

251

APPENDICES

266

VITA

353

viii

LIST OF TABLES
TABLE

PAGE

3.1 Description of Website Typologies

61

3.2 Sampling Frame for Consumer Reviews (through February 2009)

74

3.3 Probability of Selection in a Stratified Simple Random Sample
of 120 Cases per Drug per Website

74

4.1 Number of Consumers Reporting Gender across All Websites

88

4.2 Number of Consumers Reporting Gender According to Drug Taken

88

4.3 Number of Consumers Reporting Age across All Websites

89

4.4 Number of Consumers Reporting Age According to Drug Taken

90

4.5 Number of Consumers Reporting Length of Time on the
Drug across All Websites

91

4.6 Number of Consumers Reporting Length of Time on the
Drug according to Drug Taken

92

4.7 Number of Consumer Posts According to Year Posted
across all Websites

93

4.8 Number of Consumer Posts for Each Drug According to Year Posted

94

4.9 Number of Consumers Who Provided a User ID or Email
Address across All Websites

94

4.10 Number of Consumers Who Provided a User ID or Email
Address According to Drug Taken

95

4.11 Inter-coder Agreement Analysis

97

4.12 Top 5 Effect Categories Mentioned by Consumers for Lexapro

102

4.13 Effects of Lexapro Mentioned by at Least 3% of Consumers

102

4.14 Number of Consumers on each Website Mentioning the
Most Popularly Reported Effects of Lexapro

105

ix

4.15 Lexapro Effects Mentioned by >3% of Consumers according
to Website Classification

106

4.16 Top 5 Effect Categories Mentioned by Consumers for Seroquel

110

4.17 Effects of Seroquel Mentioned by at Least 3% of Consumers

111

4.18 Number of Consumers on Each Website Mentioning the
Most Popularly Reported Effects of Seroquel

113

4.19 Seroquel Effects Mentioned by >3% of Consumers
According to Website Classification

114

4.20 Most Frequently Mentioned Effects of Lexapro in Expert Text
(frequency >3% of total mentions of effects on either website)

117

4.21 Most Frequently Mentioned Effects of Seroquel in Expert Text
(frequency >3% of total mentions of effects in either website)

121

4.22 Excerpts from Experts and Consumers on Selected Mental/Mood
Effects of Lexapro

128

4.23 Comparison of Experts and Consumers on Appetite and
Weight Effects of Lexapro

129

4.24 Comparison of Experts and Consumers on Sexual Effects
of Lexapro

130

4.25 Excerpts from Experts and Consumers on Brain Fog/Zombie
Effect of Seroquel

136

4.26 Comparison of Experts and Consumers on Sleep Effects
of Seroquel

137

4.27 Excerpts from Experts and Consumers on Selected Sleep Effects
of Seroquel

138

4.28 Comparison of Experts and Consumers on Lab Tests and
Chronic Conditions Mentioned for Seroquel

139

4.29 Gender of Consumers who Mentioned an Effect of Lexapro
According to Drug Effect Category

142

4.30 Reporting of Gender and Drug Effect Category for Lexapro

143

x

4.31 Male and Female Consumers Compared to Those Who Did Not
Report Gender on Drug Effects for Selected Categories of Lexapro

144

4.32 Age of Consumers Who Mentioned an Effect of Lexapro
According to Drug Effect Category

145

4.33 Reporting of Age by Drug Effect Category for Lexapro

146

4.34 Consumers Taking Lexapro According to Length of Time Taken
and Drug Effect Category

147

4.35 Reporting Length of Time Taking Lexapro According to
Drug Effect Category

148

4.36 Gender of Consumers Who Mentioned an Effect of Seroquel
According to Drug Effect Category

150

4.37 Reporting Gender by Drug Effect Category for Seroquel

151

4.38 Age of Consumers Who Mentioned an Effect of Seroquel
According to Drug Effect Category

152

4.39 Reporting Age by Drug Effect Category for Seroquel

153

4.40 Consumers Taking Seroquel by Length of Time Taken
and Drug Effect Category

154

4.41 Reporting Length of Time Taking Seroquel by Drug
Effect Category

155

4.42 Frequency of Consumers Within Each Website Who Mentioned a
Code Within the Category Assessing the Overall Experience

159

4.43 Number of Consumers Mentioning Codes under Assessing the
Overall Experience, According to Website Classification

160

4.44 Frequency of Consumers Within Each Website Who Mentioned a
Code Within the Category Dealing with Side Effects/Finding
Optimum Effectiveness, Mentioned by at Least 3% of Consumers on
Any Website

162

4.45 Codes Under Dealing with Side Effects/Finding Optimum
Effectiveness that Reached Statistical Significance (p<.05)
According to Website Classification

163

xi

4.46 Frequency of Consumers Within Each Website Who Mentioned a
Code Within the Category Do I Need Meds

164

4.47 Number of Consumers Mentioning Codes Under Do I Need Meds
According to Website Classification

165

4.48 Frequency of Consumer Comments on Drug Theme Categories (in bold
text) and the Most Frequently Mentioned Code Within that
Category (in plain text)

169

4.49 Number of Consumers Mentioning Codes under Other Drug
Theme Categories According to Website Classification

170

4.50 Frequency of Consumers Within Each Website Who Mentioned a
Code Within the Category My Doctor, Mentioned by at
Least 3% of All Consumers

173

4.51 Number of Consumers Mentioning Codes under My Doctor
According to Website Classification

174

4.52 Frequency of Consumer Comments on Other Theme Categories
(in bold text) and the Most Frequently Mentioned Code
Within that Category (in plain text)

178

4.53 Codes From All Theme Categories That Were Mentioned
in Expert Text

180

4.54 Number of Consumer and Expert Cases that Mention a Code
Under Assessing the Overall Experience

183

4.55 Expert and Consumer Descriptions of Assessing the
Overall Experience

184

4.56 Consumers and Experts on the My Doctor Code: Talking
with Doc/Doc Explained/Consult Doc

188

4.57 Excerpts from Consumers and Experts on My Doctor

189

4.58 Most Frequently Mentioned Effects of the Most Recent 20 Consumer
Posts From Each Website Compared to All Consumer Posts for Lexapro

194

4.59 Less Frequently Mentioned Effects from Recent Posts Compared
to the Full Dataset for Lexapro

195

xii

4.60 Most Frequently Mentioned Effects of the Most Recent 20 Consumer
Posts From Each Website Compared to All Consumer Posts for Seroquel

197

4.61 Less Frequently Mentioned Effects of Recent Posts From Each Website
Compared to the Full Dataset for Seroquel

198

4.62 Most Frequently Mentioned Themes of Most Recent 20 Posts From
Each Website Compared to the Full Dataset of Both Drugs

199

4.63 Data Checking by Time Period of Consumers’ Posts and Drug Effect
Categories for Lexapro and Seroquel Combined

207

4.64 Data Checking by Time Period of Consumers’ Posts on Selected
Code Categories for Both Drugs Combined

208

4.65 Data Checking for Anonymity of Users by Drug Effect Categories
for Lexapro and Seroquel Combined

210

4.66 Data Checking for Anonymity of Consumers on Statistically Significant
Code Categories for Both Drugs Combined

211

4.67 Data Checking for Anonymity of Consumers on Selected Mental
or Mood Effects for Lexapro and Seroquel Combined

212

4.68 Sampling Frame (N=7,114) Search for Scripted Comments

214

xiii

LIST OF FIGURES
FIGURE

PAGE

2.1. Traditional and Evolving Dynamics in the Production of
Psychotropic Drug Knowledge

57

4.1 Most Popularly Mentioned Lexapro Effects by
Consumers across Websites

104

4.2 Most Popularly Mentioned Seroquel Effects by
Consumers across Websites

112

4.3 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text
Measured by Number of Mentions

118

4.4 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text
Measured by Proportion of All Mentions of Effects

119

4.5 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text
Measured by Number of Mentions

122

4.6 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text
Measured by Proportion of All Mentioned of Effects

123

4.7 Comparison of Frequency of Mentions of Lexapro Effects between
Experts and Consumers, by Effect Category

126

4.8 Comparison of Most Frequently Mentioned Lexapro Effects between
Experts and Consumers

127

4.9 Comparison of Frequency of Mentions of Seroquel Effects between
Experts and Consumers, by Effect Category

134

4.10 Comparison of Most Frequently Mentioned Seroquel Effects between
Experts and Consumers

135

4.11 Proportion of Mentions of the Most Popular Themes by Experts and
Consumers, Respectively, Out of Total Mentions of All Themes

182

4.12 Proportion of Mentions of the Most Popular Codes Within the
Category Dealing with Side Effects/Finding Optimum Effectiveness
Out of Total Mentions Within the Category

187

xiv

Chapter 1: Statement of Problem
The central issue examined in the proposed research concerns the construction of
expertise in the age of the Internet. To address the central issue, this study focuses on an
area – psychotropic drugs prescribed and used as medicines – to examine evolving
relations of power in the production and dissemination of knowledge in today’s
prescription drug market.
Expert knowledge of psychotropic drugs is that which is produced using
procedures of science, and represents the official account of drugs’ uses and effects. The
forthcoming review of literature will show, however, that this scientifically-derived
expert knowledge has become highly contested. The blurring lines between
pharmaceutical industry marketing and scientific activities, and the near monopoly of the
industry over production and dissemination of expert/scientific knowledge of
psychotropic drugs has resulted, at a minimum, in well-documented publication biases
and considerable uncertainty about drug efficacy and safety (Huston & Moher, 1996;
Ioannidis & Lau, 2001; Melander, Ahlqvist-Rastad, Meijer, & Beermann, 2003; Perlis et
al., 2005; E. Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008). Also, to reach a
“valid” understanding of drugs’ effects, researchers have persistently muted the direct
voice and speech of the patient in favor of a presumably more objective (biomedical,
scientific, statistical) discourse (Jacobs & Cohen, 1999).
In parallel, the Internet allows researchers, clinicians, and consumers to review
drug experiences and information from thousands of consumers without professional
mediation, and presumably without pharmaceutical industry supervision over content.
The Internet thus makes more apparent multiple and sometimes contradictory claims to
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knowledge. How these less scientific ways of knowing about psychotropic drugs made
accessible through the web contribute to or dilute the expert/scientific knowledge base, or
how they constitute their own knowledge base, remains virtually unexplored.
Moreover, “democratizing” the production of knowledge and consumers’
broadened acceptance of what constitutes legitimate, trustworthy, or credible information
results in a trans-disciplinary debate about the appropriate role of experts and non-experts
in policy, media, science, and culture, as well as the true nature of what is being
applauded as “democratization” (Dahlberg & Siapera, 2007; David, 2007; Keen, 2007;
Siegel, 2008). Applied to the construction of knowledge about psychotropic drugs, the
fundamental pragmatic concern of this debate is whether expert knowledge on
psychotropic drugs is sufficient for building a knowledge base and helpful to those who
believe they need expertise to come to an understanding or decision about a drug issue, or
whether expertise is a shroud that actually limits or distorts the knowledge base and
disadvantages those seeking expertise because of conflicts of interest and other biases.
Has the Internet rendered expertise in the area of psychotropic drugs obsolete?
Following from this, the main question of the research was: Does the accumulated
consumer or layperson knowledge that the Internet allows dissolve the traditional
boundary between expert/scientific and consumer/lay knowledge? The research
specifically sought to examine the content, in terms of drug effects and themes, of drug
information on consumer-constructed and expert-constructed web sources. A grounded
theory approach as part of a mixed-methods research strategy was used to analyze the
content of five websites containing drug information for two popularly prescribed
psychotropic drugs from different drug classes. As a practical consideration, how does
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each source help and hinder treatment decision-making for clinicians and for actual and
potential consumers?
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Chapter 2: Literature Review
Definitions and Concepts
Psychotropic drugs.
Psychotropic drugs of relevance in the present analysis are those drugs available
by prescription, consumed as medicine, and intended to alter the behavior, mood,
thinking, and/or feeling of the individual ingesting the drug. Psychotropic drugs can be
analyzed on numerous levels, such as for their effects on biological processes or their
personal, social, cultural, political, and economic meaning and symbolism, and each level
of meaning or understanding interacts with drug effects (Cohen, McCubbin, Collin, &
Perodeau, 2001). In the marketplace, a psychotropic drug may be considered an
“experience good,” meaning a good whose value or quality cannot be known until the
good has been personally experienced (Azoulay, 2002). In Foucauldian analysis,
psychotropic drugs may be considered technologies of the body that carry disciplinary
messages of transformation and self-surveillance to the consumer (Clarke, Mamo,
Fishman, Shim, & Fosket, 2003). The proposed research does not reduce psychotropic
drugs to a single defining quality or use, but rather acknowledges that many ways of
understanding drug use or effects may be equally valid.
That being said, there are some pharmacological basics that may elucidate the
nature of drug knowledge. First, a basic tenet of pharmacokinetics is that the blood or
plasma concentration of drugs is related to drugs’ effects, but for most psychotropic
drugs, no clear or simple relationship has been found (Brunton, Lazo, & Parker, 2006). In
trials of antidepressants, for example, “such a high proportion of patients respond to
placebo that it is difficult to determine the plasma level associated with efficacy” (p.
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128). Second, at the population level, therapeutic dose ranges for all drugs will overlap
with toxic dose ranges. This is also true at the individual level for antipsychotic drugs,
which are typically selected based on the likely tolerability of adverse effects.
Complicating all of this, a single individual may not always respond the same way to the
same drug given at different times. Third, psychotropic drugs primarily act initially on
the transport of specific neurotransmitters, but cause a cascade of secondary effects and
adaptive processes that still elude researchers.
In sum, much is still not known physiologically about how, why, or for whom
psychotropic drugs “work.” Drugs have multiple effects, which are unpredictable for
individuals and too complicated for current scientific processes to tease apart. However,
even if there did exist a “perfect” knowledge of the physiology of drug action, it would
be an incomplete knowledge because drugs’ effects are as much social phenomena as
they are biological (Cohen et al., 2001).
Knowledge.
Methods and procedures of science are widely accepted as producing – or at least of
providing the optimum means of progressing towards – what may be called “true”
knowledge characterized by objectivity and neutrality. It is arguable, however, that
knowledge produced by scientific methods (henceforth, scientific knowledge) is
incomplete, limited, and not free from bias due to cultural and political influences. The
alternative, critical hypothesis that informs the proposed research posits that knowledge
takes various forms, may be dispersed in an incomplete and often contradictory manner
among individuals, and cannot be concentrated, organized, integrated, or “knowable” by
any one or elite group of individuals (Foucault, 1980; Hayek, 1945). Central to the
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research is the best utilization of dispersed knowledges, a position which may
consequentially suspend oppositions between scientific and non-scientific knowledge, or
objective and subjective ways of knowing.
This paper also adopts Michel Foucault’s concept of knowledge as inextricably and
inevitably linked to power (power/knowledge) (Foucault, 1980). According to Foucault,
power is dispersed, exercised from innumerable points, and refers to relations rather than
a possession or privilege of a dominant class. Power may be repressive, but is more often
productive by, for example, producing knowledge and discourses which are exercised at
the level of everyday life in activities like self-surveillance and self-discipline. Foucault
describes:
there is no power relation without the correlative constitution of a field of
knowledge, nor any knowledge that does not presuppose and constitute at
the same time power relations… It is not the activity of the subject of
knowledge that produces a corpus of knowledge, useful or resistant to
power, but power-knowledge, the processes and struggles that traverse it
and of which it is made up, that determines the forms and possible
domains of knowledge. (Rabinow, 1984, p. 175)
The effectiveness of the positive, productive characteristics of power rests on the
installation of a field of empirical truth, or what Foucault terms a politics or regime of
truth (Foucault, 1980). The politics of truth encompasses: the types of discourse a society
accepts and makes function as true, the mechanisms used to distinguish true from false
statements, the procedures accorded value for acquiring truth, and the status afforded to
those authorized to say what counts as true. The analysis of power/knowledge, then, is
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not concerned with discerning true from false statements, but rather stresses the historical
conditions of possibility for what counts as truth. In the current politics of truth, the
procedures and practitioners of science hold great currency. As a result, seemingly
natural objects (like disease or schizophrenia) are best understood only in relation to the
science or expertise that posits them, as “the very discourse that is supposed to discover
the reality of the thing’s being, the truth of disease itself..., has always already actively
contributed to the constitution of the object” (Rawlinson, 1987, p. 377). If scientificmedical knowledge appears neutral in medical discourse (i.e., what is said by those
speaking as medical experts), it is because the knowledge offered is constructed as
external to power (Peterson & Bunton, 1997). Thus, while it is mostly inaccurate to
construe medical experts as figures of domination who possess power that could be given
to someone else, it is accurate to say that they are important links in a set of power
relations capable of producing knowledge.
Expertise and the role of experts in society.
Political rule in liberal societies has greatly depended on experts and the authority of
truth to govern populations (Rose, 1993). Experts are authorized to construct knowledge
around an identified object, and political rule is exercised in light of the knowledge of
that which is to be governed. The expert knowledge is not typically a new knowledge or
expertise over an object where no knowledge or expertise had existed before, but rather
often represents a reorganized, reformatted, and concentrated form of a local, dispersed,
or subjugated knowledge (Mitchell, 2002). Thus, experts are those who can speak and
enact truth, and serve as the means of circulation of this reorganized and concentrated
knowledge.
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In advanced liberal societies, such as presently in the U.S. according to many
social scientists, experts are increasingly distanced from overt political rule through a
shift in location of experts and expert knowledges to the market governed partly by
consumer demand (Rose, 1993). Advanced liberal rule depends on the self-government
of individuals “whereby each individual binds themselves to expert advice as a matter of
their own freedom… what starts off as a norm to be implanted into citizens can be
repossessed as a demand which citizens can make of authorities” (p. 296). As opposed to
the use of coercive or repressive techniques based on expert knowledge of a human
subject or population, advanced liberal societies seek to govern through regulated spheres
of autonomy in which an individual’s relation to oneself is constituted and shaped by a
proliferation of discourses and technologies.
Expertise in areas of medicine, law, science and similar professions has traditionally
emerged in society through the institutionalization of a field of knowledge, setting up of
professional bodies, training and accreditation, and other techniques for regulating and
managing the respective knowledge and activities (Abbott, 1988). This expert
knowledge, though, is a contested knowledge in that there are always parallel
disagreements and struggles both within expert circles and from the outside margins
(such as that of the ill person or psychiatric patient) (Foucault, 1980). Constituting the
outside margins are the local, particular, subjugated knowledges which have been
“disqualified as inadequate to their task or insufficiently elaborated; naïve knowledges,
located low down on the hierarchy, beneath the required level of cognition or
scientificity” (p. 82). According to norms of science (and the current politics of truth)
such knowledge may be considered either a flawed form of knowledge or something
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other than knowledge altogether. Social studies of health and illness have often used the
term “lay beliefs” in reference to local, particular experiences, perspectives, meanings,
and ways of managing health and the body, and have only recently accorded these the
status of “lay knowledge” (Popay & Williams, 1996). Alternatively construed, that which
may be or become subjugated knowledge often involves an expertise (local and
particular) too widely dispersed to provide a means for political power or corporate
profits (Mitchell, 2002). This knowledge contains the “historical knowledge of struggles”
and helps to reveal the contestations, multiple claims, local variations, and sometimes
violence in the politics of truth (Foucault, 1980, p. 83). For the present analysis, to
operationally define or label what knowledge is would entail “settling on paper issues
that are not settled in reality, where they are the stake of ongoing social struggles”
(Bourdieu, 1988, p. 778). Reference throughout this paper is therefore simply made to
scientific knowledge and consumer knowledge – the former referring to that which is
accepted as true using procedures of science (often called “knowledge” or “fact”), and the
latter referring to that which holds less significance in determining what is accepted as
true (often called “belief” or “opinion”).
Evolving market conditions.
The individual and collective health of bodies in the U.S. is a political and economic
issue because health, reproduction, and disease are central to economic processes and
therefore subject to political control. Evolving market conditions, including
medicalization, consumerism, direct-to-consumer advertising of prescription drugs, and
the user-generated Internet, continually alter and transform power relations surrounding
access to and demand for knowledge, and power over its production.
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Medicalization refers to the increasing number of life and bodily experiences that are
placed within medical jurisdiction and subject to technical solutions (Conrad, 2007).
Consumerism refers to the increased responsibility citizens carry to choose health goods
and services through the marketplace (Gabe & Calnan, 2000). Unique to the health
domain, this form of consumerism involves an end user who does not necessarily
“choose” the good since this decision may be mediated by the doctor, and who does not
usually directly purchase the good because of health insurance and third-party payments
(Busfield, 2006; Lakoff, 2004). Nevertheless, health in modern America is promoted and
perceived as a commodity under which everyday lifestyle choices are subsumed, and
health care is increasingly subject to consumer market forces (Conrad, 2005; Lewis,
2006). This consumerist trend, however, is less likely to apply to certain populations,
such as children receiving Medicaid benefits or adults institutionalized in long-term care
facilities. In this paper, the term “consumer” is meant to apply to a participative adult
population. The commodification of health and increased responsibility put on consumers
to “take control” of their care and treatment, for example by gaining medical knowledge,
combines with medicalization to extend self-care and self-discipline into more and more
corners of individuals’ daily lives (i.e, through self-surveillance, risk assessment,
consumption of appropriate goods/services for treatment/prevention of various problems)
(Clarke et al., 2003).
Direct-to-consumer advertising (DTCA) of drugs available only by prescription
has helped fuel both consumerism and medicalization by motivating individuals to
proactively seek a drug, as well as more generally expanding the range of human
distresses presumed amenable to drug treatment (Davis, 2006; McCurdy, 2003). As
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testimony to the former, one estimate found that nearly 8.5 million Americans each year
request and receive a drug that they heard about or saw in an advertisement (McCurdy,
2003). Between half and three-quarters of consumer requests for a specific or general
drug for depression were complied with by physicians according to one randomized
controlled trial (Kravitz et al., 2005). DTCA is intended to blur the boundaries between
mild and severe distress and to suggest that all degrees of suffering – or even a lifestyle
wish that causes no apparent suffering – are amenable to drug treatment (Davis, 2006;
Gilbert, Walley, & New, 2000). The life one wants, that is, to be thinner, happier, more
productive, more confident, better liked, and better rested, is promoted as a doctor visit
away. This brand of “cosmetic psychopharmacology” has been particularly successful for
easily self-diagnosed problems such as for weight, baldness, and erectile dysfunction, as
well as for shyness and other behavioral, performance or personality difficulties
(Applbaum, 2006; Avorn, 2005; Conrad & Leiter, 2004; Lexchin, 2006).
Pharmaceutical companies may also use DTCA to market a disease to build
awareness of an underutilized psychiatric diagnosis and subsequently sell the drug to treat
the disease (Conrad, 2005). “Mood stabilizer” drugs, for example, had scantly been
discussed until after 1995 when the anti-convulsant drug, Depakote, was approved by the
FDA for treating mania (Healy, 2006a). The campaign for Bipolar Disorder and mood
stabilizers involved DTC television and magazine advertisements, popular media
coverage such as a 2002 Time magazine cover story titled Young and Bipolar, new
medical journals devoted to the disease, drug company-funded online patient groups,
Internet sites, and scientific and medical conferences. Pediatric Bipolar Disorder, an
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extremely rare diagnosis 10 years ago, has today an estimated prevalence among youth
reaching up to 1 million (Smarty & Findling, 2007).
Direct-to-consumer advertising, as part of the overall phenomena of
medicalization and consumerism, has served to transform relationships between product
and consumer, and consumers and themselves. Paradoxically, the shift of the site of
responsibility for screening and managing health from the doctor’s office to the home of
the consumer increases while it transforms and disperses the processes of medicalization
(Clarke et al., 2003). The ongoing maintenance of health has become an individual goal,
while the realm of what is considered “health” expands to include nearly any lifestyle
choice, and consumer demand for health knowledge and technologies increases.
The Internet.
The Internet has created conditions for access to knowledge from multiple sources with
sometimes contradictory messages, and carries the potential to alter power relations
involving the production of what is deemed legitimate health (including psychotropic
drug) knowledge. According to a Harris Interactive Poll, 110 million Americans use the
Internet at least sometimes to seek health information (Taylor & Leitman, 2002). This
figure represents 80% of all adults online and 53% of all adults in the population. A 2008
survey reported the Internet to be the most widely used resource by adults for finding
health information, though doctors were the most trusted source for information (Elkin,
2008). Thirty-four percent of online health searchers reported visiting Wikipedia,
message boards, and discussion forums, mostly to find or exchange information about a
specific disease, condition, or treatment. Use of user-generated online content is
particularly prominent among consumers age 18 to 34 and those with at least some
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college education. A group of about 10 million Internet users regularly post health
information online, and nearly 9 million users visit personal blogs for health information
("Today in eHealth news: Heard on the street," 2007, January 4). With a full 23% of
Americans without access to the Internet, it is accurate to assert that only a sub-set of
adults use and contribute to the user-generated Internet, suggesting that its role and
effects in health knowledge production and dissemination have only begun to develop.
Still, media commentators insist that the cutting edge of today’s evolving market is that
“the rise of consumerism across American society today has positioned the consumer as
king and the Internet as queen in the realm of healthcare communications” (O'Neill,
2007, p. 13).
The openness of the Internet highlights the always existing tension between
expertise and democracy, and appears to swing the pendulum towards the extension of
democratic participation (in the sense that the system is open to non-experts) while
shrinking the perceived need or value of, and possibly attempting to redefine, expertise.
Public participation in areas of science, medicine, and technology, especially as they
intersect with morals and ethics, may be offered as a solution to the “problem of
legitimacy,” or crisis of confidence, in these fields (Collins & Evans, 2007). The growing
use and participation on the Internet has helped create a parallel “problem of extension,”
referring to the problem of identifying the point at which public involvement should be
curtailed in order to maintain the presumably necessary boundary between expert and lay
knowledge.
Some social commentators take the position that the abundance and variety of
health information available through the Internet makes it ever more necessary to rely on
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expert-provided disciplined analysis and understanding to decipher truth from non-truth
(Collins & Pinch, 2005; S. Turner, 2001). The Internet is described as a chaotic mess of
anonymous, uninformed, and unaccountable amateur opinions and claims that crowd
thoughtful analysis by trained, qualified, and accountable experts (Keen, 2007; Siegel,
2008). This perspective assumes the traditional criterion of qualifications or credentials
for judging expertise (Collins & Evans, 2007). Too much “democratization” of
knowledge to an unqualified lay public may have serious adverse social consequences as
highly valued concepts of truth, reliability, and accountability become obscure or empty.
An alternative view of the Internet’s potential effects posits that the Internet is
“democratizing” only as much as it allows marginalized discourses – those that only
weakly influence the public sphere – “to develop their own deliberative spaces…; to link
up with other excluded voices…; and subsequently to contest those meanings and
practices dominating mainstream public spheres” (Dahlberg & Siapera, 2007, p. 134).
Monetary requirements to ensure search engine optimization and extensive hyperlinked
networks make it more likely that dominant and institutionalized discourses are codified
“as so-called quality and thus trusted” (Dahlberg, 2005, p. 166). Rather than a fear of
expert knowledge being drowned in a sea of ill-considered lay opinions, then, this
perspective emphasizes that expert knowledge continues to dominate discourse on the
Internet through the same corporate and professional influences that permeate off-line
realms of knowledge production and dissemination. Thus, “democratization” of
marginalized and counter discourses may need to be strategically fostered, rather than
limited or regulated, on the Internet.
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Expert Drug Knowledge in the Off-Line World
Expert (scientific/medical) drug knowledge.
Discourse serves to constitute the subjects to whom and of whom it speaks, as well as to
create conditions for what is possible and acceptable to say or claim as true (Rabinow,
1984). In line with this function, a scientific biomedical discourse has shaped the
definition and treatment of a range of human maladies and distresses over the last 50
years (Dixon-Woods, 2001; Gabe, Kelleher, & Williams, 1994). This discourse has
thrived in tandem with cultural expectations and health policies that promote an ideal of a
healthy and productive citizen (Gardner, 2003), as well as professional and regulatory
demands that prescribed drugs be disease-targeted and tested for efficacy with specific
scientific methodologies (Lakoff, 2004). For psychiatry, in particular, “the financial
muscle of the pharmaceutical industry has helped to favor a predominantly biological
view of psychiatric disorder,” which has driven psychiatric treatment and the research
agenda (Moncrieff & Thomas, 2002, p. 216).
Expert knowledge about psychotropic drugs is primarily produced using procedures of
science, exemplified by the randomized controlled clinical trial. The resulting knowledge
is officially disseminated through the FDA-approved drug label and funneled to
practicing clinicians through publication of trial results in medical journals, the
Physician’s Desk Reference (PDR), pharmaceutical representatives and medical
education venues. However, significant conflicts of interest posed by pharmaceutical
industry activity in both science and marketing threaten the integrity of the “expert”
evidence base (Cohen, 2005; Healy, 2006b; Woosley, 1994). Pharmaceutical companies
do not only manufacture the promoted drug, but, it will be shown, also produce and
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disseminate the information to be used by clinicians and consumers to make treatment
decisions. This problem is not new or unknown to researchers – and perhaps also to
clinicians and consumers – as researchers on many occasions have suggested the
“manipulation of medical knowledge by the pharmaceutical industry…is endemic in
psychiatry” (Moncrieff & Thomas, 2002, p. 216).
Procedures of science in the making of drug knowledge.
Scientific procedures and regulatory demands for drug approval have combined to
make certain requirements, termed in phases of drug testing, for producing valid
knowledge about a drug. Phase III trials are intended to provide the most definitive
efficacy data and additional safety data once the drug completes pre-clinical through
Phase II testing. These efficacy trials take the form of short-term (usually 3-8 weeks),
double-blind, randomized, controlled studies (RCT), which are presumed – assuming
homogeneity of patients and their proper randomization – to generate causal links
between treatment and outcome. The RCT format has trumped other methodologies as
the “gold standard” for ascertaining a treatment’s efficacy (Cohen, 2005; Oates, 2006). In
psychopharmacology, however, the procedures of the RCT may be misapprehended and
misapplied in several ways.
First, as opposed to other areas of medicine in which objective pathologies of the
body are amenable to technological intervention and monitoring, psychiatry and
psychopharmacology have no standard other than the behaviors listed in the Diagnostic
and Statistical Manual of Mental Disorders (DSM) to identify what is being treated. The
creation of diagnostic categories in the DSM can be likened to an opinion poll among
experts, as the authors of the text clearly suggest: “Before DSM-IV, diagnostic manuals
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were generally constructed by expert consensus” (American Psychiatric Association,
1998, p. 1). Revisions to the current manual were mandated by the DSM-IV task force to
be “data based,” which paradoxically institutionalized the consensus-derived categories
of previous editions while allowing the text to now be promoted as empirically informed
(Kutchins & Kirk, 1997). DSM authors further state that the manual’s categorical
distinctions between disorders cannot be supported logically (American Psychiatric
Association, 1994), thus begging the question of what exactly is being treated in a
psychopharmacological RCT (Cohen & Jacobs, 2007)?
Correlatively, the determination of a psychiatric diagnosis and drug treatment
effectiveness is unique because they are each based on the person’s subjective complaints
and feelings, as well as the doctor’s observation of the person’s behavior as in accordance
or not with what the person expresses (Freund & McGuire, 1999). However, the RCT
format effectively mutes the participant’s voice in favor of the investigator’s voice
through the use of investigator-rated measurements, narrowly defined outcomes which
are of medical/professional interest, limited or no opportunities for unstructured or
spontaneous speech by the participant, and limited interaction between the participant and
investigator (Jacobs & Cohen, 1999). Conventional symptom-based checklists and
laboratory tests for biological effects (i.e., heart rate, blood pressure, plasma
concentration) that are widely used in trials for medical products are only minimally
relevant to psychopharmacology.
Finally, RCT criteria to ensure internal validity and rigorous testing appear to be
misapplied or misapprehended in psychopharmacology trials. For example, placebos
have demonstrated considerable efficacy – often equivalent or superior to the treatment
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drug – in psychopharmacology (Kirsch, Moore, Scoboria, & Nicholls, 2002), yet this
response receives little serious discussion in the literature with most researchers viewing
it as a methodological problem that “complicates clinical trials of efficacy” (Oates, 2006,
p. 118). The placebo response is further obscured in drug trials through the frequent use
of inert placebos and abrupt drug discontinuations (Cohen & Jacobs, 2007). The doubleblind is used in RCT procedures to minimize the bias of expectation and suggestion,
though rarely do studies report methods for ensuring or testing maintenance of the blind.
Use of inert placebos may further contribute to penetration of the blind in
psychopharmacology trials in which active drugs nearly always have noticeable adverse
effects. Third, RCT procedures for assessing adverse effects are underdeveloped and
receive little attention compared to methods for measuring and reporting efficacy
outcomes (Cohen, Hughes, & Jacobs, in press; Greenhill et al., 2003). The most
frequently used methods for collecting information on adverse effects involve “openended questioning” and “unsolicited reports” of the patient, which undoubtedly
underestimate the frequency of many events and may mask the severity of others. Other
methodological limitations of the RCT as used in psychopharmacology include:
inattention to implications of widespread polypharmacy on drug efficacy and effects,
discontinuation designs that may be confounded by drug withdrawal effects, failure to
adequately recognize drug withdrawal effects, lack of post-treatment follow-ups of the
previous drug experience, insufficient consideration of non-surrogate measures such as
social and functional outcomes, and a general neglect of the psychoactive nature of
psychotropic drugs (Charlton, 2001; Cohen & Jacobs, 2007; Lagomasino, DwightJohnson, & Simpson, 2005; Moncrieff, 2001). All of the above outlined factors combined
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provide legitimate grounds for contesting the validity of the primary means of production
of expert drug knowledge.
Nevertheless, the information derived from pre-clinical through Phase III research
is negotiated between the FDA and sponsoring pharmaceutical company and serves as the
basis for the drug product label (Murphy & Roberts, 2006). According to FDA
representatives, the drug label is “the closest one can get to the truth regarding the
scientific information known about a drug” (p. 36), and represents the “formal,
government-approved definition of a drug’s benefits and risks” (Avorn, 2006, p. 2409).
However, litigation has revealed negotiations between the FDA and a pharmaceutical
company spanning 5 years “over changing the drug’s label to include adverse event data
that had been submitted to the agency but not made fully available to the public”
(Kesselheim & Avorn, 2007, p. 310). The FDA has consistently supported the argument
that a pharmaceutical company should not be expected to provide adverse event
information other than that required to be printed in the drug label. Except for these few
cases in which documents are revealed as part of litigation, it remains largely unknown
what information in the drug label remains absent, minimized or reconfigured as a result
of the negotiation process.
Information about a drug’s full effects, which remains incomplete upon initial
drug approval, is theorized to eventually emerge through long-term use in the general
population. Phase IV post-marketing trials are deemed necessary to examine a drug’s
long-term effectiveness, rare and distal adverse effects, withdrawal effects, costeffectiveness, the impact of a drug on quality of life, and other important clinical
outcomes (Corrigan, 2002). However, as of 2006, at least 71% of post-marketing studies
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that drug companies committed to conducting when their product was approved by the
FDA remain uncompleted or never started (Avorn, 2007). Post-marketing surveillance
systems, such as the FDA’s MedWatch, are under-utilized, tedious to complete, and
subject to many of the same inadequacies in data collection identified above with clinical
trial research (Kessler, 1993; Medawar & Herxheimer, 2003). Information that is
theorized to emerge from wide-spread drug use is not reliably collected nor promptly
added to the drug’s officially recognized profile (the drug label) (Avorn, 2006;
Kesselheim & Avorn, 2007).
Pharmaceutical company influence in scientific drug knowledge production.
An issue that magnifies methodological deficiencies of psychopharmacology
trials and lack of regulatory enforcement by the FDA is the fact that the pharmaceutical
industry supports 70% of all costs of clinical trial research in the United States, and
contributes over half of the budget for the Center for Drug Evaluation and Research
through user fees (Avorn, 2007). Frequently, large Phase III RCTs occur in the context of
multi-site, often multi-country trials conducted by contract research organizations
(CROs) that are hired by the sponsoring pharmaceutical company (Relman & Angell,
2002). Medical education and communication companies (MECCs) are hired to
“ghostwrite” and strategically plan the resulting publications, while the pharmaceutical
company’s marketing department coordinates the process from beginning to end (Healy,
2004; Sismondo, 2007). This entails deciding which studies to pursue and for what
indication, who a publication should be authored by, and what journal it should appear in.
Accordingly, the sponsorship of drug trials is inextricably linked to their design
and outcomes. Out of 42 published articles of head-to-head comparisons of newer
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antipsychotic drugs, 33 (78.6%) were funded by a pharmaceutical company and 90%
reported outcomes in favor of the sponsoring company’s drug (Heres et al., 2006). In
different comparisons of the same drugs, this resulted in contradictory findings as “it
appears that whichever company sponsors the trial produces the better antipsychotic” (p.
189). Two additional reviews of drug studies found odds ratios of 4.05 and 3.6,
respectively, for a positive recommendation resulting from pharmaceutical industryfunded compared to non-industry-funded publications (Bekelman, Mphil, & Gross, 2003;
Lexchin, Bero, Djulbegovic, & Clark, 2003). A recent analysis comparing outcomes of
published clinical trials and FDA reviews of the same data for 12 antidepressant drugs
discovered that 94% of the former showed positive outcomes, whereas only 51% of trial
outcomes were positive according to the FDA analysis (E. Turner et al., 2008). These and
other well-documented publication biases leave considerable doubt about the credibility
of the major “scientific” source for drug information (Ioannidis & Lau, 2001; Melander et
al., 2003; Papanikolaou, Churchill, Wahlbeck, & Ioannidis, 2004; Perlis et al., 2005). In
an essay titled “Medical journals are an extension of the marketing arm of pharmaceutical
companies,” a former British Medical Journal editor suggested a remedy to this farreaching problem: medical journals should stop publishing clinical trials (Smith, 2005).
In sum, FDA approval of a drug, which results from pre-clinical through Phase III
testing, provides a “cognitive closure” in which clinicians and consumers accept the
given “scientific” facts about the drug (Busfield, 2006). The drug testing and approval
process may be ineffectual, though, because the pharmaceutical company makes the facts
and selects the data to present.
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Limitations to scientific testing in psychopharmacology and the peculiar complexity of
the industrial-regulatory process are not often noted once the official “badge of
effectiveness and safety” is issued by the regulatory agency (p. 305).
Dissemination and credentialed practice of scientific drug knowledge.
In the offline world, scientific drug knowledge is typically disseminated to
credentialed medical practitioners through published peer-reviewed journals (discussed in
the previous section), pharmaceutical representatives or “detailers,” medical education
venues, and medical texts, particularly the Physicians Desk Reference (PDR).
Pharmaceutical companies are intimately involved with each of the above activities and
products, with the effect of increasing the grey area between marketing and science.
Pharmaceutical representatives, or “detailers.”
Marketing expenditures in the pharmaceutical industry have grown from $11.4 billion
in 1996 to $29.9 billion in 2005, according to industry reporting and surveys (Donahue,
Cevasco, & Rosenthal, 2007). A recent independent source estimates a more realistic
figure to be $57.5 billion (Gagnon & Lexchin, 2008). Physician and hospital detailing by
pharmaceutical representatives is the largest expense, making up approximately 65% of
marketing expenditures of top-selling psychotropic drugs. The job of the detailer is to
provide “details” to the psychiatrist about the products they represent, and up to 90% of
doctors report meeting with detailers (Lexchin, 1993) with an average frequency of 4
times per month (Wazana, 2000). At the same time, while many doctors indicate they
place little value on detailers as a source of accurate and objective drug information,
studies demonstrate strong evidence that detailing effectively influences doctors to
prescribe the promoted drug. The significance of the detailer, however, is not only that
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such promotional practices are effective, but also that they represent an “extension of a
hierarchically structured marketing apparatus – based on rationalized principles of
management and market analysis – into social spaces previously thought to be occupied
only by doctors and patients” (p. 285). Detailers track the effectiveness of their
educational-promotional efforts by purchasing marketing maps that provide information
on individual doctor’s prescribing habits (Greene, 2004). Marketing maps may, for
example, enable a detailer to target “stubborn” doctors with a different strategy, or to
invite doctors prescribing in high volume to speak at a professional symposium.
Pharmaceutical detailing represents one of the most targeted and well-funded
promotional efforts aimed directly at individual clinicians who, under this scenario, may
be considered another type of medical/health consumer.
Opinion leaders and medical-educational venues.
As an “experience good,” the adoption of a new drug by psychiatrists is largely
dependent on word-of-mouth and learning (Azoulay, 2002). This highlights the need for
pharmaceutical companies to engage “opinion leaders” and to sponsor continuing
medical education, professional symposiums, and scientific conferences. Opinion leaders
are prominent experts in the field who receive honoraria and fees to speak at scientific or
medical conferences, and to contribute to textbooks and journal articles (Relman &
Angell, 2002). Unlike pharmaceutical advertisements under FDA regulation, opinion
leaders are able to diffuse to their colleagues the unapproved or novel uses of a drug.
Pharmaceutical companies further provide the most support, in the form of funding and
organization, of the above mentioned educational and professional events (Relman &
Angell, 2002). Some researchers have found bias in favor of the sponsoring company’s
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drug in continuing medical education curricula, even when institutional CME guidelines
were in place (Wazana, 2000). Additionally, psychiatrists often receive industry-funded
meals, free samples, all-expenses-paid travel to attend pharmaceutical-sponsored
educational events, and other gifts. Data from Vermont and Minnesota, two states that
now require disclosure of drug company payments to doctors, indicate that psychiatrists
earn more from pharmaceutical companies than any other medical specialty (Harris,
2007, June 27). Moreover, “psychiatrists who took the most money from makers of
antipsychotic drugs tended to prescribe the drugs to children the most often” (para. 8).
While doctors report that they are not influenced by pharmaceutical “education” and giftgiving, the evidence consistently indicates increased prescribing of sponsored drugs by
doctors who attend such events or accept pharmaceutical gifts (Lexchin, 1993; Wazana,
2000).
Credentialed medical experts’ practice of scientific drug knowledge.
Clinicians and psychiatrists, as licensed intermediaries between the drug and the
end consumer, are provided access to scientifically produced drug knowledge through the
above outlined channels (Lakoff, 2004). The knowledge actually utilized by these
practitioners is typically more pragmatic than that produced by scientific methods, and
reflects only the portion of scientific/medical knowledge that is relevant to the conditions
likely to be encountered in routine clinical practice (Freund & McGuire, 1999). This
“recipe knowledge” may include such scientifically given facts as the recommended
treatment for a condition or age group, side effects, and contraindications. Psychiatrists
and clinicians may also rely on less “scientific” sources, such as popular media, the
Internet, discussion with colleagues, and clinical experience (Phillips, Kanter,
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Bednarczyk, & Tastad, 1991; Relman & Angell, 2002; Woosley, 1994; Wyatt, 1991).
Patient requests may further impact practice with evidence demonstrating, for example,
high physician compliance with specific or general drug requests (53% and 76%,
respectively) to treat major depression (Kravitz et al., 2005). Of course, a variety of other
factors may also help shape actual clinical practice, such as the need or desire of the
clinician to satisfy the demands or anxieties of a patient, to quell an overwhelming
workload, or to quickly terminate a difficult or time-consuming consultation (Weiss &
Fitzpatrick, 1997).
Popular media and the Internet.
The lay press may serve as a “filtering mechanism” for doctors and scientists to identify
important findings from the vast amount of information found in medical journals
(Phillips et al., 1991). However, on a daily basis health and medical reporters are
“inundated with press kits, announcements, faxes…from drug companies and the public
relations firms that represent them” ("Miracle drugs or media drugs?," 1992, March, p.
142). Popular media articles are commonly written with input from a pharmaceutical
company’s marketing firm as part of the public relations campaign to promote the drug
(Healy, 2006b). Even media coverage of articles appearing in peer-reviewed journals
have been found to frequently exaggerate findings, neglect harms, and fail to adequately
identify study limitations or author conflicts of interest (Moynihan et al., 2000; Woloshin
& Schwartz, 2002).
While much of the research literature focuses on the Internet as a tool for consumers,
psychiatrists and clinicians may also use the Internet to research clinical information,
read articles from medical journals, and communicate with colleagues (Trickett, 2007,
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May 28). A 2002 survey of U.S. physicians found that most (70%) report using three or
fewer websites to regularly find medical information, with WebMD consistently topping
the list of online sources (Von Knoop, Lovich, Silverstein, & Tutty, 2003). Nearly all
physicians (96%) reported that information they found online impacted their knowledge
of available treatments, including drugs. A slightly smaller majority (73%) reported that
the information impacted their prescription decisions.
Clinical experience.
In addition to official scientific drug knowledge funneled to clinicians through the
previously discussed channels, clinical experience may be a primary source of knowledge
utilized to make decisions about psychiatric diagnosis, and the appropriateness and
effectiveness of a treatment (Charlin, Tardif, & Boshuizen, 2000; Wyatt, 1991). This is
especially so in selecting psychotropic drugs because the “difficulty in applying valid and
sensitive measures of therapeutic effect” requires selection based on the individual’s
likely tolerability of adverse effects or knowledge of a previously favorable response to
the drug (Brunton et al., 2006, p. 429). As already mentioned, the speech and expressions
of the psychiatric patient are uniquely important in psychopharmacology, and are equally
so in clinical practice with psychotropic drugs. Though because medical training and
professional ideologies may effectively restrict problem-solving to the specialized tools
of the profession (Nordin, 2000), it is likely that the clinician interprets the impact and
meaning of drug effects differently than the individual experiencing it first-hand
(McCubbin & Cohen, 1996). For example, the psychiatrist may primarily seek
congruence of the patient’s story with prevailing diagnostic systems such as the DSM
(Tucker, 1998), and some recognized scientific facts about the drug. Through taking the
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patient’s treatment or “medication history,” the clinician embarks on an interpretive
process of meaning-making that may or may not remotely reflect the true nature and
impact of the drug as experienced by the user (Cohen, 2003). This is partially empirically
demonstrated by studies finding poor correlation between clinician-rated and patientrated psychopathology measures (Lasalvia, Ruggeri, & Santolini, 2002). Clinician-rated
psychopathology is also poorly correlated, while patient-rated psychopathology is
moderately to highly correlated, with subjective quality of life.
Additionally, several studies have revealed insufficiencies in the process of
relating expert drug knowledge to actual or potential drug users within the clinical
consultation. In multiple surveys, tardive dyskinesia, a common serious adverse effect of
certain antipsychotic drugs, was simply unmentioned by psychiatrists as a risk to patients.
In a survey of patients taking antipsychotic medications, over half (59%) reported that
other treatment options had not been presented and 46% indicated that they had not
received any information about potential adverse effects of the prescribed treatment
(Gray, Rofail, Allen, & Newey, 2005). In a survey of 223 patients receiving medications
for a diagnosis of bipolar disorder, between 60% and 70% of respondents reported
dissatisfaction with receiving too little information from their clinicians about adverse
effects, what to do in case of experiencing an adverse effect, and whether the medication
would affect sexual functioning (Bowskill, Clatworthy, Parham, Rank, & Horne, 2007).
After interviews with 51 patients starting antidepressant drug treatment, the most
commonly reported unmet information need concerned adverse effects, followed by the
role of treatment in recovery, expected length of treatment, and the risk of physical and
psychological dependency on the drug (Garfield, Francis, & Smith, 2004). Such
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omissions by psychiatrists and clinicians, whether intentional or not, violate the principle
of informed consent and serve to undermine the credibility and reliability of clinical
expertise.
Due to the distorting effects on scientific drug knowledge of extensive
pharmaceutical company involvement in the production of drug fact-making and
subsequent dissemination to practicing experts, it may be justifiably argued that clinicians
are unequipped and unable to provide a “balanced” risk-benefit appraisal to drug
consumers. Further, the esteemed status of the credentialed medical expert may be
threatened if the specialized knowledge that distinguishes expert from non-expert loses
credibility and relevance. Despite professional ethics and licensing requirements intended
to instill trust and proclaim competence, many psychiatrists may themselves have only
limited understanding of drugs’ full effects.
Consumer Drug Knowledge in the Off-line World
In trying to come to a “valid” understanding of drugs’ effects, the voice and speech of
the patient has traditionally been muted or neglected in favor of a presumably more
objective biomedical discourse (Hyden, 1997; Jacobs & Cohen, 1999). With this, the
depth and complexity of an individual’s suffering and treatment are reduced or eliminated
(Miller & Crabtree, 2005). While it may be legitimately argued that the patient’s “voice”
is irrelevant to a scientific understanding of disease (defined in Western models as
pathological alterations at cellular or molecular levels), the role of the patient’s voice in
psychiatric medicine might be profoundly different because there exist no accompanying
physical signs or symptoms to aid a psychiatric diagnosis and treatment plan (except for
substance-induced conditions and conditions, such as dementias, consequent to various
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physical diseases). Absent both strict disease determinations in psychiatry and patients’
voices in psychiatric drug research, it is important to explore what power this biomedical
discourse and professionally-mediated treatment reflect.
The drug consumer may consider information from a variety of sources to
interpret and label symptoms and make treatment decisions. Common sources for the
consumer include their doctor or psychiatrist, advice from non-medical helping
professionals or non-professionals in their social network, scientific/medical texts such as
the PDR or the drug label, DTC advertising and popular media, Internet sites and
discussion forums, personal and shared experiences, and personal beliefs about health,
disease healing and medicine (Harmon, 2005; S. Williams & Calnan, 1996). Consumers
typically seek information that is congruent with the everyday experience of their
problem (Kivits, 2004), which may or may not include strictly biomedical interpretations
and categorizations. This carries potential for dissonance between the consumer’s
explanation and perceived needs, and psychiatric/medical explanations and cures.
A consumer’s reliance on a clinician or psychiatrist for drug information may be
caricatured on a continuum ranging from rejection of the value and/or validity of expert
knowledge, to autonomy in gathering and digesting expert knowledge, to complete
dependence on the expert for relaying knowledge and making associated treatment
decisions (Fox & Ward, 2006). Autonomous consumers generally accept medical
explanations for their suffering and may carefully research treatment options prior to the
medical encounter in order to offer their clinician specific treatment suggestions. Some
may even lie about their symptoms to ensure they receive their desired drug (Harmon,
2005). Others may experiment with increasing or decreasing their already prescribed dose
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or trying different medications borrowed from a friend. Particularly among drug
consumers under age 40, the popular media have reported, “there’s this increasingly
widespread attitude that ‘we are our own best pharmacist’” (para. 22) and that a medical
degree “is useful, but not essential, and certainly not sufficient” (para. 6). As an aside, it
may be hypothesized that consumers in the autonomous and perhaps rejection range
would be more likely to contribute to consumer-generated online health and prescription
drug sites than dependent consumers.
Personal and shared experience.
Any “expertise” or special knowledge a patient may be granted by professionals is
rooted in experience (Caron-Flinterman, Broerse, & Bunders, 2005). Consumers have
first-hand knowledge of the impact of illness on their body and social life, and the
benefits and pitfalls of tried treatments. The consumer is the only one who can decide the
usefulness of the treatment for their life circumstances (Kazdin, 1999; Nordin, 2000). The
notion of efficacy – a statistically significant superiority of the drug over placebo of
paramount importance in psychopharmacology – is minimally relevant to clinical
significance and the total drug experience.
Personal experience and the insight gained from others with similar experiences is
often perceived and utilized by consumers as a relevant, useful, and trustworthy source
for gaining knowledge and making treatment decisions (S. Williams & Calnan, 1996). A
recent survey found that experiencing an adverse effect, but not contact with a clinician,
receipt of a medical diagnosis or admission to a hospital, was significantly related to
increased awareness of a prescribed drug’s adverse effects (Papanikolaou & Ioannidis,
2003). Similarly, consumers may be warned, for example, about severe withdrawal
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effects of certain antidepressants from an experienced friend, but not from their
prescribing physician who may be unaware of such an effect as it is often not part of the
drug’s official profile (Cohen, 2007). Inasmuch as drug effects are unpredictable for any
one individual, the experience of others may serve as a trusted and “objective” – in terms
of the direct testing of an “experience good” without apparent conflict of interest – source
of information.
Some social scientists have strongly recommended viewing scientific and lay
knowledges as necessary complements, suggesting that they are equal in value and
contribution to the overall knowledge of a domain, though different in their content and
epistemology (Goodare & Lockwood, 1999; Popay & Williams, 1996). Accordingly,
either one or both may be wrong on occasion. This paper is further concerned with
power relations and the politics of truth – that is, how scientific knowledge about drugs is
legitimated (through associations of it as objective, reliable, and valid) while consumer
knowledge is more often de-legitimated or made inferior (through associations of it as
subjective, idiosyncratic, and naïve). This dynamic surrounding the production of drug
knowledge is partly due to the construction of “medication” as an expert domain, and
persists despite possible distortions in the objectivity, reliability, and validity of
scientifically produced knowledge largely due to pharmaceutical companies’ far-reaching
involvement. The user-generated Internet introduces a new component to conventional
power relations in drug knowledge production and dissemination.
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Expert and Consumer Knowledge in the Online World
The dynamics of knowledge on the web.
The original Internet was dubbed “the information superhighway” – a name which no
longer seems suitable to describe its current dynamics and uses. Today’s Internet –
variously called the programmable web, the user-generated web, or Web 2.0 – is about
participation, collaboration, and communication (Tapscott & Williams, 2006). The
difference reflects more than just a shift in popular use of a technology, but rather
suggests a greater cultural impact and a different way of thinking about knowledge.
Dynamics of the user-generated Internet of interest for this paper include the evolving
roles and expectations of consumers in the online realm, the potential of the Web to
anticipate later acknowledged realities, and the competition for online space and
attention.
The development of the user-generated web consisted of a bottom-up
transformation of traditional practices in multiple market sectors (Tapscott & Williams,
2006). The assumption of a passive consumer who quietly accepted a finished good
(including information) or service was challenged by self-organized online consumer
communities in media, journalism, software development, and other areas that fulfilled
unmet needs in a grassroots way. By 2006, “the programmable Web eclipsed the static
Web every time: Wikipedia beat Britannica; Blogger beat CNN; Epinions beat Consumer
Reports…and craigslist beat Monster” (p. 38-39). These leaders among consumers have
arguably ignited a shift in the relations of power to become something more like
“prosumers” who participate in the creation or production of the good or service they are
consuming (p. 125). Consumers more broadly appear to carry expectations for formerly
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static websites to provide opportunities to participate, collaborate, or interact with the site
and/or with other users. Inevitably, such openness leads to multiple claims to knowledge
and uncertainty as to claims’ credibility and authenticity in an inherently non-transparent
realm (credibility on the Internet is discussed in detail in following sections). Despite
difficulties, the potential of Web 2.0 is ballooning as companies and research institutes in
all sectors are grappling with innovative business, marketing, and research models to
accommodate this cultural shift ("Let data speak to data," 2005; Tapscott & Williams,
2006).
As a result of increasing consumer participation and interaction online, the Web
may carry the potential to anticipate what only later is officially acknowledged as a
reality (Rogers, 2003). In the case of psychotropic drugs, an actual or potential consumer
on the Internet can find the official medical/professional/industry accounts of a drug’s
uses and effects, as well as unofficial accounts from consumers and “fringe” groups that
may “enrich and complicate more official accounts” (p. 196). Insofar as the Web is a
grassroots technology used by individuals to (often spontaneously) self-organize and
“have a voice”, the Web may be the “first to know” of novel or underground drug uses
and professionally unrecognized desirable or adverse drug effects (p. 196). This is
certainly the case with “brain shivers” – an adverse effect associated with antidepressant
use and withdrawal, which was recognized by clinicians and researchers only after online
discussion of the phenomena among consumers became too overwhelming to dismiss
(Christmas, 2005). Clinical trial reports indicated some incidence of “dizziness,”
“vertigo,” and “sensory disturbances” upon drug “discontinuation,” but the experience of
consumers was congruent with difficult-to-describe electrical shocks to the head and
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often a feeling of severe drunkenness – even after missing just one dose of certain
antidepressants. The discrepancy, not only in terminology, but in depth of understanding
resulted in individual doctors and pharmacovigilance centers dismissing, minimizing, or
misclassifying consumers’ complaints (Medawar, Herxheimer, Bell, & Jofre, 2002).
Brain shivers continued to be defined and described so differently by experts and
consumers that the phenomenon recognized by one appeared foreign to the other. Further,
the medical community seemed reluctant to take seriously the “anecdotal” reports of
consumers, despite the rapid growth of websites dedicated to discussing the issue. In this
case, the Web was the “first to know” of brain shivers and could be described as
anticipating a later acknowledged reality, as the medical community did eventually
recognize this effect to be a “new” drug problem even without an understanding of its
causal mechanisms. Of course, there are numerous examples in the off-line world of
patients recognizing iatrogenic effects of an intervention before professionals and having
their recognition contested or discounted (Popay & Williams, 1996; S. Williams &
Calnan, 1996). The web as potentially anticipatory adds a new component to this existing
power relation.
Finally, with unlimited virtual space on the Internet and the ease of publishing
one’s views online, the most valuable resource in the online realm may be attention
(Dahlberg, 2005). Millions of web pages make it less likely that any one page will be
noticed by an audience of considerable size. Search engines do not frequently reveal their
algorithms for returning search term results, so it is not possible to definitively outline all
of the most important elements in the determination of online attention. To tip the scales
in one’s favor may require maintaining an extensive network of inbound hyperlinks,
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reproduction of one’s content on other sites, and costly pay-per-click advertising. Sites
can also purchase such items as “prime time” and “sole supplier” status on search engines
to minimize the chances that a competitor site will garner similar attention.
In the health domain, some medical researchers, practitioners, and regulatory
authorities as high up as the World Health Organization are advocating for regulation of
health websites using quality ratings and seals of approval (Eysenbach, Powell, Kuss, &
Sa, 2002; Fox, 2010). Such actions would presumably protect consumers from wrong or
potentially dangerous information and, simultaneously, assert what gets counted as
legitimate health information (Brown, 2002). These efforts have not been in vain as an
unknown number of search engines “already exclude or marginalize health websites that
don’t meet recommended medical grading system requirements” (Lewis, 2006, p. 528),
which may include consumer-led sites and other “unconventional” health resources.
However, the negotiation of space and attention is continually challenged by the
Internet’s openness. For example, the rise in consumer complaint forums has been met by
companies “attempting to defend themselves by setting up anti-domains” before
consumers have an opportunity to register them (Harrison-Walker, 2001, p. 398). Days
prior to launching the site Priceline.com, the company purchased the domain Pricelinesucks.com and a variety of other spin-off names. The hugely popular video site YouTube
allows individuals to post video clips which are searchable by other users using keywords
attached to the video. A recent high-profile video featured a five minute segment from a
former sales representative for Eli Lilly’s antipsychotic drug Zyprexa, “who reveals what
Lilly officials told him to say about the drug’s side effects” (Thomaselli, 2007, p. 4).
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Pharmaceutical companies are in return posting positive and entertaining videos about
their products on the site. Wikipedia is another prime example of the battle over virtual
space (and knowledge in Wikipedia’s case). A detailed look at Wikipedia follows in the
Limitations section.
It is clear that the negotiation of space and attention on the Web is not as
straightforward or transparent as one might easily believe, and certainly is not a
haphazard or spontaneous occurrence. The above strategies to guarantee attention require
extensive monetary or networking resources, favoring those corporations and
organizations with pre-existing resources in the off-line world (Dahlberg, 2005). Quality
ratings for health websites serve to reinforce traditional power relations in the production
and dissemination of the respective knowledge. These dynamics reveal some of the
inequalities in what is promoted as an inherently democratic medium supposedly
governed by the free choice of users. The user-generated web is a contested terrain with
competition for attention and claims to knowledge. The actual and potential altering of
power relations around knowledge production has caused heated debate among
researchers and social commentators about the evolving role of expertise in the age of the
Internet.
Credibility on the Internet.
Users of the Internet may come across a variety of information on any particular
health topic, and thus are no longer limited to receiving a pre-filtered presentation from a
traditional gatekeeper such as a trusted doctor (Eysenbach, 2008). However, sources of
information across all domains are non-transparent in the online realm. It is difficult to
know what conflicts of interest and scientific or financial stakes are involved in the
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construction of expert sites, just as it is difficult to gauge the presence of unauthentic
accounts contributed by persons with vested interests in consumer sites (Clarke et al.,
2003). In parallel, an identity as an expert can be as easily misrepresented as an identity
as a consumer. What this amounts to for Internet users is a shift in the importance of
source credibility to a greater reliance on message credibility (Eysenbach, 2008). Rather
than relying on any particular claim or assertion based on expertise, Internet users appear
more often to cross-check bits and pieces of information across sites with less concern for
whether the author is speaking from credentials or experience (David, 2007; Eysenbach,
2008; Sillence, Briggs, Harris, & Fishwick, 2007).
This dynamic of the Internet causes some medical authorities to disapprovingly
judge the Internet to be “an unruly, unregulated space marked by plurality of claims to
knowledge and authority” (Lewis, 2006, p. 528). This perception has led to concern
among many medical researchers and practitioners about the “quality” of information
found online (Eysenbach et al., 2002; Ferguson, 2002). However, what may be needed is
a new model for judging the credibility of these anonymous, distributed, co-constructed
web sources that are becoming so popular and familiar among Internet users. One such is
the “field-dependent model” in which credibility depends on the user accepting the
principles and practices specific to the field or context within which the site operates
(Warnick, 2007). For example, an independent media (Indymedia) site based on
principles of open peer publishing, constructing alternative accounts, and the
impossibility of objective reporting will not be judged credible using the same standards
of mainstream journalism which is based on a very different set of principles. The fielddependent model explains that users “must look to his or her own assessments, based on
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what is said on the site, in its comments, its external links, and on other sites” in order to
decide whether the content may be viewed as credible (Warnick, 2007, p. 62). Under this
model and suitable to many medical domains in which criteria for providing “complete”
and “accurate” information are necessarily problematic, credibility is a subjective concept
arrived at with consideration of the user’s prior experience, knowledge, and needs
(Eysenbach, 2008). Consumer-constructed sites are not generally meant to provide
scientific health information to readers, but rather exist for a variety of other purposes
that may be judged “credible” in their own respective contexts. This model gives agency
to Internet users and allows for different standards to be applied to the variety of web
sources existing in multiple contexts. Of course, regulatory concerns regarding health
content appear unjustified in the absence of equally vigorous attempts within the medical
community to ensure the unbiased flow and content of “official” health information.
More broadly emerging is a re-evaluation of ways of producing what is judged to
be legitimate knowledge in online communities. The emergent and community models
illustrate how knowledge is differently produced within online groups. In the emergent
model of a user-generated site, thousands of individual users each contribute a small part
(like a review of a product) and out of this emerges a coherent body of work (Wales,
2005). Credibility on these sites is established through reputation mechanisms, such as
the ranking system on Slashdot or the complex system of user reviews on Amazon. In
Slashdot’s ranking system of technology news stories, users gain reputation and influence
by their invested participation in the community and their ability to meet the information
needs of other users (David, 2007).
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The community model is characterized by a dedicated group of volunteers who work
together to create and maintain the site’s content (Wales, 2005). As in any organization or
community, users get to know one another as part of their continued interactions and the
collaborative process is thought to ensure the site’s quality and credibility. The nonprofit, volunteer-led encyclopedic website Wikipedia is the most notorious example of
the community model. A core group of about 524 users (0.7% of all Wikipedia users) do
about half of the site’s editing. Any Internet user may create or contribute to an entry
anonymously or as a registered user, though only 18-21% of all edits are anonymous. The
English-version Wikipedia has over 1 million entries and had reached top 50 website
status by 2005, receiving more traffic than the New York Times (Tapscott & Williams,
2006). The strengths of Wikipedia include its constant growth in the addition of new
entries on obscure and niche topics, and its rapid and in-depth coverage of recent events.
Wikipedia’s openness also makes it vulnerable to inaccuracies, vandalism, and “edit
wars” in which disagreeing users change one another’s edits. However, despite the
inevitability of errors in any encyclopedia, an obscenity randomly inserted in a Wikipedia
article is removed in an average of 1.7 minutes. Disagreements and inaccuracies may be
particularly a problem for entries in philosophy, politics, and culture, but for science
topics Wikipedia has recently been found to be about as accurate as The Encyclopedia
Britannica (Carnevale, 2006). In a study of exposure of user-generated sites in popular
search engine returns for health-related searches, Wikipedia appeared on the first page of
Google and Yahoo in 63% of searches, making it the most frequently cited usergenerated resource ("Diving deeper into online health search," 2007).
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Thus, “Wikipedia, like the larger open system of the Internet, is charting new territory in
which widespread use is not contingent on widespread trust, at least on the terms
established by earlier expert systems” (David, 2007, p. 185).
The credibility of the user-generated web and of individual contributions within
specific websites is an unresolved and evolving issue. Despite their lack of credibility in
certain quarters, user-generated sites are highly trafficked and carry validity for their
constituents and users. Revisions to concepts of truth, credibility, legitimacy, and
expertise brought on by the Internet are at the heart of discussion and debate among
Internet researchers in a variety of fields (David, 2007; Keen, 2007; Warnick, 2007). As a
beginning attempt to add to this discussion in the area of psychotropic drugs, the present
research sought to compare the information found on expert and consumer online
sources. This is to distinguish the aim of the research from one that seeks mainly to
determine the truth value of specific claims.
Consumer drug knowledge and the Internet.
Consumers may use the Internet to supplement, verify, translate, or replace
information from other sources (Eng & Beauchamp, 2005). The almost unlimited
information available on the Internet creates the opportunity to find personalized and
individualized information, as consumers can keep searching until they find information
that resonates with their experience and beliefs. A 2002 survey of 10,000 U.S. patients
found that most patients (75%) report visiting 2 to 5 websites regularly to find health
information (Von Knoop et al., 2003). Similar to results from physician respondents,
patients consistently report WebMD as a top online source. WebMD is constructed and
monitored by medical professionals and contains health information presented as
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scientifically legitimated. It is intended for an audience of other experts and the lay
public. It is unknown whether the reported popularity of WebMD is due to its relevance
to and fulfillment of information needs, or to its success in negotiating online space
through search engine placement and advertisements.
Second, consumers may use the Internet to share their experiences, give advice
and recommendations, or act as a resource linking individuals to other relevant sources
(Hardey, 2002). This use of the Internet transforms consumers into producers of health
information (Hardey, 2001). Personal web pages describing illness, for example, may be
considered “a new genre” of the illness narrative, in which the story is unmediated by a
health professional or researcher, receives guaranteed instant publication to a global
audience, and is dynamic in nature in that the story can be continually updated (p. 395).
Information-, advice-, and resource-sharing are similarly accomplished in online
community groups, discussion forums, and chat rooms, with a range of discourses
potentially represented (Fox & Ward, 2006). In a consumer-led discussion forum called
CrazyBoards, “fluency in the language of psychopharmacology is taken for granted.
Dozens of drugs are referred to in passing by both brand name and generic, and no one is
reticent about suggesting medications and dosage levels” (Harmon, 2005) (para. 37). In
this case, users approximate the “autonomous” consumer discussed previously, as the
doctor appears necessary primarily to purchase the desired drug rather than for
information-gathering and decision-making.
Finally, the frontier of Internet uses by consumers may include creation of a consumer
research community in which consumers across the country offer ongoing data about
their symptoms and treatments in order to create a large database comparable to, and
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more timely, accessible, and relevant than, data from clinical trial research. One website,
PatientsLikeMe.com, has been exploring this frontier since March 2006 with consumer
research communities for Lou Gehrig’s disease, multiple sclerosis, HIV, and, as of early
2008, mood disorders (Goetz, 2008, March 23). Participants on the site can provide
information as often as they wish on their symptoms, symptom severity, treatments, and
dosages, and the website’s software automatically converts the information into charts
and graphs for ongoing monitoring. These quantitative measures are supplemented with
discussion forums that provide participants opportunity for elaboration. Further, by filling
out a personal profile, the site instantly matches up a newcomer with other participants
who share similar symptom and/or treatment profiles. The creator of the site, the brother
of a person who died from Lou Gehrig’s disease, envisions that it “might complement
large-scale and long-term clinical research by conducting observational research ‘on the
fly’” (para. 52) and supports this by adding that data “are present not just in laboratories
or universities or proverbial halls of science but in everyday life” (para. 54). Such
research came to fruit in November 2007 when a small group of the Lou Gehrig’s disease
community chose to seek lithium treatment from their doctors on the basis of an
unpublished study in Italy that showed promising results. Each member of the group uses
the site to share and track treatment effects with the intent to expeditiously verify or cast
doubt on the scientific research results. With this and future possible drug “trials,” the
creators and users of the site perceive the site’s potential to transform health research:

most health-care data is inaccessible due to privacy regulations or
proprietary tactics… When you and thousands like you share your data,
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you open up the health-care system… We believe that the Internet can
democratize patient data and accelerate research like never before. (para.
33)
PatientsLikeMe.com has received attention in the New York Times and numerous
health blogs as a potential disrupter to the health care industry and medical research
(Goetz, 2008, March 23; Schonfeld & Morrison, 2007). They also published a paper
about Lou Gehrig’s disease in the European Journal of Neurology and received their first
scientific award for a poster presentation in 2007 at the British Neuropsychiatry
Association (Wicks, 2008; D. Williams, 2007). When proactive consumers take it upon
themselves to create and disseminate the knowledge they feel a need for and even form
their own drug trials, it may arguably represent a contestation of consumer exclusion
from conventional processes of knowledge production.
Expert drug knowledge and the Internet.
Just as there has been an explosion in consumer-constructed health websites, there
has been an equal explosion of expert-constructed sites. These include international and
governmental health authorities, healthcare hospitals, academic institutions and insurers,
medical research organizations and databases, professional associations, pharmaceutical
companies, non-profit organizations formed around a particular psychiatric diagnosis,
individual and group medical expert web pages, and many more (Parr, 2002). Such expert
sources typically aim to interpret and/or disseminate scientifically legitimated medical
knowledge about psychiatric diagnosis and treatment. The Internet, in contrast to all other
mediums, provides a means to accomplish this in a highly accessible and up-to-date
manner. At the same time, the dynamic linking of web pages means that the producers of
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messages have decreased power over the placement, timing, and context within which
their message is presented (Weare & Lin, 2000). Thus, the Internet “is arguably
facilitative of a different kind of knowledge base about health and illness (it is not just a
new and different medium, but helps to alter the nature of the knowledge accumulated)”
(p. 78). While interesting to note, it is beyond the scope of this review and of the
proposed research to explore how medical knowledge may actually be transformed by
this new method of transmission.
Pharmaceutical companies, like companies in all sectors, are finding innovative
ways to communicate with consumers online and maintain a strong market presence.
Direct-to-consumer prescription drug websites have been found in multiple analyses to
present incomplete and limited drug information, especially concerning drug risks and
harms (Davis, Cross, & Crowley, 2007; Hicks, Wogalter, & Vigilante, 2005; Macias &
Lewis, 2003). Using a sample of 44 drugs, Davis and colleagues (2007) compared risk
statements on the manufacturers’ websites to statements on the FDA label. Websites
promoting drugs with only 1 adverse effect occurring at a rate greater than 10% generally
reported this effect (90.9%). Only 15.3% of websites promoting drugs with 4 or more
adverse effects occurring at this rate reported all of these effects. The greater the number
of adverse effects, the less likely the consumer would learn of them on the
manufacturer’s website. This finding is particularly notable given the unlimited virtual
space available to present comprehensive information. Hicks and colleagues (2005)
examined the structure of 20 randomly selected drug manufacturer websites to determine
the relative accessibility of information pertaining to benefits and risks. Risk information
was found to be located deeper into the website structure and more difficult to access
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than information about benefits as measured by the amount of scrolling and number of
clicks required for viewing.
However, DTC websites are only the tip of the iceberg in online communication.
Pharmaceutical companies looking for new opportunities to influence consumer behavior
are keenly aware of the power of consumer forums to build trust and offer support
(O'Neill, 2007). A DTCA strategy termed “patient-centric marketing” recognizes that
“the most effective method for true health engagement includes online patient
communities” (p. 13). This involves recruiting “brand advocates” to build an “online
community of like-minded consumers” who can create content that is “clear, jargon-free,
and provided by the ‘citizen’ for the emotional and personal credibility” (p. 16). It is not
known whether a “consumer” site sponsored by a pharmaceutical company or a
pharmaceutical representative visiting a genuine consumer site would acknowledge the
sponsorship or presence.
Another innovation draws on the influence of “respected physicians” to suggest
specific health websites to their patients (Von Knoop et al., 2003). A pharmaceutical
company may offer “prepackaged content for physicians’ personal websites,” which
ensures that “doctors and patients alike find consistent messages…about the
appropriateness of a particular treatment option” and that “information about a
company’s product is perceived [by the patient] as objective and credible” (p. 32).
Finally, similar to pharmaceutical company financial sponsorship of medical journals and
medical educational venues, one study found that 58% of the top 50 websites retrieved
from Google and Yahoo searches of the term “schizophrenia” were funded by drug
companies (Read, 2008). Most frequently, these were pharmaceutical company sites, sites
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that represented or served families of persons with schizophrenia, commercial sites with
product for sale, and non-governmental organizations. Pharmaceutical company funded
sites were significantly more likely to espouse a biomedical cause of schizophrenia and
focus on psychotropic drug treatment.
The participation, collaboration, and interaction that characterize the usergenerated web are obviously equally applicable to consumers and corporate stakeholders.
The Internet allows any individual with online access to produce or consume information
without a professional intermediary, though, in many instances it appears that the
immense resources and allies of pharmaceutical companies still tip the scales in their
favor.
Previous Forms of Internet Research
An unknown number of websites allow consumers to rank and review consumer
products and services, such as digital cameras, software, airlines, and now prescription
drugs. Research on consumer review sites and online community groups related to mental
health issues and drug use is limited in number and scope. Many qualitative studies into
discussion groups for depression describe benefits of community group participation,
such as social support and coping, or describe help-seeking behaviors in the online
context (Powell, McCarthy, & Eysenbach, 2003). Content analysis has been used by
some researchers to examine the completeness or balance of drug information found on
pharmaceutical company websites (Davis et al., 2007; Macias & Lewis, 2003; Waack,
Ernst, & Graber, 2004). Several other studies have used content analysis, grounded
theory approaches, or a mix of the two to describe characteristics and themes of
patient/consumer discussion groups. In one such mixed approach, the researchers created
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codes for their pre-identified conceptual concerns in an electronic support group for
persons with fibromyalgia, and created additional codes for emerging themes identified
during readings (Barker, 2008). In fibromyalgia (Barker, 2008) and multiple sclerosis
(Parr, 2002) online patient forums, researchers concluded the groups at various times
(and sometimes simultaneously) contested and subverted expert medical knowledge, as
well as reinforced and expanded the scope of expert medical knowledge. At least two
additional studies have used solely a grounded theory approach to compare themes in
online discussion board and narrative content between males and females with breast or
prostate cancer (Gooden & Winefield, 2007) and posthemorrhagic stroke (Stone, 2007).
These studies were interested in differential informational and supportive needs for men
and women, and the potentially supportive role of the online group, after diagnosis and
treatment.
Few studies have attempted to explore consumer sites for their potential
contribution to the overall knowledge of a topic, such as psychotropic drugs. One study
retrospectively analyzed 1 year of discussion on an online forum for individuals with
Parkinson’s disease for information pertaining to adverse effects of prescribed drugs
(Schroder, Zollner, & Schaefer, 2007). Using a structured classification system for
adverse drug effects to analyze the data, the researchers identified 153 adverse drug
reactions on the forum, including a high rate of dermatological problems consistently
described by participants as being “severe and stressful” (p. 1163). In the case of one
antiparkinsonian drug, the incidence of skin problems in clinical trials was 0.8%
compared to a 23% rate of mention in discussion forum entries. In contrast,
cardiovascular adverse events, which were identified in clinical trials as a primary risk,
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were rarely discussed in the forum. It thus appeared that consumers online were more
likely to discuss effects with the most burden or most obvious manifestation.
Finally, there are a dearth of studies that go beyond the boundaries of
conventional methodologies to explore power and discourse in the online realm. Moore
and Clarke (2001) used a critical interpretive approach to compare the conventions and
heterogeneity of medical and popular online representations (visual and textual) of
human genitalia. Their analysis included biomedical images for medical students, images
found in popular newsgroups about human sexuality, and pornography. It appeared that
traditional patterns of anatomical representation abound online, offering a narrow,
technical, and singular view of genital anatomies. Pornographic sites provided the most
diversity in representing various body types and ages, though in this genre each variation
was fetishized for a consumerist purpose.
Rogers and colleagues are pioneers in mapping debate and discourse on the
Internet, as they have done for issues of climate change (Rogers & Marres, 2000) and
genetically modified foods (Rogers & Zelman, 2002). They accomplish this through
mapping hyperlinks to determine the relevant players in an issue debate and to describe
the concentrations and patterns of hyperlinks within and between various types of sites
(i.e., .com, .org., .gov). They further identify and trace the recurrence of key phrases
across sites in an issue debate. In the case of the climate change debate, the presence of a
statement by the United Nations appeared to have particularly shaped the debate. Actors
in the debate used the officially recognized, scientifically-backed statement to affirm,
reinforce, contest, or otherwise position their own stance.
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In studying the web as an anticipatory medium, Rogers (2004) gave the drug
Viagra a “more honest identity” by capturing and exposing the range of uses,
experiences, and arguments about the drug from a variety of actors (p. 24). He used
groups of Internet “surfer-experts” to answer a basic question: “What is Viagra, and
whom is it for?” (Rogers, 2003, p. 198). The surfer-experts were instructed to compile
lists of Viagra uses found in accounts of the drug from any source, and were given free
reign to search the Internet using their personally preferred methods. Lists were
compared among the surfers resulting in the conclusion that Viagra “has become a
lifestyle drug for men in their 30s and 40s, to be obtained from virtual doctors, having
had referrals from ‘death by Viagra’ search engine queries or from banner ads on porn or
racy sites” (p. 204). The exploration of unofficial online accounts of the drug led the
researchers to further conclude that “Viagra leads a richer, more youthful and
experimental life than it is granted by doctors, the medical industry and by the
manufacturer – all of whom retain Viagra as a prescription drug for a patient with a
medical ailment” (p. 209).
The present research built on the distinct aims and methods of earlier projects by
describing the content and themes of expert and consumer sites starting from a critical
conceptual approach and using grounded theory methods within a mixed-methods
research strategy.

Grounded Theory
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Grounded theory was originally developed by Glaser and Strauss (1967) for the purpose
of generating theory grounded in empirical data, as opposed to testing hypotheses based
on abstract theorizing. Theory generation is accomplished by using a number of analytic
tools. The most popular are coding, memo-writing, theoretical sampling, and the constant
comparative method. The grounded theory research process is an iterative process of
collecting and analyzing data, with the expectation that codes and concepts derived
remain provisional as the research progresses. This method most closely resembles an
inductive process, but arguably requires both inductive and deductive inquiry (Berg,
2000). The researcher is formulating hypotheses about appropriate concepts and
connections between them, while continuing to test these hypotheses (using the constant
comparative method, for example) and generate new ones with additional data collection
and analysis.
Since its origin, the above basic grounded theory guidelines have been used as
part of a variety of research strategies and for multiple aims other than building theory
(Corbin & Strauss, 2008). A number of methodologists recognize that grounded theory
guidelines are best viewed as a set of principles and practices for conducting qualitative
data analysis, rather than a set of methodological rules or requirements (Charmaz, 2006).
Its original developers, Glaser and Strauss, too, eventually disagreed on the appropriate
methods for conducting grounded theory research and continued developing the method
independently of one another (Denscombe, 2007). Glaser believed the researcher should
maintain a distance from the data and allow meaning to emerge by a neutral examination
of manifest content. Strauss adopted a more interpretive approach claiming that the role
of the researcher was to find meaning in the data, which usually required looking beyond

50

superficialities. More recently, several scholars have provided constructionist and
postmodern adaptations of grounded theory (Charmaz, 2006; Clarke, 2005). The present
research drew from elements of recent versions of grounded theory, including the work of
Corbin and Strauss (2008), Charmaz (2006), and Clarke (2005).
In their most recent edition of Basics of Qualitative Research, Corbin and Strauss
(2008) describe grounded theory as a general approach to research that is appropriate not
only for theory development as originally formulated, but also for superficial description
or in-depth analysis. In-depth analysis “is more likely to generate new knowledge and
deeper understandings because it tends to go beyond what everyone already knows” (p.
51). The present research aimed for an in-depth analysis, which included a presentation
of reported medication effects and generated themes/categories. In keeping with the
social constructionist framework, categories/themes were not assumed to emerge from
the material, as “rather than discovering order within the data, we create an explication,
organization, and presentation of the data” (Charmaz, 2006, p. 140).
Summary
Pharmaceutical industry influence over the production and dissemination of
scientific drug knowledge on which clinicians, other professionals, and consumers may
rely is ubiquitous and inescapable. The effect of such influence is the extensive blurring
of marketing and science, and an emerging critical questioning of the validity and
integrity of the “scientific” evidence base for psychotropic drugs. In parallel, the Internet
has provided an opportunity to review drug information from thousands of consumers
without professional mediation. Most research positions expert health or drug knowledge
as the standard, authoritative source to which other forms and sources of knowledge are

51

compared for their accuracy, completeness, validity, and so on. It is unknown how
consumer-constructed and expert-constructed web sources for psychotropic drugs may
compare if neither form of knowledge was a priori privileged as a standard.
Conceptual Approach
The central issue of the proposed research concerns the construction of expertise in the
age of the Internet. The research asks: Has the Internet rendered expertise in the area of
psychotropic drugs obsolete? The validity, credibility, and integrity of scientific/medical
knowledge in the area of psychotropic drugs have become highly contested in recent
years, as extensively explored in the review of literature. The Internet is 1) an evolving
communication medium, 2) a network of computers and people, 3) a socially constructed
virtual reality, and 4) a potentially transforming component to traditional power relations
in knowledge production and dissemination (Markham, 2004). The push-and-pull
dynamics of traditional and presently evolving power relations, illustrated in Figure 2.1,
leads to an unspecified situation for the production and dissemination of psychotropic
drug knowledge in the Internet age.
Social constructionist (Berger & Luckmann, 1967) and critical perspectives
(Foucault, 1980) frame this investigation into the production of psychotropic drug
knowledge on the Internet. This research takes the position that there is no pre-constituted
objective social world waiting for specific procedures to unveil and articulate. Working
from Foucault’s concept of power/knowledge, “truth” is not so much discovered as it is
produced according to historically situated conditions that make up the politics of truth –
that is, who is authorized to speak, what objects are worthy of inquiry, and the techniques
and procedures for acquiring truth and enabling one to distinguish between true and false
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statements (Rawlinson, 1987). However, to say that truth is constructed, or that drug
effects are constructed, may be a misnomer as it implies a falsely clear distinction
between the “objective” existence of the physical object, and its “constructed” existence
of representations and meanings (Mitchell, 2002). It may be more precise to say these
things are “made,” or according to Foucault “produced,” out of processes that are at the
same time material and cultural, and as much real as abstract. Teasing apart the “real”
object, for example the physical drug, from its personal, social, cultural, political, and
economic meanings and uses is arguably a fruitless task because all of these elements
interact to produce what a person experiences as or what scientists make to be
“psychotropic drug.”
This perspective also has a number of implications for the online textual material
used for analysis in this research. “Text” here specifies any written language, images,
symbols, or other that “means something to someone, it is produced by someone to have
meanings for someone else” (Krippendorff, 2004) (p. 19). First, a text’s message or
meaning is not something objective to be found or identified by the researcher, but rather
is subject to an interpretation process according to the context developed by the
researcher (Krippendorff, 2004). Researchers working within different disciplines, such
as economics, psychology, or political science, will interpret the same text from different
perspectives and within different contexts. None of the resulting analyses would be more
“right” than the other, just as none would represent “the” message or meaning inscribed
in the text.
Second, a social constructionist perspective rejects the traditional sender-receiver
model of communication in favor of the consideration of intertextuality, meaning that
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text is always related to larger discourses and is often understood in reference to
presumed knowledge of other texts (Titscher, Meyer, Wodak, & Vetter, 2000). For
example, a text may explicitly or implicitly articulate a position on the role of patients in
healthcare decision-making within a biomedical, political, or consumer activist discourse.
As humans are “routinely both producing and awash in seas of discourses,” so are texts,
as products of human thought and action, embedded in these discourses (Clarke, 2005, p.
145). One text may be connected with multiple and various, sometimes conflicting,
discourses. Also, ascribing meaning to a text often depends on the reader’s presumed
knowledge of other texts, which may include general everyday knowledge or experience,
publicized current events, or an understanding of humor or satire, among others
(Warnick, 2007). Consequentially, “Because of intertextuality, there can in principle be
no objective beginning and no clear end, since every discourse is bound up with many
others and can only be understood on the basis of others” (Titscher et al., 2000, p. 26).
Third, text content speaks to something other than itself. For example, words and
images may inform, evoke a feeling, encourage action or behavioral change, and much
more. This implies that the researcher must look beyond the physicality of the text to
consider how the text is used and what and how it encourages. At the same time, meaning
making on the Internet “is an emergent process that commences when the user first
encounters the site and then develops his or her understanding based on signs, pathways,
forms of expression, and representations encountered on the site” (Warnick, 2007, p.
104). Moreover, users can create entirely different texts in their use of hyperlinks so that
one user’s individuated pathway is nearly non-replicable. The fragmented and
hyperlinked nature of the Internet gives the creator of an online text little control over the
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context within which the text will be discovered or how the text may be interpreted in
light of that context. Yet, authors of online text may still be deliberate and strategic in the
use of hyperlinks to position the site within an issue network (the entire network of linked
organizations and sites around a particular issue, such as climate change or childhood
autism) (Rogers & Zelman, 2002). To hyperlink to another organization makes the
players and positions of the linked organization relevant to the overall discussion or
debate, and “In this way, the act of not linking, non-reciprocal linking, or un-linking
similarly reveals a politics of association” (italics in original; p. 3). In sum, different
readers will navigate to and from the same site differently, making it difficult or
impossible to represent a “typical” user reading of either expert- or consumer-constructed
drug accounts.
Finally, discourse in the proposed research is defined as “communication of any
kind around/about/on a particular socially or culturally recognizable theme,” which may
entail analysis of language, images, symbols, and nonhuman objects (Allan, 2006, p.
148). According to Foucault, discourse creates “conditions of existence” for what is
possible and not possible to say, just as power/knowledge creates “conditions of
possibility” for what is acceptable and not acceptable to say as true (Peterson & Bunton,
1997). Individuals’ language to describe personal problems, health, illness, or treatment,
then, is enabled and constrained by culturally available explanations proliferated through
discourse. Discourse also partly constitutes the object it describes through the use of
discursive strategies (Rabinow, 1984). For example, a discursive strategy utilized in
biomedical discourse may be to construct a subject – “patients” – on an axis of
disempowered/empowered with an increase in empowerment contingent on gaining
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certain medical knowledge. The typically taken-for-granted functions and strategies of
discourse must be continually considered and assessed in research comparatively
analyzing consumer and expert descriptions of a treatment, or else the researcher carries
the risk of again reinforcing traditional power relations and norms of popular discourse.
Research Questions
The main question of the proposed research is: Does the accumulated consumer or
layperson knowledge that the Internet allows dissolve the traditional boundary between
expert and consumer/lay knowledge?
The research specifically sought to examine the content of drug information in
consumer-constructed and expert-constructed web sources. This was accomplished by
using a grounded theory approach resting on critical and constructivist frameworks to
analyze the content of five websites containing drug information for two popularly
prescribed psychotropic drugs from different drug classes. Also, as a practical
consideration, the research asked, how does each source help and hinder treatment
decision-making – both for clinicians and for actual and potential consumers?
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Figure 2.1 Traditional and Evolving Dynamics in the Production of Psychotropic Drug
Knowledge
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Chapter 3: Methodology
Research Strategy
A grounded theory approach was used as part of a mixed-methods research
strategy for an in-depth textual analysis. The grounded theory approach was defined in a
broad sense: “a research strategy that involves working with the concepts and categories
of the research subjects” (Dyson & Brown, 2006, p. 190). A primary competing research
strategy for textual materials is content analysis, in which analysis is guided by prestructured expectations. Specific to textual analyses of drug effects, researchers utilizing
a content analytic approach might use a hierarchical classification system used in medical
research, such as the MEDRA dictionary or a drug-specific effects checklist, to guide
coding. However, these classification systems are typically designed for coding adverse
drug effects, and therefore already reflect a particular perspective related to drug use.
That is, the dominant medical perspective that classifies psychotropic drug effects into
main/therapeutic effects and side/adverse effects is built into these classification systems.
As discussed earlier, however, there is reason to believe that users do not experience
effects this way and that the main effect/adverse effect division is often arbitrary and
changeable (Moncrieff & Cohen, 2009).
A significant component of the present research, and the fundamental point of
departure between the present research and previous work in this area, was the
consideration of power related to knowledge. Most previous analyses of consumer
treatment accounts have included only thematic analyses or have imposed medical
classification systems or standards on the data prior to analysis. For this research, it was
presumed that consumer perspectives and experiences were best represented by
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maintaining the concepts and categories that consumers provided, rather than classifying
them into some form of a dominant medical framework of drug effects. The grounded
theory approach was selected for the present research because it helped extinguish some
imbalances of power (if they exist) related to the construction of labels and categories by
not privileging either source (expert or consumer) as a standard for quality or accuracy.
The grounded theory approach is arguably one of the more interpretive qualitative
research methods, as there is little pre-established structure to guide coding. It is difficult
for other researchers to replicate a grounded theory study, which may be the major
problem and limitation of this approach. The present study attempted to address this
limitation through a couple of modifications. While still interpretive and flexible in terms
of not applying an outside pre-determined template of codes and meaning on the data, the
codebook was “fixed” at certain points in the process to calculate inter-coder agreement
indices. Many codebook revisions were decided by agreement between two coders, rather
than by the interpretation of a single coder. In these ways, the coding process was
“standardized” more than would be expected in a strictly qualitative, grounded theory
study. Further, most analyses included some combination of frequency tables, chi-square
tests for independence of categories, and descriptive excerpts from the text.
In sum, this research followed a unique mixed-methods strategy based on a
grounded theory approach to analyzing text. The influence of power on information was a
central component of this research, and was best considered using a grounded theory
approach. Other, more structured research strategies to analyze this textual data may have
produced a different set of results, particularly in terms of the naming of drug effects and
in their ultimate classification. For example, this study ended with no clear division
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between many conventionally considered therapeutic and adverse effects, a result which
likely would not have been possible had the researcher started with a classification
system structured to record “adverse drug effects.” The major leverage this grounded
theory approach offered over other strategies, then, was a critical analysis (in terms of
examining an issue from outside the mainstream or dominant framework) of data that
well represented (in terms of groundedness) drug experiences.
The Sample
Website typologies and inclusion criteria.
Five exemplar websites were sampled for in-depth analysis according to their
status as expert-constructed (two sites) or consumer-constructed (three sites) sources with
the goal of representing typologies. Representing a variety of websites (as opposed to, for
example, a greater variety of drugs) was important to this study because it related to
practical concerns of consumers who may question how drug information is similar or
different across sites. Table 3.1 summarizes these typologies. Expert-constructed
websites were categorized as professional health and consumer-centric, and one site
representing each category was selected for analysis. Professional health sites are created
and monitored by professionals in the medical or health field, typically involving medical
journalists who gather and write content, and medical doctors who serve as consultants
and oversee content. Content on professional health sites is promoted as reflecting
recognized standards of scientific and medical excellence. For the purposes of the present
research, then, the key criterion marking a website as “professional health” is the
oversight of content by a team of medical doctors. Professional health sites are intended
for both lay and professional audiences, and may include a component for discussion
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among the site’s users. Consumer-centric sites are similar in all ways except for the latter.
As opposed to having an added component for user interaction, consumer-centric sites
attempt to infuse principles of Web 2.0 by specifically designing the site to maximize
participation and interaction of users.
Table 3.1
Description of Website Typologies

Consumer-constructed

Expert-constructed

Typology

Description of Typology

Selected Site

Professional
health

 created and monitored by medical or
health professionals
 reflect recognized standards of
scientific/medical excellence
 intended for both lay and professional
audiences
 may include a component for discussion
among the site’s users

www.webmd.com

Consumercentric

 created and monitored by medical or
health professionals
 reflect recognized standards of
scientific/medical excellence
 intended for both lay and professional
audiences
 specifically designed to maximize
participation and interaction of users

www.revolutionhealth.com

Rigid structure,
narrowly
defined function

 pre-defined fields for user input
 limited ability for extended conversation

www.askapatient.com

Loose structure,
defined but fluid
function

 no or few pre-defined fields for user input
 conversation is structured around
medication classes/brands

www.crazymeds.us

No structure,
vaguely defined
function

 no pre-defined fields for user input
 users construct structure and function by
adding conversations/threads

www.theicarusproject.net
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Inclusion criteria for expert-constructed websites were: 1) the site was operated
by a non-governmental group or organization, and 2) there was no evidence that the
selected websites were owned by the same company or that they share professional
contributors. The latter criterion was stipulated because many popular news and health
sites exist as networks in which medical and other professionals who write or oversee
content do so for the entire network of sites. Analyzing two expert-constructed sites that
were designed by the same team of professionals would have been redundant in this
research. Criteria for the selected websites were verified by examining pages within the
“about us” (or similar) section. If the site was owned, for example, by a private or public
corporation, then criterion 1 was met. For criterion 2, the staff, editorial team, expert
reviewers, and management boards as listed on each website was examined by the
principal investigator.
In contrast, consumer-constructed sites pertaining to psychotropic drugs are more
heterogeneous in terms of the structure and function of the site – from 1) rigid structure
and a narrowly defined function, to 2) loose structure and a defined, but fluid function, to
3) no structure and vaguely defined functions. An exemplar consumer-constructed site
was selected to reflect each point along the continuum of structure and function. Multiple
and varied discourses surrounding drug treatment were anticipated to naturally appear on
this continuum due to the lack of a unitary “voice” among consumer discourses.
Inclusion criteria for consumer-constructed websites were: 1) the site content was
viewable without requiring registration or membership conditioned on moderator
approval, and 2) the site had a minimum of 200 contributions to an identifiable section or
discussion about psychotropic drugs. The latter criterion was included because a
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preliminary search for consumer sites on the Internet revealed many sites with as few as
three contributions to a discussion, which would not have furthered the aims of this
research. Requiring a minimum of 200 contributions narrowed the consumer-constructed
sample to those most likely to enrich the analysis. This also introduced a selectivity bias
that favored larger websites. Larger website size may reflect greater fulfillment of the
needs of site users, greater resources or marketing ability to garner attention, or
something more random, such as being mentioned by a popular media outlet. Thus, small
websites with few contributors were excluded from selection in this study.
Description and limitations of search strategies.
This research used a combination of search engine and collector site searches, and
field immersion to sample websites that best represented the outlined typologies. Given
the range of website typologies under consideration, it was difficult to apply a standard
search and selection criteria for all 5 sites. Expert sites typically appear at the top of most
search engine results, but may be better selected for the purposes of this research
according to their “quality” rank by highly regarded collector sites. Consumer sites may
appear in the first few pages of search engine results (after the first few pages, search
returns become barely related to the search terms), but may be equally or more likely to
be retrieved on collector sites, as well as from time and experience within a field or
community. Table 3.1 lists the exemplar site selected for each typology in the proposed
research, and Appendix A provides visual snapshots of each website’s homepage and
Lexapro page.
A considerable difficulty with sampling websites on the Internet is the
unknowable population of websites to sample from (Weare & Lin, 2000). One popular
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strategy among researchers is to use search engines, such as Google and Yahoo.
Depending on the study aim, the researcher may randomly select from search returns,
choose all returned sites consecutively up to a certain number, or screen sites according
to certain inclusion/exclusion criteria. Search engine sampling is an arguably valid
strategy because it replicates what most Internet users may retrieve and view. However,
some major disadvantages to this method limited its usefulness for the present research.
First, as the Internet continues to grow, the proportion of sites indexed in the major
search engines decreases. It is unlikely that any combination of search engines would
retrieve even half of pertinent websites. Second, as mentioned in the review of literature,
search engine results for health information may be biased towards sites earning medical
seals of approval for content quality (Dahlberg, 2005; Fox, 2010). Consumer-constructed
health sites are typically not considered for such accolades and are, therefore, less likely
to be located in the top search engine returns. Currently, major search engines like
Google are specifically designing health search algorithms to return government health
and medical institution websites at the top of returns, while “everything else is pushed
down and out” (Fox, 2010, para. 6). Beyond open initiatives such as this, however, each
search engine has unreported rules for site indexing and search retrieval, making it
difficult to determine what is missing and why.
A second frequently used strategy is to base sampling on “collector sites” (Weare &
Lin, 2000). This method relies on an individual or organization with a specialized interest
to collect and list links to relevant websites. The major advantage of this technique is its
ability to locate obscure and special interest sites that are not retrieved by search engines,
possibly for some of the reasons cited in the previous paragraph. The disadvantage of this
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technique is the existence of unknown biases resulting from non-standardized collection
methods by the lists’ authors.
The present study used a combination of the above strategies for selecting the 5
websites. While every attempt was made to provide clear and transparent criteria for the
selection of websites, the specific selection process for each site was unique to its
grouping (expert or consumer) and typology (see discussion of selection below). It is
unknown whether this particular set of 5 websites would be replicated by other
researchers using a similar selection method. However, with the dynamic nature and
enormity of the Internet, it is unclear that any one sample would be duplicated even with
a more highly consistent or systematic approach.
Selection of expert-constructed website sample.
The “professional health” type of expert-constructed site was selected based on its
status as a highly-trafficked, long-established, and trusted source for the official account
on illness and treatment. It was retrieved from a list of the top 20 health information
websites compiled by HealthRatings.org, a joint project of Consumer Reports WebWatch
and the Health Information Institute. The project ranked health information sites
according to highest site traffic and then rated each of the 20 most popular sites according
to 10 quality indicators. These included disclosure of ownership information, advertising
and sponsorships, ease of use and accessibility, currency, privacy, coverage and content,
authors and interests, references and resources, editorial policies, and health information.
The site ranking highest in popularity and meeting all inclusion criteria was
WebMD.com. This site scored an overall rating of “very good” and a rating of
“excellent” for health information. Launched over 10 years ago, this site has a long-
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established reputation among professional health sites and has received numerous awards
and recognitions from media and health fields. The site content is developed by staff
writers and journalists with contributors from Medicinenet.com and reviewers from an
Independent Medical Review Board. Health content covers a wide range of illnesses and
conditions, treatments, strategies for healthy living, good nutrition, proper fitness, better
parenting, mental health, and even pet health.
The second type of expert-constructed sites, “consumer-centric,” represents a
newer strand of health website that have not yet been organized or ranked in this same
way. One of the first consumer-centric health site ventures was launched by an AOL cofounder in April 2007, though beta versions of the site were being tested well before the
official launch ("AOL co-founder to launch revolutionhealth.com," 2007). This site,
revolutionhealth.com, already has hundreds or thousands of registered users associated
with any one psychotropic drug. The 2007 eHealthcare Leadership Awards named this
site as “Best Overall Internet Health Site” for its excellence in providing strong health
content, interactive opportunities, and good web design and navigation ("2007 web
awards winners," 2008). Revolutionhealth.com exemplifies the current movement of
expert-constructed health sites towards consumer-centric and Web 2.0 principles. The site
boasts having “125 online tools aimed at helping individuals take control of their wellbeing” (“About revolution health,” para. 3). Health content is pulled from a network of
partners, including clinics, other health news sources, and health publishers. Similar to
WebMD, content on RevolutionHealth covers a wide range of illnesses, treatments, and
healthy living tips and tools. Of note, both expert-constructed websites allow space for
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user-generated content, including posting of consumer ratings and reviews (see Figures
A8 and A11).
Selection of consumer-constructed website sample.
Search engines, a collector site, and insight gained from field immersion were used to
find consumer-constructed websites pertaining to psychotropic drugs and to select a
sample that best represented a range of structures and functions. First, in February 2008
Google and Yahoo search engines were searched for one drug using the following
keywords and Boolean operators: “(consumer OR patient) (discussion OR rating OR
review OR support) Lexapro”. This search in Google returned 130,000 hits, and in Yahoo
returned 2,000,000 hits. The first 50 hits from each search engine were reviewed. Only 1
site, AskAPatient.com, returned in Google and no site returned in Yahoo met the
inclusion criteria of unrestricted viewing of content and a minimum of 200 consumer
contributions. AskAPatient.com was returned in Google twice, as the second and fortyfifth hit. Excluded returns from Google and Yahoo combined were: 27 links to expertconstructed health information that may have included a community forum component,
21 links to consumer-constructed websites that did not contain the minimum number of
contributions for the drugs under study, 16 links to online pharmacies, 7 links to
pharmaceutical company websites, 5 portal sites with advertisements, 5 government
websites, 5 broken links, and 12 links to miscellaneous sites including commercial
product sites, academic institutions, health insurance, and attorney solicitations.
AskAPatient.com well represents a consumer-constructed site with rigid structure
and a narrowly defined function. The site has a set number of pre-defined fields for drug
consumers to input comments, with the apparent function of sharing basic demographic
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information, “side effects” of medications, and a brief comment about a specific drug
(see Figure A2). Other than consumer ratings and reviews, content on this site is scarce
and includes only links to websites providing additional drug information and an opinion
poll on a topic of the week.
The second website was selected upon reviewing a collector site called
PsychCentral.com, a directory of online mental health resources created and maintained
by professionals in psychology. The site has been indexing online mental health support
groups for 16 years and currently receives over 650,000 visits per month. The 94 listings
indexed within the site’s page for “Resources” for “Medication,” and 74 listings indexed
within the subcategory “Support Groups” for “Mental Health” were searched. One
website, CrazyMeds.us, on the medication resources page, and two websites,
CrazyMeds.us and CrazyBoards.org, on the support groups for mental health page met
the inclusion criteria. Both well represented the intermediate position of loose structure
and fluidly defined function, though CrazyMeds.us was structured specifically around
medication issues rather than general mental health issues. CrazyMeds.us was also listed
as receiving a top rating on a scale from zero (“the worst”) to 10 (“the best”) based on
2,323 consumer votes. CrazyBoards.org received a top rating based on 416 consumer
votes. CrazyMeds.us was selected for the proposed analysis because its function was
more closely targeted to the purpose of this research and it appeared to receive higher site
traffic based on the number of votes. Discussions on the CrazyMeds.us forum are loosely
structured according to class and brand name of psychiatric drugs, with an apparent
function of allowing users to discuss sometimes complicated medication issues. The
creator of the website (a non-medically trained consumer) also writes a main information
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page for each drug that users are encouraged to visit prior to posting questions in the
forum. Users of the CrazyMeds forum generally have a more sophisticated understanding
of drug issues than might the typical consumer.
Excluded websites under the “medication resources” listings on PsychCentral.com
were: 60 listings that linked to consumer reviews of specific drugs on PsychCentral.com
(none of the 4 drugs under study had the minimum contributions on PsychCentral.com to
be included in the analysis), 22 expert-constructed websites presenting information on
specific adverse effects of drugs, 5 websites offering medication purchase assistance
programs, 3 websites that did not have a minimum 200 contributions for the drugs under
study, 2 forums for physician health programs, and 1 medical news site. Excluded
websites under the support groups for mental health listings were: 36 websites and
forums relating to general mental health issues and/or services not pertaining to the drugs
under study, 20 newsgroups or mailing lists, 9 closed or private forums requiring a
moderated membership, 4 websites that did not have a minimum 200 contributions for
the drugs under study, 2 websites moderated by medical professionals, and 1 broken link.
The site best representing the unstructured, multi-functioning typology was selected
based on the researcher’s immersion in online health sites, mental health communities,
and health blogs. TheIcarusProject.net is an online community of current and former
psychiatric patients that stands out from other mental health communities for its relatively
advanced website that includes multiple opportunities for online participation and
interaction. Content on the site is largely user/community-generated, including user
blogs, articles, art, as well as links to relevant news, publications, and volunteer
opportunities. Pertinent to this research, the site contains a discussion forum with an
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unstructured “psychiatric medications” thread in which users can post or discuss any
issue related to any psychotropic drug (see Figure A6). The function of the forum is not
pre-structured, rather the users of the forum construct its function by determining what
drugs and topics are discussed. This site meets all other inclusion criteria for consumerconstructed sites.
Data Collection
Selected psychotropic drugs.
Specific psychotropic drugs were used as the point of entry for all sites. If a site
was not structured according to specific drugs, then text pertaining to “psychotropic
drugs” served as the subject of analysis. Text regarding two psychotropic drugs from
different drug classes was analyzed for each group: 1) an antidepressant, escitalopram
(Lexapro), and 2) an antipsychotic, quetiapine (Seroquel), These drugs were chosen
because they each appeared on the top 10 drug products of 2006 based on number of
prescriptions or retail dollars. Escitalopram was approved by the FDA in 2002 and had
approximately 30 million prescriptions dispensed in 2006 in the United States ("Top 10
products by U.S. dispensed prescriptions," 2007). Quetiapine was approved by the FDA
in 1997 and was ranked as the ninth best-selling drug in 2006 with $3 billion in U.S.
retail sales ("Top 10 products by U.S. sales," 2007).
Units of analysis.
Existing online text pertaining to the drugs under study for each group served as the
source of data. The recording unit of analysis was individual web pages within each site’s
root domain that contained information about the drugs under study, or “psychotropic
drugs” more generally (for 1 website, see below). Each individual consumer review on
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WebMD, RevolutionHealth, and AskAPatient represented a single case for the analysis.
Similarly, each individual discussion forum poster on CrazyMeds and TheIcarusProject
represented a single case. For example, if AnonymousUser35 posted a total of 10
comments about Lexapro throughout several different discussion threads on CrazyMeds,
those comments were collected so that all comments by AnonymousUser35 would
represent only a single case. Expert drug information copied from expert-constructed
websites also counted as one case each, creating a sample size of 4 for expert-constructed
material (2 sites x 2 drugs = 4 cases).
Data collection procedures.
Relevant text was copied from each website and pasted into either a Microsoft
Word 2007 document or Microsoft Excel 2007 spreadsheet. All consumer reviews and
discussion posts available on each website through the end of February 2009 were
manually cut and pasted into the spreadsheet. In addition to consumer reviews and posts
on consumer-constructed sites, the two expert-constructed sites selected for this study
also allowed consumers to post individual drug reviews. Therefore, consumer
reviews/posts from all 5 websites were represented in this research.
In some cases, consumers posted additional information, including their gender,
age, and length of time taking the drug. When provided, these data were copied as
additional columns (variables) in the spreadsheet along with the date the comment was
posted and whether the consumer posted an email address or user name.
On expert-constructed sites, the relevant webpage for each drug was located using
the website’s internal search engine. All text pertaining to each drug, excluding
advertisements and sidebar hyperlinks, was copied and pasted into a Word document.
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Consumer reviews for Lexapro and Seroquel were copied and pasted into the Excel
spreadsheet.
All consumer reviews for the two drugs on AskAPatient and discussion threads on
CrazyMeds were copied and pasted into the spreadsheet. TheIcarusProject discussion
forum was loosely centered on “psychotropic medications,” rather than containing an
identifiable section specific to the drugs under study. Therefore, any discussion threads
related to Lexapro or Seroquel as well as general topics involving psychotropic
medications were copied and pasted into the spreadsheet. Once discussion threads from
CrazyMeds and TheIcarusProject were copied, each unique poster was identified. Then,
discussion posts were manually regrouped according to posters’ user names so that all
comments by a single user were grouped together as a single case.
To ensure proper use in the data analysis software program, all cases (consumer
reviews) had to be formatted identically in the spreadsheet. To accomplish this,
standardized columns were created and missing cells were filled in with “not given” for
text variables and “999” for numeric variables. The variables gender, age, and length of
time on the drug were transformed into categorical variables. Whether the user posted an
email or user ID was a nominal (yes/no) variable. If provided, the actual email address or
user ID was copied into the spreadsheet to assist with data cleaning, and was deleted prior
to data analysis. Multiple comments using the same email/user ID were searched for as
part of data cleaning and, when present, merged into a single comment to count as one
case. Finally, the data was purged of duplicate entries.

Sampling procedures.
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The data collection procedures resulted in a sampling frame of 7,418 consumer
reviews/cases (see Table 3.2) and 4 expert cases. Overall, there were more consumer
cases for Lexapro (62.5%) than Seroquel (31.9%), and more consumer cases came from
expert-constructed sites (62.3%) than consumer-constructed sites (37.7%). Sampling
from consumer cases occurred three times during this research, each by using the random
numbers generator tool in Microsoft Excel. First, 85 cases from the sampling frame were
randomly chosen for preliminary codebook development (see following section). Second,
a coding sample of 1,080 cases was randomly chosen from the sampling frame and,
finally, 216 cases from the coding sample were randomly selected for a coding agreement
analysis. All 4 expert cases were coded for the analysis.
The coding sample of 1,080 consumer cases (14.6% of the sampling frame) was
selected using a stratified simple random sample of 120 cases per drug per website (120
cases x 4 websites x 2 drugs, plus 120 cases x 1 website). Due to the larger percentage of
consumer cases found on expert-constructed sites, this sampling strategy had the effect of
oversampling cases from consumer-constructed sites and under-sampling those from
expert-constructed sites. This was deemed appropriate because the primary focus of this
research involved a comparison between expert- and consumer-constructed websites, and
an analysis of consumer reviews found on expert-constructed sites was not part of the
original research proposal. Table 3.3 shows the probability of selection for any single
case within each stratum.

Table 3.2
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Sampling Frame for Consumer Reviews (through February 2009)

Lexapro

Seroquel

AskAPatient

1,093

791

“Psychotropic
Drugs”
--

CrazyMeds

266

227

--

493 (6.6%)

TheIcarusProject

--

--

420

420 (5.7%)

WebMD

1,402

722

--

2,124 (28.6%)

RevolutionHealth

1,873

624

--

2,497 (33.7%)

Total (%)

4,634 (62.5%)

2,364 (31.9%)

420 (5.7%)

7,418

Total (%)
1,884 (25.4%)

Table 3.3
Probability of Selection in a Stratified Simple Random Sample of 120 Cases per Drug
per Website
Lexapro Seroquel “Psychotropic Drugs”
(n/N)

(n/N)

(n/N)

AskAPatient

11%

15.2%

--

CrazyMeds

45%

52.9%

--

TheIcarusProject

--

--

28.6%

WebMD

8.6%

16.6%

--

RevolutionHealth

6.4%

19.2%

--
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Software.
Data coding and analysis was performed using QDA Miner version 3.2 released by
Provalis Research in 2009. QDA Miner is a mixed methods data analysis software
package ideal for content analysis, grounded theory, and other textual analyses. Unlike
other qualitative data analysis programs, however, QDA Miner allows flexibility on the
level that a case is assigned. For the present research, this meant that each consumer
review could be imported from Microsoft Excel as a single case with a set of variables
attached to it (i.e., age, gender, etc.). Expert cases were imported into QDA Miner from
Microsoft Word. Appendix B provides 3 screenshots of coded cases in QDA Miner.
Data Analysis
Codebook development.
An initial codebook was developed by coding 85 randomly selected cases from the
sampling frame. This was a means to begin working with the data in preparation for the
full coding sample. The end product of this phase was not a final or fixed codebook, but
rather a substantial preliminary codebook that continued to evolve during subsequent
stages of the coding process. In keeping with the grounded theory approach, no checklist
or organizational frame was relied on to pre-structure the data. All codes were developed
based on the drug effects and themes that the researcher observed in the data. However,
the list of codes was eventually grouped in a logical way in a collaborative discussion
between the researcher and a second coder (see subsequent section) in order to ease the
coding process and facilitate a more organized analysis. Similar drug effects were
grouped into a category of effects, which was determined by logic (i.e., like goes with
like) as well as basic understanding of body systems (i.e., what belongs to
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musculoskeletal versus gastrointestinal systems). For example, the codes “weight gain,”
“weight loss,” “appetite increase,” and “appetite decrease” were grouped into a category
called “Weight and Appetite Effects.” Codes such as “constipation,” “diarrhea,”
“nausea,” and “urinary problems” were grouped into a category called “Gastrointestinal
and Urinary Effects.” Similarly, drug themes sharing a fundamental concept were also
grouped into a category. For example, each code reflecting a strategy used to counteract
medications’ side effects was grouped into a category called “Dealing with Side
Effects/Finding Optimum Effectiveness.” The product of preliminary codebook
development (i.e., the initial version of the codebook) can be found in Appendix C. The
most recent version of the codebook can be found in Appendix D. Finally, more detailed
descriptions of each code in the most recent codebook can be found in Appendix E.
Coding agreement analysis.
To increase reliability and credibility of findings, a coding agreement analysis
was conducted for two independent coders on 20% of the coding sample. The second
coder was professionally known to the lead investigator, but had not previously worked
within or studied issues related to mental health or psychopharmacology. The second
coder received a Masters degree in Applied Social Research in 2002 and, on this basis,
was judged qualified to understand and assist in coding. This coder was first briefed on
the purpose of the project and then trained in the use of the software by practice coding
the 85 cases from the initial development of the codebook using the preliminary
codebook developed by the lead investigator. An additional 20 cases from the sampling
frame were then randomly chosen for a practice coding agreement analysis using the
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preliminary codebook. Acceptable agreement was reached (Scott’s Pi = 0.77) on these 20
cases, and disagreements were resolved by discussion.
Once the training and practice coding for the second coder was completed, a 20%
coding agreement sample (216 cases) was randomly selected from the coding sample of
1,080 cases. Inter-coder agreement was calculated in QDA Miner for each category of
codes (i.e., weight gain, weight loss, appetite change were all in the category “Weight
and Appetite Effects”) on the level of code occurrence within a case using Scott’s pi.
Scott’s pi is a statistical measure for inter-rater agreement of nominal level variables that
takes into account chance agreements that occur from guessing (Krippendorff, 2004). It
was calculated as:

While there is no firmly established rule for interpreting inter-coder agreement indices,
0.70 is often an appropriate minimum level of agreement, particularly for more
conservative statistics such as Scott’s pi. A Scott’s pi index of at least 0.70 was prespecified in this project to indicate an acceptable level of inter-coder agreement.
However, this being a grounded theory approach to examining the data, it was
expected that the codebook would continue to evolve as additional cases were reviewed.
It was important that the coding agreement analysis reflected the evolving, rather than
static, nature of the codebook. For this reason, the agreement coding was completed in
two phases. Both coders coded the first 100 cases of the agreement sample and a Scott’s
Pi was calculated. The two coders together reviewed each disagreement and came to a
mutual decision about its resolution. After discussion of individual coding decisions, the
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coders discussed and agreed upon revisions to the codebook (i.e., collapsing or splitting
codes). Then, the same process was performed with the remaining 116 cases of the
agreement sample. No changes could be made to the codebook while coding agreement
was in process because both coders were required to use identical codebooks. The
remaining cases in the coding sample (n=864) were coded by the lead investigator.
Grounded theory coding.
Coding in grounded theory refers to “naming segments of data with a label that
simultaneously categorizes, summarizes, and accounts for each piece of data” (Charmaz,
2006, p. 43). Data was analyzed line-by-line for reported drug effects and
themes/concepts in an iterative process of initial and focused coding. These were not
distinct phases with a strict temporal sequence. The research began with initial coding but
moved back-and-forth between initial and focused coding as the research progressed. Invivo codes, as opposed to researcher-derived codes, were used as frequently as possible
when determining a code name. This meant that code names reflected as much as
possible the language and terms of the research subjects. For example, rather than create
a code called “drowsiness” or “somnolence,” which reflects the standard terminology in
drug literature, this study borrowed descriptive terms found in consumer comments, such
as “extreme sleepiness,” to serve as code names.
Initial coding stuck very close to the data and was intended to capture and
condense meanings. Reported drug effects for Lexapro or Seroquel were coded only on
the level of initial coding. Effects were coded literally and with as little interpretation as
possible by the researcher. For example, statements such as “I was always sleepy” or
“could’ve slept 23 hours a day” would have been coded as “excessive sleeping/tired”
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within the category “Sleep Effects.” The constant comparative method of comparing data
to data was used to ensure consistency in categorizing drug effects. For instance, effects
such as “foggy head,” “dopey” and “slowed thinking” were coded together, as were
effects such as “fatigued,” “tired,” and “lethargic.” Consistency and reliability were
enhanced, then, by continually comparing new instances of an effect or variations of an
effect to already coded effects.
Focused coding was intended to condense, synthesize, and explain larger
segments of data using the most frequent and/or significant codes from the initial coding
phase (Charmaz, 2006). Focused coding was more conceptual and served to develop the
properties and dimensions of themes/concepts (Corbin & Strauss, 2008). As part of this
process, the constant comparative method was again used to compare data to data, data to
codes, and codes to other codes. As additional data were coded, the description and range
of each theme became more defined. Themes that began to overlap were merged
together, whereas as a single theme with considerable range or variation may have been
divided. For example, originally separate themes of “riding out the storm” and “waiting”
were later merged into one theme because the central concept of “time” was present and
overlapping in both.
Memo-writing, a conventional grounded theory technique, served as an additional
window into the processes of coding. Memos are simply notes begun at the initial coding
phase and intended to provide the researcher a means to track coding decisions and
evolving ideas about data, codes, and concepts. They also serve as a methodological log
for maintaining transparency and reflexivity in the research process (Corbin & Strauss,
2008). In this research, memos were used at various times to 1) define and describe codes
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or themes, 2) make comparisons between data and data, data and codes, codes and codes,
3) bring raw data into the memo, 4) explain coding decisions, and 5) identify gaps in the
analysis (Charmaz, 2006). For example, one gap in the analysis related to how best to
describe consumers’ categorization of drug effects. Memos attached to specific cases
documented the tentativeness of codes such as “less severe,” “severe,” “best effect,” or
“worst effect.” Other memos described the range and dimension of a theme. The code
“my doctor was wrong” originally reflected consumer comments about being
misinformed by their doctor, but as additional data were coded, broadened to include
consumer comments about feeling uninformed after visiting their doctor, or of having a
disagreement with their doctor. Memos were used to make note of these developments
and refinements. All memos written during the coding process, along with the date, case
number, and code are provided in Appendix F.
Statistical analysis.
Sample characteristics, reported drug effects, and themes were summarized in
frequency tables. For some comparisons, such as of gender, age, and length of time on
the drug across each website, empty cells prevented a statistical analysis. When cell
frequencies were appropriately robust, chi-square was used in QDA Miner to test the null
hypothesis that the categorical variables were independent. When possible, categories
were collapsed to increase cell frequencies to 5 or higher, such as for age and length of
time taking the drug. Comparisons using the chi-square test were made for: 1) gender,
age, and time taken by drug, 2) commonly reported effects by website on which the
comment was posted, 3) commonly reported effects by website classification as expertor consumer-constructed, 4) categories of drug effects by variables of gender, age, and
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time taken, 5) themes by website classification, 6) commonly reported effects and effect
categories by time period the comment was posted, and 7) drug effect categories and
themes by anonymity of the user.
For numbers 3 and 5 above, chi-square was used to test the null hypothesis that
there was no association between a reported drug effect or theme and the website the
effect or theme originated from. For these analyses, websites were grouped according to
their status as expert-constructed (RevolutionHealth and WebMD) or consumerconstructed (AskaPatient, CrazyMeds, and IcarusProject) in order to minimize empty
cells and small cell frequencies.
All significance tests were two-tailed with p-values set at <0.05, unless otherwise
stated. In some instances and as stated in the findings, a correction was made for multiple
comparisons by dividing the alpha level of 0.05 by k number of comparisons.
Usability of consumer sites according to “typical” web use.
An important and practical aspect of this research related to the “usability” of consumer
sites for the typical Internet user. It is difficult to duplicate or estimate a “typical” web
search for any given topic because of the near infinite possible pathways to navigate the
Internet. One survey reported that 41% of respondents visited 2 or 3 websites when
seeking health information online, and another 20% visited 4 or 5 websites (Fox, 2006).
Consumer-generated media, such as discussion forums and message boards, have become
increasingly important as 34% of online health seekers reported using these resources to
gather information that weighed in on their health-related decision (Elkin, 2008). It is
also reasonable to assume that a “typical” online health seeker would review only a
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handful of consumers’ posts on consumer review or discussion sites, rather than sifting
through the full set of reviews as done in the present research.
As an attempt to preliminarily speak to the usability of consumer sites for
consumers and professionals needing to make health-related decisions, the most recent 20
consumer posts from each website were extracted to examine how well they represented
the full dataset of consumer reviews/posts. This analysis was limited to the 4 websites
that reported drug effects: AskaPatient, CrazyMeds, RevolutionHealth, and WebMD
(n=960). For Crazymeds, the 20 users with the most recent posts were extracted for each
drug. It was reasoned that if these 80 recent posts reported drug effects in a similar
proportion to the full dataset (and depending on how the full dataset compared to expert
text), then consumer reviews may be preliminarily accepted in terms of their
representativeness as an additional source of information during “typical” web use. If
there were significant differences in proportions of reported effects between recent posts
and the full dataset, then consumers and professionals may be “harmed” by accessing
incomplete information from consumer reviews during a “typical” web search. Either
conclusion is preliminary as additional strategies are needed to fully understand and
examine the usability issues of online consumer reviews.
Preliminary data checking.
In May 2008 as a preliminary exploration prior to data collection, nine Web 2.0
researchers, bloggers, and webmasters were contacted with inquiries as to the state-ofthe-art for identifying or preventing unauthentic accounts on sites for consumer reviews
or discussion. Five responses were received.
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Computer science graduate student and developer of the Wikiscanner software,
Virgil Griffith, suggested auditing Wikipedia edits of pharmaceutical companies as a way
to gauge their presence in one of the most popular user-generated communities on the
Internet. Wikiscanner is a free online tool used to search anonymous user edits from
Wikipedia’s log of IP addresses. Between February 2002 and August 2007, there were
over 34.5 million anonymous edits to Wikipedia entries, making up about 21% of all
Wikipedia edits during that period (Griffith, n.d.). Griffith purchased a database of over
2.6 million Internet Protocol (IP) addresses owned by organizations and found that
187,529 different organizations (7% of the database) contributed at least 1 anonymous
Wikipedia edit. Dozens of high profile edits were immediately publicized, such as from
the Federal Bureau of Investigations (FBI), Central Intelligence Agency (CIA), Walmart,
Exxon, Diebold, and several others (Hafner, 2007). Also publicized and of relevance to
this research topic, a person with access to the pharmaceutical company AstraZeneca’s
network deleted a sentence about the risk of suicidal thinking and behavior associated
with the drug Seroquel (quetiapine). By 2005 Wikipedia was a top 50 website, making it
likely that pharmaceutical companies may have had an interest in shaping relevant
content on the site. Prior to the launch of Wikiscanner, it was also assumed that
anonymous edits would remain “anonymous” in the traditional sense of “unidentified.”
Thus, a review of edits from pharmaceutical company networks provided a unique
opportunity to gauge the activity of these organizations in popular user-generated media.
As another preliminary exploration prior to data collection, Wikiscanner was used
to search Astra-Zeneca, Eli Lilly, and GlaxoSmithKline for Wikipedia edits.
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Any edited entries related generally or specifically to medications or pharmaceutical
companies were identified and copied into a Microsoft Word document.
Data checking of the research sample.
Consumer reviews from the present research sample were checked in an attempt
to uncover possible bias that may have resulted from unauthentic consumer accounts. The
first strategy addressed the hypothesis that pharmaceutical representatives may not be
interested in a consumer website until it had gained some popularity among users. If a
bias existed, it may appear in more recent comments. A check of the data compared early
and recent comments for an imbalance of overly favorable comments in recent entries.
Consumer reviews and discussion posts were divided into an early period (2002-2005)
and a recent period (2006-2009) and compared across drug effect categories. The analysis
of the 20 most recent posts from each website (above section) was also used to contribute
to this portion of data checking.
The second strategy addressed the hypothesis that pharmaceutical representatives
may prefer to contribute comments anonymously, if that option was given. A check of the
data compared drug effects reported by anonymous users to user-registered/identifiable
comments for an imbalance of positive reported effects in the anonymous group.
CrazyMeds was excluded from this check because all users on the discussion forum had
an identifiable user name. A chi-square test was used to test for an association between
anonymity of the user and reported drug effects. The analysis proceeded with all data
included regardless of possible bias found using these strategies. It was pre-specified that
a finding of bias was to be used to add nuance to conclusions relating to the analytic
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situation – that of expertise in the age of the Internet. Such a bias was anticipated to be an
important dynamic playing into those already identified in Figure 2.1.
A final check was to look for what appeared to be “scripted” comments taken
from the drug manufacturer’s website or downloadable medication guide. QDA Miner
software was used to search the sampling frame (7,418 cases) for 14 common phrases
found on the manufacturer’s drug website and medication guide for each of the two drugs
being examined. The search was broadened to key words, such as “maintain* treatment,”
after a search of full sentences and phrases returned no results. For example, the above
key words were pulled from the following sentence on Lexapro.com, “In patients who
have already responded to treatment with Lexapro for their depression, maintaining
treatment with Lexapro was shown to prevent the depression from returning.” Retrieved
entries from the 14 key words/phrases were individually scrutinized. This strategy
stemmed from the comment of one consumer discussion forum owner cited previously:
“They'll (pharmaceutical representatives) defend their meds if something hasn't been
100% proven, using studies that were funded by their companies or just pulling stuff out
of the PI sheets. Sometimes it's as if they copied a paragraph or two from the company's
website and pasted it into a post.” In instances where a comment duplicated or nearly
duplicated information found on the manufacturer’s website or patient information sheet,
the comment was excluded from analysis. Comments that appeared similar to, but did not
duplicate these sources were included in the analysis. A count of the frequency of such
instances was kept and used to again nuance the final conclusions.
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Chapter 4: Findings
Sample Characteristics
The coding sample consisted of 1,080 consumer reviews and discussion posts from 5
websites, and 4 expert cases from 2 websites. Most consumers on AskaPatient and
WebMD reported their gender, age, and length of time on the drug (Tables 4.1, 4.3, and
4.5). The majority of consumers on the remaining 3 websites did not report gender or age,
and at least half did not report length of time on the drug.
Gender.
On average and considering that 42.7% of the sample did not report gender, most
consumers reported themselves as female (41.4%). The remaining 15.9% reported
themselves as male. A chi-square test of gender by drug taken (Table 4.2) showed no
association between these two variables (chi-square=1.426, df=2, p=0.49).
Age.
Similarly, 53.5% of consumers across websites did not report their age.
Approximately 33% of consumers reported an age between 25 and 54 years old, with a
slight majority (13.4%) of those consumers reporting to be in the younger 25-34 bracket.
Another 8.5% of consumers reported an age less than 24 years, and just less than 5%
reported an age over 55 years. A chi-square test of age by drug taken (Table 4.4) did
show an association between the two variables (chi-square=14.355, df=6, p=0.026).
Consumers in the younger age groups of 7-18 and 25-34 reported slightly higher use of
Seroquel, whereas a higher percentage of consumers aged 19-24 and 35-44 were taking
Lexapro.
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Length of time on drug.
Approximately 35% of the sample did not report the length of time taking
Lexapro or Seroquel, but 37% reported taking the drug for less than 6 months (Table 4.5).
Another 18% reported taking the drug between 1 and 5 years, and less than 2.5% reported
taking it for more than 5 years. A chi-square test (Table 4.6) of this variable by drug
taken did show an association (chi-square=20.423, df=6, p=0.002). Consumers taking the
drug for less than 6 months were more often using Lexapro, while consumers taking the
drug for 2 years or more were more often using Seroquel.
Year posted.
Consumer reviews were posted as early as 2002 on RevolutionHealth, 2003 on
AskaPatient, CrazyMeds, and IcarusProject, and 2007 on WebMD (Table 4.7). More than
68% of consumer reviews were posted from 2006-2008. Approximately 24% of reviews
were posted in or before 2005, and nearly two-thirds of those came from
RevolutionHealth. Table 4.8 shows there were also more reviews for Lexapro than
Seroquel in 2002-2003 (Lexapro received FDA approval in 2002), and more reviews for
Seroquel in 2004-2005 (Seroquel received FDA approval for a second indication in
2004).
User ID/email.
More than half (55.7%) of consumers did provide a user ID or email address with
their review or post (Table 4.9), however, this number reflected the fact that all users on
CrazyMeds and IcarusProject have a unique user ID for posting and for receiving private
messages from other users. Table 4.10 shows a slightly higher proportion of consumers
using Seroquel provided a user ID or email address.
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Table 4.1
Number of Consumers Reporting Gender across All Websites
Askapatient CrazyMeds IcarusProject

RevHealth

WebMD

Total
(%)

(N=240)

(N=240)

(N=120)

(N=240)

(N=240)

Female

158

64

25

22

179

448
(41.4%)

Male

81

27

4

10

50

172
(15.9%)

Not
Given

1 (0.4%)

149
(62.1%)

91 (75.8%)

208
(86.7%)

11
(4.6%)

462
(42.7%)

Table 4.2
Number of Consumers Reporting Gender According to Drug Takena
Lexapro (%)

Seroquel (%)

(N=480)

(N=480)

Female

216 (45.0%)

207 (43.1%)

Male

77 (16.0%)

91 (19.0%)

Not Given

187 (39.0%)

182 (37.9%)

a

Chi-square=1.426, df=2, p=0.49
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Table 4.3
Number of Consumers Reporting Age across All Websites
Age

Askapatient CrazyMeds IcarusProject RevHealth WebMD
(N=240)

(N=240)

7-12

2

1

13-18

13

2

1

19-24

41

1

2

25-34

75

2

5

35-44

52

6

45-54

41

4

55-64

11

1

65-74

1

1

75+

1

not
given

3 (1.3%)

224
(92.6%)

(N=120)

2

110 (91.7%)

89

Total (%)

(N=240)

(N=240)

1

1

5 (0.5%)

1

4

21 (1.9%)

22

66 (6.1%)

3

60

145
(13.4%)

2

50

110
(10.2%)

4

53

104
(9.6%)

1

32

45 (4.2%)

3

5 (0.5%)

1

2 (0.2%)

14
(5.8%)

579
(53.5%)

228 (95%)

Table 4.4
Number of Consumers Reporting Age According to Drug Takena
Age

Lexapro (%)

Seroquel (%)

(N=480)

(N=480)

7-18 b

7 (1.5%)

18 (3.8%)

19-24

38 (7.9%)

26 (5.4%)

25-34

64 (13.3%)

76 (15.8%)

35-44

67 (14.0%)

43 (9.0%)

45-54

46 (10.0%)

56 (11.7%)

55+ b

26 (4.4%)

26 (5.0%)

232 (48.3%)

235 (49.0%)

not given
a

Chi-square=14.355, df=6, p=0.026
Categories were collapsed for this analysis.

b
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Table 4.5
Number of Consumers Reporting Length of Time on the Drug across All Websites
Time
Taken

Askapatient

CrazyMeds

IcarusProject

RevHealth

WebMD

(N=240)

(N=240)

(N=120)

(N=240)

(N=240)

<1 mth

67

23

3

43

51

187
(17.3%)

1-6
mths

72

38

2

42

59

213
(19.7%)

6 mths 1 yr

29

16

1

11

28

85
(7.9%)

1-2 yrs

29

21

6

27

83
(7.7%)

2-5 yrs

34

20

8

46

110
(10.2%)

5-10 yrs

7

4

2

11

24
(2.2%)

10 yrs+

1

1

2 (0.2%)

17
(7.1%)

378
(34.9%)

not
given

1
(0.4%)

120
(49.6%)

2

112
(93.3%)

91

128
(53.3%)

Total
(%)

Table 4.6
Number of Consumers Reporting Length of Time on the Drug according to Drug Takena
Lexapro (%)

Seroquel (%)

(N=480)

(N=480)

<1 mth

106 (22.1%)

78 (16.2%)

1-6 mths

122 (25.4%)

89 (18.5%)

6 mths - 1 yr

42 (8.6%)

42 (8.6%)

1-2 yrs

43 (9.0%)

40 (8.3%)

2-5 yrs

46 (9.6%)

62 (12.9%)

5 yrs+ b

9 (1.9%)

17 (3.5%)

112 (23.3%)

152 (31.7%)

Time Taken

not given
a

Chi-square=20.423, df=6, p=0.002
The categories 5-10yrs and 10yrs+ were collapsed for this analysis.

b
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Table 4.7
Number of Consumer Posts According to Year Posted across all Websites
Year Askapatient CrazyMeds IcarusProject RevHealth WebMD
Posted
(N=240)
(N=240)
(N=120)
(N=240) (N=240)
2002

Total
(%)

19

19 (1.8%)

2003

2

1

7

36

46 (4.3%)

2004

15

1

23

48

87 (8.0%)

2005

26

23

57

106
(9.8%)

2006

47

26

68

141
(13.0%)

2007

81

88

26

6

52

253
(23.4%)

2008

52

127

15

3

148

347
(32.1%)

2009a

17

25

3

40

85 (7.9%)

a

Data in this row represents January and February 2009.
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Table 4.8
Number of Consumer Posts for Each Drug According to Year Posted
Year Posted Lexapro (%) Seroquel (%)
(N=480)

(N=480)

2002

17 (3.5%)

2 (0.4%)

2003

25 (5.2%)

13 (2.7%)

2004

22 (4.6%)

41 (8.5%)

2005

31 (6.5%)

52 (10.8%)

2006

57 (11.9%)

58 (12.1%)

2007 117 (24.4%)

110 (22.9%)

2008 163 (34.0%)

167 (34.8%)

2009a

48 (10.0%)

37 (7.7%)

a

Data in this row represents January and February 2009.

Table 4.9
Number of Consumers Who Provided a User ID or Email Address across All Websites
Askapatient CrazyMeds IcarusProject RevHealth WebMD

Total
(%)

(N=240)

(N=240)

(N=120)

(N=240)

(N=240)

(YES)
ID/email
was given

60

240

120

33

150

603
(55.7%)

(No) ID/
email was
not given

180

207

90

477
(44.1%)

94

Table 4.10
Number of Consumers Who Provided a User ID or Email Address According to Drug
Taken
Lexapro (%) Seroquel (%)
(N=480)

(N=480)

(YES) ID/email was given 226 (47.1%)

257 (53.5%)

(No) ID/email was not given 254 (52.9%)

223 (46.5%)

Inter-Coder Agreement Analysis
Two coders coded a random sample of 216 cases in two phases (n=100 in phase 1,
n=116 in phase 2). Table 4.11 shows the results of the inter-coder agreement analysis.
Acceptable overall agreement was found in both phases (Scott’s Pi=0.756 in phase 1,
Scott’s Pi=0.751 in phase 2). In general, agreement was higher for drug effects than for
themes and concepts. After each phase of agreement analysis, the two coders discussed
and resolved disagreements (see Appendix G). Many of the coding disagreements were
traced to a lack of clarity or understanding by the second coder. For example, upon
reviewing the codes of both coders, it became clear that the second coder was unsure
when to appropriately apply codes within the category “Evidence of Causality” because
of a misunderstanding about the purpose of those codes. The second coder also had
difficulty applying codes for “Discontinuing/Missed Doses” due to a lack of knowledge
of what “discontinuing” meant. In other cases, such as for “Other Drug Issues” and
“Support and Advice,” the second coder applied these codes more liberally than the
principal investigator, despite the provided descriptions of the concepts each of these
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codes encompassed. Finally on a few occasions, such as for “Other Effects” of the drugs,
and as part of the process of grounded theory coding, the principal investigator began
applying codes to text segments that broadened the scope of the code. For example, the
code “no/limited side effects” which falls under the “Other Effects” category, was
initially defined to only include comments that clearly stated there were no side effects of
the drug. During coding, however, the principal investigator observed many comments
that seemed to define drug effects according to the absence (rather than the presence) of a
specific effect (i.e., “I’ve experienced no weight gain on this drug”). These comments
were coded by the principal investigator as “no/limited side effects,” and often left
uncoded by the second coder.
The remaining coding and analysis proceeded as planned because the overall intercoder agreement statistic was above the minimally acceptable level of 0.70, and because
most coding disagreements were related to 1) a lack of clarity or understanding of
terminology and/or code definitions by the second coder, and 2) the evolving nature of
the grounded theory coding method in which codes continued to expand and collapse
throughout the process. The coders agreed that there did not appear to be unfounded leaps
from data to codes. Revisions to the codebook to clarify codes and ease the coding
process were made after each phase of the agreement analysis based upon the two coders’
discussions.
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Table 4.11
Inter-coder Agreement Analysis
Scott’s Pi, part
1

Scott’s Pi, part
2

(N=100)

(N=116)

1

0.82

Gatrointestinal and Urinary Effects

0.851

1

Head/Face Effects

0.889

0.683

1

0.884

Mental or Mood Effects

0.889

0.809

Musculoskeletal and Neurological Effects

0.826

0.811

Nose/Throat/Chest Effects

0.591

0.81

Other Effects

0.632

0.361

Sexual Effects

0.852

1

Skin Effects

0.949

0.653

Sleep Effects

0.928

0.913

0.476

0.628

1

0.633

Classification of Effects

0.202

0.644

Contraindications

-0.005

0.791

Dealing with Side Effects/Finding Optimum
Effectiveness

0.668

0.723

Drug Effects
Appetite and Weight Effects

Lab Tests and Chronic Conditions

Themes/Concepts
Assessing the Overall Experience
Citations and Links
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Scott’s Pi, part
1

Scott’s Pi, part
2

(N=100)

(N=116)

1

0.598

Evidence of Causality

0.333

0.504

Finances / The System

0.918

0.948

Friends and Family

0.556

0.646

My Diagnosis/Reason for Use

0.74

0.69

My Doctor

0.645

0.741

Other Drug Issues

0.904

0.563

Other Drugs and Drug Combinations

0.485

0.822

Pharmaceutical Companies/FDA

0.398

0.597

Support and Advice

0.936

0.56

Theories of Drug Action

0.668

0.741

TOTAL

0.756

0.751

Discontinuing/Missed Doses

Drug Effects According to Consumers
Overview of drug effect categories.
The most recent codebook in Appendix D shows 11 categories of drug effects. Effects
were grouped broadly in order to facilitate robust analyses. The categories that resulted
were not based on a standardized medical dictionary, and the meaning of the specific
groupings should not be exaggerated in the final conclusions. In most cases where
categories were used for analysis, individual effects were further examined to determine
where differences lay.
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Appetite and weight effects were grouped in their own category, paralleling what
might be called metabolic effects in a standardized dictionary. These effects appeared
frequently enough in the data to warrant their own category, rather than be grouped with,
for example, gastrointestinal effects. Similarly, sexual effects, which could have
alternatively been grouped under genito-urinary effects, and sleep effects recurred
frequently enough to merit autonomous categories. At the same time, there were few
instances of other genito-urinary effects (i.e., involving urination and menstruation), so
these were combined with gastrointestinal effects (i.e., nausea/vomiting, constipation,
etc.) to create a single category called gastrointestinal and urinary effects.
Head/face effects involved physical effects of those body parts, such as headache and
jaw clenching. Codes under nose/throat/chest effects and skin effects were similarly
grouped. Again, these were grouped broadly, rather than broken down into smaller
categories of respiratory effects, sensory effects, and so on. Mental or mood effects
included all non-physical, psychological and behavioral drug effects.
Musculoskeletal and neurological effects were grouped into 1 category because of slight
overlap in these effects, such as for tingling sensations and numbness which could be
reasonably classified under either body system. Also, there were too few effects within
either category alone to stand on its own.
The category “lab tests and chronic conditions,” referred to effects that show up only on
laboratory tests, such as high blood sugar or cholesterol, and that may cause chronic
disease conditions, such as diabetes. These were grouped together, rather than distributed
across various body systems, because previous research in this area found that consumers
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online less frequently mentioned these types of effects specifically as compared to
information provided in expert sources.
Finally, “other effects” included codes that were infrequently mentioned and could not
be otherwise classified.
Lexapro.
Table 4.12 shows the percentage of consumers mentioning an effect grouped by the
category of effects. For example, the category “sexual effects” included codes for lost sex
drive, trouble with orgasm, and other sexual effects.. “Mental or mood effects” was the
most commonly reported category of effects with almost 62% of consumers mentioning
them.
Table 4.13 lists all effects of Lexapro mentioned by at least 3% of consumers. The
top 4 most mentioned effects were related to symptoms and sleep. Approximately 30% of
consumers reported improvement in symptoms, such as anxiety, depression, or mania, as
an effect of Lexapro. Another 15.8% reported new or worsening symptoms as an effect of
Lexapro, including new or worsened panic attacks, depression, or mania. Sleep changes
ranging from excessive sleepiness to insomnia were mentioned by about 24% and 13% of
consumers, respectively. All other effects mentioned could be considered “side effects.”
Figure 4.1 and Table 4.14 show the 9 most reported effects for Lexapro across 4
websites, measured by code occurrence in a case (posts from IcarusProject were not
included in analyses of drug effects). Figure 4.1 visually displays the lack of consistency
of consumer reporting across these websites. With p-values set at 0.001 for multiple
comparisons, statistically significant chi-square coefficients were reached for half of
these effects, indicating that there was an association between symptom improvement,
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extreme sleepiness, nausea/vomiting, and lost sex drive, and the website the post
originated. Compared to the other 3 websites, WebMD showed a relatively low number
of consumers mentioning what are usually considered “side effects” of the drug,
including sleep changes, new or worsened symptoms, brain fog/zombie, weight gain, and
nausea/vomiting. Across all 9 top reported effects, consumers on AskaPatient reported
these effects in high numbers, whereas consumers on CrazyMeds reported a
comparatively low number of drug effects. RevolutionHealth had the highest percentage
of consumers mentioning symptom improvement compared to the other 3 websites, and
the lowest percentage of consumers mentioning weight gain. For the remaining listed
effects, consumers on RevolutionHealth provided varied reports.
In Table 4.15, Lexapro effects mentioned by at least 3% of consumers are compared
across consumer-constructed websites (AskaPatient and CrazyMeds) and expertconstructed websites (RevolutionHealth and WebMD). Only 1 of the 28 effects listed
reached statistically significant p-values at the 0.001 level (dreams vivid/nightmares),
indicating that for a majority of effects there was no association between the effect and
the classification of the website as consumer- or expert-constructed. More consumers
posting on expert-constructed websites reported Lexapro improved their symptoms
(p=.037), while more consumers on consumer-constructed websites reported the drug
worsened or induced new symptoms (p=.034). All effects that would be popularly labeled
as side effects or adverse effects were each mentioned more by consumers on consumerconstructed rather than expert-constructed websites, with the exception of loss of
appetite.
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Table 4.12
Top 5 Effect Categories Mentioned by Consumers for Lexapro
Category of effects

% of consumers mentioning the effect

Mental or mood effects

61.7%

Sleep effects

36.0%

Appetite and weight effects

22.5%

Sexual effects

20.2%

Gastrointestinal and urinary effects

16.7%

Table 4.13
Effects of Lexapro Mentioned by at Least 3% of Consumers
Drug effect

% of consumers mentioning the effect
(N=480)

Symptoms reduced / improved

30.4%

Extreme sleepiness / tired

23.8%

Symptoms new / worsened

15.8%

Trouble sleeping / insomnia

13.3%

Emotionally stable / calm / "normal"

13.1%

Weight gain

13.1%

Nausea / sick stomach / vomiting

12.1%

Numb / detached / lack of energy or
interest

11.3%

Brain fog / zombie

10.8%

Lost sex drive/low libido

10.6%
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Drug effect

% of consumers mentioning the effect
(N=480)

Trouble achieving orgasm

8.5%

Headache increased

7.1%

Jaw clenching / grinding

6.9%

Energy increased / euphoria / mania

6.9%

“Sweating like a pig”

6.5%

Dreams vivid / nightmares

6.3%

Abnormal movements

5.6%

Agitated / restless

5.4%

Loss of appetite

4.8%

Weight loss

4.8%

Other misc effects

4.6%

Dizzy / lightheaded / faint

4.6%

Diarrhea / gas

4.6%

Dry mouth / sore throat

4.4%

Increase appetite / cravings

4.2%

Ability to do things in absence of
symptoms

4.0%

Yawning

3.1%

Other sexual effects

3.1%
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Figure 4.1 Most Popularly Mentioned Lexapro Effects by Consumers across Websites
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40%

45%

Table 4.14
Number of Consumers on each Website Mentioning the Most Popularly Reported Effects
of Lexaproa
AskaPatient CrazyMeds RevHealth WebMD

Chisquare

pvalue

N=120

N=120

N=120

N=120

Symptoms
improved

45

18

50

33

24.543

0.000

Extreme
sleepiness/tired

41

22

35

16

18.735

0.000

Symptoms new/
worsened

31

15

19

11

14.396

0.002

Brain fog/zombie

27

8

13

4

--

--

Trouble sleeping
/insomnia

26

7

19

12

15.236

0.002

Weight gain

26

16

9

12

12.301

0.006

Nausea/sick
stomach/ vomiting

22

6

24

6

23.123

0.000

Lost sex
drive/libido

24

5

10

12

17.497

0.001

Emotionally
stable/calm/
"normal"

23

6

18

16

11.467

0.009

a

p-value set at 0.001 for k=35 comparisons in Tables 4.14 and 4.15
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Table 4.15
Lexapro Effects Mentioned by >3% of Consumers according to Website Classificationa
Drug effect

Consumerconstructed
(N=220)

Expertconstructed
(N=220)

Chi-square

p-value

Symptoms reduced /
improved

62

83

4.358

0.037

Extreme sleepiness /
tired

62

51

1.400

0.237

Symptoms new /
worsened

47

30

4.470

0.034

Trouble sleeping /
insomnia

32

31

0.018

0.892

Emotionally stable /
calm / "normal"

29

34

0.457

0.499

Weight gain

41

21

7.409

0.006

Nausea / sick
stomach / vomiting

27

30

0.179

0.672

Numb / detached /
lack of energy or
interest

31

22

1.718

0.19

Brain fog / zombie

34

17

6.340

0.012

Lost sex drive/low
libido

28

22

0.804

0.37

Trouble achieving
orgasm

24

16

1.745

0.186

Headache increased

20

13

1.594

0.207

Jaw clenching /
grinding

23

9

6.653

0.01
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Consumerconstructed
(N=220)

Expertconstructed
(N=220)

Chi-square

p-value

Energy increased /
euphoria / mania

17

15

0.134

0.714

“Sweating like a pig”

19

11

2.276

0.131

Dreams vivid /
nightmares

25

5

14.222

0.000

10

1.923

0.166

Drug effect

Abnormal
movements

17

Agitated / restless

19

7

5.856

0.016

Loss of appetite

9

14

1.142

0.285

Weight loss

13

10

0.411

0.521

Other misc effects

12

9

0.448

0.503

Dizzy / lightheaded /
faint

12

10

0.191

0.662

Diarrhea / gas

14

8

1.715

0.19

10

0.000

1.00

Dry mouth / sore
throat

10

Increase appetite /
cravings

12

8

0.835

0.361

Ability to do things
in absence of
symptoms

6

13

2.685

0.101

Yawning

12

3

--

--

Other sexual effects

8

6

0.294

0.587

a

p-value set at 0.001 for k=35 comparisons in Tables 4.14 and 4.15
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Seroquel.
Table 4.16 shows the percentage of consumers mentioning an effect of Seroquel
grouped by the category of effect (also see Appendix D). Sleep effects were mentioned
by over 60% of consumers, followed by nearly 52% of consumers mentioning mental or
mood effects.
Table 4.17 lists all effects of Seroquel mentioned by at least 3% of consumers.
The top 2 effects were related to sleep, including the drug helps sleep or causes too much
sleep and tiredness. About a quarter of consumers mentioned an improvement in
symptoms, such as anxiety, mania, or hallucinations, and about 10% mentioned these
same symptoms newly appearing or worsening. Weight gain was mentioned by 22.5% of
consumers, and increased appetite and cravings (especially sugar and carbohydrate
cravings) were mentioned by 12.7% of consumers.
Figure 4.2 and Table 4.18 show the most commonly reported effects for Seroquel
across 4 websites. The bar chart in Figure 4.2 illustrates greater homogeneity in reported
effects across websites as compared to the same chart in Figure 4.1 for Lexapro. With pvalues set at 0.002 for multiple comparisons involving the originating websites,
statistically significant chi-square coefficients were reached for 2 of the 8 effects listed:
extreme sleepiness and weight gain. Consumers on AskaPatient mentioned these effects
at a considerably higher rate than the other 3 websites. Consumers on RevolutionHealth
mentioned symptom improvement more often than consumers on other websites, and
mentioned new or worsening symptoms the least often. WebMD also had fewer reports
of new or worsening symptoms compared to the 2 consumer-constructed websites, and
had the least mentions of all websites of abnormal movements.
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In Table 4.19, effects listed by at least 3% of consumers are compared across
consumer- and expert-constructed websites. One of the 18 effects listed showed
significant values at the p<0.002 level, indicating that there was an association between
new/worsened symptoms and the classification of the website on which it was reported.
Significantly more consumers on consumer-constructed websites reported Seroquel
worsened or induced new symptoms (p =.000), while more consumers on expertconstructed sites reported it improved their symptoms (p=.008). Similarly, a higher
percentage of consumers posting on consumer-constructed sites reported the drug made
them excessively sleepy and tired (p=.009), while those on expert-constructed websites
reported that it helps with sleep (p=.105).
In sum, effects on mental or mood symptoms and effects on sleep were reported
by consumers for both drugs more often than any other types of effects. In general,
reporting across websites was more heterogeneous for Lexapro than for Seroquel.
Consumers across each website and for both drugs reported improvements in mental or
mood symptoms at a higher rate than worsened or induced symptoms. However, the trend
for both drugs was that consumers on expert-constructed sites reported higher rates of
symptom improvement (and helpful sleep on Seroquel), but generally lower rates of side
effects.
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Table 4.16
Top 5 Effect Categories Mentioned by Consumers for Seroquel
Category of effects

% of consumers mentioning the effect

Sleep effects

60.6%

Mental or mood effects

52.9%

Appetite and weight effects

30.8%

Musculoskeletal and neurological effects

18.1%

Other effects

16.0%
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Table 4.17
Effects of Seroquel Mentioned by at Least 3% of Consumers
Drug effect

% of consumers mentioning the effect
(N=480)

Helps me sleep

35.6%

Extreme sleepiness / tired

33.1%

Symptoms reduced / improved

24.8%

Weight gain

22.5%

Brain fog / zombie

15.2%

Increased appetite / cravings

12.7%

Symptoms new / worsened

10.2%

Abnormal movements

8.8%

Emotionally stable / calm / "normal"

7.9%

Difficult to wake up

6.3%

Other misc effects

5.0%

Dizzy / lightheaded / faint

4.8%

Blood sugar high / diabetes

4.8%

Dry mouth / sore throat

4.6%

Dreams vivid / nightmares

4.4%

Numb / detached / lack of energy or
interest

4.2%

Memory loss

3.8%

Hungover / drunk

3.1%
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Figure 4.2 Most Popularly Mentioned Seroquel Effects by Consumers across Websites
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Table 4.18
Number of Consumers on Each Website Mentioning the Most Popularly Reported Effects
of Seroquela
AskaPatient CrazyMeds RevHealth WebMD

Chisquare

pvalue

N=120

N=120

N=120

N=120

Helps me sleep

38

39

50

44

3.298

0.348

Extreme
sleepiness/ tired

60

33

39

27

23.276

0.000

Symptoms
improved

21

26

42

30

10.76

0.013

Weight gain

45

17

23

23

21.792

0.000

Increase appetite/
cravings

18

21

9

13

6.366

0.095

Brain fog/zombie

21

16

19

17

0.953

0.813

Symptoms new/
worsened

19

19

4

7

--

--

Abnormal
movements

17

11

9

5

7.828

0.05

a

p-value set at 0.002 for k=25 comparisons in Tables 4.18 and 4.19
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Table 4.19
Seroquel Effects Mentioned by >3% of Consumers According to Website Classification
Drug effect

Consumerconstructed

Expertconstructed

(N=220)

(N=220)

Helps me sleep

77

Extreme sleepiness /
tired

Chi-square

p-value

94

2.625

0.105

93

66

6.856

0.009

Symptoms reduced /
improved

47

72

6.983

0.008

Weight gain

62

46

3.059

0.08

Brain fog / zombie

37

36

0.016

0.899

Increased appetite /
cravings

39

22

5.427

0.02

Symptoms new /
worsened

38

11

16.569

0.000

14

5.114

0.024

Abnormal
movements

28

Emotionally stable /
calm / "normal"

25

13

4.115

0.042

Difficult to wake up

19

11

2.276

0.131

Other misc effects

13

11

0.175

0.675

Dizzy / lightheaded /
faint

11

12

0.046

0.831

Blood sugar high /
diabetes

13

10

0.411

0.521

15

7

3.049

0.081

Dry mouth / sore
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Drug effect

Consumerconstructed

Expertconstructed

(N=220)

(N=220)

Dreams vivid /
nightmares

16

Numb / detached /
lack of energy or
interest

Chi-square

p-value

5

6.026

0.014

13

7

1.878

0.171

Memory loss

11

7

0.924

0.337

Hungover / drunk

10

5

1.720

0.19

throat

a

p-value set at 0.002 for k=25 comparisons in Tables 4.18 and 4.19

Drugs Effects According to Experts
Lexapro.
Table 4.20 lists a count and proportion of the most frequently mentioned effects of
Lexapro in expert text. For example, abnormal movements were mentioned 1 time on
RevolutionHealth and mentioned 4 times on WebMD. As a proportion of the total
frequency of mentions of all effects, abnormal movements made up 2.6% and 3.2% of all
mentions of effects on RevolutionHealth and WebMD, respectively. In all but two
instances (agitated/restless and brain fog/zombie), WebMD cited effects more often than
RevolutionHealth. However for several effects, RevolutionHealth showed a higher
proportion of the frequency of mentions. For example, WebMD mentioned new or
worsening symptoms twice as often as RevolutionHealth (8 times versus 4 times). Out of
all mentions of effects on RevolutionHealth, though, 10.3% were related to new or
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worsening symptoms, whereas 6.5% of total mentions on WebMD were this effect.
Figures 4.3 and 4.4 illustrate this difference using the top 6 most frequently mentioned
effects in expert text as measured by number of mentions (Figure 4.3) and proportion of
all mentions (Figure 4.4). Four of the top 6 effects were the most frequently mentioned
regardless of measurement: blood related changes, suicidal thinking/planning, symptoms
new/worsened, and other misc effects. The remaining 2 effects changed depending on
whether the measurement was number or proportion of mentions. In both cases, WebMD
had the highest number of mentions (nausea/vomiting and dizzy/lightheaded/faint),
whereas RevolutionHealth had the highest proportion of mentions (brain fog/zombie and
agitated/restless).
The most frequently mentioned effect in WebMD fell under the code “other misc
effects,” which included effects that were sparsely reported across websites, such as
serotonin syndrome, toothache, kidney failure, and bronchitis. The most frequently
mentioned effects in RevolutionHealth were agitated/restless, suicidal thinking/planning,
and symptoms new/worsened, each appearing 4 times in that text. Additionally, 4 of the
14 effects listed in Table 4.20 were mentioned in one expert text and not the other. In
only 1 of these instances did RevolutionHealth cite an effect (brain fog/zombie) not
mentioned on WebMD.
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Table 4.20
Most Frequently Mentioned Effects of Lexapro in Expert Text (frequency >3% of total
mentions of effects on either website)
# of times effect is mentioned in text
(% of all mentions of effects in text)
RevolutionHealth

WebMD

Other misc effects

1 (2.6%)

13 (10.5%)

Agitated/restless

4 (10.3%)

3 (2.4%)

Suicidal thinking/
planning

4 (10.3%)

5 (4.0%)

Symptoms new/
worsened

4 (10.3%)

8 (6.5%)

Brain fog/zombie

3 (7.7%)

0 (0%)

0 (0%)

9 (7.3%)

Dizzy/lightheaded/ faint

2 (5.1%)

7 (5.6%)

Extreme sleepiness/tired

2 (5.1%)

4 (3.2%)

Trouble sleeping/
insomnia

2 (5.1%)

3 (2.4%)

Nausea/sick
stomach/vomiting

1 (2.6%)

6 (4.8%)

Heartbeat changes

1 (2.6%)

4 (3.2%)

Abnormal movements

1 (2.6%)

4 (3.2%)

Fever/chills/infection

0 (0%)

4 (3.2%)

Other sexual effects

0 (0%)

4 (3.2%)

Blood related changes
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Figure 4.3 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text Measured
by Number of Mentions
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Figure 4.4 Top 6 Most Frequently Mentioned Lexapro Effects in Expert Text Measured
by Proportion of All Mentions of Effects
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Seroquel.
Table 4.21 lists a count and proportion of the most frequently mentioned effects of
Seroquel in expert text. RevolutionHealth mentioned 11 effects more frequently than
WebMD, with 5 of these related to mental or mood changes. WebMD mentioned 8
effects more frequently than RevolutionHealth, all of which were physical effects.
Figures 4.5 and 4.6 illustrate that the proportion of total mentions of effects remained
consistent with the number of mentions on each website. For example, RevolutionHealth
mentioned suicidal thinking/planning and symptoms new/worsened more frequently than
WebMD as measured both by the number of mentions and proportion of all mentions.
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The most frequently mentioned effect in WebMD was dizzy/lightheaded/faint (7
mentions). In RevolutionHealth, they were brain fog/zombie and symptoms
new/worsened (5 mentions each). For 3 of the 21 effects listed in Table 4.21, an effect
was mentioned on one expert website and not the other. Increased energy/euphoria/mania
and increased appetite/cravings were mentioned 2 times and 3 times, respectively, on
RevolutionHealth and zero times on WebMD. Other labs and chronic conditions, such as
pancreatitis and underactive thyroid, were mentioned 4 times on WebMD and not at all
on RevolutionHealth.
For both drugs, it appeared that the expert text on WebMD more frequently mentioned
physical effects, such as blood-related changes and nausea/vomiting, while
RevolutionHealth more frequently mentioned mental or mood “side effects,” such as
brain fog/zombie and agitated/restless. Most of the commonly reported effects in Tables
4.20 and 4.21 were cited at least once in both texts, however for both drugs there were
considerable discrepancies between websites in the relative attention (measured by
number and proportion of mentions) given to effects.
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Table 4.21
Most Frequently Mentioned Effects of Seroquel in Expert Text (frequency >3% of total
mentions of effects in either website)
# of times effect is mentioned in text
(% of all mentions of effects in text)
RevolutionHealth

WebMD

Brain fog/zombie

5 (7.6%)

1 (1.0%)

Symptoms new/worsened

5 (7.6%)

1 (1.0%)

Dizzy/lightheaded/faint

2 (3.0%)

7 (6.9%)

Suicidal thinking/ planning

4 (6.1%)

2 (2.0%)

Weakness

4 (6.1%)

2 (2.0%)

Abnormal movements

2 (3.0%)

5 (4.9%)

Vision/eye changes

3 (4.5%)

3 (2.9%)

Headache increased

3 (4.5%)

2 (2.0%)

Agitated/restless

3 (4.5%)

1 (1.0%)

Heaviness/soreness/
pain/numbness

3 (4.5%)

1 (1.0%)

Urinary changes/ problems

3 (4.5%)

1 (1.0%)

Increased appetite/ cravings

3 (4.5%)

0 (0%)

Extreme sleepiness/ tired

2 (3.0%)

4 (3.9%)

Other misc effects

2 (3.0%)

4 (3.9%)

Blood sugar high/ diabetes

1 (1.5%)

4 (3.9%)

Other labs or chronic
conditions

0 (0%)

4 (3.9%)

Fever/chills/infection

2 (3.0%)

3 (2.9%)
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# of times effect is mentioned in text
(% of all mentions of effects in text)
RevolutionHealth

WebMD

Heartbeat changes

2 (3.0%)

3 (2.9%)

“Sweating like a pig”

2 (3.0%)

2 (2.0%)

Trouble sleeping/ insomnia

2 (3.0%)

1 (1.0%)

Energy increased/
euphoria/mania

2 (3.0%)

0 (0%)

Figure 4.5 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text Measured
by Number of Mentions

Number of times effect is mentioned in text
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Figure 4.6 Top 6 Most Frequently Mentioned Seroquel Effects in Expert Text Measured
by Proportion of All Mentioned of Effects

Proportion of total mentions of effects
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Drug Effects by Experts versus Consumers
Lexapro.
Experts and consumers both mentioned the category mental or mood effects more
frequently than any other category of effects (Figure 4.7). There was considerable
discrepancy between experts and consumers for musculoskeletal/neurological effects,
mentioned more often by experts, and sleep effects, mentioned more often by consumers.
Figure 4.8 compares experts and consumers on the most frequently mentioned
individual effects from both groups. Consumers gave considerably more attention than
experts to symptom improvement, extreme sleepiness, and weight gain. New or
worsening symptoms was one of the most frequently mentioned effects by consumers
(Table 4.13), but mentions of this effect actually made up a larger proportion of total
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mentions in the expert text (Figure 4.8). Experts gave the most attention to other misc
effects, blood related changes, suicidal thinking/planning, and dizzy/lightheaded/faint,
while consumers mentioned these effects much less frequently.
As seen in Figure 4.8, experts and consumers did have comparable rates of
mentions for new or worsening symptoms (7.4% and 6.5% of mentions, respectively) and
nausea/sick stomach/vomiting (4.3% and 4.1% of mentions, respectively). Table 4.22
provides a representative selection of excerpts from each website of text coded
“symptoms new/worsened,” with some overlap of suicidal thinking/planning as, when
mentioned, the latter effect often co-occured with the former. Experts provided a laundry
list of new or worsening symptoms for users to beware of. As the excerpts in Table 4.22
demonstrate, the expert list of symptoms and consumers’ reports of new/worsening
symptoms appeared to largely overlap. Reports from consumers, however, provided
situational examples and context for how the effect may be experienced or manifested in
a single individual.
Tables 4.23 and 4.24 compare experts and consumers on frequency of mentions and
descriptions of weight and appetite effects and sexual effects, respectively. These
categories were selected to compare and contrast expert and consumer descriptions
because of their richness of data. Table 4.23 shows that out of all mentions of effects
within the category weight and appetite effects, experts gave the most attention to loss of
appetite, while consumers gave the most attention to weight gain. WebMD described
increased appetite as rare and decreased appetite as infrequent. An almost even number of
consumers (4.2% and 4.8%, respectively) mentioned each of these effects at least once,
though decreased appetite was mentioned more frequently as a proportion of all mentions
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of weight and appetite effects. Additionally, experts described each effect on weight and
appetite to be less serious or less severe, while consumers demonstrated more clearly
differentiated perspectives such as “hugest problem of all” and “appalling” in relation to
weight gain, and “an extra bonus” in relation to weight loss.
Table 4.24 summarizes the same information for sexual effects of Lexapro. Most of the
mentions of sexual effects in expert text were related to other sexual effects, such as the
nondescript “sexual problems” or priapism (all from WebMD). Consumers gave more
attention to lost sex drive (42.2% of mentions) and trouble achieving orgasm (37% of
mentions), and much less attention to other sexual effects (11.9% of mentions). Lost sex
drive was mentioned by 10.6% of consumers, though WebMD described this effect as
infrequent and RevolutionHealth did not cite this effect at all. At the same time, trouble
achieving orgasm was mentioned by slightly fewer consumers (8.5%), but was labeled a
frequent effect by WebMD. Trouble achieving orgasm and other sexual effects were
described as less serious or less severe by experts, while lost sex drive was rated as
severe by WebMD (worded as “decreased interest in sex”). Consumers described all
sexual effects using terms such as “the absolute worst, “extremely frustrating,” and
similar. Some consumers made comments like, “I want to quit…so I can have a frigging
orgasm,” or “can’t perform sexually so you get depressed and anxious.”
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Figure 4.7 Comparison of Frequency of Mentions of Lexapro Effects between Experts
and Consumers, by Effect Category
Experts

Consumers
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9.8%

5.6%
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39.3%
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Figure 4.8 Comparison of Most Frequently Mentioned Lexapro Effects between Experts
and Consumers

Mentioned by consumers
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1.7%

% of all mentions of effects by experts or consumers, respectively
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Table 4.22
Excerpts from Experts and Consumers on Selected Mental/Mood Effects of Lexapro
Effects: Symptoms new/worsened; Suicidal thinking/planning
WebMD (Expert) “Tell the doctor immediately if you notice worsening
depression/other psychiatric conditions, unusual behavior changes
(including possible suicidal thoughts/attempts), or other mental/mood
changes (including new/worsening anxiety, panic attacks, trouble
sleeping, irritability, hostile/angry feelings, impulsive actions, severe
restlessness, very rapid speech)”
“Tell your doctor immediately if any of these unlikely but serious
side effects occur: unusual or severe mental/mood changes (e.g.,
nervousness, unusual high excitement/energy, rare thoughts of
suicide)…”
RevHealth
(Expert)

“Call your doctor at once if you have any new or worsening
symptoms such as: mood or behavior changes, anxiety, panic attacks,
trouble sleeping, or if you feel impulsive, irritable, agitated, hostile,
aggressive, restless, hyperactive (mentally or physically), more
depressed, or have thoughts about suicide or hurting yourself”

AskaPatient

“And then the worst crippling panic attacks I have ever had to date”
(#8)
“I got even more depressed that I EVER WAS, even before taking
the med” (#33)
“I seemed to become more aggressive and assertive. I would just
speak my mind whenever I got angry, and had no fear. I seemed to
become more “mean” and “mad” and I just didn’t like myself” (#41)

CrazyMeds

“had some hypomania then extreme agitation then suicidality. The
agitation was awful, felt like I was going to jump out of my skin –
and my mind was racing.” (#172)
“2 hours of alternating panic attacks/crying jags” (#130)

RevHealth
(Consumers)

“A couple of days later I had my first manic experience which lasted
about 30 minutes of complete reckless driving, I probably should
have gotten arrested. And a few minutes later I came down into deep
depression” (#258)
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WebMD
(Consumers)

“I have been very hostile and irritable on this med and my panic
attacks have been coming more often and they have been much
worse! I have no patience with my kids or my fiancé, or basically
anyone around me.” (#364)

Table 4.23
Comparison of Experts and Consumers on “Appetite and Weight Effects” of Lexapro
% of mentions out of
all “weight and
appetite effects”

Description of effect

Code

Experts

Consumers

WebMD

Rev
Health

Increased
appetite/
cravings

20%

16.8%

“rare”
& “less
severe”

--

Weight
gain

20%

--

“less
serious”
(weight
changes)

50.3%

% of consumers
mentioning effect;
description of effect
4.2%

13.1%

absolutely
ravenous;
out of
control;
hugest
problem of
all;
no relief
even with
exercise

Loss of
appetite

40%

16.1%

“common”
& “less
severe”

--

4.8%

Weight
loss

20%

16.8%

--

“less
serious”
(weight
changes)

4.8%

better
control over
appetite;
an extra
bonus;
good for
now;
hope it
continues
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Table 4.24
Comparison of Experts and Consumers on “Sexual Effects” of Lexapro
% of mentions out of
all “sexual effects”
Code
Lost sex
drive

Experts Consumers
22.2%

Trouble
achieving
orgasm

33.3%

Other
sexual
effects
(i.e.,
“sexual
problems”)

44.4%

42.2%

37.0%

11.9%

Description of effect
WebMD

Rev
Health

“unlikely
but serious”

--

“common”
& “less
severe”
“infrequent”
& “less
severe”

Consumers
Mentioned
by 10.6%
of
consumers

“less
Mentioned
serious” by 8.5% of
consumers
--

Mentioned
by 3.1% of
consumers

the absolute
worst;
really suck;
very
bothersome;
extremely
frustrating;
bad;
this is crazy

Seroquel.
Figure 4.9 compares the frequency of mentions of effects by experts and consumers
according to effect categories. Experts and consumers both mentioned effects within the
mental or mood category more frequently than effects in any other category, though the
rate was considerably higher in the consumer group (39.3% vs. 23.9%). The second
highest rate of mentions was musculoskeletal/neurological effects by experts, and sleep
effects by consumers. Rates of mentions were most similar (though not exactly
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comparable) between the two groups for gastrointestinal/urinary effects, sexual effects,
skin effects, and head/face effects.
Figure 4.10 compares experts and consumers on the most frequently mentioned
individual effects from both groups. There were large discrepancies for effects related to
sleep, symptom improvement, and weight gain, with consumers far more frequently
mentioning these effects. The effect “helps me sleep,” reflecting the use of Seroquel as a
sleep aid, was not at all mentioned in the expert group. There were less extreme
discrepancies in the effects most often mentioned by experts, including
dizzy/lightheaded/faint, vision/eye changes, weakness, and suicidal thinking/planning.
Experts and consumers had somewhat comparable rates of mentions for three
effects: brain fog/zombie (3.6% and 5.6% of mentions, respectively), abnormal
movements (4.2% and 3.5% of mentions), and other miscellaneous effects (3.6% and
1.7% of mentions). The physical effect, abnormal movements, was also similarly
described by both groups. Experts listed “jerky muscle movements you cannot control,”
“involuntary quivering,” and “abnormal movements” among other terms, and consumers
reported phrases such as “body jerks,” “restless legs,” “twitches,” “tremors,” and
“involuntary movements.” There were, however, differences between experts and
consumers in describing the mental/mood effect of brain fog/zombie. Table 4.25 provides
a representative selection of excerpts coded “brain fog/zombie” from each website. Most
notably, the expert text stated the effect technically, while the consumer text provided
examples of the possible impact and consequence of the effect on an individualized level.
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Tables 4.26 and 4.27 compare experts and consumers on the frequency of
mentions and descriptions of Seroquel’s sleep effects. Consumers’ attention was divided
evenly between extreme sleepiness/tired and helps me sleep, as measured both by the
frequency of mentions out of all sleep effects and the percentage of consumers who
reported the effect. Experts most frequently mentioned extreme sleepiness, followed by
trouble sleeping/insomnia, and labeled each as less severe/serious. In contrast to
WebMD’s description of both of these effects as frequent, approximately 33% of
consumers mentioned extreme sleepiness while only 2.3% of consumers reported trouble
sleeping. Additionally, the sample excerpts of selected sleep effects in Table 4.27 show a
qualitatively different understanding of these effects between experts and consumers.
While experts cited “drowsiness” and “tiredness” as possible effects of Seroquel,
consumers reported “coma like sleep,” “extreme sleeping,” and being “unwakable” for
many hours. This same effect was described by consumers as both helpful and unhelpful
depending on the context and circumstance of the consumer’s life.
Figure 4.9 shows that out of all mentions of effects according to category, 8.6% of
mentions in the expert group fell under the category “lab tests and chronic conditions.”
This was the least frequently mentioned category of effects by consumers, taking only
0.5% of consumers’ mentions, and just over 7% of consumers mentioned an effect within
this category at all. Within this category, Table 4.28 shows that most attention was given
by experts and consumers to increased blood sugar and diabetes (33% and 50% of
mentions within the category, respectively). Effects on the liver were not mentioned in
any expert text, but were reported by a small fraction of consumers (0.8%).
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Table 4.28 also demonstrates an inconsistency in reporting among expert
websites. RevolutionHealth only listed 1 of the 6 effects falling under this category, and
did not attach a description or label to blood sugar high/diabetes. WebMD cited an
increase in blood sugar as an infrequent effect in one paragraph and as a rare effect in
another paragraph. On both occasions the effect was labeled severe or potentially severe.
Other effects listed as infrequent or rare by WebMD were mentioned by relatively few
consumers, but increased blood sugar/diabetes was mentioned by considerably more
(4.8% of consumers) and received much greater attention (50% of mentions within this
category, and 1.7% of mentions within all drug effects).
For each of the 2 drugs, both experts and consumers gave the most attention to
mental or mood effects. Consumers most frequently mentioned positive and negative
changes in mental or mood symptoms, along with sleep and weight effects. Expert text
more often attended to negative changes in mental or mood symptoms, such as suicide
and agitation, along with other physical effects, like nausea/vomiting. Expert text tended
to list possible mental or mood effects in summary form, while consumer text provided
context and situational examples. There were clear and major differences in how effects
were described by each group. For example, expert descriptions of “less serious” did not
match consumer descriptions of “the worst” for certain weight and sexual effects.
Similarly, expert frequency estimates of “common” and “infrequent” were not
proportional to the rate of mentions in consumer text, especially for sleep effects of
Seroquel and sexual effects of Lexapro. However, since the consumer rate of mention
does not equal frequency of the effect, the latter finding might again only reflect
consumers’ perceived severity.
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Figure 4.9 Comparison of Frequency of Mentions of Seroquel Effects between Experts
and Consumers, by Effect Category
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39.3%

Figure 4.10 Comparison of Most Frequently Mentioned Seroquel Effects between
Experts and Consumers

Mentioned by consumers
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Table 4.25
Excerpts from Experts and Consumers on “Brain Fog/Zombie” Effect of Seroquel
Effect: Brain fog/zombie
WebMD (Expert) “Common side effects…. Difficulty speaking…………….Severe”
RevHealth
(Expert)

Quetiapine can cause side effects that may impair your thinking or
reactions”
“Other serious side effects include:… confusion, problems with
vision, speech, or balance”

AskaPatient

“With this drug I cannot function the next day, I have a foggy mind
and feel I just cannot move around” (#514)

CrazyMeds

“…slow, dumb, exhausted” (#603)
“It just put me in total zombie land, and caused me to fall asleep with
my eyes open a few times” (#657)
“I could intermittently find myself someplace and have no idea why I
was there or what I was doing… I have never experienced such a
profound blankness. I found myself in the walk-in closet, and had to
deduce why I might be in there… ‘Ok, I am completely dressed, so
I’m not doing that…’” (#634)

RevHealth
(Consumers)

“decreasing mental acuity, decreased gross motor function, excessive
fine motor tremor, your basic zombie” (#747)
“my mind went all numb and I couldn’t think straight” (#781)

WebMD
(Consumers)

“I wake up in the morning feeling sluggish and drugged. On some
days I have such a hard time shaking the fogginess off that I am
completely withdrawn” (#905)
“It also makes it hard to communicate as well. If someone asks me
something after taking it I’m very incoherent” (#941)
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Table 4.26
Comparison of Experts and Consumers on “Sleep Effects” of Seroquel
% of all mentions of
“sleep effects”
Code

Expert description

Experts

Consumers

WebMD

Rev
Health

% of consumers
mentioning the
effect

Extreme
sleepiness/
tired

66.7%

45.1%

“common” &
“less severe”

“less
serious”

33.1%

Helps me
sleep

0%

44.7%

--

--

35.6%

Trouble
sleeping/
insomnia

33.3%

2.6%

0%

7.7%

Difficult to
wake up

“common” &
No
“less severe” description
--
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--

2.3%

6.3%

Table 4.27
Excerpts from Experts and Consumers on Selected “Sleep Effects” of Seroquel
Effects: Helps me sleep; Extreme sleepiness/tired
WebMD (Expert)

“Common side effects: drowsiness……………Less Severe”
“tiredness”

RevHealth
(Expert)

“The following warnings are available for this medication:…. May
cause drowsiness”

AskaPatient

“So while it does provide me sleep…it’s the kind of sleep that
wouldn’t allow me to be woken, even if my house is on fire. I am not
able to be woken from this coma like sleep for hours. That scares
me.” (case #515)
“extreme sleeping” (#570)

CrazyMeds

“I like what this drug does to me (sleepy bye bye land)” (#613)
“You’ll sleep until next Tuesday. Of course, that could be a good
thing, depending on how your life is at this moment” (#1084)

RevolutionHealth

“Seroquel puts me to sleep. It’s that simple. I take it and within an
hour I’m out – unwakable – for the next 12 or more hours” (#739)
“helped very, very effectively with sleep: 30 minutes max after
taking 125-150mg at night, I am out for good” (#808)
“the worst side effect is the sleepiness – I sleep 10-12 hours a day
and still have periods when I have to nap (or could fall asleep
standing up)” (#773)

WebMD

“It helped me sleep very well, but I was very groggy in the morning”
(#871)
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Table 4.28
Comparison of Experts and Consumers on “Lab Tests and Chronic Conditions”
Mentioned for Seroquel
% of all mentions of
“lab tests and
chronic conditions”

Expert description

Expert Consumers
Blood sugar
high/diabetes

33.3%

51.0%

WebMD

Rev
Health

“infrequent”/“rare”
Not
& “severe” (Blood described
sugar);

% of
consumers
mentioning
the effect

4.8%

“rare” & “severe”
(Diabetes)
Other labs or
chronic conditions

26.7%

13.7%

“infrequent”/“rare”
& “less severe”/
“severe”

--

1.5%

Blood related
changes

13.3%

2.0%

“rare” & “severe”

--

0.2%

Cholesterol high

13.3%

11.8%

“infrequent” &
“less severe”

--

0.6%

Blood pressure
changes

13.3%

11.8%

“common”/
“infrequent” &
“less
severe”/“severe”

--

1.3%

0%

9.8%

--

0.8%

Liver
levels/hepatoxicity/
hepatitis

--
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Drug Effects by Variables
Lexapro and gender.
Male and female consumers reported similar effects of Lexapro across all drug effect
categories, except for sexual effects (Table 4.29) where more males (41.6%) than females
(17.1%) mentioned an effect. Table 4.30 compares consumers who did and did not report
gender across drug effect categories, and shows a significant difference at the p<0.002
level (corrected for multiple comparisons) for appetite and weight effects, and mental or
mood effects. Each category was reported more frequently by consumers who did report
gender. Table 4.31 further compares each gender to those who did not report gender for 3
categories of effects. Both appetite and weight effects, and mental or mood effects were
significantly different only for females (p=0.001 and 0.000, respectively). Sexual effects
were tested because they approached significance in the previous comparison, and were
found here to only significantly differ for males (p=0.000).
Lexapro and age.
There were no significant differences in the proportion of consumers in 3 age brackets
(7-24, 25-44, and 45+) who mentioned an effect of Lexapro according to effect category
(Table 4.32). Considerably fewer consumers in the 45+ age bracket (56.9%) reported
mental or mood effects compared to 7-24 year old consumers (75.6%) and 25-44 year old
consumers (73.3%). Each age group reported appetite and weight effects more frequently
than those who did not report their age, though the rate was highest for the youngest age
group (33.3%). Other differences included a slightly higher reporting of sleep effects in
the youngest age group (51.1%) and middle age group (43.5%), compared to the oldest
age group (31.9%) and those who did not report their age (29.7%). The middle age group

140

had the highest proportion of consumers reporting musculoskeletal and neurological
effects (18.3%), compared to the youngest age group (8.9%) and those who did not report
their age (9.1%). Table 4.33 compares consumers who did and did not report age across
drug effect categories. Two categories reached statistical significance at the p<0.003 level
(corrected for multiple comparisons), and in each case more consumers who did provide
their age reported effects in these categories.
Lexapro and length of time taken.
Table 4.34 compares reported effects of Lexapro in effect categories by the length of
time the consumer had been taking the drug. To minimize empty and small cells, time
categories were collapsed into 2 groups: consumers taking the drug for less than 6
months, and longer than 6 months. Three of the 10 effect categories were significantly
different between groups, and each was reported more frequently by consumers taking
Lexapro for less than 6 months. These categories included “side effects” that would be
expected to resolve over time. Also, it would be unlikely for individuals experiencing
many of these effects to remain on the drug if the effects persisted for longer than 6
months. Most of the categories that did not show a significant difference between groups,
particularly sexual effects, appetite and weight effects, and mental or mood effects,
would generally be sustained over time and not expected to disappear as part of the initial
“side effects” of Lexapro.
Table 4.35 compares drug effect categories by consumers who did and did not report
how long they had been taking Lexapro. Three of the categories were significantly
different between groups at the p<0.003 level. Similar to the gender and age variables,
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consumers who did provide the length of time taking Lexapro reported these effects at a
higher rate than those who did not provide that information.
Table 4.29
Gender of Consumers who Mentioned an Effect of Lexapro According to Drug Effect
Categorya
Female
(N=215)

Male
(N=77)

Chisquare

pvalue

37 (17.1%)

32 (41.6%)

18.816

0.000

Appetite and Weight Effects

63

16

2.028

0.154

Other Effects

34

8

1.324

0.250

Musculoskeletal and Neurological
Effects

28

13

0.725

0.395

Mental or Mood Effects

154

51

0.692

0.405

Head or Face Effects

30

13

0.406

0.524

Nose Throat Chest Effects

18

8

0.297

0.586

Gastrointestinal and Urinary Effects

35

12

0.016

0.899

Sleep Effects

83

30

0.007

0.934

Sexual Effects

a

p-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31
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Table 4.30
Reporting of Gender and Drug Effect Category for Lexaproa
Gender given
(N=292)

Gender not given
(N=188)

Chisquare

pvalue

Mental or Mood Effects

205 (70.0%)

91 (48.7%)

21.914

0.000

Appetite and Weight Effects

79 (27.0%)

28 (15.0%)

9.472

0.002

Sexual Effects

69 (23.5%)

27 (14.4%)

5.922

0.015

Sleep Effects

113

59

2.444

0.118

Musculoskeletal and
Neurological Effects

41

18

2.02

0.155

Other Effects

42

34

1.268

0.260

Skin Effects

25

11

1.156

0.282

Nose Throat Chest Effects

26

12

0.945

0.331

Head or Face Effects

43

24

0.322

0.570

Gastrointestinal and Urinary
Effects

47

32

0.095

0.758

a

p-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31
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Table 4.31
Male and Female Consumers Compared to Those Who Did Not Report Gender on Drug
Effects for Selected Categories of Lexaproa
Female
(N=215)

Gender not given
(N=188)

Chisquare

pvalue

Appetite and Weight
Effects

63 (29.2%)

28 (15.0%)

11.55

0.001

Mental or Mood Effects

154 (71.3%)

91 (48.7%)

21.541

0.000

37

27

0.543

0.461

Male
(N=77)

Gender not given
(N=188)

16

28

1.324

0.25

Mental or Mood Effects

51 (66.2%)

91 (48.7%)

6.774

0.009

Sexual Effects

32 (41.6%)

27 (14.4%)

23.116

0.000

Sexual Effects

Appetite and Weight
Effects

a

p-value set at 0.002 for k=25 comparisons of gender in Tables 4.29 – 4.31
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Table 4.32
Age of Consumers Who Mentioned an Effect of Lexapro According to Drug Effect
Categorya
7-24 yrs
(n=45)

25-44 yrs
(n=131)

45+ yrs
(n=72)

Chisquare

pvalue

Mental or Mood Effects

34 (75.6%)

96 (73.3%)

41 (56.9%)

6.913

0.032

Sleep Effects

23 (51.1%)

57 (43.5%)

23 (31.9%)

4.637

0.098

Head or Face Effects

9

22

7

2.718

0.257

Musculoskeletal and
Neurological Effects

4 (8.9%)

24 (18.3%)

10 (13.9%)

--

--

Other Effects

4

21

14

--

--

Sexual Effects

13

32

13

1.982

0.371

Skin Effects

6

11

5

1.475

0.478

Appetite and Weight
Effects

15 (33.3%)

37 (28.2%)

17 (23.6%)

1.328

0.515

Gastrointestinal and
Urinary Effects

6

24

10

0.992

0.609

Nose Throat Chest Effects

5

11

9

0.927

0.629

a

p-values set at 0.003 for k=18 comparisons involving age in Tables 4.32 and 4.33
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Table 4.33
Reporting of Age by Drug Effect Category for Lexaproa
Age given
(n=248)

Age not given
(n=232)

Mental or Mood Effects

171 (69.0%)

125 (53.9%)

11.519

0.001

Appetite and Weight Effects

69 (27.8%)

38 (16.4%)

9.061

0.003

Sleep Effects

103 (41.5%)

69 (29.7%)

7.248

0.007

Musculoskeletal and
Neurological Effects

38 (15.3%)

21 (9.1%)

4.372

0.037

Sexual Effects

58

38

3.679

0.055

Nose Throat Chest Effects

25

13

3.296

0.069

Skin Effects

22

14

1.39

0.238

Head or Face Effects

38

29

0.795

0.373

Gastrointestinal and Urinary
Effects

40

39

0.04

0.841

Other Effects

39

37

0.004

0.947

a

Chisquare

p-values set at 0.003 for k=18 comparisons involving age in Tables 4.32 and 4.33
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pvalue

Table 4.34
Consumers Taking Lexapro According to Length of Time Taken and Drug Effect
Categorya
Taken <6 months Taken >6 months
(n=228)
(n=140)

Chisquare

pvalue

Musculoskeletal and
Neurological Effects

45 (19.7%)

9 (6.4%)

12.27

0.000

Gastrointestinal and Urinary
Effects

59 (25.9%)

7 (5.0%)

25.686

0.000

Head or Face Effects

50 (21.9%)

9 (6.4%)

15.482

0.000

Sleep Effects

107 (46.9%)

45 (32.1%)

7.823

0.005

Nose Throat Chest Effects

28 (12.3%)

7 (5.0%)

5.343

0.021

Skin Effects

26 (11.4%)

7 (5.0%)

4.357

0.037

Sexual Effects

46

35

1.176

0.278

Appetite and Weight Effects

63

36

0.162

0.687

Mental or Mood Effects

159

95

0.143

0.705

Other Effects

37

24

0.052

0.819

a

p-values set at 0.003 for k=18 comparisons involving time taken in Tables 4.34 and 4.35
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Table 4.35
Reporting Length of Time Taking Lexapro According to Drug Effect Categorya
Time taken
given (n=368)

Time taken not
given (n=112)

Chisquare

pvalue

Appetite and Weight Effects

99 (26.9%)

8 (7.1%)

19.353

0.000

Sleep Effects

152 (41.3%)

20 (17.9%)

20.531

0.000

Mental or Mood Effects

254 (69.0%)

42 (37.5%)

36.093

0.000

Musculoskeletal and
Neurological Effects

54 (14.7%)

5 (4.5%)

8.302

0.004

Head or Face Effects

59 (16.0%)

8 (7.1%)

5.65

0.017

Nose Throat Chest Effects

35

3

--

--

Skin Effects

33

3

--

--

Sexual Effects

81

15

3.986

0.046

Other Effects

61

15

0.653

0.419

a

p-values set at 0.003 for k=18 comparisons involving time taken in Tables 4.34 and 4.35

Seroquel and gender.
Male and female consumers did not differ in reported effects (grouped by category) for
Seroquel (Table 4.36). Table 4.37 further shows no differences at the p<0.003 level
between consumers who did give their gender compared to those who did not give that
information.
Seroquel and age.
Reported effects of Seroquel grouped by category did not differ significantly (p<0.003)
between the age brackets of 7-24, 25-44, and 45+ years old (Table 4.38) or between
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consumers who did report their age and those who did not report that information (Table
4.39). Similar to trends in Lexapro data, the youngest age category mentioned appetite
and weight effects (40.9%) and sleep effects (72.7%) more often than the other age
groups and those who did not report age.
Seroquel and length of time taken.
Table 4.40 compares effect categories for Seroquel by the length of time consumers had
taken the drug (less than and more than 6 months). Significantly more consumers taking
Seroquel for longer than 6 months mentioned appetite and weight effects (44.7% versus
27.5%) and lab tests and chronic conditions (13.7% versus 3.0%) at the p<0.003 level.
Two effect categories were significantly different between consumers who did provide
the length of time taking Seroquel and those who did not give that information (Table
4.41). Consumers taking Seroquel for less than or more than 6 months all reported sleep
effects (62.9% and 69.6%, respectively) at a higher rate than consumers who did not
provide the time taken (48.7%).
In sum, a high number of consumers not reporting the above variables prevented a
detailed examination of differences in drug effects by gender, age, and time taken.
Instead, comparisons were made according to broader drug effect categories. The primary
finding was that the more information consumers provided, the more likely the consumer
was to report a drug effect. In general, there were fewer differences for Seroquel than for
Lexapro in reported effects by each of the 3 variables. Men were more likely than women
to mention sexual effects of Lexapro. There were no differences between the genders for
effects of Seroquel. The youngest age group tended to more frequently mention sleep and
weight effects for both drugs. Finally, more consumers reported what appeared to be
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initial “side effects” of Lexapro, whereas more reported sustained effects lasting longer
than 6 months (i.e., weight and blood sugar) of Seroquel.
Table 4.36
Gender of Consumers Who Mentioned an Effect of Seroquel According to Drug Effect
Categorya
Female
(N=207)

Male
(N=91)

Chisquare

pvalue

Musculoskeletal and Neurological
Effects

51

14

3.173

0.075

Other Effects

37

10

2.256

0.133

Head or Face Effects

11

9

2.114

0.146

Skin Effects

12

2

--

--

2 (1.0%)

2 (2.2%)

0.724

0.395

Gastrointestinal and Urinary Effects

14

4

--

--

Sleep Effects

132

54

0.528

0.467

Mental or Mood Effects

111

52

0.316

0.574

Nose Throat Chest Effects

26

10

0.147

0.701

Lab Tests and Chronic Conditions

18

9

0.109

0.741

70 (33.8%)

31 (34.1%)

0.002

0.967

Sexual Effects

Appetite and Weight Effects
a

p-values set at 0.002 for k=18 comparisons involving gender in Tables 4.36 and 4.37
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Table 4.37
Reporting Gender by Drug Effect Category for Seroquela
Gender given
(N=298)

Gender not given
(N=182)

Chisquare

pvalue

Musculoskeletal and
Neurological Effects

65 (21.8%)

22 (12.1%)

7.2

0.007

Lab Tests and Chronic
Conditions

27 (9.1%)

7 (3.8%)

4.668

0.031

Skin Effects

14

2

--

--

Appetite and Weight Effects

101

47

3.449

0.063

Gastrointestinal and Urinary
Effects

18

6

1.791

0.181

Nose Throat Chest Effects

36

15

1.753

0.185

Head or Face Effects

20

7

1.747

0.186

Sleep Effects

186

105

1.056

0.304

Mental or Mood Effects

163

91

1.001

0.317

Sexual Effects

4

2

--

--

Other Effects

47

30

0.042

0.837

a

p-values set at 0.003 for k=18 comparisons involving gender in Tables 4.36 and 4.37
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Table 4.38
Age of Consumers Who Mentioned an Effect of Seroquel According to Drug Effect
Categorya
7-24 yrs
(n=44)

25-44 yrs
(n=119)

45-75+ yrs
(n=82)

Chisquare

pvalue

Appetite and Weight
Effects

18 (40.9%)

41 (34.5%)

29 (35.4%)

0.598

0.742

Gastrointestinal and
Urinary Effects

2

10

2

--

--

Head or Face Effects

6

6

6

3.486

0.175

Lab Tests and Chronic
Conditions

5

4

10

--

--

Mental or Mood Effects

25

68

42

0.752

0.686

Musculoskeletal and
Neurological Effects

9

29

13

2.14

0.343

7 (15.9%)

14 (11.8%)

12 (14.6%)

0.617

0.735

Other Effects

5

21

10

1.626

0.444

Skin Effects

2

6

4

--

--

Sleep Effects

32 (72.7%)

74 (62.2%)

52 (63.4%)

1.621

0.445

Nose Throat Chest Effects

a

p-values set at 0.003 for k=16 comparisons involving age in Tables 4.38 and 4.39
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Table 4.39
Reporting Age by Drug Effect Category for Seroquela
Age given
(n=245)

Age not given
(n=235)

Chisquare

pvalue

Appetite and Weight Effects

88 (35.9%)

60 (25.5%)

6.068

0.014

Nose Throat Chest Effects

33 (13.5%)

18 (7.7%)

4.264

0.039

Skin Effects

12

4

--

--

Sleep Effects

158

133

3.131

0.077

Head or Face Effects

18

9

2.795

0.095

Musculoskeletal and
Neurological Effects

51

36

2.443

0.118

Mental or Mood Effects

135

119

0.959

0.327

Other Effects

36

41

0.675

0.411

Gastrointestinal and Urinary
Effects

14

10

0.538

0.463

Lab Tests and Chronic
Conditions

19

15

0.343

0.558

a

p-values set at 0.003 for k=16 comparisons involving age in Tables 4.38 and 4.39
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Table 4.40
Consumers Taking Seroquel by Length of Time Taken and Drug Effect Categorya
Taken <6 months Taken >6 months
(n=167)
(n=161)
Lab Tests and Chronic
Conditions

Chisquare

pvalue

5 (3.0%)

22 (13.7%)

12.356

0.000

Appetite and Weight Effects

46 (27.5%)

72 (44.7%)

10.499

0.001

Musculoskeletal and
Neurological Effects

40 (24.0%)

28 (17.4%)

2.147

0.143

13

7

1.691

0.193

Sleep Effects

105 (62.9%)

112 (69.6%)

1.639

0.2

Nose Throat Chest Effects

25 (15.0%)

19 (11.8%)

0.709

0.4

Other Effects

26

30

0.544

0.461

Mental or Mood Effects

96

87

0.395

0.53

Skin Effects

7

9

0.345

0.557

Head or Face Effects

12

12

0.009

0.926

Sexual Effects

2

2

--

--

Gastrointestinal and Urinary
Effects

a

p-values set at 0.003 for k=17 comparisons involving time taken in Tables 4.40 and 4.41
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Table 4.41
Reporting Length of Time Taking Seroquel by Drug Effect Categorya
Time taken
given (n=328)

Time taken not
given (n=152)

Chisquare

pvalue

Appetite and Weight Effects

118 (36.0%)

30 (19.7%)

12.843

0.000

Sleep Effects

217 (66.2%)

74 (48.7%)

13.286

0.000

Nose Throat Chest Effects

44 (13.4%)

7 (4.6%)

8.488

0.004

Musculoskeletal and
Neurological Effects

68 (20.7%)

19 (12.5%)

4.743

0.029

Skin Effects

16

0

--

--

Head or Face Effects

24

3

--

--

Mental or Mood Effects

183

71

3.439

0.064

Gastrointestinal and Urinary
Effects

20

4

--

--

Lab Tests and Chronic
Conditions

27

7

2.075

0.15

Other Effects

56

21

0.818

0.366

Sexual Effects

4

2

--

--

a

p-values set at 0.003 for k=17 comparisons involving time taken in Tables 4.40 and 4.41

Themes Mentioned by Consumers
Overview of theme categories.
Themes around drugs and drug use were grouped in the umbrella category “My Drug,”
which was divided into 7 main categories under which codes fell (see codebook in
Appendix D). While coding for drug effects was restricted to Lexapro and Seroquel only,
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use of codes within “My Drug” were open to any general or specific comments about
drug use. The first category was “Assessing the Overall Experience,” reflecting
consumers’ weighing of benefits and costs of the drug. Two codes in this category,
“Lexapro/Seroquel is a miracle/saved my life” and “I hate Lexapro/Seroquel,” were the
only codes under “My Drug” that solely included comments specific to the drugs under
study (Table 4.42). The second category was “Dealing with Side Effects/Finding
Optimum Effectiveness,” reflecting consumers’ attempts and strategies for counteracting
drugs’ side effects and/or for enhancing drugs’ effectiveness. The next category, “Do I
Need Meds?” included consumers’ comments about wanting to remain on or quit drug
treatment for their problems, desires or attempts at alternative non-drug treatments, and
reflections on how drugs have affected them. The fourth category, “Evidence,” involved
consumers’ attempts to decipher the exact nature and cause of a particular effect they
experienced, and also included comments about the lack of research on a use, effect, or
other aspect of a drug. The “Other Drug Issues” category included various other codes
involving drug dependence and withdrawal, dosing issues, miscellaneous descriptions of
symptoms related to a diagnosis, comparisons of brand versus generic drugs, and the
phenomenon of drug effects weakening or changing over time. The sixth category was
“Other Drugs and Drug Combinations,” which included comments about effects of drugs
other than Lexapro and Seroquel, recommendations for or warnings against specific drug
combinations, and lists of consumers’ current and past drug regimens. The final category
under “My Drug” was “Theories of Drug Action,” reflecting consumers’ comments about
how drugs work in their brains or bodies.
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In addition to the “My Drug” umbrella category, there were 5 other smaller categories
called: “My Doctor,” “Finances/The System,” “Family and Friends,” “Pharmaceutical
Companies/FDA,” and “Support and Advice.” The final codebook included 6 codes
under “My Doctor,” all of which reflected some type of interaction, conflict, or question
related to doctors. The “Finances/The System” category included comments related to the
expense or affordability of drugs, insurance-related issues, involuntary hospitalization
and forced medication, and other comments about navigating through hospitals and “the
system.” All comments about family and friends fell under the appropriately named
category. This included stories about a drug’s effect on a family member or friend, a drug
effect that a family member or friend observed in the consumer, and situational
information related to having supportive or unsupportive family and friends. Codes
falling under the “Pharmaceutical Companies/FDA” category included statements about
the FDA approval status of a drug or indication, and remarks about the business interests
of pharmaceutical companies in making and marketing drugs. Finally, comments from
consumers who were worried about possible drug effects or who were seeking the
experiences or advice of other users were coded under the “Support and Advice”
category.
My drug: Assessing the overall experience.
Table 4.42 shows the frequency of consumers within each of the 5 websites who
mentioned a code in this category. Specific to Lexapro and Seroquel, slightly more
consumers described these drugs as “a miracle/saved my life” (10.9%) than the opposite,
“I hate this drug” (8.0%). This ratio remained true across all websites, except for
AskaPatient where an almost even number of consumers described the drugs both ways.
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The remaining codes in this category included comments about any drug experience,
and so were not specific to Lexapro and Seroquel. Comments were also coded in this
category only if there was a clear assessment or weighing of benefits and costs of a drug.
Again, a slightly higher percentage of consumers across all websites described the
benefits of a drug’s use outweighing its costs (9.4% versus 7.3%). However, the largest
percentage of consumer comments within this category described drugs’ limited
helpfulness (15.3%). Neither benefits nor costs necessarily outweighed one another, but
rather the drug was “just okay,” “not my wonder drug,” or the drug had no discernable
effect either way. Finally, “YMMV” or “your mileage may vary” was a popular slogan,
especially among the consumer discussion forums, and meant that each individual is
different and may have a different experience or come to a different assessment from the
one being described. It was often used as a caveat so as not to discourage or overly
encourage readers about trying a particular drug.
Table 4.43 provides a comparison of these codes with websites grouped according to
their status as expert- or consumer-constructed. Statistical significance was reached for
only 1 code, “YMMV,” due to its predominance on the 2 consumer discussion forums.

158

Table 4.42
Frequency of Consumers Within Each Website Who Mentioned a Code Within the
Category “Assessing the Overall Experience”
All
consumers

Ask a
Patient

Crazy
Meds

(N=1080)

(N=220)

(N=220)

Lexapro/Seroquel is
a miracle/saved my
life/I recommend ita

10.9%

13.3%

6.3%

--

12.5%

11.7%

I hate
Lexapro/Seroquel/
Stay away from ita

8.0%

13.8%

2.9%

--

6.3%

9.2%

All in all, I am
positive/ Side effects
tolerableb

9.4%

8.8%

12.5%

9.2%

11.3%

5.4%

Not worth it/ Side
effects too greatb

7.3%

7.5%

9.2%

6.7%

8.8%

4.2%

No or limited
helpfulness/ Not my
wonder drugb

15.3%

8.8%

20.0%

19.2%

20.0%

10.4%

YMMV (Your
mileage may vary)b

7.3%

3.3%

14.2%

23.3%

2.1%

1.7%

a

Icarus
Project

Rev
Health

WebMD

(N=120) (N=220) (N=220)

Frequencies include only comments specifically referring to Lexapro or Seroquel;
excludes comments from IcarusProjet
b
Frequencies include comments referring to any drug; not limited to comments only
about Lexapro or Seroquel
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Table 4.43
Number of Consumers Mentioning Codes under “Assessing the Overall Experience,”
According to Website Classification
Consumerconstructed

Expertconstructed

Chisquare

pvalue

(N=600)

(N=480)

Lexapro/Seroquel is a
miracle/saved my life/I
recommend it

47a

58

1.294

0.255

I hate Lexapro/Seroquel/ Stay
away from it

40a

37

0.127

0.721

All in all, I am positive/ Side
effects tolerable

62b

40

1.247

0.264

Not worth it/ Side effects too great

48b

31

0.935

0.334

No or limited helpfulness/ Not my
wonder drug

92b

73

0.003

0.955

YMMV (Your mileage may vary)

70b

9

37.711

0.000

a

“Consumer-constructed” count includes consumers from AskaPatient and CrazyMeds
(n=480)
b
“Consumer-constructed” count includes consumers from AskaPatient, CrazyMeds, and
IcarusProject

My drug: Dealing with side effects/finding optimum effectiveness.
Table 4.44 lists the frequencies of consumers who mentioned a code within the category
“Dealing with Side Effects/Finding Optimum Effectiveness.” The top 4 strategies
mentioned by the most total consumers were: wait to see if the side effect eventually goes
away on its own (19.2%), stop taking the drug and/or switch to another drug (18.4%),
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adjust the dosage of the drug (13.7%), and add another drug to counteract the side effect
or to enhance the effectiveness of the current drug (10.4%).
Users of CrazyMeds mentioned each of these strategies more often than users of each of
the other websites. While over 25% of users on CrazyMeds commented about or
suggested adding another drug to a regimen, less than half of that percentage on any of
the other 4 websites made similar comments or suggestions. In a similar pattern,
CrazyMeds users commented more about mixing caffeine and alcohol with drugs,
checking and monitoring blood levels, effects of and strategies for diet and exercise, and
learning to simply accept and live with certain undesirable drug effects.
When websites were grouped according to their status as expert- or consumerconstructed, 4 of the 11 strategies listed in Table 4.45 were statistically significantly
different between groups (Table 4.45). All 4 were more often mentioned on consumerconstructed sites than expert-constructed, though the difference for “add another med”
was largely due to the predominance of that code on CrazyMeds. Users of the 3
consumer-constructed sites more often commented on changes in diet and exercise to
counteract side effects or enhance drug effectiveness, and the importance of starting on a
low dose of a drug and titrating slowly up to the target dose. Few users on AskaPatient
described “other methods,” so the statistically significant difference between groups is
due to the more frequent use of this code on CrazyMeds and IcarusProject. Users of these
discussion forums described such “other” strategies as crushing, cutting and scraping the
coating of off pills to counteract over-sensitivities to some drugs, using Vaseline and
other accessories to counteract certain sexual drug effects, and having friends or family
nearby to talk them through a particularly intense mental or mood drug effect.
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Table 4.44
Frequency of Consumers Within Each Website Who Mentioned a Code Within the
Category “Dealing with Side Effects/Finding Optimum Effectiveness,” Mentioned by at
Least 3% of Consumers on Any Website
All
consumers
(N=1080)
Add another med

10.4%

Avoid / Drink
more
caffeine/alcohol

1.5%

Ask a
Patient

Crazy
Meds

Icarus
Project

(N=220)

(N=220)

(N=120)

2.9%

25.4%

9.2%

10.4%

3.3%

1.7%

4.6%

0.0%

0.4%

0.0%

4.6%

10.8%

1.7%

8.8%

3.3%

0.0%

4.2%

2.5%

0.4%

0.4%

7.9%

14.6%

7.5%

3.3%

4.6%

12.5%

20.8%

5.0%

16.7%

9.2%

0.0%

4.2%

1.7%

2.1%

0.0%

Rev
Health

WebMD

(N=220) (N=220)

Changing time of
day

6.3%

Check blood levels

1.4%

Diet / Food /
Exercise

7.6%

Dose adjustment

13.7%

Learn to live with
it

1.6%

Other methods

4.4%

0.4%

11.7%

6.7%

3.3%

0.8%

Ride out the storm
/ Eventually goes
away / Waiting

19.2%

14.2%

27.1%

18.3%

25.8%

10.0%

Switch meds / Stop
med

18.4%

14.6%

29.2%

11.7%

19.6%

13.8%

Taper SLOWLY /
Low starting dose

6.8%

7.1%

10.8%

7.5%

5.4%

3.3%
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Table 4.45
Codes Under “Dealing with Side Effects/Finding Optimum Effectiveness” that Reached
Statistical Significance (p<.05) According to Website Classification
ConsumerExpertChipconstructed
constructed
square
value
(N=600)
(N=480)
Add another med
79
33
11.357
0.001
Diet / Food / Exercise

63

19

16.265

0.000

Other methods

37

10

10.682

0.001

Taper SLOWLY / Low
starting dose

52

21

7.793

0.005

My drug: Do I need meds?
Table 4.46 shows the frequency of consumers who mentioned a code under the category
“Do I Need Meds?” and Table 4.47 shows that each code reached statistical significance
according to website classification (“Making a plan/Just in case…” was not included in
the significance test because of empty cells). The most popular codes in this category
were “Trying/tried alternative treatment” (mentioned by 8.0% of all consumers) and
“Drugs won’t work/I’m done/I don’t need it” (7.4%). The former code included all
comments about having tried, wanting to try, or recommendations to try a non-drug
treatment, such as a psychotherapy, cognitive-behavioral therapy, group therapy, holistic
therapies, and electro-convulsive therapy, among others. The latter code included
comments from consumers who wanted to quit drug treatment altogether, who
determined they no longer needed or wanted drug treatment, or who thought drug
treatment was not working to solve their particular problems.
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In contrast to the previous category where CrazyMeds dominated, the present
category was dominated by users of IcarusProject. More users of IcarusProject (25.8%)
than any other website commented that they wanted to quit or did not need drug
treatment, however more users of this forum (11.7%) compared to the other sites also
commented that drug treatment may be part of their long-term solution. The code
“Making a plan/Just in case…,” reflecting consumers’ making prevention, emergency, or
back-up plans, was only brought up in the 2 consumer discussion forums and not on the
other websites.
Table 4.46
Frequency of Consumers Within Each Website Who Mentioned a Code Within the
Category “Do I Need Meds?”
All
consumers
(N=1080)

Ask a
Patient
(N=220)

Crazy
Meds
(N=220)

Icarus
Project
(N=120)

7.4%

4.6%

8.8%

25.8%

4.2%

2.9%

3.1%

0.8%

4.2%

11.7%

2.5%

0.4%

Looking
back.../Since I
stopped the
med...

4.7%

3.3%

6.7%

12.5%

2.5%

2.5%

Making a plan /
Just in case...

1.6%

0.0%

3.3%

7.5%

0.0%

0.0%

Trying/Tried
alternative tx

8.0%

2.5%

8.8%

35.8%

5.4%

1.3%

Drugs won't work
/ I'm done / I
don't need it
Going back on
meds / Meds may
be the solution
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Rev
WebMD
Health
(N=220) (N=220)

Table 4.47
Number of Consumers Mentioning Codes Under “Do I Need Meds?” According to
Website Classification
Consumerconstructed
(N=600)

Expertconstructed
(N=480)

Chisquare

pvalue

Drugs won't work / I'm done / I
don't need it

63

17

18.825

0.000

Going back on meds / Meds
may be the solution

26

7

7.441

0.006

Looking back on it.../Since I
stopped the med...

39

12

9.483

0.002

Trying/Tried alternative
treatment

70

16

26.268

0.000

Other “My Drug” categories.
Table 4.48 provides the frequency of consumers mentioning a code within the
remaining 4 categories under “My Drug,” as well as the most popular code within each
category. Each of the categories and codes listed were dominated by users of the 2
consumer discussion forums. Table 4.49 shows significance testing for these codes,
except for “Theories of Drug Action” because of empty cells. Under the category
“Evidence,” the code “drug or something else?” was mentioned by over 10% of all
consumers. This code reflected the idea of uncertainty as to the nature or cause of an
observed drug effect. Most often cited causes of a drug effect were the drug itself, other
drugs the consumer was taking, lifestyle choices (diet, exercise, etc), a return of their
mental illness, or a placebo effect. For example, in a review of Seroquel on AskaPatient,
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a consumer noted, “I do have some memory and concentration problems, but these could
be related to 25 years with depression and bipolar disorder, or to the other meds I take
(Wellbutrin 400mg, Depakene 400mg).” A user on CrazyMeds remarked that some
people find Seroquel helpful for depression, but “Whether it’s the consistent sleep or the
drug itself I’m not entirely sure, but I suspect it’s a combination of the two.” Again
referring to Seroquel, a user on IcarusProject commented, “I don’t know if I gained
weight from it (Seroquel). I am fat to start with, plus I was taking lithium and
depressed/not exercising.” Other users commented more generally on the dilemma, “it’s
kinda hard to tell hebee jebees from side effects, or crazyness, or drugs doing what they
are supposed to do.” Still other users provided a best guess as to the cause of an effect or
advice, such as “try one med at a time. If you have reactions or side effects after
beginning two meds at once, you won’t know which to blame.”
Under the category “Other Drug Issues” the codes relating to drug dependence/
withdrawal, and diagnosis/symptoms were both mentioned by 10.5% of all consumers,
though very few consumers outside of the 2 discussion forums mentioned the latter. The
former code included comments about drug discontinuation or withdrawal experiences,
and advice about how to properly discontinue a drug to avoid adverse effects. Most users
who offered advice about discontinuation suggested tapering slowly off the drug rather
than stopping “cold turkey.” For example, users on CrazyMeds advised “taking a very
low 5mg (of Lexapro) every few days to keep the brain zaps away,” or that “generally
10% reduction a week is a good rule of thumb.” This code also included the idea of
becoming “dependent” on the drug by, for example, having to take increasing amounts
over time to achieve the same effect or having to remain on the drug because of
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intolerable discontinuation effects. As one user shared, “The first time I tried coming off
Lexapro (earlier this year), I had anxiety and general pissed off and agitated feeling. So, I
just went back to my normal dose.” A user on WebMD voiced a common apprehension
about Seroquel, “It really does work but I am concerned that I will never get off of it and
develop sleep patterns of my own. I can’t sleep a full night without it.”
A full 25% of all consumers commented on or described their current drug cocktail or
their previous drug history (code: “My drug combo/So many damn meds…”). Most of
these comments came from the 2 discussion forums as well as a high percentage from
RevolutionHealth. Table 4.49 shows that this was the only of the above-mentioned codes
that did not achieve a significant chi-square value between expert- and consumerconstructed websites. Comments within this code included references to specific drug
cocktails users have tried or are trying, as well as the general concept of having tried
many different drugs in the past. A typical recounting of a drug history might resemble
this comment from a CrazyMeds user, “I have tried other drugs – Zoloft, Wellbutrin,
Prozac, Cymbalta. I couldn’t tolerate Wellbutrin and Cymbalta. I felt numb emotionally
on Zoloft. Prozac caused anorgasmia yet did nothing for my depression.” More generally,
users referred to the idea that they’ve “tried virtually every medication out there,” they’ve
been on the “med merry-go-round” for a long time, or they’ve “taken so many damn
meds” that they have difficulty recalling which ones had what effects on them.
The final category, “Theories of Drug Action,” was the least mentioned by consumers
across websites, and was again dominated by users of the 2 discussion forums. This
category included all descriptions of how or why drugs work in the body and brain, as
well as references to drugs being “potent” or “selective” in their action on the brain. For
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example, users of CrazyMeds often attempted to explain differences in drug efficacy or
the safety of a particular drug combination by referencing drugs’ action in the body:
“Lots of pdocs (psychiatrists) in my area are giving stims (stimulants) to people that have
to take AP’s (antipsychotics). In theory, the dopamine actions are occurring in different
places. There are 5 dopamine pathways...” Similarly, “Celexa hits the serotonergic
system less hard, which might be a pro concerning side effects.” No consumers on
WebMD or AskaPatient and few consumers on RevolutionHealth (1.3%) mentioned the
most common code within this category, and a chi-square test was not completed due to
these zero frequencies.
In sum, all of the above “My Drug” themes were dominated by users of the 2 discussion
forums. Users of CrazyMeds offered the most strategies for dealing with side effects,
while users of IcarusProject commented most on the need for drugs and alternative
treatments. Taken together, the “My Drug” themes showed a rich variety of concerns,
experiences, and perspectives of consumers.
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Table 4.48
Frequency of Consumer Comments on Drug Theme Categories (in bold text) and the
Most Frequently Mentioned Code Within that Category (in plain text)

Evidence

All
Ask a
Crazy
Icarus
Rev
WebMD
consumers patient
Meds
Project
Health
(N=1080) (N=220) (N=220) (N=120) (N=220) (N=220)
15.3%
9.6%
31.3%
29.2%
7.9%
5.4%

Drug or something
else?

10.4%

5.0%

23.3%

20.8%

4.6%

3.3%

Other Drug Issues

34.1%

20.4%

60.4%

58.3%

28.8%

14.6%

Dependence /
Withdrawal

10.5%

5.4%

18.8%

24.2%

6.3%

4.6%

Diagnoses /
Symptoms

10.5%

0.8%

22.1%

40.0%

3.3%

0.8%

Other Drugs and
Drug Combinations

32.4%

12.5%

51.7%

63.3%

32.9%

17.1%

My drug combo / So
many damn meds…

25.4%

10.8%

35.0%

46.7%

29.2%

15.8%

Theories of Drug
Action

3.9%

0.4%

10.8%

9.2%

1.7%

0%

Targets/restores brain
molecules/chemicals/
neurotransmitters

2.3%

0%

7.1%

4.2%

1.3%

0%
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Table 4.49
Number of Consumers Mentioning Codes under Other Drug Theme Categories
According to Website Classification
Consumerconstructed
(N=600)
93

Expertconstructed
(N=480)
19

Chisquare

pvalue

38.217

0.000

OTHER DRUG ISSUES:
Dependence/Withdrawal

87

26

23.486

0.000

OTHER DRUG ISSUES:
Diagnoses/Symptoms

103

10

64.76

0.000

OTHER DRUGS/COMBINATIONS:
My drug combo/So many damn meds…
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108

3.76

0.053

EVIDENCE: Drug or something else?

My doctor.
Table 4.50 shows the frequency of consumers who mentioned a code within the
category “My Doctor,” and Table 4.51 shows significant chi-square tests for each code
according to website classification as expert- or consumer-constructed. Similar to themes
under “My Drug,” themes under “My Doctor” were dominated by users of the 2
discussion forums. The code “talking with doc/doc explained/consult doc” was the most
popular theme across each website, except for IcarusProject where the most popular
theme was “I’m taking control/I’m my own best advocate.” The former code included all
references to having talked with the doctor, needing to consult the doctor, and
information the doctor explained or decisions the doctor made about drugs or drugs’
effects. For example, consumers often relayed some information their doctor explained to
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them, “My doctor says Lexapro wakes most people up but can have the opposite effect,
as it started to have with me.” Many consumers noted a doctor-made decision, “I was
ready to switch to another SSRI…but my doctor decided to add Wellbutrin instead.” This
code also included suggestions to or advice about talking with the doctor, such as general
statements “Consult your doctor,” more directive statements “If it’s akathesia, talk to
your doc about ultram,” or cautions to “talk to your doctor before doing anything” that
might impact your medication regimen. Finally, consumers generally advised others to be
open and honest when talking to the doctor about their concerns and needs, “Being
lifeless, lazy, flat, zombie…is not acceptable. Tell your Doctor that you are NOT willing
to just exist.”
The next code, “doctor won’t listen/we disagree/ I wasn’t informed,” was mentioned by
over 10% of all consumers, including almost 30% of consumers on IcarusProject. This
code reflected disagreements and conflicts between the consumer and their doctor,
remarks about the doctor being wrong about a drug or drug effect, and the idea that the
doctor did not support, listen to, or properly inform them about medication issues. Some
consumers described a disagreement with their doctor about the appropriate course of
action and made a decision to listen or not listen to the doctor’s instructions, “I begged
the doc to take me off this and he didn’t want to so I took myself off of it.” A consumer
on RevolutionHealth summarized the experience of the doctor being wrong about what to
expect from a drug, “Pdoc assured me that it would help me sleep. It made me
excessively tired but not sleepy. In fact, I slept less which I can’t cope with.” Similarly,
some consumers complained about being misinformed or poorly informed by their
doctor, “my pdoc definitely down-played the effects on my memory. I had a rude
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awakening at just how much I would lose, and for how long. It makes me angry too.”
Many consumer comments under this code relayed feelings of not being listened to or
validated by the doctor, “Is there anyone who had/has this experience with such a low
dose? My Pdoc sometimes looks at me like I am making all this stuff up, I am not. I am
depressed but not stupid.”
The most popular “My Doctor” code among IcarusProject users and mentioned by
about 9% of all consumers was “I’m taking control/I’m my own best advocate.” These
were comments about consumers becoming informed or advocating for themselves to the
doctor, often by doing their own research on a drug, monitoring their treatment, or
asserting their treatment-related decisions to their doctor. Many consumers offered
general advice, such as “definitely do your own research on all things,” or explained their
understanding of an issue “based on my research.” Some consumers requested specific
drugs from their doctor or suggested that others do so, “Read about each one
(medication) and pick one that you think you would like to try, actually pick a few
because he’s (the doctor) probably going to object to a few of them. Try one and see how
it works.” Also typical were consumers making treatment-related decisions on their own,
such as adjusting their dose of a drug, “I also decided last week to try to decrease my
Seroquel dose and see if I could sleep a little less and have more energy. I didn’t ask my
doctor.”
The final codes under “My Doctor” mentioned by at least 3% of all consumers were
“trusting the doctor?” and “other doctor-related issues.” About 8% of all consumers, and
a fifth or more on each of the discussion forums, were hesitant to fully trust their doctor’s
word. Some consumers were seeking to verify with others some information the doctor
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had given them, such as “my psychiatrist says Lexapro is the Cadillac of SSRI’s, is this
really true or just a one person bias?” At other times, consumers would chime in with
suspicion or caution about a doctor-made decision of another consumer, “The fact that
she (the doctor) even considered lithium with your history of epilepsy means she’s
throwing darts.” Finally, a small percentage of consumers (4.3%) made a comment
related to “the doctor” that did not fit in the above codes, such as advice for finding a new
doctor or praise for having a supportive doctor.
Similar to findings for “My Drug,” the comments for “My Doctor” reflected an array of
relationships and interactions with, and feelings towards doctors.
Table 4.50
Frequency of Consumers within Each Website who Mentioned a Code Within the
Category “My Doctor,” Mentioned by at Least 3% of All Consumers
All
consumers
(N=1080)

Ask a
Patient
(N=220)

Crazy
Meds
(N=220)

Icarus
Project
(N=120)

Rev
Health
(N=220)

(N=220)

16.8%

5.4%

37.5%

28.3%

11.3%

7.1%

10.3%

5.4%

13.3%

29.2%

7.1%

5.8%

I'm taking control
/ I'm my own
best advocate

9.0%

2.1%

16.7%

34.2%

2.9%

1.7%

Trusting the
doctor ?

8.2%

0.8%

20.0%

22.5%

2.5%

2.5%

Other doctorrelated issues

4.3%

0.8%

7.9%

16.7%

0.8%

1.3%

Talking with doc
/ Doc explained /
Doctor won't
listen / We
disagree

173

WebMD

Table 4.51
Number of Consumers Mentioning Codes under “My Doctor” According to Website
Classification
Consumerconstructed
(N=600)

Expertconstructed
(N=480)

Chisquare

pvalue

Talking with doc / Doc
explained / Consult doc

137

44

35.703

0.000

Doctor won't listen / We
disagree / I wasn't informed

80

31

13.668

0.000

I'm taking control / I'm my own
best advocate

86

11

47.3

0.000

Trusting the doctor ?

77

12

37.656

0.000

Other doctor-related issues

41

5

21.935

0.000

Finances/the system.
Table 4.52 shows the frequency of consumer comments within the remaining
theme categories along with their most popular code. Under “Finances/The System,”
6.5% of all consumers made a comment related to the expense of drugs and insurancerelated issues. This code appeared from consumers on all websites, though only once on
AskaPatient. Many of the comments under this code were related to the cost of brand
name drugs compared to generic drugs, and the involvement of insurance companies in
trying to reduce costs by forcing consumers to switch to cheaper generics. A typical
comment related to this was, “I have to switch from Lex to Celexa because of insurance
BS and I really hope it doesn’t get any worse than it is,” or “The main downfall to
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Lexapro is it is another drug on the “hit list” of drugs my insurance company hates to pay
for, so it costs me a fortune every month.” Some consumers found the expense worth it,
“it costs me $50 for a month’s supply. It’s pricey, but so far, absolutely worth it,” while
others were simply unable to afford it, “due to loss of insurance and cost of prescription I
had to stop taking it.” A number of consumers found free samples given to doctors by
drug companies to be an invaluable supplementary source, “I survive at least half the
time on samples from pdoc because this stuff is so damn expensive.”
Family and friends.
At least 6% of consumers on each website mentioned their family or friends in their
drug review or discussion post. The most popular code in this category was “Drug did
*this* to them/ doing what they did,” which most often included descriptions of drug
experiences of family members or friends. Consumers shared things like, “my ex
boyfriend took it (Seroquel) to sleep and slept like the dead,” “a close friend of mine
developed NMS from Seroquel,” or “I found out over the holidays that both my mother
and aunt are on Seroquel too and it seems to be really helping them (both BP like me).”
Often the experiences of family or friends influenced the consumer’s perspective or
decision on taking the drug, such as in the latter comment where the consumer was
encouraged to try Seroquel based on the positive experience of her family. Others shared
the negative experiences of family or friends in order to warn others of possible dangers,
“My husband was in a study sponsored by Lilly using large doses of Seroquel, 800mg a
day. Within 6 months he had full blown type 2 diabetes…no blood sugar issues in the 34
years prior to this. Bad, bad, bad Seroquel!”
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Pharmaceutical companies/FDA.
Under “Pharmaceutical Companies/FDA” the code “it’s a business” included any
remark about pharmaceutical companies being in the business of selling drugs. No
consumers on the expert-constructed sites and only 1 consumer on AskaPatient made a
comment that fell under this code. Many comments centered around the relationship
between pharmaceutical company representatives and doctors, “my doctor must have
been getting some great perks from the drug company as he kept trying to push it on me,”
or “I hate to piss off my regular doc, but I’m afraid she might be basing my treatment on
what the Lexapro rep with all the samples told her.” Consumers also made references to
“drug company hype,” “financial reasons NOT to do a study,” “pharmacomafia,” and a
number of comments about the financial incentives to develop, market, and provide
samples for brand name drugs versus generic drugs. “Other” pharmaceutical company
issues, mentioned by 2.5% of all consumers, largely involved miscellaneous comments
about lawsuits against drug companies, questions concerning “who’s watching” the
pharmaceutical industry, and views about the “medical model.”
Support and advice.
Nearly 15% of all consumers elicited others’ experiences of drugs, or described
being scared or worried about taking a drug, usually after reading of others’ experiences
on the Internet. In a review of Lexapro, a consumer on AskaPatient remarked they were
“rather scared of going off (of Lexapro) after reading about it on this site, but think that’s
the only solution at this point,” and another user on the site was worried because, “I am
quite health conscious and read some reviews where people put on a lot of weight.” Many
consumers were seeking advice from others with first-hand experience, “Has anyone had
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experience with generic Lex? Anyone switched from the name brand to the generic?”
Another popular question related to Lexapro was, “Do sexual side effects ever wear off?”
In general, though, most questions shared some common themes: “Is this normal?” “Has
anyone else experienced this?” “Do you think this drug has caused/will cause this
effect?” and “Will this go away?”
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Table 4.52
Frequency of Consumer Comments on Other Theme Categories (in bold text) and the
Most Frequently Mentioned Code Within that Category (in plain text)
All
consumers
(N=1080)
Finances/The
System
Expenses/Insurance
Friends and Family
Drug did *this* to
them/ Doing what
they did

Ask a
Crazy
Icarus
Rev
WebMD
patient
Meds
Project
Health
(N=220) (N=220) (N=120) (N=220) (N=220)

8.1%

0.8%

14.2%

27.5%

5.0%

2.9%

6.5%

0.4%

11.7%

18.3%

5.0%

2.9%

11.3%

6.7%

12.9%

31.7%

7.9%

7.5%

5.0%

2.1%

7.5%

14.2%

2.9%

2.9%

Pharmaceutical
Companies/FDA
It’s a business

6.1%

0.4%

13.3%

23.3%

1.3%

0.8%

2.6%

0.4%

6.3%

10.0%

0.0%

0.0%

Other pharma/
regulatory/FDA
issues

2.5%

0.0%

3.8%

14.2%

0.0%

0.4%

6.3%

34.2%

38.3%

8.3%

8.3%

4.2%

32.1%

27.5%

7.5%

7.9%

Support and
Advice
Seeking experiences
/ Worried about
effects

16.9%

14.5%
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Themes by Experts versus Consumers
Overview of expert themes.
Expert text included codes from each of the 6 main thematic categories reviewed above
for consumers (My Drug, My Doctor, Finances/The System, Family and Friends,
Pharmaceutical Companies/FDA, and Support and Advice). However, from consumer
text, there were 61 codes across the 6 categories. Table 4.53 lists the 28 of these 61 codes
(45.9%) that were mentioned in the expert text. There remained 33 themes mentioned by
consumers from the 6 categories that did not come up in the expert text. Of the 28 themes
mentioned, 4 of them came up in all 4 expert cases: talking with doc/doc
explained/consult doc, dose-related issues, other drug issues, and targets/restores brain
chemicals. Sixteen of the 28 codes (57%) came up on one expert site and not the other.
The 4 above-stated codes mentioned by all expert cases were also the most frequently
mentioned codes in expert text (there were multiple mentions of each code in a single
case). The code “talking with doc…” was mentioned in these 4 cases a total of 109 times.
As a proportion of total mentions of all themes, this meant that 52.7% of all mentions of
theme codes by experts were related to “talking with doc/doc explained/consult doc.” In
contrast, a total of 181 consumers mentioned this theme 316 times, so that 5.1% of all
mentions of theme codes by consumers were related to “talking with doc…” To ensure a
fair comparison, the same proportion was taken for consumers using total mentions of
only the 28 themes in expert text (rather than dividing the 316 mentions by total mentions
of all 61 themes), and 11.2% of all mentions by consumers out of those 28 themes were
related to “talking with doc…”
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Figure 4.11 compares experts and consumers on the proportion of all thematic
mentions according to the most popular themes of each group (note: “talking with doc…”
is not included on this table). The second most popular theme in expert text was issues
related to dosing, such as what to do in the case of a missed dose or overdose, as well as
instructions to take the drug as prescribed and with food and water. Next were “Other”
drug issues, which were largely related to proper storage of the drug, for example, “do
not refrigerate.” Two of the 4 most popular themes of consumers did not show up in
expert text: “My drug combo/so many damn meds” and “No/limited helpfulness/not my
wonder drug.”
Table 4.53
Codes From All Theme Categories That Were Mentioned in Expert Text
RevolutionHealth (N=2)

WebMD (N=2)

OTHER drug issues

2

2

Talking with doc / Doc
explained / Consult doc

2

2

Targets/Restores brain
chemicals

2

2

Dose related issues / advice

2

2

Dependence / Withdrawal

1

2

Check blood levels

1

2

Ride out the storm/
Eventually goes
away/Waiting

1

2

Other pharma/FDA issues

1

2
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RevolutionHealth (N=2)

WebMD (N=2)

YMMV

1

2

FDA approval status

2

Family/friend observed an
effect

2

Expense / Insurance

2

Generic/other drug
equivalence

2

Dose adjustment

2

Other methods (to deal with
side effects)

1

1

Efficacy/Safety not
established

1

1

All in All, I am positive /
Side effects tolerable

2

Switch meds / Stop med

2

Taper SLOWLY / Low
starting dose

2

Other doctor-related issues

1

Don't take this drug/
combination

1

Possible effects / What to
expect from other drugs

1

Avoid / Drink more
caffeine/alcohol

1

Other general support

1
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RevolutionHealth (N=2)

WebMD (N=2)

I'm taking control / I'm my
own best advocate

1

Diet / Food / Exercise

1

Routine

1

Figure 4.11 Proportion of Mentions of the Most Popular Themes by Experts and
Consumers, Respectively, Out of Total Mentions of All Themesa
Experts

Mentioned by consumers

My drug combo/so many damn meds

0.0%
6.5%
1.4%

Ride out the storm/eventually goes away/waiting

Switch med/stop med

No/limited helpfulness/not my wonder drug

Mentioned by experts

Consumers

5.4%
1.0%
3.9%
0.0%
3.6%
11.6%

Dose related issues

OTHER drug issues

Targets/restores brain chemicals

3.2%
4.8%
1.2%
1.9%
0.7%

% of all themes mentioned 1 or more times by experts or consumers, respectively
a

There may be more than 1 mention in a single case. As an example, 274 consumers
mentioned “My drug combo/so many damn meds” a total of 400 times. The code
frequency (400) divided by the total number of mentions of all 60 themes equals 6.5%.
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Assessing the overall experience.
Table 4.54 compares consumers and experts on codes within “assessing the overall
experience.” Just over 15% of consumers made an assessment of the benefits and costs of
a drug experience and decided that the drug was of limited benefit or that it was “just
okay.” Another 9.4% of consumers decided that the drug benefits outweighed costs, and
7.3% decided that costs outweighed benefits. In expert text, only the “benefits outweigh
costs” code appeared, while the other 2 codes were absent. WebMD mentioned this code
for each drug under study (see exact statement in Table 4.55), while no codes under this
category appeared in the expert text of RevolutionHealth. Table 4.55 provides excerpts
that illustrate each position.
Table 4.54
Number of Consumer and Expert Cases that Mention a Code under “Assessing the
Overall Experience”
Category: “Assessing Benefits and Costs”

Consumers
N=1080
N (%)

Experts
N=4
N (%)

All in all, it is worth it (Benefits outweigh costs)

102 (9.4%)

2 (50%)

Side effects are too great (Costs outweigh benefits)

79 (7.3%)

0

165 (15.3%)

0

No or limited helpfulness
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Table 4.55
Expert and Consumer Descriptions of “Assessing the Overall Experience”
All in all, it is worth it
EXPERT: “Remember that your doctor has prescribed this medication to you because he
or she has judged that the benefit to you is greater than the risk of side effects” (WebMD)
CONSUMER:
“I have almost no sex drive…a dry mouth most of the time… (and) have gained some
weight. But as long as I don’t have to deal with the panic attacks I am ok.” (#445)
“If you gain weight on this drug, I have found it is very hard to shed it off while still on
it. But, it is so much better to be bootylicious than suicidal” (#138)
“I wake up and feel a little doped out in the mornings however I can live with that
considering it’s saved me from the tragedy of no sleep and late night TV!” (#572)

Side effects are too great
EXPERT: N/A
CONSUMER:
“Lexapro did not work for me. I felt distant, with no emotions. No, I wasn’t depressed
anymore but I’m not sure the side effects were worth it!” (#34)
“Felt like a new man for 5 months. Best most secure days of my life. I quit – you guessed
it – NO sex drive, maybe one erection a week and impossible to orgasm.” (#433)
“Gained 30 pounds in seven months…enough weight gain that I am going off this drug
even though it works” (#571)
No or limited helpfulness
EXPERT: N/A
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CONSUMER:
“Helped depression, but caused weight gain, which caused more depression… a vicious
cycle.” (#11)
“Lexapro sucked. My doctor prescribed lexapro and it didn’t make me feel any better.”
(#263)
“I was prescribed Seroquel, and I do have to say that it did bring me back to a more stable
state at the time. That state was not exactly anything to write home about, but at least it
was an improvement over where I was before.” (#650)
“Not the perfect med but better than others I have tried…less side effects too.” (#920)

Dealing with side effects/finding optimum effectiveness.
Figure 4.12 shows the proportion of mentions of the most popular codes of experts and
consumers within the category “dealing with side effects/finding optimum effectiveness”
out of total mentions of all codes within that category. Only 1 code, “Add another med,”
was mentioned by one group (consumers) and not the other (experts). The most
frequently mentioned code among experts (24% of mentions) was “other methods,”
which primarily included cautions to stand up slowly to avoid dizziness and to take care
when driving a vehicle. Consumers who mentioned this code provided similar advice, as
well as offered additional recommendations, such as allow plenty of time for sleep at
night, set multiple alarm clocks, and take a shower in the morning to help wake up.
The most frequently mentioned code among consumers (24% of mentions) was
“ride out the storm/eventually goes away/waiting,” which also took 12% of all mentions
within this category in the expert text. Expert text stated that it may take “4 weeks or
longer” for Lexapro and “several weeks” for Seroquel before feeling the “full benefits” of
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the drug. Consumers made similar statements, “they take a few weeks to kick in,” or
“took a few weeks to get used to, excellent results after that!” While expert text
uniformly listed a 4 or “several” week time frame, there was a wider range of time frames
cited by consumers, from “it took about 1 week to really kick in,” to “after 18 months,
my body is well-adjusted to it and it helps a great deal with regulating my mood.” Both of
the latter statements were from reviews of Lexapro. Unlike expert text which only
mentioned a time frame for benefits to be felt, consumers also shared information on how
long it took for “side effects” to go away. Some consumers offered general rules of
thumb, “initial side effects should go away within a week or two. If they don’t, they’re
there to stay,” and others shared their personal experience of side effects, “Depressed and
zoned out bad first couple of weeks. Sexual side effects went away after 2-3 months.”
While expert text did not comment on the popular consumer code “add another
med,” consumers infrequently mentioned the popular expert code “check blood levels.”
Expert text emphasized the importance of regular monitoring of blood sugar levels while
on Seroquel, and periodic monitoring of other laboratory tests on either drug. Consumers
offered the same information and encouragement, however, at a lower rate of mention
compared to the frequencies of other codes in this category.
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Figure 4.12 Proportion of Mentions of the Most Popular Codes Within the Category
“Dealing with Side Effects/Finding Optimum Effectiveness” Out of Total Mentions
Within the Category

Experts

Most popular codes within category

Add another med

Consumers

0.0%
11.8%
8.0%

Switch meds/Stop med

17.3%
12.0%
14.9%

Dose adjustment

12.0%

Ride out the storm/Eventually goes away

Check blood levels

24.0%
16.0%
1.2%
16.0%

Taper SLOWLY/Low starting dose

Other methods

6.5%
24.0%
3.8%

% of all mentions of codes within category by experts and consumers, respectively

My doctor.
The code “talking with doc…” was the most frequent code found in expert text as it
appeared 109 times in those 4 cases, and 18.4% of words from the total text of experts
were highlighted with that code (see Table 4.56). Table 4.57 provides excerpts by experts
and consumers from codes in “My Doctor.” Expert text had a uniform discourse around
“talking with the doc…,” always pointing to the doctor as the major source for
information, expertise, and guidance. Consumers also pointed to doctors as a major
source for those things with remarks such as “as usual, talk to your doctor” and “I would
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recommend trying it if your doctor suggests it.” Beyond this, however, consumers
demonstrated a broader range of relationships with the doctor by frequently commenting
on how their doctor was wrong, their doctor did not inform them of certain potential
effects, their doctor didn’t believe them when they shared a particular drug experience,
and so on as Table 4.57 illustrates.
Table 4.56
Consumers and Experts on the “My Doctor” Code: “Talking with Doc/Doc
Explained/Consult Doc”
Consumers

Experts

1080

4

16.8% (n=181)

100%

Total number of occurrences of the code

316

109

% of words coded out of total text

3.8%

18.4%

Sample size
% of cases that mention the code
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Table 4.57
Excerpts from Consumers and Experts on “My Doctor”

Expert text

Codes: Talking with doc / Doc explained / Consult doc
Doc was wrong / We disagree / I wasn't informed
Trusting Doc ?
“Tell your doctor about…”; “Tell your doctor if…”
Talk to your doctor before…”
Call your doctor at once if…”; “Tell the doctor immediately if…”
“Do not…without telling your doctor”; “Do not…without first
talking to your doctor”
“Your doctor will need to check you at regular visits…”
“Consult your doctor or pharmacist for more details”;
“Contact your doctor for…”
“…unless your doctor instructs you otherwise”
“Discuss the risks and benefits with your doctor”

AskaPatient

“I was told by my Psychiatrist that the only side effects were
sleepiness and POSSIBLE weight gain. I was not warned of the
diabetes risk or other side effects” (#494)
“I’m not sure that the tingling that I’m feeling is from Anxiety like
my psychiatrist says, or as a side effect of the Lexapro. I think it’s
the lexapro” (#58)
“my doctor must have been getting some great perks from the drug
company as he kept trying to push it on me despite my repeated
telling him how awful it was” (#16)

CrazyMeds

“I see Dr on the 6th – but he is fast and furious in his visits and I
would like input from the “experts” as well as him. I do take his
advise but also like other input” (#217)
“I’ve actually read that weight loss was possible and my doctor
made it sound like side effects in general are rare and minor. It’s
pretty confusing.” (#132)
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“Only doctors can diagnose and treat an illness. Some doctors tend
to get pissed off by patients who know too much about medications,
so tread lightly when and where appropriate.” (#1083)
“Some psychiatrists are really stupid.” (#638)
“All docs I’ve had, from gp to pdoc2, are obsessed with Cymbalta as
a pain aid. Only pdoc1 listened to me when I told her it didn’t touch
my pain,… Pdoc2 is totally fixated on Cymbalta for pain. They all
have the same mantra: ‘It’s been tested for pain and it works.’”
(#685)
RevolutionHealth

“I chose this medication over Paxil because my doctor told me it
would be faster acting and have less side effects.” (#298)
“I think I might stay on it just long enough to show up in my pdoc’s
office in this “condition” so that he can see first hand what I’m
talking about.” (#768)
“I’ve told the doc this and he says it will get better, but it’s been
about 2 months and I am still completely incoherent in the morning.”
(#791)

WebMD

“It took my new doctor a while to find the right dose for me… It
took may psychiatrists to finally figure it out. None of them
completely understood all the past meds I was on and the weight
gain I experienced on all of them.” (#959)
“…my whole body would jump and twitch… I was scared to drive
my car fear that I would cause an accident. My doctor tells me that
its not because of seroquel but I disagree.” (#841)
“…it makes me extremely sleepy so I am not sure why she has
prescribed this medication twice a day. I’ve spoken to her numerous
times about this issue because it is affecting me staying awake at my
job…” (#866)

Icarus

“People need to feel empowered with education and choice before
taking stuff (and don’t necessarily trust the docs to tell you
everything you need to know).” (#986)
“I finally got some appropriate drugs after the TENTH psychiatrist
I’ve seen in my life. (patience is key when looking for the right
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drugs and the right person who actually bothers to keep up on the
current research and actually bothers to listen to you as an
individual…)” (#962)
“I argued with my doc because I had no life. All I did was sleep. She
was more concerned with me being stable, but the side effects were
so bad.” (#991)

Dose-related issues.
“Dose-related issues” made up 11.6% of all mentions of themes in expert text, as Figure
4.11 shows, compared to 3.2% of all mentions of themes by consumers. Under this code,
experts provided information on what to do in the case of an overdose, “seek emergency
medical attention,” or a missed dose, “take it as soon as you remember…(or)…skip the
missed dose and resume your usual dosing schedule.” Experts further emphasized to take
only the prescribed dose as instructed by the doctor and to “not start, stop, or change the
dosage of any medicine before checking with your doctor or pharmacist first.”
Consumer comments under this code largely involved attempts to ascertain the
lowest and highest appropriate and/or effective doses, “For Lexapro, 20mg is about the
ceiling, though some people get doses as high as 40mg…It would be a good idea to stick
to 10mg until you’re able to evaluate the effectivity of the drug…” A paradoxical dosing
guideline for Seroquel came up several times, “Seroquel is highly sedating in the lower
doses (i.e., 25, 50, 100, etc),” while “higher doses can be used for treatment of acute
mania” including psychosis and bipolar mania, but not for insomnia. Rather than stating a
general rule, many consumers simply shared with others their personal experience at
various doses, “seroquel at low dose 50 knocks me out, 100 tired for about an hour, 200
at bed nothing, that’s just me.” Some consumers spoke of the “right dosage,” or “correct
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dosage,” noting that there is no single dose that works for everyone or for all problems,
but that “once you find what it is you will know it.” Other comments that appeared in
consumer text included the comparability of extended release versions of drugs to regular
dosing, and the possibility of using a drug PRN, or “as needed,” instead of on a daily
schedule.
In sum, expert text included less than half of the themes mentioned by consumers,
and a majority of these themes were mentioned on only 1 or the other expert site. Expert
text offered unitary discourses around benefits versus costs of the drug, and the doctor.
Expert and consumer text shared several similar strategies for dealing with side effects,
but consumers provided many additional practical strategies not covered in expert text.
Comments about dosing issues were divergent between groups, with consumers making
more specific dosing inquiries and suggestions and expert text making general references
to seeking professional assistance for many dosing issues.
Usability of Consumer Sites According to “Typical” Web Use
Lexapro.
Tables 4.58 and 4.59 compare the most recent 20 posts from AskaPatient,
CrazyMeds, WebMD, and RevolutionHealth (n=80) to the full dataset of consumer
reviews for Lexapro (n=480). Table 4.58 compares the groups on the effects most
mentioned by consumers, and shows considerable comparability for these 9 effects. One
effect, extreme sleepiness/tired, reached a significant chi-square value (chi-square=4.026,
df=1, p=0.045), with more consumers reporting this effect in recent posts. Overall for the
most popularly mentioned effects of Lexapro, the 20 most recent posts from each website
demonstrated comparable frequencies to the full dataset of consumer reviews.
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Table 4.59 makes a similar comparison for less frequently mentioned effects of
Lexapro. There were 5 effects mentioned by greater than 3% of consumers in the full
dataset, but mentioned by fewer than 3% of consumers in recent posts. All 5 were
physical effects, such as dizziness, sweating, and weight loss. Internet users relying on
the first 20 posts on these websites run the risk of missing or underestimating these few
effects. All other effects mentioned by more than 3% of consumers in the full dataset
were also mentioned by at least that many in recent posts.
There were another 5 effects mentioned by few consumers (<3%) in the full
dataset that were mentioned by more consumers (>3%) in recent posts. Two of these
were mental or mood effects: suicidal thinking/planning/attempts and crying
spells/emotional rollercoaster. The full dataset contained 3 cases each of hot flash/heat
stroke and vision/eye changes, all of which were present in recent posts. A typical
Internet user seeing all 3 cases out of 80, rather than out of 480, might over-estimate the
frequency of these effects. Again, though, all other effects mentioned by less than 3% of
consumers in the full dataset were also mentioned by that many or fewer in recent posts.

Table 4.58
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Most Frequently Mentioned Effects of the Most Recent 20 Consumer Posts From Each
Website Compared to All Consumer Posts for Lexapro
Recent posts Full dataset
(N=80)
(N=480)
32.5%
30.4%

Symptoms reduced / improved
Extreme sleepiness / tireda

32.5%

23.8%

Symptoms new / worsened

18.8%

15.8%

Trouble sleeping / insomnia

11.3%

13.3%

Emotionally stable / calm / "normal"

15.0%

13.1%

Weight gain

13.8%

13.1%

Nausea / sick stomach / vomiting

11.3%

12.1%

Numb / detached / lack of energy or interest

8.8%

11.3%

Brain fog / zombie

12.5%

10.8%

a

Chi-square=4.026, df=1, p=0.045

Table 4.59
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Less Frequently Mentioned Effects from Recent Posts Compared to the Full Dataset for
Lexapro
Recent
posts
(N=80)

Recent
posts
%

Full
Full
dataset dataset
(N=480)
%

Effects mentioned by >3% of consumers in
full dataset, and <3% of consumers in most
recent posts
“Sweating like a pig”

2

2.5%

28

7.1%

Loss of appetite

2

2.5%

21

5.3%

Weight loss

2

2.5%

21

5.3%

Dizzy/lightheaded/faint

2

2.5%

20

5.1%

Other misc effects

1

1.3%

19

4.8%

Helps me sleep

5

6.3%

9

2.3%

Suicidal thinking / planning / attempts

3

3.8%

6

1.5%

Crying spells / emotional rollercoaster

3

3.8%

4

1.0%

Hot flashes / heat stroke

3

3.8%

3

0.8%

Vision / eye changes

3

3.8%

3

0.8%

Effects mentioned by <3% of consumers in
full dataset, and >3% of consumers in most
recent posts

Seroquel.
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Tables 4.60 and 4.61 compare the most recent 20 posts from the 4 websites (n=80) to
the full dataset of consumer reviews for Seroquel (n=480). Table 4.60 makes this
comparison using the most frequently mentioned effects of Seroquel, and again shows
good comparability for these 9 effects. One effect, brain fog/zombie, reached statistical
significance (chi-square=3.958, df=1, p=0.047), with more consumers in recent posts
reporting this effect. Otherwise, recent posts and the full dataset appeared to be
comparable in reported frequencies of the most popular effects of Seroquel.
Table 4.61 makes a similar comparison using the less frequently mentioned effects of
Seroquel. Four effects were mentioned by 3% or more of consumers in the full dataset,
and by few or no consumers in recent posts. Two were mental or mood effects, and two
were physical effects. In contrast, the second half of the table lists the 4 effects mentioned
by few consumers (<3%) in the full dataset and by a greater number (>3%) in recent
posts. All 4 were physical effects. For the remaining effects of Seroquel, recent posts and
the full dataset were comparable.

Table 4.60
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Most Frequently Mentioned Effects of the Most Recent 20 Consumer Posts From Each
Website Compared to All Consumer Posts for Seroquel

Helps me sleep

Recent posts Full dataset
(N=80)
(N=480)
41.3%
35.6%

Extreme sleepiness / tired

32.5%

33.1%

Symptoms reduced / improved

28.8%

24.8%

Weight gain

20.0%

22.5%

Brain fog / zombiea

22.5%

15.2%

Increased appetite / cravings

11.3%

12.7%

Symptoms new / worsened

11.3%

10.2%

Abnormal movements

8.8%

8.8%

Other misc effects

8.8%

5.0%

a

Chi-square=3.958, df=1, p=0.047

Table 4.61
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Less Frequently Mentioned Effects of Recent Posts from Each Website Compared to the
Full Dataset for Seroquel
Recent
posts
(N=80)

Recent
posts
%

Full
Full
dataset dataset
(N=480)
%

Effects mentioned by >3% of consumers in
full dataset, and <3% of consumers in most
recent posts
Dry mouth / sore throat

1

1.3%

21

5.3%

Dreams vivid / nightmares

1

1.3%

20

5.0%

Numb / detached / lack of energy or interest

1

1.3%

19

4.8%

Sweating like a pig

0

0%

11

2.8%

Effects mentioned by <3% of consumers in
full dataset, and >3% of consumers in most
recent posts
Headache increased

3

3.8%

10

2.5%

Heartbeat changes

4

5.0%

9

2.3%

Loss of appetite

3

3.8%

5

1.3%

Breathing problems / shortness of breath

3

3.8%

4

1.0%

Themes.
Table 4.62 shows the 25 most frequently mentioned themes in recent posts (n=160)
compared to the full dataset (n=960) for both drugs combined. For nearly all of the listed
themes, recent posts showed a higher proportion of consumers mentioning the theme
compared to the full dataset, though in most of the cases the differences appeared slight.
Diet/food/exercise under the “dealing with side effects…” category was the only code
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mentioned by considerably fewer consumers in recent posts. Overall, the number of
consumers mentioning themes appeared to be comparable between the 2 groups.
Table 4.62
Most Frequently Mentioned Themes of Most Recent 20 Posts from Each Website
Compared to the Full Dataset of Both Drugs
Recent
posts
(N=160)

Recent
posts
%

Full
dataset
(N=960)a

Full
dataset
%

18

11.3%

76

7.9%

14

8.8%

56

5.8%

Talking with doc / doc explained /
consult doc

27

16.9%

147

15.3%

Trusting the doctor ?

16

10.0%

62

6.5%

A miracle / saved my life / I
recommend

18

11.3%

105

10.9%

I hate this drug / stay away from it

15

9.4%

77

8.0%

All in All, I am positive / side effects
tolerable

22

13.8%

91

9.5%

Not worth it / side effects too great

14

8.8%

71

7.4%

No or limited helpfulness / It's not my
wonder drug

29

18.1%

142

14.8%

YMMV

13

8.1%

51

5.3%

MY DOCTOR

Doctor won't listen / we disagree / I
wasn't informed
I'm taking control / I'm my own best
advocate

MY DRUG: Assessing the Overall
Experience
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Recent
posts
(N=160)

Recent
posts
%

Full
dataset
(N=960)a

Full
dataset
%

Add another med

19

11.9%

101

10.5%

Diet / food / exercise

6

3.8%

72

7.6%

Dose adjustment

29

18.1%

142

14.8%

Ride out the storm / eventually goes
away / waiting

30

18.8%

185

19.3%

Switch meds / stop med

32

20.0%

185

19.3%

Drugs won't work / I'm done / I don't
need it

12

7.5%

49

5.1%

Trying/tried alternative treatment

7

4.4%

43

4.5%

Drug or something else?

18

11.3%

87

9.1%

Dependence / withdrawal

14

8.8%

84

8.8%

Diagnoses / symptoms

15

9.4%

65

6.8%

Dose related issues

18

11.3%

95

9.9%

Generic/other drug equivalence

15

9.4%

85

8.9%

My drug combo / so many damn meds...

39

24.4%

218

22.7%

Possible effects / what to expect from
other drugs

17

10.6%

81

8.4%

17

10.6%

124

12.9%

MY DRUG: Dealing with Side
Effects/Finding Optimum Effectiveness

MY DRUG: remaining sub-categories

SUPPORT AND ADVICE

Seeking experiences / worried about
effects
a

Excludes postings from IcarusProject.
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Preliminary Data Checking
Communication with web 2.0 informants.
Prior to starting the present research, 9 Web 2.0 researchers, bloggers, and
webmasters were contacted with inquiries as to the state-of-the-art for identifying or
preventing unauthentic accounts on sites for consumer reviews or discussion. Five
responses were received, and no one was able to offer a sure method. However, a few
responses were noteworthy:
The owner/moderator of a consumer-constructed discussion forum related to
psychiatric medications described:
We had someone from Cephalon [a pharmaceutical company] come by.
The person was easy to spot. Again I'm fine with it. It's just like science.
They have to defend their positions and we have to defend ours… As we
didn't agree with this person all the time they just stopped showing up…
As we're good with pattern recognition we can easily spot someone from
the industry by the language they use. I no longer have time to read other
sites, so I don't know if they are popping up elsewhere. Given that they
have set up their own sites I seriously doubt if they are going to bother
with peer-to-peer sites / user generated media / whatever they are calling
us this month.
In a follow-up email, the owner elaborated on the type of language an industry
representative might use:
Pharm reps write somewhere between high school and college-level, they
don't use too many technical terms if they can avoid them. They speak to
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effects and only mild, temporary side effects. They will mention off-label
usage, but everything is one condition at a time. Drug-drug interactions
are only for meds someone is currently taking. They'll defend their meds
if something hasn't been 100% proven, using studies that were funded by
their companies or just pulling stuff out of the PI sheets. Sometimes it's as
if they copied a paragraph or two from the company's website and pasted
it into a post.
The Head of Operations of an expert-constructed health site that integrates expert
knowledge and consumer participation responded:
Discussions with marketing personnel at a number of pharmaceutical
companies (not individual sales reps) suggest a more cautious approach.
Because many social networking websites with consumer blogs contain
potentially unreported serious adverse events (SAE), pharma personnel are
"discouraged" from visiting these websites because if they see an
unreported SAE, they would be bound to report it to the FDA. [Our
website] is working in collaboration with several pharma companies to
submit a citizens petition (at the request of the FDA) for guidance on
responsibilities for SAE reporting for on-line communities… For [our
website], we also screen our patient comments for promotional messages
and anything with a promotional message is deleted…
Hope that helps shed a bit of light on "official" FDA guidance, senior
pharma response, and our activities. What happens at the rep level,
however, is tough to monitor. That said, with 250,000+ individuals
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enrolled in [our website], its hard to think that "sales representatives going
against FDA/company policies" can skew the data significantly.
David and Pinch (2005) found that individuals contributing to product review
sites may have a number of agendas apart from sharing a genuine experience or expertise.
In their analysis of 50,000 user reviews of 10,000 books and CDs on amazon.com, they
found that about 1% of user reviews were plagiarized either verbatim or with variations.
Plagiarized reviews appeared to promote a certain agenda, carry out personal attacks, and
boost the user’s reputation in the amazon.com tiered reputation system, among other
things. They concluded that the great majority of reviews, however, “can probably be
taken at face value and are authors’ attempts to give their own honest appraisal of the
product” (p. 23). Both authors were contacted as part of the above inquiry, and neither
was aware of a program or method to judge the authenticity of user contributions. The
software program they developed to detect plagiarism on amazon.com is partly available
open-source, but would not have fit the needs of the present research (and would have
require considerable re-programming for use on another website).
Wikiscanner search.
Wikiscanner was used to search Astra-Zeneca, Eli Lilly, and GlaxoSmithKline for
Wikipedia edits. Any edited entries related generally or specifically to medications or
pharmaceutical companies were identified. A detailed listing of search results can be
found in Appendix H. Briefly, there were 949 edits by persons on Astra Zeneca’s
network, of which 23 (2.4%) were relevant to medications or drug companies. These
included 1 or more edits to the following entries: AstraZeneca, Federal Food, Drug, and
Cosmetic Act, FDA, Good Manufacturing Practice, Omeprazole, Quetiapine,
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Risperidone, and Thalidomide. In addition to the publicized quetiapine edit mentioned
above, a sentence about the heavy marketing of omeprazole in the face of generic
competition was deleted and summaries of several studies in which omeprazole
outperformed its competitor drug were added. Such edits may be considered controversial
or salacious as there is a very possible conflict of interest involved. However, there were
only 3 such edits, equaling 13% of the 23 relevant edits and 0.3% of all 949 edits.
There were 832 edits returned for Eli Lilly, of which 38 (4.6%) were relevant to
medications or drug companies. In one edit, 6 contraindications were deleted for
drotrecogin alfa, including for pregnancy, breast feeding, and use in patients under 18
years of age. A link for Lilly’s drug Cialis was added to the page for erectile dysfunction.
The word “deceptive” was deleted in a description of Lilly’s marketing campaign for a
drug. On the user talk pages for fluoxetine (where users discuss and justify edits to an
entry), a person from the Eli Lilly network stated, “I have been taking fluoxetine and had
very little in the way of side effects - just a small amount of nausea at the start. It has
been very successful in treating my depression so far and I'm feeling good for the first
time in ages…”
Finally, a search for GlaxoSmithKline returned 1,148 edits, of which 31 (2.7%)
were related to medications or the drug industry. Under the entry for “GSK,” someone
from their network added a section titled “Good Works” and a paragraph describing the
company’s global leadership in eradicating lymphatic filariasis (elephantiasis).
Otherwise, Wikipedia edits from these companies appeared innocuous, even when they
were related to specific medications the company had a financial interest in (see
Appendix H). Of course, it was also apparent that each company did monitor entries
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relevant to their respective company or a specific drug they marketed, as a majority of
relevant edits were done to their own company and drugs.
In sum, it appears that verifying whether users are authentically representing
themselves on the Web is an elusive quest. The owner and moderator of one popular
consumer discussion forum seemed unaffected by possible intrusions of corporate
representatives, and the Head of Operations of a consumer-centric health site suggested
such intrusions are discouraged, probably infrequent, and minimally impacting. The
Wikiscanner search further indicated that anonymous activity of persons on
pharmaceutical company networks in the highly popular Wikipedia was relatively
infrequent during 2002-2007.
Data Checking of the Research Sample
Recent posts vs. older posts.
Tables 4.58 and 4.60, discussed in the previous section, show that the most recent
consumer posts for both drugs are comparable to the full dataset on “symptoms
improved” and “symptoms new/worsened.” Thus, there did not appear to be an imbalance
of favorable comments for either drug in the most recent posts.
Table 4.63 divides all consumer posts from 4 websites (excluded IcarusProject)
and both drugs by the time period the comment was posted: 2002-2005 and 2006-2009.
There were significantly fewer comments in the more recent time period for effects
related to sleep, and gastrointestinal and urinary systems. Table 4.64 lists the frequency
of consumers who mentioned each code within these 2 categories of effects. Fewer
consumers in recent posts mentioned constipation, diarrhea/gas, and nausea/vomiting
under gastrointestinal effects, and excessive sleeping/tired, helps me sleep, and trouble
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sleeping/insomnia under sleep effects. However, none of these effects individually
reached statistical significance. There also did not appear to be a patterned bias in
reporting of sleep effects, as the “positive” effect (helps me sleep) and the remaining 2
“negative” or “adverse” sleep effects were each reported by fewer consumers in the most
recent time period.
If a bias of overly favorable reports of drug effects were present, it may be most
likely to appear within mental or mood effects. Table 4.64 therefore also compares
commonly reported effects within this category against the time period of the post.
Significantly more consumers in the recent time period reported vivid dreams or
nightmares, and significantly fewer reported an increase in energy, euphoria or mania.
Both of these effects could be considered “positive” or “negative” depending on
individual context and the severity of the effect. A nearly equal proportion of consumers
across time periods mentioned new or worsening symptoms, but significantly fewer
consumers in the recent period mentioned an improvement in symptoms (25.5% versus
35.0%, respectively).
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Table 4.63
Data Checking by Time Period of Consumers’ Posts and Drug Effect Categories for
Lexapro and Seroquel Combined
2002-2005 posts
(N=203)

2006-2009 posts
(N=757)

Chisquare

pvalue

Sleep Effects

115 (56.7%)

348 (46.0%)

7.312

0.007

Gastrointestinal and Urinary
Effects

30 (14.8%)

73 (9.6%)

4.407

0.036

Lab Tests and Chronic
Conditions

2

37

--

--

Other Effects

40

113

2.727

0.099

Head or Face Effects

26

68

2.652

0.103

Appetite and Weight Effects

47

208

1.534

0.215

Mental or Mood Effects

122

428

0.829

0.363

Nose Throat Chest Effects

16

73

0.591

0.442

Skin Effects

9

43

0.486

0.486

Musculoskeletal and
Neurological Effects

32

114

0.062

0.804

Sexual Effects

21

81

0.021

0.884
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Table 4.64
Data Checking by Time Period of Consumers’ Posts on Selected Code Categories for
Both Drugs Combined
2002-2005 posts 2006-2009 posts
Chip(N=203)
(N=757)
square
value
Gastrointestinal and
Urinary Effects
Constipation

2.0%

0.8%

--

--

Diarrhea / gas

3.9%

1.8%

3.127

0.077

Nausea / sick stomach /
vomiting

9.9%

6.3%

2.999

0.083

Urinary changes / problems

1.0%

1.5%

--

--

Sleep Effects
Difficult to wake up

2.0%

3.8%

--

--

Extreme sleepiness / tired

33.5%

26.9%

3.381

0.066

Helps me sleep

20.7%

18.9%

0.333

0.564

Trouble sleeping / insomnia

9.4%

7.3%

0.987

0.321

Yawning

1.5%

1.6%

--

--

Mental or Mood Effects
Brain fog / zombie

13.3%

12.8%

0.034

0.854

Dreams vivid / nightmares

2.5%

6.1%

4.155

0.042

Energy increased / euphoria /
mania

6.4%

3.3%

4.05

0.044

Numb / detached / lack of
energy or interest

7.4%

7.7%

0.017

0.896

Symptoms new / worsened

12.3%

13.3%

0.148

0.7

Symptoms reduced / improved

35.0%

25.5%

7.215

0.007
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Anonymous versus identifiable posts.
Table 4.65 shows results of chi-square testing of drug effect categories for consumer
reviews posted by anonymous and identifiable users. Two categories, “lab tests and
chronic conditions” and “head or face effects,” reached statistically significant chi-square
values. For the remaining categories, there was no association between reported drug
effects and anonymity of the user. Table 4.66 lists the percentage of consumers from each
group who mentioned a code within the two statistically significant categories of effects.
More consumers who provided an identifiable user name reported problems with
increased blood sugar and/or diabetes. More consumers in the anonymous group reported
increased headache, hearing/taste/smell changes, and jaw clinching/grinding.
Again, if a bias of favorable accounts were present, it may be more likely to appear
within mental or mood effects. There was a non-significant chi-square value for “mental
or mood effects” as a category, but selected effects within the category were examined
more closely to ensure a thorough review of the data. Table 4.67 shows the number of
consumers mentioning the 5 most frequently reported mental or mood effects for Lexapro
and Seroquel combined. Only 1 effect, emotional stability or calm, reached statistical
significance (chi-square=4.503, p=0.034), with more consumers who posted
anonymously reporting this effect. Anonymous users also more frequently mentioned
new or worsening symptoms (p=0.057), and almost equally to identifiable users
mentioned improvements in symptoms (32.3% and 27.6%, respectively). Therefore,
while there was an imbalance of positive comments relating to emotional stability in the
anonymous group, the imbalance did not continue through to other mental or mood
effects.
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Table 4.65
Data Checking for Anonymity of Users by Drug Effect Categories for Lexapro and
Seroquel Combined
Anonymous Users
(N=477)

Identifiable Users
(N=243a)

Lab Tests and Chronic
Conditions

11

13

4.629

0.031

Head or Face Effects

57

17

4.284

0.038

Mental or Mood Effects

307

140

3.114

0.078

Other Effects

87

32

3.000

0.083

Sleep Effects

258

120

1.429

0.232

Sexual Effects

57

23

1.006

0.316

Gastrointestinal and
Urinary Effects

59

26

0.431

0.512

Nose Throat Chest Effects

49

23

0.117

0.733

Appetite and Weight
Effects

134

71

0.100

0.752

Skin Effects

25

13

0.004

0.951

Musculoskeletal and
Neurological Effects

76

39

0.002

0.968

a

Chisquare

pvalue

Excludes users from CrazyMeds because all users of this forum have an identifiable user
name.
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Table 4.66
Data Checking for Anonymity of Consumers on Statistically Significant Code Categories
for Both Drugs Combined
Anonymous Users
(N=477)

Identifiable Users
(N=243)

Lab Tests and Chronic
Conditions
Blood pressure changes

0.6%

0.8%

Blood sugar high / diabetes

1.0%

4.1%

Cholesterol high

0.0%

0.4%

Liver levels / hepatoxicity /
hepatitis

0.2%

0.8%

Other labs or chronic conditions

0.6%

0.8%

Head or Face Effects
Headache / migraines reduced

0.4%

0.0%

Headache increased

5.9%

3.7%

Hearing, taste, smell changes

1.3%

0.4%

Jaw clenching / grinding

4.4%

2.5%

Vision / eye changes

1.9%

1.6%
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Table 4.67
Data Checking for Anonymity of Consumers on Selected “Mental or Mood Effects” for
Lexapro and Seroquel Combined
Anonymous Users
(N=477)
N (%)
154 (32.3%)

Identifiable Users
(N=243)
N (%)
67 (27.6%)

Emotionally stable / calm

65 (13.6%)

Symptoms new / worsened

Symptoms improved

Chisquare

pvalue

1.681

0.195

20 (8.2%)

4.503

0.034

69 (14.5%)

23 (9.5%)

3.612

0.057

Brain fog / zombie

65 (13.6%)

36 (14.8%)

0.188

0.664

Numb / detached / lack of
energy or interest

44 (9.2%)

18 (7.4%)

0.675

0.411

Scripted comments.
Table 4.68 shows results of the search for 14 common key words and phrases found on
the drug manufacturers’ websites and medication guides. From the sampling frame of
over 7,000 consumer comments, half of the 14 phrases were found in 1 or more
comment. For most of the phrases, there was no resemblance between the consumer’s
comment and information on the manufacturers’ websites or medication guides. For 1
phrase, a consumer was citing information from the drug’s patient information leaflet.
One consumer returned for the phrase “safe” stated that he was a pharmacy technician,
but that he took Seroquel and found it to be “SAFE, EFFECTIVE.” This consumer
advised, “If you follow the drug guidelines and your doctors recommendations you will
be fine!” This comment was included in the sampling frame, but was not randomly
selected for the coding sample.
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Finally, 1 consumer comment returned for the phrase “takes time” posted an
extremely positive comment about Lexapro, “I am so glad that I did (try Lexapro)! It
takes time, so stick with it and you will be so glad you did….Lex has rocked my world in
the best way. For once in my life I feel like I HAVE a life…For me it has been nothing
short of a miracle. I praise and thank God, A LOT!” The search phrases “continue to
take” and “takes time” came from the following sentence on Lexapro.com: “Remember,
it is important to continue to take your medicine for as long as your healthcare
professional advises, even if you start feeling better. Otherwise your symptoms could
return or worsen. Full recovery takes time.” The above consumer comment, while highly
favorable, did not duplicate information on Lexapro.com and was kept in the sampling
frame (though it was not randomly selected for the coding sample).
Taking the 3 data checking strategies together, there did not appear to be any consistent
patterns of bias. There was an imbalance of favorable comments related to emotional
stability by anonymous users, but this imbalance did not appear for other mental/mood
effects. Further, there were few differences in reporting according to time period or
newness of the post. Since this is a preliminary effort at exploring the authenticity issue
of online consumer reviews, continued vigilance and additional probing is certainly
necessary.
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Table 4.68
Sampling Frame (N=7,114) Search for “Scripted” Comments
Search terms
Effective in the treatment

# of
returns
0

Conclusion about comment(s)

Can be taken every

0

Proven effective; proven to
be an effective

0

Significantly improved

2

No resemblance

Controlled studies; clinical
studies

2

Cited information from PI sheet

Continue to take your
medicine; continue to take

20

No resemblance

Full recovery takes time;
takes time

8

Case #4367 was a very positive comment

Increas* serotonin

2

No resemblance

Maintain* treatment; prevent
the depression

1

No resemblance

Keep taking your medicine;
take your medicine

0

May take several weeks

0

Work* well and generally
safe; safe

46

Symptoms don’t improve

0

Initial presentation of bipolar;
precipitat*

0

In case # 4784, user stated he is a pharmacy
technician, but that he takes Seroquel
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Chapter 5: Strengths and Limitations
Research Strategy
Coding and analysis for this project relied on the researcher-interpreter as
instrument. Researcher bias, including taken-for-granted assumptions, prior knowledge,
and personal responses to the data, is a problem for all researchers to handle reflexively
and transparently. Several strategies were used in this research to minimize the overall
impact of the researcher’s perspective. First, coding stuck close to the data, especially for
drug effects where little interpretation was needed. Also, theory construction was not part
of this research project, which minimized the potential for broad generalizations and
unfounded conceptual leaps.
Second, an advantage of using QDA Miner for this project was its ability to track
every key stroke. The software included a “Command Log” function in which every
command, code, or change to the data was tracked for ultimate transparency. Memos
written by the researcher and attached to codes or cases further served to track the
evolution of ideas and to make note of unusual cases or uncertain coding decisions.
Finally, a 20% randomly selected sample of the data was coded by 2 independent
coders and acceptable agreement was reached. While it is in the nature of a grounded
theory approach for the codebook to continually evolve, for this research many codebook
revisions were decided through discussion between the 2 coders (after independent
coding was completed).
A primary aim of grounded theory coding is to produce categories that fit closely
with the data (Corbin & Strauss, 2008). The credibility, in terms of the trustworthiness
and believability, of the present research was enhanced by minimizing interpretation of
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data, maintaining transparency in the coding process, and including a second independent
person to test for agreement.
Authenticity of the Sample
Due to the inherent anonymity of the Internet coupled with marketing imperatives
of pharmaceutical companies, it is possible that pharmaceutical company representatives
may be covertly contributing to consumer-constructed sites, thus compromising the
integrity of the data as genuine consumer experiences. The credibility of the usergenerated web and the authenticity of individual contributions within specific websites is
an unresolved and evolving issue. Further, it is difficult to identify possibly unauthentic
accounts, and there is no precedent for a method to accomplish this task. Despite their
lack of credibility in certain quarters, however, user-generated sites are highly trafficked
and carry utility for their constituents and users.
Revisions to concepts of truth, credibility, legitimacy, and expertise brought on by
the Internet are at the heart of discussion and debate among Internet researchers in a
variety of fields (David, 2007; Keen, 2007; Warnick, 2007). Adding to this discussion,
the present research sought to investigate the similarities and differences in the drug
information presented by experts and consumers on various websites. This is to
distinguish the aim of the research from one that seeks mainly to determine the truth
value of specific claims.
The present research included a few strategies to attempt to check the data for
possible bias. All findings were used to nuance the final conclusions regarding the
construction of expertise on the Internet. The research compared recent consumer
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comments to earlier comments, anonymous comments to identifiable ones, and searched
for “scripted” comments copied from pharmaceutical company material.
Second, the substantial number of contributions on the consumer-constructed sites
sampled in this research (minimum 200 contributions) was further intended to reduce the
overall impact of possible intrusions. Third, preliminary research was conducted by
contacting Web 2.0 researchers, bloggers, and webmasters, and by performing a
wikiscanner search of Wikipedia edits.
It is likely that the issue of authenticity on the web will continue unresolved for
some time due to the nature of this medium. The information and data resulting from the
above strategies are not conclusive evidence, but do offer the suggestion that most
consumer accounts can be accepted at face value as genuine consumer accounts. They
also suggest the possibility that a small proportion of favorable accounts regarding drugs
might be posted by drug company representatives posing as consumers. Given the market
imperatives of drug promotion, the immense financial means of the pharmaceutical
industry, and the enticing marketing opportunity consumer review sites offer, a skeptical
watchfulness regarding this issue is prudent.
The present research sought to contribute to this discussion via the various checks
on consumer comments completed as part of data analysis. The selection of websites with
a high number of contributors was a final strategy to ensure rich and varied data. None of
the above measures, however, can speak to the authenticity of reported consumer
experiences as actual experiences, and almost no previous research has sought to
investigate this problem. Until systematic assessments of this kind do occur, it cannot be
assumed that the data here are genuine consumer experiences; rather they only present
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themselves to be consumer experiences. They also appear to be regarded by most web
users as genuine experiences, making an exploration of their content an important, though
not wholly sufficient initial step for research. This is the chief limitation of the data, and
must be a top priority for continued research if such data is to be made meaningful and
useful.
Generalizability and Applicability
Applicability refers to findings that provide the insight or understanding that
allows them to be used in a practical way in policy, practice, or as an addition to a
knowledge base (Corbin & Strauss, 2008). The findings of the present research were not
intended to be generalizable in the sense of being representative of a larger population.
This research was not able to speak to the unknown population of consumer-constructed
or expert-constructed websites on the Internet, but the findings did result in a deeper
understanding and insight of the content distributed across the selected sites. The
sampling of exemplar sites reflecting typologies further increased the applicability of the
finding, which is discussed in more detail in the Conclusion.
Units of Analysis
Individual consumers were counted as a single case in this study. For the 2 sites with
discussion forums, all comments from a user across multiple discussion threads were
collected and put together to count as a single case. Some users may have had 1 entry,
whereas other users may have posted dozens of comments. It is further likely that the
heaviest users – in terms of the number of comments they posted – have a stronger
presence and a different standing within the community compared to those who sparsely
post. To other community members, the comments of heavy users may hold more weight
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or be more authoritative, and may influence others’ comments and the direction of the
discussion. The present study did not differentiate between these users, so that consumers
who posted 1 time and those who posted 30 times were given the same weight. The
analysis, therefore, did not replicate a “typical” reading of this text because it did not
effectively capture the nuances and particularities of each online community. To partially
address this limitation, measurements of code frequency (which included multiple
mentions within a case), rather than case occurrence (which counted each case 1 time
regardless of the number of times the code appeared), were sometimes used to reflect the
relative attention given to certain themes/effects by heavy users.
Statistical Analysis and Comparisons
There were a high percentage of consumers who did not report variables of gender, age,
and length of time taking the drug. These large amounts of missing data and low cell
frequencies prevented some statistical analyses. To work around this problem, some
categories were collapsed, such as in the analysis of age group by drug taken where the 2
oldest and 2 youngest age categories were combined.
At other times, sparse reporting of individual drug effects, for example sweating
or rash, necessitated examining them as categories of effects, such as “skin effects.” The
development of categories for individual effects was based on prior knowledge of body
systems, as well as the logic and discussion of the two coders. Inter-coder agreement
indices, however, were based on categories of effects and acceptable agreement was
reached. Regardless, there is inherently some interpretation involved in grouping items
together. Whenever statistical tests relied on categories of effects, individual effects
within that category were further examined to determine where differences, if any, may
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have resided. Most analyses included some combination of examining effect categories,
individual effects, and descriptive excerpts from the data. This strategy of looking at the
data in multiple ways was intended as a checks and balance for bias that may have
existed at any individual angle.
Another difficulty emerged in finding a common metric to compare expert text and
consumer comments. Simple frequencies of the number of cases from each group or how
many total times each group mentioned an effect did not provide meaningful comparisons
because of differences in the quantities (n=4 for experts, n=1080 for consumers) and type
(informational text versus consumer reviews) of data. An admittedly cumbersome
common metric was found in taking the proportion of mentions of an effect/theme out of
all mentions of effects/themes. For example, it was not revealing to state that 100% of
expert cases mentioned the “talking with the doc…” code and just over 16% of
consumers mentioned this code. Similarly, because of the large discrepancy in the
amount of data for each group, it was difficult to interpret what it meant for that code to
be mentioned 109 times in 4 expert cases and 316 times in 181 consumer cases.
However, a comparison could be made in the proportion of those frequencies of mentions
out of all mentions, in this case being 52.7% of all mentions of themes in expert text and
5.1% in consumer text. While unwieldy and not intuitive to grasp, this metric offered the
advantage of estimating the relative attention given by each group to specific effects and
themes. This metric was complemented by excerpts of text from each group to add depth
and richness to the comparison.
Finally, this was an exploratory study intended for hypothesis generation, rather
than hypothesis testing. There was a lot of data to sort through and a large number of
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comparisons were made. In such exploratory studies with many comparisons, it is likely
that some significant findings will occur in error. In this study, corrections for multiple
comparisons were made in some cases. However, a more general cautious approach to
the data was warranted whereby no specific p-value was interpreted too strongly. Rather,
conclusions were based on the overall pattern of results. Conclusions of the present
research should further serve as planned hypotheses to test in additional future samples.
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Chapter 6: Discussion
Additional Data on Popularly Reported Drug Effects
Lexapro.
Consumers taking Lexapro mentioned effects related to sleep, weight, and sex more
often than any other type of effects (excluding mental/mood effects). This finding is
congruent with other research surveying consumers on “side effects” of antidepressants.
iGuard.org, an online service that collects drug safety information from their “patient
community,” randomly surveyed 700 of its members who were taking at least 1 of 5
antidepressants, including Lexapro (Cascade, Kalali, & Kennedy 2009). The aim was to
gather “real-world” information about antidepressants’ side effects. Of the 229
consumers (38%) who reported 1 or more side effects, the most frequently reported
effects were: problems with sexual functioning (24.5%), sleepiness (23.1%), and weight
gain (21.4%). A survey of over 3,000 Consumer Reports’ readers being treated for
depression and anxiety found a 40% incidence of sexual dysfunction and 20% incidence
of weight gain (“Drugs vs. talk therapy,” 2004). These frequencies are not too different
from findings in the present research in which 20.2% of Lexapro consumers mentioned
“sexual effects,” 23.8% excessive sleepiness, and 12.1% weight gain (although “appetite
and weight effects” were mentioned by 22.5%).
Controlled trials have reported widely varying rates of sexual dysfunction with
antidepressants, sometimes ranging from 20% to 80%. The 20.2% rate of mention for
sexual effects of Lexapro found in the present study, then, is on the low end of estimates.
An 8-month double-blind study comparing Lexapro (n=274) to another antidepressant
and placebo found 48.7% of Lexapro participants reported sexual dysfunction at 8 weeks
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(Clayton, et al., 2007). This was significantly more than that reported on the other
antidepressant or placebo (however, the study was funded by the manufacturer of the
other antidepressant). The rate fell only slightly by the 8-month study ending (43.6%),
but was no longer significantly different from the other drug.
The FDA-approved drug label for Lexapro cites lower rates of sexual dysfunction. Less
than 2% to up to 7% of clinical trial participants for major depressive disorder and
anxiety are listed as experiencing decreased libido or impotence. These effects were
described in WebMD as “infrequent” and “unlikely.” However, within the category of
sexual effects, lost sex drive was the most frequently mentioned effect by consumers in
this study (10.6%). The FDA label further reports that 2% and 6% of participants in
depression and anxiety trials, respectively, experienced anorgasmia, and 9% and 14%,
respectively, experienced ejaculation disorder. Trouble achieving orgasm was listed as a
“common” and “less serious” effect in WebMD, and mentioned by 8.5% of consumers
taking Lexapro. Thus, the officially “infrequent” effect of lost sex drive came up more
frequently in the present sample of websites than what is supposed to be the more
“common” effect of delayed orgasm.
The drug label for Lexapro also cites lower rates of sleepiness and weight gain
compared to consumers in this study and findings from iGuard.org. Somnolence, a term
than encompasses drowsiness and sedation, has a 6% incidence in depression trials and
13% incidence in anxiety trials according to the drug label, compared to the over 23%
rate of mention in both the present and iGuard.org studies.
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Weight gain is not listed as a side effect on the drug label, rather the following
statement is present, “Patients treated with Lexapro in controlled trials did not differ from
placebo-treated patients with regard to clinically important change in body weight” (p.
13). Following the lead of the drug label, neither weight gain nor weight loss were
mentioned at all on WebMD, and RevolutionHealth only spoke to “weight changes” as
“less serious.” WebMD did list increased appetite as a “rare” effect. Again 22.5% of
consumers in this study mentioned appetite and weight effects of Lexapro, and over a
fifth of consumers in the iGuard.org survey reported weight gain on antidepressants.
The primary “side effects” of Lexapro that were reported by consumers in this
study appear congruent with findings from other consumer surveys. However, the rate of
sexual effects was on the low end of the varying estimates found in controlled trials. The
rates of sleep and weight effects were considerably higher than those listed from
controlled trials on the drug label. Descriptions of effects in the 2 expert texts appeared to
largely reflect data provided on the FDA-approved drug label.
Of note, the popularity of an effect among consumer reviews may reflect its
subjective burden on consumers more than its actual incidence in the drug using
population or severity in terms of potential health complications. This limits the
usefulness of comparing frequencies across consumer surveys, controlled trials, and the
drug label. Caution should be taken not to over-interpret any single finding. Nevertheless,
such comparisons are a first step to exploring the similarities and differences of these
sources, and some comparisons, such as the above absence of weight gain on the drug
label compared to a high rate of mention among consumers, are quite striking.

224

Seroquel.
For Seroquel, the most commonly reported effects by consumers in this study
were related to sleep and weight. Over 60% of consumers mentioned sleep effects, and
over 30% mentioned appetite and weight effects. Antipsychotic induced weight gain is a
well-known and concerning issue that can often precipitate more serious metabolic
diseases (Correll, et al., 2009; Goudie, Cooper, & Halford, 2004; Taylor & McAskill,
2000). On the FDA-approved drug label for Seroquel, there is a confusing discrepancy on
the incidence of weight gain in controlled trials. A table on page 17 cites that an average
of 22% of subjects in trials for schizophrenia and bipolar mania, and 8% in trials for bipolar
depression experienced weight gain greater than 7% of total body weight. However, a table
on page 28 that lists all adverse effects in trials for schizophrenia and bipolar mania cites a
5% incidence of weight gain, and 4% incidence in trials for bipolar depression. WebMD
cited weight gain on Seroquel as “common” and both expert texts described it as less serious
or less severe. Over 22% of consumers in this study mentioned weight gain specifically,
corresponding to the highest estimate provided on the drug label. Consumer descriptions of
weight gain were not generally congruent with the “less serious” label, as many reported
feeling extremely burdened by the extra weight and uncontrollable, ravenous appetite, and
occasionally reported a dangerous amount of rapid weight gain.
Off-label use of prescription medications is common, and can exceed 50% for many
psychiatric medications (Radley, Finkelstein, & Stafford 2006). In the present study, over
one-third of consumers taking Seroquel reported that the drug helped them sleep, and nearly
the same number reported the drug caused excessive sleepiness. Expert texts included no
mention of the drug as a sleep-enhancing agent, as it is not a FDA-approved indication,
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though this appeared to be a popular use of the drug according to consumer accounts. Studies
of antipsychotic use in large psychiatric hospitals support this finding and suggest that
Seroquel is frequently used in practice to induce sleep (Philip, et al., 2008; Stowell, et al.,

2009). An analysis of Veterans Administration data for 2007 showed that over 60% of
the 279,778 unique patients who received an antipsychotic prescription were using the
drug for an off-label indication (Leslie, Mohamed, & Rosenheck, 2009). Seroquel had the
largest proportion of off-label use (42.9%) compared to all other prescribed
antipsychotics. Off-label uses included PTSD and Anxiety, among other diagnoses, but
did not include insomnia, as data for the study was based on official diagnoses used for
prescription reimbursement (use of Seroquel for trouble sleeping is unlikely to show up
on those records).
The drug label for Seroquel states, “Somnolence was a commonly reported adverse
event” occurring in 18% of patients in schizophrenia trials, 16% in bipolar mania trials, and
57% in bipolar depression trials. Expert text in this study cited “drowsiness” as a “common”
and less serious or less severe effect. In a departure from the drug label, expert text further
listed insomnia as another “common” effect of Seroquel. The latter effect was mentioned by
just over 2% of consumers in this study, indicating that, at least for this sample of consumers,
sleepiness (whether helpful or not helpful) was a tremendously more “common” drug effect
than insomnia.

Reports from consumers in this study seem to reflect real-world use of Seroquel
as a sleep-aid, among other frequent off-label uses. Appearing to generally reflect data
from the drug label, information about the drug’s sleep effects on expert text was limited
to listing “drowsiness” and “insomnia” as “common” side effects. As an aside, the latter
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effect was barely represented in the present sample of consumers. The other commonly
reported effect of Seroquel, weight gain, was listed on the drug label with generally lower
incidence rates than the rate of mentions found in the current sample of consumers.
Effect Classification
The findings from this study support Moncrieff and Cohen’s (2006) suggestion that the
labels “side effects” and “therapeutic effects” may be misnomers that cannot be easily
applied to psychotropic drug effects. One of the more difficult aspects to developing the
codebook was in classifying drug effects. The initial codebook included categories for
“side effects,” “beneficial effects,” and effects appearing “neutral.” This became
impossible to maintain during coding because many of the most commonly reported
effects were described by consumers as beneficial, or adverse, or both at the same time.
For example, the sleep effect of Seroquel was often described to be a benefit of the drug
in the evenings when sleep was needed, and an undesirable effect during the mornings
when alertness was needed. In listing drug effects, a consumer on AskaPatient recorded
the dilemma as such, “fatigue (good for sleep though).” Memos written by the researcher
in December 2009 and February 2010, noted ideas to merge the “helps me sleep” code
with the “excessive sleeping” code because they so frequently appeared in the data to be
one-in-the-same effect of sedation (i.e., some consumers found the drug to induce just
enough sleep, while others found it to induce too much sleep). In the end, the two codes
were not merged in the hopes of facilitating a more meaningful analysis of sleep effects.
Also reported, though less often, were the benefits of Lexapro’s “side effects” of
delayed orgasm and lost sex drive. A minority of consumers were pleased to find they
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“can last longer” during sexual intercourse, and/or that their previously high sex drive
was now more “normal.”
Similar to the sleep effect described above, some mental or mood effects appeared
to manifest on a spectrum. The codes “emotionally stable/calm/normal” and
“numb/detached/lack of energy or interest,” for example, shared the basic property of a
“mellowing” effect that manifested more or less strongly in different individuals. Over
9% of consumers mentioned that the “calming effect” of Lexapro or Seroquel put them
on an “even emotional keel” or “levels out emotions” and allowed them to “handle things
better.” Just over 7% of consumers commented that the drug “made me not care about
anything,” “desensitizes me,” made them “numb to the world,” “apathetic,” and “felt no
emotion (happy or sad!).” The mellowing effect was often clearly distinguished as
desirable or undesirable by the consumer, though some consumers felt ambivalent about
how to classify it. A consumer reviewing Lexapro on RevolutionHealth remarked that the
drug produced “such an even keel that it feels strange…I feel like Spock on the old Star
Trek series – very rational and systematic, not at all emotional.” A user on CrazyMeds
commenting on the mellowing effect of Lexapro neatly summarized the problem, “I
rather wonder how a person being treated for anxiety is supposed to decide when ‘not
being concerned’ is an undesirable side-effect rather than a desired outcome.”
For the purposes of codebook development, it appeared to be more precise to
conceptualize that the drugs produced general effects, such as sedation, that some people
in certain situations found helpful and some people in certain situations found unhelpful
(Moncrieff & Cohen, 2006). To produce a more accurate representation of consumers’
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accounts, the initial codebook categories (i.e., beneficial, side, and neutral effects) were
dissolved early in the coding process in favor of coding all effects simply as “effects.”
Variation among Consumers
Consumer reviews on WebMD and RevolutionHealth were different from those on
consumer-constructed sites in important ways. Significantly more consumers on
consumer-constructed websites reported Seroquel worsened their symptoms (p=.000),
while more consumers posting reviews on the expert health sites reported it improved
their symptoms (p=.008). This trend was repeated for Lexapro, but the difference did not
reach statistical significance at the p<.002 level. In addition to greater reporting of
symptom improvement, consumers on expert-constructed sites reported generally lower
rates of “side effects.” For example, consumers for both drugs on RevolutionHealth
reported the highest rate of symptom improvement compared to the other websites. For
Lexapro, they reported the lowest rate of weight gain, and for Seroquel, the lowest rate of
new or worsening symptoms.
Consumers on CrazyMeds mentioned drug effects at a generally lower rate than
consumers on the other 3 websites, but contributed considerably more than the other sites
to drug themes. This means that between the 2 consumer-constructed sites reporting
effects for specific drugs, consumers on AskaPatient mentioned drug effects at a much
higher rate than those on CrazyMeds. AskaPatient also generally reported “side effects”
at higher rates than any of the other 4 websites.
These differences may be explained by actual differences in the types of consumers
who use these various sites. Many users on CrazyMeds demonstrate an advanced
knowledge of psychopharmacology and spend more time discussing drug combinations,
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dosing issues, and the like as opposed to straightforwardly reporting drug effects. It
could be reasoned that consumers using AskaPatient may be disconcerted with more
mainstream health sources due to negative drug experiences, and looking for an
alternative space to find and share such experiences. The structure of AskaPatient
supports this hypothesis, as the site specifically solicits information under 2 main fields:
“comments” and “side effects.” As a logical extension, consumers on WebMD and
RevolutionHealth may represent the “average,” mainstream drug consumer with an
“average” drug experience (i.e., some positive, some negative, but mostly hovering
around a middle point). However, the consistent pattern of imbalance that both favored
symptom improvement and demonstrated lower rates of side effects on WebMD and
RevolutionHealth suggests something other than solely contributions from “average”
consumers. There could be several possible explanations. One, rather than “average”
consumers, reviews on these sites come from persons with especially positive drug
experiences. Two, perhaps expert health sites have filtered consumer drug reviews to
reduce overly negative accounts. Such a practice could reasonably be attributed to
financial imperatives related to banner advertisements by pharmaceutical companies.
Three, the “culture” and virtual physical environment of the websites have influenced the
type of comments that are posted. Visual cues, such as medical advertisements and
related graphics, may contribute to a “pro-drug” or “pro-medicine” environment that
attracts those who share a favorable attitude toward drug use and repel those who have a
negative attitude or are more critical of drug use. Over time, normative themes may
become established by way of these graphics and the accumulated text contributed by
consumers. Users of that site may tend to conform to those normative themes rather than
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post commentary that departs from them. Thus, the structure of the virtual physical and
social environment of websites may influence certain behavior patterns of site users.
Regardless, unless the online health searcher who uses consumer reviews actively
seeks a variety of sources to retrieve those reviews, these differences in consumers’
reporting of drug effects across websites could potentially and unknowingly hinder
informed decision-making.
It was hoped as part of this research to also examine differences in reported drug
effects according to consumers’ gender, age, and length of time taking the drug. If
variation had been found, it would add detail and precision that might increase the value
of the information as a body of knowledge. Such detail could prove useful for postmarketing surveillance. At the same time, added variation potentially increases ambiguity
for individuals making treatment decisions. Most consumers in this sample of online
reviews did not provide information on the above variables, which prevented a fruitful
analysis of possible differences in reporting. Future research may find it useful to contact
consumer reviewers who leave an email address, or use an online survey to gather data
that would include these variables.
How do Expert and Consumers Sources Help and Hinder Decision-Making?
Drug effects.
Consumer and expert text reported many of the same drug effects, and differed
primarily in their descriptions and the attention given to certain effects. First, while
expert text listed drug effects, consumer text described drug experiences. Language used
to list effects in expert text tended to be vague (i.e., “drowsiness”) and fixed (i.e., “less
severe”). The information on expert sites (e.g., the professionally-delivered drug
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information on expert sites, which does not include the consumer reviews on those sites)
was homogenized and the diversity of experiences was erased. Expert text successfully
eliminated ambiguity, making room for more simple and straightforward treatment
decisions for health seekers. Expert text appeared to follow the lead of the FDA-approved
drug label in providing the official account of drugs’ effects. Controlled trials, on which
the drug label and presumably expert text is based, are designed to capture averages and
report standardized data. It is therefore of little surprise that the language and design of
expert text reflected that of its information source.
The information reported by consumers represented a greater diversity of perspectives,
and effects were presented in a more specific and relatable manner in terms of providing
situational examples. For example, what can be learned from consumers is that
“drowsiness” caused by Seroquel can sometimes translate to “coma-like sleep” or having
to miss work or school because of the inability to stay awake. For the code “symptoms
new/worsened,” expert text summarized in list form the adverse mental or mood effects
reported in FDA black box warnings on the drug labels. These were the most frequently
mentioned effects in expert text. Consumers reported these same effects, but with many
examples of how they might manifest in various combinations and to varying degrees
(see Table 4.22).
Next to mental or mood effects, expert text most often mentioned physical “side
effects” of drugs, such as nausea/vomiting, dizziness, and blood related changes.
WebMD (though not RevolutionHealth) listed a number of (usually rare) physical effects
that could only be diagnosed with laboratory tests, and that could cause serious disease
conditions if left undetected. Only a couple of these effects (i.e., increased blood sugar)
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were discussed by more than a few consumers. Expertise regarding the human body and
drugs’ actions on the body may be necessary to ensure patient safety in cases of rare
adverse effects or those with less obvious manifestation (i.e. that require laboratory tests
to detect). While consumer accounts offer rich descriptions of many drug effects, less
discussed effects carry the risk of becoming lost in the volume of data.
It is difficult in expert text to decipher the relative burden of lists of effects simply
labeled “less serious” and “serious.” In this study, those labels applied by experts’ did not
always match up with the perceived importance or severity of effects according to
consumers. One hypothesis is that expert text may label effects according to their impact
on the physical body, so that weight gain and sexual dysfunction are generally “less
severe” effects while a blood clot in the lung is “severe.” Consumers may be more likely
to label effects according to the impact on their lives as a whole, including the physical
body, psychological and emotional well-being, and social lives. Weight gain becomes a
more serious effect judged by its impact on the person’s life, while a possible symptom of
something more detrimental to the body, such as coughing or trouble breathing, may go
undetected because it carries less subjective burden on the life of the person experiencing
it. It is arguable, then, whether consistency in expert and consumer descriptions of the
“severity” of effects is possible or even desirable. Of course, for many effects, it seems
reasonable to assess the effect according to its total impact on a life. Expert text might
increase its relevance to consumers by either better explaining the meaning of its current
labels or expanding its label system to include effects’ broader impact.
A cursory browse (as may be typical for the average Internet user) through consumer
reviews offers a strong general impression of what the drug may be “like” through
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concrete, descriptive examples of individuals’ experiences. In such a brief review,
though, the Internet user would likely miss many less popularly discussed but still
potentially momentous effects. There is an increased likelihood when relying on
consumer accounts that persons might miss important information about potential drug
effects that can only be detected on the basis of laboratory tests. In contrast, for the
“typical” online health seeker, expert text provides succinct and readable summaries of
both common and rare, less serious and serious drug effects.
Finally, experts and consumers differed in the attention each group gave certain effects.
Consumers taking both drugs appeared to be most concerned with effects on symptoms,
sleep, and weight, whereas expert text primarily attended to physical effects. Consumers
taking Lexapro frequently discussed weight gain, though this effect did not appear at all
in 1 expert text and only appeared as “weight changes” in the other. About one-third of
consumers taking Seroquel reported the drug helped them sleep, but there was no
mention in expert text of the drug’s potential beneficial or desirable impact on sleep.
Expert text simply listed “drowsiness.”
In sum, expert and consumer text reported many of the same drug effects, but the
relative attention given to particular effects was not distributed similarly among the
groups and descriptions of drug effects were often qualitatively different. Consumers
frequently discussed effects that were either more obvious or especially burdensome,
such as weight gain, changes in sleep, and mental or mood changes. Other than
repetitions of the black box warning from the drugs’ labels, expert text more frequently
mentioned physical effects, which are more likely to be manifested in less obvious ways
or carry fewer practical burdens. Consumers offered full and descriptive accounts of drug

234

effects, but the usability of this information is limited by the volume of data that must be
sorted through. Expert text offered succinct and comprehensive summaries of drug
effects, but the meaningfulness of this information is limited by the lack of context. In
answer to the first research question, “Does the accumulated consumer knowledge that
the Internet allows dissolve the traditional boundary between expert/scientific and
consumer/lay knowledge?” it seems that both groups have legitimate claims to expertise,
and both forms of knowledge (that based on the scientific method and that based on
experience) are beneficial for informed decision-making. The limitations of one are made
up by the advantages of the other. However, if consumer reports were more organized
and accessible (their major limitation currently), then the expert accounts found on
WebMD and RevolutionHealth could arguably be considered superfluous. Similarly, if
expert accounts increased their relevance by more richly describing the range of drug
effects, then online consumer reviews may not be such a necessary innovation for the
thousands of active and potential drug consumers who rely on them.
Themes.
Consumers mentioned more than double the number of themes found in expert text in
relation to drugs, doctors, family and friends, expense and insurance, pharmaceutical
companies, and general support and advice. Among the themes overlapping between
experts and consumers, consumers showed a range and diversity of perspectives, while
expert text reflected a more uniform discourse. For example, expert text provided lengthy
lists of possible drug “side effects,” but only 1 statement on 1 of the sites referenced an
assessment of benefits and costs, and it was clearly in favor of drug use. As part of their
drug reviews, consumers often made assessments of benefits and costs, and came to
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favorable, unfavorable, and uncertain decisions. More often than anything, consumers
came to the conclusion that the drug was for any variety of reasons of limited benefited.
Consumers also stressed that each person must make their own individual assessment
(“your mileage may vary”), which is important given the lack of predictability of
psychotropic drug effects.
There was a strikingly uniform discourse in expert text around “the doctor.” Expert text
was adamant, as measured by the number of times the code appeared in the text as well as
the percentage of words from the total text that received the code, about telling, calling,
talking to, consulting with, discussing with, or otherwise making no drug-related decision
without getting instruction from the doctor. It was the most frequently mentioned of all
themes in expert text, and the only theme involving the doctor that was repeated
continuously throughout each section of expert text. This circular pattern of selfreferences whereby whatever the problem, the doctor holds the answer serves to
strengthen the popularly accepted notion of an esteemed status and specialized
knowledge of the medical doctor.
Consumers appeared to rely on their general practitioner or psychiatrist for their skills
and technical expertise in medicine, and, with some exceptions, the research found little
evidence that consumers were trying to exclude their doctor from their care and treatment
by searching and sharing information online. This conclusion is supported by recent
focus group research finding that online health seekers felt empowered by instant access
to information, but were still unwilling to give up face-to-face interactions with their
doctor (Donnelly, Shaw, & van den Akker 2008). Comments about telling, talking to,
discussing with, et cetera the doctor were frequent in consumer text. The difference

236

between expert and consumer text was that consumers also demonstrated a range of other
interactions with and feelings towards the doctor. As discussed in the review of literature,
previous research has demonstrated insufficiencies in the communicating of drug
information from doctors to patients/consumers. Those findings are further supported by
consumer comments in this study.
Consumer reviews offered the advantage of a diversity of perspectives, as there is
no single consumer “voice” parallel to the unitary biomedical discourse found on
mainstream professional health sites. In parallel, expert text seemed to reinforce the
conventional stereotype of the omniscient doctor and the construction of “medication” as
an expert domain.
Theoretical Explanations of Findings
This research used Foucault’s ideas of power/knowledge and a politics of truth as
the conceptual framework for analysis. Foucault’s description of knowledge as dispersed,
often in an incomplete and contradictory manner, appears to be supported by the findings
of this research. Each consumer (and expert) offered a piece of a larger puzzle by
highlighting different aspects of the varieties of drug experiences. There was no uniform
discourse among consumers, but instead multiple, sometimes overlapping and sometimes
contradictory discourses were present. The extent to which the effects reported by
consumers were already informed by “expert” information is unknown, and should
temper the conclusions. However, it appeared that given the opportunity to contribute
directly to a knowledge field, particularly one involving an “experience good” like
psychotropic drugs, consumers were able to identify and describe many of the same
effects reported as part of more scientific methods. If such knowledge is dispersed, as this
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research suggests, then the question becomes one of understanding how the power
associated with knowledge becomes linked to one set of truth-making procedures and not
another. That is, if experts and consumers can both legitimately and meaningfully
contribute to a body of knowledge utilizing their respective resources (scientific method
and experience), then differences in status, attention, and influence of that knowledge
source may relate to power.
While Foucauldian concepts framed the original research, other theoretical
explanations of the findings are possible. A more pragmatic framework might
alternatively argue that the domain of medicine as an expertise is the human body, and
that the expert text in this research provided a comprehensive and concise accounting of
drugs’ effects in this regard. Its labels rightly represented the impact of an effect on the
body. Expert text also provided information about important effects that would likely go
unnoticed by those without medical expertise. Thus, medical expertise in the domain of
psychotropic drugs may be essential and beneficial to those who need it. Further, while
consumers reported many of the same effects listed in expert text, the presence of bias
and lack of structure inherent in this data source has limited its usefulness (and therefore
its use) in the construction of drug knowledge. The scientific method (in its ideal form),
with its systematic attempts to decipher true effects from noise, may be preferable to an
unsystematic and (in this case) largely anonymous collection of presumably consumer
voices. Still, consumer accounts do appear to add valuable contextual information to the
understanding of drugs’ effects and their impact on a person’s life. The expert sites in this
study may have recognized this fact, as evidenced by opportunities provided for
consumers on the sites to rate and write about their drug experiences.
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The findings of this study could also be interpreted in terms of evolving tensions
between expertise and democracy, with the Internet representing an expansion of
Habermas’ public sphere. Never before has there been the opportunity for public
participation in constructing official drug knowledge or for potentially identifying drug
problems. Online patient communities, such as PatientsLikeMe and iGuard, are
capitalizing on this expansion of consumers’ roles. Consumer comments analyzed in the
present study did not support fears of some analysts who claim amateur or lay content is
uninformed, possibly dangerous, and pushes out necessary expertise (Keen, 2007; Siegel,
2008). On the contrary, consumers reported many of the same effects as listed on expert
sites, though with sometimes major differences in the evaluation of effects’ significance.
These differences could not be used to label consumers’ reports as less accurate or of
lesser quality, but rather may best serve as a supplement to the typically briefer and more
narrowly focused expert descriptions. Further, some critical theorists argue that the
Internet is democratizing only inasmuch as marginalized or silenced voices are
represented (Dahlberg & Siapera, 2007). Expert sites in this study provided opportunities
for consumers (a traditionally silenced group in clinical drug research) to have “voice,”
thereby supporting the notion of the Internet as a democratizing space. However,
important differences were found between consumer accounts on expert-run and
consumer-run sites, along with considerable imbalances in the number of consumers
expressing certain themes or topics of concern between sites. As mentioned, these
differences may reflect consumers’ attempts to maintain congruence with the norms of
the community (website). They may also suggest that there exist real sub-communities of
psychotropic drug consumers who have shared experiences and interests related to drug
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use. Habermas’ public sphere was modified by Hauser who presented the notion of a
“rhetorical public sphere,” which is “a discursive space in which strangers discuss issues
they perceive to be of consequence to them and their group” (1999, p. 64). The activity of
members in a rhetorical public sphere is issue-oriented, then, rather than class-based,
which may help conceptualize the distinct interests and concerns of consumers across
websites in this study. The Internet may facilitate the expansion of rhetorical public
spheres, with the sample of websites in the present study perhaps reflecting this evolution
in its infancy. As online patient communities continue to grow and additional research
sheds light on their advantages and disadvantages, it is possible that this new form of a
public sphere might influence regulatory policy for drugs, including safety surveillance,
the classification of unpleasant effects as “serious” or other, and the conduct of research.
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Chapter 7: Conclusion
Hypotheses for Future Research
The grounded theory approach used in this study was intended as an exploratory step
that would assist in the formulation of hypotheses for more structured future research.
Several questions emerged. First, the “real” frequencies of sleep, weight, and sexual
effects of Lexapro need to be further investigated. Considerable discrepancies exist
between frequencies of mention of these effects in this study, which are supported by
other consumer surveys, and incidence rates in the published drug label. Does the high
percentage of consumer reports of these effects reflect an actual greater incidence than
that captured (or reported) in trials analyzed by the FDA? If these effects are in fact
occurring at a higher incidence, then how was this missed in large-sized clinical drug
trials? Alternatively, does the higher percentage found in consumer reports only reflect
the perceived burden or some other aspect of these effects, but not an actual higher
frequency of occurrence? A couple of research strategies could examine these questions.
A large, known (i.e., face-to-face) population of Lexapro consumers could be followed
for cross-sectional or longitudinal data of drug effects based on structured checklists and
open-ended response. Controlled trials could incorporate simple targeted measures for
weight, sleep and sexual effects, rather than continue to rely on “spontaneous” or
“unsolicited” self-report for such data (a method which tends to underestimate the true
frequency of events) (Greenhill, et al., 2003; Hughes & Cohen, 2010).
For more serious drug effects, data from this study or additional studies of consumer
reports could be compared to data from the main mechanism through which professionals
report serious effects they observe in patients, FDA’s MedWatch. The MedWatch system
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relies on voluntary reports primarily from medical professionals to detect safety issues
once a drug has been released to the market. A comparison of consumer and professional
voluntary reports might shed some light on the use of a consumer platform for safety
surveillance. A number of details should be included in an adverse drug reaction report in
order for the report to be meaningful, including age, gender, weight, length of time on the
drug, intensity or severity of the effect, drug history, family history, effect of withdrawal,
and effect of rechallenge, among other items. Future research could examine how well
consumers already report these items in online consumer reviews, and make further
suggestions for how to improve consumer reporting of drug effects. These findings can
also be compared to the average completeness of MedWatch reports, which are
specifically designed to elicit this information. Second, according to findings from this
study and published research from large hospitals, Seroquel’s primary use and effect is
related to sleep. This is an off-label use of the drug, and not an “officially” recognized
primary drug effect (as “drowsiness” is only listed as a “less serious” “side effect”).
Future research can examine more closely differences between diagnosis and reason for
use. One hypothesis is that while the official diagnosis or indication (listed for insurance
reimbursement) may be, for example, bipolar mania, the “reason” for prescribing or using
Seroquel specifically may be more narrowly related to its desirable effects on sleep. This
hypothesis runs parallel to Moncrieff and Cohen’s (2009) argument that psychotropic
drugs have global effects, rather than specific effects on presumed neurobiological
abnormalities. Consumer review data such as that used in this study could be examined
for congruence between diagnosis, which was often listed or stated by consumers, and
reason for use, which was often explained as part of the total review.
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The present study did not explore differences in drug effects grouped by diagnosis
or reason for use. By breaking down frequencies of some “side effects” of Seroquel by
indication (bipolar mania, schizophrenia, bipolar depression), the drug label implies that
drugs have specific neurobiological action and that drug effects will differ according to
the condition being treated. The label sometimes lists considerable differences in
frequencies of effects among indications, such as a much higher rate of somnolence in
bipolar depression trials. Of course, it is unknown whether methodological issues may
have contributed to inflated or deflated estimates in some studies. While not exploring
diagnosis, the present study did find that drug effects were not easily parceled into the
categories listed on expert sources and the drug label (i.e., “side effects,” “less serious,”
etc.). As an alternative explanation to neurobiological specificity, perhaps the global
effect of sleep is experienced and reported differently by a person presenting with, for
example, a depressed versus an excitable mood. This hypothesis is supported by classic
studies of drug use in which 3 factors were found to influence drugs’ effects: 1) drug (the
pharmacologic action of the drug itself), 2) set (the person’s state of mind, mood, and
attitude at the time of drug use), and 3) setting (the physical and social setting within
which the drug use occurs) (Zinberg, 1986). Also, as mentioned in the Literature Review,
psychotropic drugs’ effects are unpredictable for any 1 person, and may even differ
within any 1 individual taking the drug at different points in times (Brunton, Lazo, &
Parker, 2006). To investigate neurobiological specificity versus global drug effects,
additional studies examining drug effects in healthy, normal volunteers could help
determine whether primary drug effects, as Moncrieff and Cohen suggest, occur
regardless of psychiatric diagnosis. Researchers conducting controlled trials of drugs
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could broaden their scope of inquiry to include a greater range of psychological and
behavioral effects (rather than a narrow focus on physical effects), as well as variables
that might influence the drug experience, such as patient expectation, positive or negative
suggestion by the doctor or researcher, and patients’ personality characteristics.
Future Research: Authenticity and Credibility
A troubling limitation of the online medium in general is the inherently unknown
authenticity of persons contributing to content. It is imperative that the investigation of
authenticity precede the continued development of and reliance on online consumers as a
legitimate information source. Authenticity is one of a few issues at the center of the
debate about filtering online searches to retrieve only “trusted” health information
sources, and is principally directed towards consumer-generated sites (as well as
“gimmick” advertising sites, such as online pharmacies). As expert health sites are
tacitly “trustworthy,” perhaps due to the alignment of their discourse with science and
medicine, the burden of proof for trustworthiness more often falls on non-expert sources.
Future research should investigate the authenticity of online consumer drug accounts in a
way that does not implicitly favor scientific ways of knowing while forcing those
offering experiential knowledge to prove their worth.
Currently, the authenticity problem is unresolved and only a few scrutinizing
attempts have been made in any field of study. For consumer drug reviews, the findings
from this study could be replicated using additional samples, websites, and drugs, and
compared to other online consumer samples, expert health information, and drug
literature.
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Another important next step is to compare online consumer comments (with
unknown authenticity) about specific drugs to face-to-face samples of consumers (with
known authenticity). If feedback from real-world community samples is found to be
equivalent to online samples, then this may provide a foundation for the continued
development of online technology to support consumer-generated drug information (see
next section). Important differences in face-to-face and online samples may provide some
interesting and useful insights into who really is contributing to “consumer”-generated
online content.
Future Research: Usability
Consumer drug accounts are scattered across the Internet, making the “usability”
of this information a chief limitation and a top priority for continued research and
development. First, as there is no “typical” online health search that can be replicated,
several samples drawn in different ways should be analyzed for representativeness as was
done in this study with the most recent 20 posts from each website. While AskaPatient
lists consumer reviews by date, WebMD sorts reviews according to diagnosis then date,
and RevolutionHealth by diagnosis then “most helpful.” It is likely that a “typical” search
would include exposure to any number of combinations of reviews based on the
particular navigation pathways and interests of the user. The preliminary work of the
present study should be expanded to replicate additional possible searches.
The present study explored the content of online consumer reports, but a more
structured examination of specific variables (such as items needed for an adverse drug
reaction report, listed in the previous section) is necessary to further devise strategies that
might increase the usability of this information source. One hypothesis stemming from
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the present research is that many consumers naturally report at least some important
items within the context of describing their drug experience. This may happen
sporadically, though, as evidenced by the large amount of missing data in this study for
gender, age, and length of time on drug. However, the 2 websites that specifically elicited
that information (WedMD and AskaPatient) had very high rates of completed data. It
appears then that consumers may be willing to provide additional details if asked for
them. Existing and developing websites that collect consumer accounts could enhance
their relevance to safety surveillance and opportunities for more advanced decisionmaking by eliciting such information.
To further increase usability, existing and developing websites could also
integrate an advanced search function that would allow users to search consumer
comments for key words, such as “weight” or “tingling,” as well as return thesaurus
terms associated with those key words, such as “appetite” with “weight” or “zaps” with
“tingling.” Currently, the websites reviewed in this study sort consumer reviews
according to date posted, indication, or helpfulness, with no additional options for
organizing or filtering the hundreds or thousands of comments.
An additional step would be to develop a “meta” website that integrates the mass
of dispersed online consumer reviews, and somehow organizes them in a logical and
useful way. Currently there are patient communities, such as patientslikeme.com and
iGaurd.org, which attempt to not only collect consumer accounts (like AskaPatient), but
also to organize and report back in summary form the data from its users. These sites rely
on the dedication of their users to monitor and report changes in their condition and
treatment on an ongoing basis. Thus, it may be reasonable to assume that these sites
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represent a more pro-active and possibly informed group of healthcare consumers,
compared to those who do not participate in consumer-generated online media and even
to those whose participation is limited to writing a single drug review on WebMD, for
example. The present research found important differences among drug consumers who
posted a review or comment on various websites. To achieve the most balanced and
representative snapshot of consumer experiences, then, these differences need to be
accounted for. Individual online patient communities are innovative and useful for many
reasons, but they are limited in the preceding respect.
However, there are currently websites for travel (kayak.com) and consumer home
and electronic goods (consumersearch.com) that pull together information from multiple
sites and present it in a single organized site. Kayak.com searches travel deals from all
the major travel sites, such as cheaptickets, travelocity, expedia, and so on, to bring the
user the best deals without having to visit each site individually. Consumersearch.com
brings together expert reviews on consumer goods, such as reviews from PC Magazine
and PC World on a laptop, and lists each full review as well as provides a summary of
pros and cons based on an assessment of all the reviews. It appears that the technology
exists to develop the usability of consumer drug reviews, and future research should
explore the logistics for its application to this domain. Such a “meta” website would
prove useful for individual drug decision-making, as well as hold potential for active
post-marketing safety surveillance.

Searching for Health Information on the Internet
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Currently, search engines such as Google are optimizing health searches to return
government and other institutional sources at higher rankings, to the exclusion of
(consumer delivered) sources lacking “quality” seals of approval (Fox, 2010).
Approximately two-thirds of online health searches start at a general search engine, and
Google leads the way garnering over 72% of U.S. searches. Thus, search results can
“make or break” a website in terms of access and attention. Previously, all searches in
Google returned websites according to “the ‘democratic’ PageRank algorithm,” which
favored websites having, for example, a high number of links in and links out, high site
traffic, ample metadata or key words, and frequent site updating. This somewhat leveled
the playing field for large and small websites, as the usefulness and relevance of the site
mattered more than the resources of the site owners.
Google’s latest initiative, in response to the ongoing debate over health
information quality on the Internet, is “to guide consumers to safe, trusted health
websites” (Fox, 2010, para. 3). This has resulted in a new mechanism for ranking
websites in health searches, whereby the most widely used expert health sites featuring
quality seals of approval, including WebMD, MayoClinic, and Medline, are highlighted
at the top of returns (preceded of course by “sponsored links,” or advertisements). This
search return strategy clearly and openly favors the “big players” with networks of
human, knowledge, and capital resources.
However, this research suggests that the “dangerousness” of consumer delivered
drug information on the Internet may be exaggerated. A cursory review of consumer drug
reviews, reminiscent of the average web user, reflected drug effects in fair proportion to a
full representative sample of consumer reviews, which in turn was largely comparable to
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effects listed on expert health sites. In this study, both expert and consumer information
sources offered distinct advantages and disadvantages. It does not appear to be true, then,
that the “best” information is universally to be found on the biggest, most well-resourced,
expert-run health sites.
The questionable objectivity and credibility of expert-derived drug information, as
outlined extensively in the review of literature, warrants a parallel, though rarely
considered caution when seeking information for making treatment decisions. In fact, it is
safe to say that the objectivity and credibility of both expert and consumer sources can be
legitimately questioned, and both sources again have benefits and limitations for
decision-making. The disparity in labeling sources “trustworthy” and “quality” may
reflect the power accorded to procedures of science and scientific/medical discourse more
than actual differences in the trustworthiness or other quality measures of information.
The promise of the Internet to “democratize” participation in constructing and delivering
knowledge in a variety of fields is dying in favor of the status quo of the off-line world.
As the historical advocates for the powerless and silenced, social workers are encouraged
to promote democratization on the Internet by seeking out consumer delivered health
sites at least as frequently as other sources during online searches. Practitioners can also
take the additional time necessary to find and utilize the most useful and relevant sites
(whatever the information source) rather than simply those that appear at the top of
search engine returns. These recommendations are not meant to favor consumer over
expert health sources, but to promote that potential of a level playing field that the
Internet theoretically allows. Social work practitioners should also support clients who
show interest in participating in the consumer-generated online realm of healthcare.
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Until the above investigations concerning authenticity and usability come to pass,
clinicians and consumers seeking drug information on the Internet may want to be open,
but cautious when reviewing consumer-generated content. A suitable approach may be to
read a similar number of reviews from multiple sources, as done in the present research,
in order to maximize the possibility of exposure to a variety of drug accounts. Anything
less, such as reading 5 or 10 reviews from a single website, should be avoided, especially
when the information is being gathered for anything more than simple curiosity. It should
also be noted that, at least in the current online environment, consumer-generated
information is complementary to, not in replacement of, a thorough review (certainly by
social work professionals, if not consumers too) of other drug information sources.
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APPENDIX A
Screen Shots of the 5 Selected Websites
Figure A1. Homepage on AskAPatient.com
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Figure A2. Lexapro page on AskAPatient.com

Figure A3. Homepage on CrazyMeds.us
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Figure A4. Lexapro page on CrazyMeds.us
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Figure A5. Homepage on TheIcarusProject.net

Figure A6. Medication page on TheIcarusProject.net
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Figure A7. Homepage on WebMD.com
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Figure A8. Lexapro page on WebMD.com
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Figure A9. Lexapro user ratings/reviews on WebMD.com
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Figure A10. Homepage on RevolutionHealth.com
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Figure A11. Lexapro page on RevolutionHealth.com
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Figure A12. Lexapro user ratings/reviews on RevolutionHealth.com
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APPENDIX B
QDA Miner 3.2 Screen Shots of Coded Data
Figure B1.
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Figure B2.

Figure B3.
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APPENDIX C
Initial Codebook: September 2009
 CITATIONS AND LINKS
o Academic Journal Internet
 DRUG EFFECTS
o Changes for the Better/Favorite or Best
Effects
 Able to live my life
 The world is good again
o Changes for the worse/”Worst” side
effects
 I feel fat now
 Sex used to be part of my life
o Consequences of Side Effects
 A disease for the rest of my life
 Can ruin my day
 Frightened
 Spun into mania by ADs/ rediagnosed manic/bipolar
 Unable to work/missing work
o Discontinuing / Missed Doses
 “withdrawals”
 Depression coming back (Disc)
 Diarrhea (Disc)
 Dizziness (Disc)
 Feel like a druggie needing a fix
(Disc)
 Feel sick (Disc)
 Hallucinations (real and
frightening) (Disc)
 Headache (Disc)
o General Beneficial Effects
 Ability to do things in absence of
symptoms
 Absence of specific symptoms
 Clear thinking/Less negative
thoughts
 Comfortable/At ease with
myself/life
 Decrease hallucinations
 Depression lifted/ Smile and laugh
more
 Emotionally stable / appropriate
 Energized
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 Irritability (Disc)
 Making me crazier than before (Disc)
 Passing out (Disc)
 Trouble sleeping (Disc)
 Visual tracers (Disc)
 Vomiting/nausea (Disc)

 Physically relaxed
 Pleasant / fun dreams
 Prevent/decrease mood swings/mania
 Reduced/eradicated anxiety
 Reduced anger
 Relatively normal / feel better
 Relief from problems/can handle stress

 Helps me sleep
 Improved concentration

 Nasal congestion/snoring
 Nausea/sick stomach
 No interest in life
 No/diminished energy
 Not sleeping well
 Overactive thoughts
 Painful sex
 Rapid pulse
 Sensitive/amplified hearing
 Sexual (nondescript)
 Shortness of breath/breathing problems
 Sore breasts
 Spasms/twitching/tremors
 Stroke/heart failure in elderly
 Suicidal thinking
 Suicide attempts
 Swollen/tight/cramped
 Tired
 Tired, but cannot sleep
 Trouble/Inability to achieve orgasm
 Urge to urinate/ wet myself
 Urinary hesitance
 Weakness
 Weight gain
 Weight loss
 Worsened / induced mania
 Worsened anxiety
 Worsened drug cravings
 Zombie

o General Effects Not Specified
 Knocked me out

o General Side Effects
 Agitation/jump out of my skin
 Bad taste in mouth
 Carb cravings
 Constipation
 Crazy, vivid dreams/nightmares
 Depressed/feeling down/worsened
depression
 Diabetes
 Difficult to wake up
 Difficulty
focusing/Confused/Fuzzy
 Discomfort
 Dizzy
 Dry/sore eyes
 Dry mouth
 Dyskinesia
 Excessive sleeping
 Feel “high”
 Feel worthless
 Flat feelings/no emotions
 Gassy
 Groggy/Foggy
 Hangover feeling
 Headache
 Heaviness/soreness/pain/numbness
in legs
 High blood pressure
 Impossible to get aroused
 Inability to reach orgasm
 Increase appetite
 Irregular menstruation
 Panic attacks
 Jaw clenching
 Jitteriness/”spazzy freak”
 Sex drive
 Light headed
 Sleep, at high doses
 Loss of appetite
 Lost sex drive/decreased libido
 Memory loss

o No Beneficial Effects
o No Effect On…
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 Anger/irritability/rage/impulse
control
 Internal thoughts/reactions
 My chemical imbalance
o
o
o
o

No Initial Benefits
No Initial Side Effects
No Side Effects
Timing
 Initial effect
 Newly emerged effect
 Over time

 FINANCES / THE SYSTEM
 Jumping through hoops
 FRIENDS AND FAMILY
 Disconnect between family
perception and user
experience
 Dosing/tapering as they did
 Drug worked well for them
 MY DIAGNOSIS / REASON FOR USE
 Anger/Irritability/Impulse
Control
 Anti-psychotic
 Anti-psychotic, at higher doses
 Anxiety
 Bipolar
 Depressed / Depression
 Fear / Inability to live life
 For a diagnosis
 For an effect
 For sleep
 I am NOT –blank MY DOCTOR
o Changing Doctors
 New docs always change your
meds
o Doctor doesn’t believe / listen to me
o Doctor identified side effect
o Doctor suggested / Doctor put me on
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 I feel out of control / cannot shut
mind off
 Insomnia due to…
 Manic/manic-depression
 Migraines
 OCD
 Schizophrenia / Schizoaffective
 Situational depression
 Stressful job
 Unable to function due to tragedy

o
o
o
o
o
o

I asked for the drug
Report to / Listen to your doctor
Seems extreme
Talk to doc / How to talk to doc
Unsure how much I trust my doctor
Verifying Doc’s info / Is my pdoc
right?

 Increase/decrease/adjust dose
 Liquid form of drug
 Lubrication/toys for sex
 Ride out the storm

o
o
o
o

Doctor was wrong about effects
Doctor wouldn’t help me wean off
GP or Pdoc
I am not a doctor, but…

 Side effect trade-off
 Switch meds
 Taper SLOWLY / Low starting dose
 Vitamins and supplements

 MY DRUG
o Contra-indications
o Dealing with Side Effects / Finding
Optimum Effectiveness
 Add another med
 Avoid/cut down on caffeine/
alcohol
 Changing time of day
 Diet/nutrition
 Differs by time of day
 Drink more coffee/caffeine
 Eat a snack with drug
 Eventually goes away
 Exercise/stay physically active

 My usual state / I know my body
 No family history
 Stop/restart drug
 While on med
 Increased dose, no help/harm
 Take exactly as prescribed

o Drug Action
 Regulates
 Targets/restores brain
molecules/chemicals
o Drug-Drug Interactions
 Don’t take this combination
 Possible effects of combo
 Try this combo
o Evidence of Causality
 Anecdotal
 Drug or other drug?
 Drug or pre-existing condition?
 Medical tests
o Finding the Right Dose
 Adjusted/tapered myself
 Different effects/uses at
different doses

 OK, but not great
 YMMV
 Returned to this drug once again
 So many damn meds for so many
years
 This time seems different! / The best
yet!
 Now I need to work on my…
 Poop out
 Worsens other conditions
 No better choices
 Not sure
 Side effects are too great

o Judging Effectiveness
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 Rating scale
o My Drug Experience
 A miracle/saved my life
 I hate this drug
 It’s not like what people say it
is
o Search for the Right One
 Doing my research
 Going back to another drug
 It’s starting to kick in
 Not enough time / too soon to
tell
 Other drugs made it worse
o Unsolved or Additional Problems
 Helped with one, but not the
other
 Helps only for a few days
 More meds for other problems
o Weighing Benefits vs Risks/Side
Effects
 All in all, I am positive / Side
effects tolerable
 Benefits not enough
 Feel great, no side effects
 PHARMACEUTICAL COMPANIES
o Brainwashed doctors
o FDA approval status
o It’s a business
o PI Sheet
 Three percent my ass!
o Sex is only a problem for med
 SUPPORT AND ADVICE
o A good mindset
o Drug Recommendations
 Better alternative than benzos
 Doesn’t help like benzos do
 Don’t take this drug!
o Seeking experiences / worried
about effects

282

 Drugs won’t work for you/me
 Generic equivalence
 I recommend trying it

o What to expect
o Withdrawal
 Looking back on it…
 May cause dependence
 Wait and see

APPENDIX D
Most Recent Codebook: April 2010
 CITATIONS AND LINKS
o Academic Journal / “Research shows…”
o Government/University
o Internet
o PI Sheet
o Within website
 DRUG EFFECTS
o Classification of Effects
 Category of Effect
 “Side Effect”
 Best/Fun Effect
 Less serious/ Less severe
 Serious/ Severe
 Worst/ Most Annoying Effect
 Frequency
 Frequent
 Infrequent
 Rare
 Timing
 Initial Effect
 Newly Emerged/ Over Time
o Contraindications (Only for Lex & Ser)
 For certain people/age groups
 With alcohol or illicit drugs
 With certain foods
 With other medicines
o Discontinuing / Missed Doses (Only for Lex & Ser)
 Gastrointestinal disc effects
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Neurological disc effects
None / No withdrawals
Other disc effects
Psychiatric/emotional/ behavioral disc effects

o Effects (Only for Lex & Ser)
 Appetite and Weight Effects
 Increase appetite/ cravings
 Loss of appetite
 Weight gain
 Weight loss
 Gastrointestinal and Urinary Effects
 Constipation
 Diarrhea/Gas
 Menstruation Irregular
 Nausea/ sick stomach/ vomiting
 Urinary changes/ problems
 Head or Face Effects
 Headache/Migraines Reduced
 Headache Increased
 Hearing, taste, smell changes
 Jaw clenching/grinding
 Vision/eye changes
 Lab Tests and Chronic Conditions
 Blood pressure changes
 Blood related changes
 Blood sugar high / Diabetes
 Cholesterol high
 Liver levels/Hepatoxicity/Hepatitis
 Other labs or chronic conditions
 Mental or Mood Effects
 Ability to do things in absence of symptoms
 Agitated / Restless
 Brain fog / Zombie
 Crying spells / Emotional rollercoaster
 Dreams vivid / nightmares
 Emotionally stable / calm / “normal”
 Energy increased / Euphoria / Mania
 Memory loss
 Numb/ detached / lack of energy or interest
 Other mental/mood changes
 Suicidal thinking/planning/attempts
 Symptoms new/worsened
 Symptoms reduced/improved
 Musculoskeletal and Neurological Effects
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 Abnormal movements
 Dizzy/Lightheaded/Faint
 Heaviness/Soreness/Pain/Numbness
 Neuroleptic Malignant Syndrome
 Seizure
 Swollen/Tight/Cramped
 Weakness
 Zaps/Tingling
Nose, Throat, Chest Effects
 Breast soreness/lactation
 Breathing problems/Shortness of breath
 Chest pain/ heartburn
 Difficulty swallowing / speaking
 Dry mouth / sore throat
 Fever/ Chills / Infection
 Heart Disease/ Inflammation
 Heartbeat changes
 Nasal changes
Other Effects
 Allergic reaction
 Alleviates side effect from another drug
 Hot flashes / heat stroke
 Hungover / Drunk
 No/Limited side effects
 Other misc effects
Sexual Effects
 Increased sex drive
 Lost sex drive/libido
 Other sexual effects
 Trouble achieving orgasm
Skin Effects
 Bruising
 Hair loss/thinning
 Itching/Rash
 Stevens-Johnson Syndrome
 Sweating like a pig
Sleep Effects
 Difficult to wake up
 Extreme sleepiness / Tired
 Helps me sleep
 Trouble sleeping / Insomnia
 Yawning

 FINANCES / THE SYSTEM
o Expense / Insurance
o Jumping through hoops / Hospitals
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 FRIENDS AND FAMILY
o Drug did *this* to them / Doing what they did
o Family/friend observed an effect
o Other family/friend issues
 MY DIAGNOSIS / REASON FOR USE
o Anger / Irritability / Impulse Control
o Anxiety / Panic
o Bipolar / Mania
o Change of life
o Depressed / Depression
o Eating problems
o For sleep/insomnia
o I am –NOT- blank
o Inability to function/ Stressful life situation
o Migraines
o Other reason / diagnosis
o PTSD
o Schizophrenia / Psychosis / Anti-Psychotic
o Skeptical of my diagnosis / Misdiagnosed
 MY DOCTOR
o Doctor won’t listen / We disagree / I wasn’t informed
o GP or Pdoc ?
o I’m taking control / I’m my own best advocate
o Other doctor-related issues
o Talking with doc / Doc explained / Consult doc
o Trusting the doctor?
 MY DRUG
o Assessing the Overall Experience
 A miracle / saved my life / I recommend (Lex/Ser only)
 All in all, I am positive / Side effects tolerable
 I hate this drug / Stay away from it (Lex/Ser only)
 No or limited helpfulness / It’s not my wonder drug
 Not worth it / Side effects too great
 YMMV
o Dealing with Side Effects / Finding Optimum Effectiveness
 Add another med
 Avoid / Drink more caffeine/alcohol
 Changing time of day
 Check blood levels
 Diet / Food / Exercise
 Differs by time of day
 Dose adjustment
 Learn to live with it
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Other methods
Ride out the storm / Eventually goes away / Waiting
Routine
Switch meds / Stop med
Taper SLOWLY / Low starting dose
Vitamins and supplements

o Do I Need Meds
 Drugs won’t work / I’m done / I don’t need it
 Going back on meds / Meds may be the solution
 Looking back on it…/ Since I stopped the med…
 Making a plan / Just in case…
 Trying/Tried alternative treatment
o Evidence
 Anecdotal
 Drug or Something Else?
 Efficacy/Safety not established
 Medical tests
 My usual state / I know my body
 Stop/Restart drug
o Other Drug Issues
 Dependence / Withdrawal
 Diagnoses / Symptoms
 Dose related issues / advice
 Generic/other drug equivalence
 OTHER
 Poop out / Effects changed
o Other Drugs and Drug Combinations
 Don’t take this drug/combination
 My drug combo / so many damn meds…
 Possible effects / What to expect from other drugs
 Try this drug/combination
o Theories of Drug Action
 Targets/Restores brain molecules/chemicals/neurotransmitters
 Unsure about mechanism/Other
 PHARMACEUTICAL COMPANIES / FDA
o FDA approval status
o It’s a business
o Other pharma/regulatory/FDA issues
o Three percent my ass!
 SUPPORT AND ADVICE
o Other general support
o Seeking experiences / worried about effects
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APPENDIX E
Most Recent Codebook with Descriptions of Codes
CITATIONS AND LINKS
 Academic journal/ “Research shows…”: Cites, quotes summarizes, references, or
links to an academic or medical journal, or to a published book or text; Also
references such as “clinical trials show…” or “research shows…”
 Government/University: Cites, links, quotes, summarizes information from a
government website or University’s website
 Internet: Cites, links, quotes, summarizes information from an Internet website that
is non-academic, non-governmental; Examples may be medicalnewstoday.com or
Wikipedia.com
 PI Sheet: Cites, quotes, summarizes, references, or links to drug label or patient
information sheet that accompanies the drug
 Within website: Cites, quotes, summarizes, references, or links to information
within the same website; Examples include a hyperlink on WebMD that links to
another page on WebMD, or a hyperlink on a CrazyMeds discussion that links to
another page on CrazyMeds
DRUG EFFECTS
 Classification of Effects
o Category of Effect
 “Side Effect”: Effects is listed or identified as a “side effect”
 Best/Fun Effect: Effect is described as the best effect, “my favorite
effect,” or similar; Effect is described as fun, enjoyable, cool.
 Less serious/Less severe: Effect is described as less serious, less
severe, “not too bad,” mild, “just a little,” or similar
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 Serious/Severe: Effect is described as serious, severe, strong,
“really bad,” extreme, or similar; Or effect results in an
emergency room visit
 Worst/Most annoying effect: Effect is described as the worst effect,
the worst side effect, “my least favorite effect,” annoying,
frustrating, or similar
o Frequency
 Frequent: Common, typical, or frequent effect
 Infrequent: Infrequent, not common effect
 Rare: Uncommon, rare effect
o Timing
 Initial Effect: Described as initial or immediate effect(s) of the drug;
Effect appeared immediately or almost immediately upon taking
the drug
 Newly emerged/Over time: Effect is a new effect that began after
having been on the drug for some time, such as “this drug has
always worked great, but after 2 years on it I am starting to sleep
16 hours a day” or “as I continued to take the drug, my anxiety
levels increased”; Effect is something that built up over time, such
as “I gained 45 lbs over 9 months of using the drug”
 Contraindications
o For certain people/age groups: Drug is contraindicated for or should be
used with caution for certain age groups (i.e., children, elderly) or certain
people (i.e., pregnant women, breastfeeding women), or for people who
have a certain medical history
o With alcohol or illicit drugs: Avoid alcohol and/or illicit substances while
taking this medication
o With certain food: Dangerous interaction may occur if you take this drug
with a certain food, i.e., grapefruit
o With other medicines: Drugs may have a dangerous interaction with other
drugs, such as anticholinergics, dopamine-like drugs, drugs that cause
drowsiness, etc.
 Discontinuing/Missed Doses
o Gastrointestinal disc effects: Gastro-intestinal effects occur or may occur
when discontinuing/withdrawing from the drug, or upon missing doses(s),
including diarrhea, nausea, vomiting, etc.
o Neurological disc effects: Neurological effects occur or may occur upon
discontinuing or withdrawing from the drug or upon missing dose(s),
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including spasms, headaches, zaps, movements, insomnia, fainting,
dizziness, etc.
o None/No withdrawals: No noticeable effects upon discontinuing
o Other disc effects: All other effects that occur or may occur upon
discontinuing or withdrawal of the drug or upon missed dose(s), such as
“Some conditions may become worse when the drug is suddenly stopped”
o Psychiatric/emotional/behavioral disc effects: Tapering off the drug or
discontinuation of the drug may cause or does cause psychiatric,
emotional, or behavioral effects, including hallucinations, depression,
irritability, mania, agitation, crying spells, feeling sick/crazy/abnormal,
etc.
 Effects
o Appetite and Weight Effects
 Increase appetite/cravings: Increased appetite, often experienced as
a ravenous insatiable appetite, or making multiple trips to the
refrigerator all through the night, and cravings for carbs and
sweets; Also includes effect of “sleep eating,” which is eating
during sleep with no memory of it happening
 Loss of appetite: Reduced appetite, loss of appetite, no appetite
 Weight gain: Weight gain of any amount
 Weight loss: Weight loss of any amount
o Gastrointestinal and Urinary Effects
 Constipation
 Diarrhea/Gas: Diarrhea, gas, and other changes in bowels
 Menstruation Irregular: Irregular menstruation, including missed
periods, additional periods, heavy periods, painful periods
 Nausea/sick stomach/vomiting
 Urinary changes/problems: Changes or problems with urine,
including changes in amount of urine, sudden urges to urinate,
wetting oneself, urinary hesitance
o Head or Face Effects
 Headache/Migraines reduced: Reduced frequency or intensity of
migraines or headaches
 Headache increased: Headache or migraine is induced, worsened,
or increased by the drug
 Hearing, taste, smell changes: Changes in hearing (i.e., sensitive or
amplified hearing), taste (i.e., bad, unpleasant, or odd taste in
mouth), or smell
 Jaw clenching/grinding: Jaw clenching, teeth grinding
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 Vision/eye changes: Vision or eye change or problems, i.e., dilated
pupils, odd eye movements, sore eyes, dry eyes, etc
o Lab Tests and Chronic Conditions
 Blood pressure changes: Blood pressure high/increased or
low/decreased
 Blood related changes: Blood related abnormal findings, including
decrease in white blood cells, decrease in blood platelets, etc;
Blood related changes, such as blood thinning, bleeding easily
from nose, anus, internal organs, etc
 Blood sugar high/Diabetes: Increased or high blood sugar, at risk of
diabetes, or diagnosis or diabetes
 Cholesterol high
 Liver levels/Hepatoxicity/Hepatitis: Abnormal liver levels, or
hepatoxicity, or hepatitis, or other changes in liver functioning
 Other labs or chronic conditions: Other lab test results or
development of chronic conditions, including pancreatitis,
prolonged Q-T interval on EKG, thyroid abnormalities, and
increased triglycerides
o Mental or Mood Effects
 Ability to do things in absence of symptoms: Ability to do things
(i.e. drive, work, go outside) that a person may have previously
unable to do because of anxious feelings, depression, etc, or better
performance or functioning at work, school, etc.
 Agitated/Restless: Agitation, feeling as though they want to jump out
of their skin, or crawl out of their skin; jitteriness, spazzy, restless,
can’t sit still, akathisia, etc.
 Brain fog/Zombie: Cognitive slowing, including problems speaking,
slurred speech, stuttering, unable to articulate words or thoughts,
slowed problem-solving abilities; Difficult to focus or concentrate,
confusion, mind fuzziness, foggy head, cloudy
 Crying spells/Emotional rollercoaster
 Dreams vivid/nightmares: Vivid dreams; odd, bizarre, or crazy
dreams that may include nightmares or may include fun/pleasant
dreams
 Emotionally stable/calm/”normal”: Emotions and/or outward
reactions are stable/steady, and not explosive or out of proportion
to the situation; Emotions are appropriate to the situation; Can
handle stress, problems, difficult situations; Feeling calm, relaxed,
or at ease with life; More comfortable with one’s life; Less
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despair, less hopeless; Also for comments such as “I felt more
normal,” “I felt like myself again,” etc
 Energy increased/Euphoria/Mania: Increased energy, or high
energy, which could be perceived as desirable or undesirable;
Giddiness, excessive cheerfulness, “wired,” “talking a mile a
minute,” euphoria, feeling “high,” feels like taking speed or
cocaine; Also includes induced or worsened hypomania, mania
 Memory loss: Memory loss, including sleep-walking type events
 Numb/Detached/Lack of energy or interest: Feeling of no emotions
(not happy, not sad, not depressed, not anything_; flat emotion,
flat feeling of nothingness; Lack of energy, lack of motivation, no
interest in life, apathy; Feeling numb or detached from emotions,
from life, from the world; feeling disassociated or unreal
 Other mental/mood changes: Other mental or mood changes not
specified by a code in this category
 Suicidal thinking/planning/attempts: Thoughts of suicide or actively
planning suicide; suicide attempts, including acts of selfinjury/self-harm
 Symptoms new/worsened: New, worsened, or increased symptoms,
including anger, aggression, being “mean,” irritable, anxiety,
fear, panic, impulsive, depressed, hallucinations, psychosis,
overactive/bizarre /uncontrollable thoughts or thinking, paranoia
 Symptoms reduced/improved: Reduction in or alleviation of
symptoms, including anger, rage, aggression, “meanness,”
depression (i.e., depression lifted, smiled and laugh more,
happier), anxiety, fear, panic, hallucinations, mania, clearer
thoughts, fewer negative thoughts
o Musculoskeletal and Neurological Effects
 Abnormal movements: Abnormal movements, including tardive
dyskinesia, or effects identified as possible or definite dyskinesia,
Parkinson symptoms, and spasms, twitching, shakes, tremors,
jerks, restless legs, etc
 Dizzy/Lightheaded/Faint
 Heaviness/Soreness/Pain/Numbness: Heaviness, soreness, pain, or
numbness in legs, feet, arms, hands, or joints
 Neuroleptic Malignant Syndrome
 Seizure
 Swollen/Tight/Cramped: Swollen or tight arms, cramping in
extremities or muscles
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 Weakness: Weakness in muscles or extremities
 Zaps/Tingling
o Nose, Throat, Chest Effects
 Breast soreness/lactation: Breasts swollen or sore, or
lactation/discharge of milk from breasts
 Breathing problems/Shortness of breath
 Chest pain/heartburn
 Difficulty swallowing/speaking
 Dry mouth/sore throat: Dry mouth or throat; Sore or irritated throat
 Fever/Chills/Infection: Fever, chills, other flu-like symptoms, or
signs of infection
 Heart disease/Inflammation: Heart disease, inflammation of the
muscle of the heart, or other heart-related conditions
 Heartbeat changes: Heart throbbing or pounding, and/or rapid
heartbeat or pulse, palpitations, slowed heartbeat, etc.
 Nasal changes: Nasal congestion, snoring, nose bleeds, runny nose,
etc
o Other Effects
 Allergic reaction
 Alleviates side effect from another drug: Seroquel or Lexapro
relieves, improves, or alleviates an effect caused by another
medication the person is taking
 Hot flashes/heat stroke: Ho flashes, heat stroke, or increased risk of
heat stroke in hot weather
 Hungover/Drunk
 No/Limited side effects: Drug has no side effects, or virtually no
side effects; Side effects are limited, or person specifically states
the drug sis not have a certain effect, i.e., “I’ve had not sexual
side effects”
 Other Misc Effects: Other misc effects not otherwise categorized
o Sexual Effects
 Increased sex drive
 Lost sex drive/libido: Decrease in sex drive, no interest in sex, loss
of libido
 Other sexual effects: Other sexual effects that do no fir the other
codes, i.e., a nondescript remark about “sexual side effects,”
painful sex, prolonged erection, or premature ejaculation
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 Trouble achieving orgasm: Difficult to achieve orgasm, difficult to
obtain an erection, difficult to achieve lubrication, lack of
sensation
o Skin Effects
 Bruising
 Hair loss/thinning
 Itching/Rash
 Stevens-Johnson Syndrome
 Sweating like a pig: From increased perspiration to profuse
sweating
o Sleep Effects
 Difficult to wake up: Difficult to wake up in the morning, which may
include comments about sleeping through alarm clocks, unable to
get out of bed until noon, etc.
 Extreme sleepiness/Tired: From drowsiness to extreme fatigue, as
well as excessive sleeping or napping, often referred to as
“extreme sleeping” or “extreme sleepiness”
 Helps me sleep: Drug effect is improved sleep; helps person sleep
better
 Trouble sleeping/Insomnia: Trouble sleeping, unable to sleep,
unable to fall asleep, not sleeping soundly, tired but cannot sleep;
includes worsened insomnia
FINANCES / THE SYSTEM
 Expense/Insurance: Any comment related to the expense of the drug, i.e., the
drug is too expensive or unaffordable; the drug is affordable; Any
comment related to insurance issues, i.e., insurance was cancelled so the
person can’t afford the drug
 Jumping through hoops / Hospitals: Description of the obstacles to
navigating “the system,” i.e., trying to find another doctor, waiting lists
and referral systems, too many patients and too few doctors, having to find
a new doc, having to get a new doc because of insurance, etc; Description
of or feelings about hospital experiences (positive or negative) and issues
around involuntary hospitalization and forced medications
FRIENDS AND FAMILY
 Drug did *this* to them / Doing what they did: Comment regarding how a
drug worked or did not work for a friend or family member, i.e., friend or
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family member did well on a specific drug and that influenced the User’s
choice of drug or it influenced their evaluation of their own drug
experience, i.e., “I think I’m just a quirk because most people I know were
just fine” on the drug; Any other anecdotal story about a person(s) who
have had a particular experience with the drug; Following the experience
of a friend or family member, i.e., “I am tapering off this drug the same
way my sister did”
 Family/friend observed an effect: An effect of the drug is pointed out,
observed, noticed by a family member or friend
 Other family/friend issues: Any other comment or information related to
family or friends, such as how their family is supportive or not supportive
of their treatment decisions, or how they get along with, take care of, or
fight with their family
MY DIAGNOSIS/REASON FOR USE
 Anger / Irritability / Impulse Control
 Anxiety / Panic: Anxiety or Anxiety Disorder, including all anxiety
disorders in the DSM (generalized anxiety disorder, social anxiety
disorder, panic disorder, etc)
 Bipolar / Mania: Bipolar or Bipolar Disorder; Mania, Manic-Depression
 Change of life: “Change of life” signs; Hot flashes
 Depressed/Depression
 Eating problems: Eating-related problems, including anorexia, compulsive
eating
 For sleep / Insomnia: Drug is taken to help with sleep or insomnia,
including insomnia due to another problems (i.e., insomnia due to anxiety)
 I am –NOT- blank: Reason for use is partly defined by the diagnosis that a
person DOES NOT have. This may include hesitance by a person to use
the drug because they do not have a particular diagnosis, i.e., “I was very
freaked out for the fact that I am NOT bipolar”
 Inability to function / Stressful life situation: Drug is used for a person who
feels out of control in their lives, they cannot “shut my mind off” or calm
down, unable to function due to fear or overactive thoughts; Person is
under too much stress and cannot handle problems/life; Drug sis used to
help a stressful life situation, i.e., anxiety due to a stressful job, depression
due to family problems, a tragedy or after having a child, etc
 Migraines
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 Other reason/diagnosis: Using the medication for a reason or diagnosis not
listed, i.e., as a preventative, to counteract side effects of another
medication, to help during withdrawal from another medication, for
ADHD, fibromyalgia, IBS, etc
 PTSD
 Schizophrenia/Psychosis/Anti-Psychotic: Schizophrenia, Schizoaffective,
Psychotic Disorder, Psychosis, used as an antipsychotic
 Skeptical of my diagnosis/Misdiagnosed: There is doubt, skepticism, or
uncertainty around their diagnosis; Person is misdiagnosed, or has been
misdiagnosed, and perhaps was put on the “wrong” drug because of the
misdiagnosis, i.e., “I am bipolar, but was misdiagnosed depressed and put
on Lexapro”
MY DOCTOR
 Doctor won’t listen / We disagree / I wasn’t informed: Any general
disagreement of conflict between the patient and doctor, i.e., “My doctor
thinks this is a miracle pill for long-term management of my symptoms,
but I am ready to get off this drug;” Doctor is wrong about an effect, i.e.,
“my pdoc said this would help my insomnia, but it made it worse;” Doctor
discounts, minimizes, or invalidates an effect the user reports, and/or the
User states that their doctor does not listen to them or believe them about
some other medication-related issue, i.e., their doctor doesn’t heed their
caution about using a drug they had a bad experience with in the past;
Doctor will not help the patient wean off the medication or does not
support the patient in wanting to switch medications; The person states
they feel like they were misinformed or not informed well about the drug
or drug effects.
 GP or Pdoc ?: Any comment regarding what type of practitioner to use for
medication-related decisions and prescriptions, i.e., a general practitioner
versus a psychiatrist versus a neurologist versus a pharmacist, etc
 I’m taking control/I’m my own best advocate: Person does their own
research, monitors their own treatment or condition, or makes some
treatment-related decision on their own, for example by quitting the drug
on their own, asking their doctor for a specific drug, etc; Comments about
having to get informed in order to advocate for yourself to the doctor and
others
 Other doctor-related issues: Any other comment or issues related to the
doctor, such as advice about looking for a new doctor, comments about
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how supportive the doctor is, or other comments that do not fir in the
other codes
 Talking with doc / Doc explained / Consult doc: Recommendation to
consult, discuss with, or report to your doctor, and/or to listen to your
doctor’s instructions; Advice or information about how to talk to your
doctor or how to prepare for a doctor’s visit; Include any other doctormade decision, i.e., my new pdoc decided to change up all my meds, or
include anything explained by the doctor, i.e., my doctor explained that my
jitteriness might be a side effect of the drug
 Trusting the doctor?: Involves all issues of trust in relation to the doctor;
User describes how they are unsure if or how much they trust their doctor
or doctors in general; User describes some information their doctor gave
them and they want to verify the information with other users; User
describes the doctor’s decision, recommendation, or lack of attention to a
problem as seeming unusual, strange, or extreme
MY DRUG
 Assessing the Overall Experience
o A miracle / saved my life / I recommend: The drug or a drug effect
is described as a miracle or as having saved their life; may also
include language like the drug was wonderful, amazing, the best
one yet, changed my life, etc; Also code if the drug is
recommended because the person loved it or had a great
experience with it
o All in all, I am positive / Side effects tolerable: Benefits of the drug
outweigh side effects, risks, and/or costs; There may still be some
side effects, but, all in all, the user feels positive about the drug;
Side effects/adverse effects/costs (including financial costs) are
insignificant and/or tolerable compared to the benefits of the drug
o I hate this drug/Stay away from it: I hate this drug, do not like this
drug, would not take this drug again, had a bad experience on this
drug; Recommendation to stay away from the drug or not to take
the drug
o No or limited helpfulness/It’s not my wonder drug: No beneficial
effects, few or limited beneficial effects; Drug is okay but not
great; It’s no miracle drug; Any comment regarding only limited
helpfulness of the drug; The drug only partially helps solve a
problem, or helps one problem but not other problems, i.e., Helped
my anxiety, but not my depression; Also includes comments about
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having to weigh pros and cons of a drug, but without having
reached a decision in the comment itself (otherwise, it would be
coded ‘all in all, I am positive’ or ‘side effects too great’).
Weighing the pros and cons reflects the ‘limited helpfulness’ of the
drug, i.e., it’s no miracle cure
o Not worth it / Side effects too great: Costs/side effects/adverse
effects outweigh any benefits of the drug
o YMMV: Your Mileage May Vary; User may have a good or bad
experience on the drug, but notes that other people may have a
similar or different experience; Any acknowledgement that
different people may have different experiences

 Dealing with side effects/Finding optimum effectiveness:
o Add another med: Add a drug to Lex or Ser to help relieve or
balance out certain drug effects, i.e., uses Wellbutrin with Lexapro
to help their sex drive, or takes Ativan with Lexapro to help them
sleep
o Avoid/Drink more caffeine/alcohol: Avoid or reduce caffeine
and/or alcohol intake to reduce side effects or adverse effects, or to
maximize drug effectiveness; Drink more caffeine (like coffee) or
alcohol to reduce certain effects (like sleepiness) or maximize
effectiveness
o Changing time of day: Try different times of day to take the drug, in
an attempt to increase effectiveness or reduce side effects
o Check blood levels: Monitor risk of diabetes and development of
other conditions with regular tests, i.e., check blood sugar levels
o Diet/Food/Exercise: Monitor diet or nutrition in order to reduce
certain effects, like weight gain, or maximize effectiveness,
including drinking lots of water, counting calories, staying away
from carbohydrates, etc.; Take drug with food or drink, i.e., eat a
snack with the drug to avoid nausea; Exercise or stay physically
active to minimize side effects or maximize effectiveness
o Differs by time of day: Side effects are better or worse depending on
time of day, i.e., drowsiness in the morning goes away by evening
o Dose adjustment: Counter, reduce, alleviate certain effects by
adjusting the dose either up or down (usually down), and/or
increase or decrease dose to increase effectiveness; Any comment
that involves adjusting a dose, including splitting or crushing pills

298

o Learn to live with it: Learn to live with, deal with, or just accept the
drug; Comment about realizing that there is nothing to be done to
relieve the effect, so the person must simply live with it
o Other methods: Any other strategy or method not already listed to
help minimize side effects or maximize effectiveness, including
stand up slowly to avoid dizziness, avoid heat, use lubrication for
sex, report effect to a hotline (like poison control, FDA, or pharma
company hotline), take PRN or as-needed by not every day, liquid
form of drug, and “side effect trade-off”
o Ride out the storm / Eventually goes away / Waiting: Remark that
“side effects” or “adverse effects” are temporary or will
eventually go away with time; User describes being willing to ride
out the side effects, assuming they will go away, or user describes
how they kept with it through the side effects and found that they
went away; Also, any comment that involves the concept of
waiting, such as drug effects, particularly benefits, are not
apparent immediately, but may “kick in” after a period of time of
waiting; A person stops taking the drug and is waiting to see what
happens next, for example, if withdrawal symptoms are going to be
bad or if their depression will come back (a “wait and see”
concept)
o Routine: Minimize side effects or maximize benefits by getting into a
routine, i.e., a bedtime routine or a sleep routine
o Switch meds/Stop med: Recommendation or decision to switch meds
and/or stop take the medication because a specific side effects has
not gone away with time, and/or the drug has stopped working, did
not work well, or had too many side effects
o Taper SLOWLY/Low starting dose: Recommend or advise to taper
up or down very slowly, or to start with a low dose and taper up,
or to not stop or quit a drug too quickly or “cold turkey”; Also
code for any comment generally related to how to start, taper, or
withdraw from a drug appropriately
o Vitamins and Supplements: Using vitamins, supplements, and/or
herbs to counteract or help relieve certain effects, i.e., Vitamins
B5, B6, and magnesium, to help with fatigue
 Do I Need Meds?
o Drugs won’t work/I’m done/I don’t need it: Drugs are not the
answer for a person’s problems; Recommendation to a User that
drugs may not be the answer to their problem, i.e., “Drugs aren’t
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going to get you to sleep if your aversion is PTSD based. Only
some heavy duty therapy is going to get around that;” user has
had enough and is done with taking medications, i.e., “No more
antidepressant!”; User wants to get off/to stop taking medications
for whatever reasons, i.e., doesn’t need them anymore, doesn’t like
them anymore, etc.
o Going back on meds/Meds may be the solution: Meds may be a
long-term or lifetime solution, or the right solution for this person,
or meds are definitely part of the overall whole situation; Decision
to go back to taking meds, or a realization that meds are needed
for them
o Looking back on it…/Since I stopped the med…: Comment
regarding what has happened since the person has stopped taking
the drug, a reflection of the drug experience now that the person is
no longer on the drug, OR a reflection of the condition or problem
now that the person is on meds. Some of these comments reflect
positive changes (i.e., I feel so much better, more like myself now
that I am off the meds; I never realized how depressed I was until I
was put on Lexapro), or negative changes (i.e., now I see how
much I really needed meds to stay stable; this med messed up my
brain for years after having stopped taking it)
o Making a plan/Just in case…” Making a back-up plan, a prevention
plan, a long-term plan, or a “just in case” or emergency plan
o Trying/Tried alternative treatment: Tried or is trying an alternative
treatment, such as talk therapy, CBT, DBT, ECT, EMDR, herbal
remedies, etc in conjunction with or as an alternative to
medication; Includes comments about medication not being the
whole answer, but only part of a bigger plan that includes other
treatment modalities or lifestyle changes for achieving or
maintaining health
 Evidence
o Anecdotal: Description or explanation of an effect or a possible
effect based on anecdotal evidence, i.e., from their observations,
from their reading of discussion forums over the years, etc
o Drug or Something Else?: An effect may come from the drug or from
another source, including another drug, another condition (i.e.,
headaches from drug or from previous neck injury?), or from
placebo effect; There is uncertainty as to the source of the effect,
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or it is explained why an effect comes from the drug versus another
source
o Efficacy/Safety not established: The efficacy and/or safety of the
drug is not established, is uncertain, or unknown, i.e., efficacy of
this drug has not been established for adolescents; Long-term
effects are unknown; There is no evidence, a lack of evidence, or
uncertainty in relation to a specific use/indication or effect, i.e., It
is unknown if this drug passes into breastmilk
o Medical tests: Recommendation or description of medical tests
(blood work, eye exams, for example) to help determine if an effect
(i.e., fatigue, spasms, blurred vision) has a physical/biological
basis
o My usual state / I know my body: Remark that a person (or
“people” in general) know their own body enough to be able to tell
if an effect is from a drug, i.e., User describes that usually they are
one way, and now they are another way (usually their blood
pressure is low, and now it is high); Also includes family history or
lack of family history (of diabetes, for example) as evidence that
the drug caused an effect
o Stop/Restart drug: Effect goes away once the person stops using the
drug, and/or the effect stops once the person stops using the drug
and returns once the user begins taking the drug again
 Other Drug Issues
o Dependence/Withdrawal: Any information or advice about
dependence (i.e., caution that drug may cause dependence; drug
did cause dependence for User), or withdrawal (i.e., how to
withdraw or discontinue from the drug safely)
o Diagnoses/Symptoms: Information, advice, discussion about
diagnosis or symptom-related issues, i.e., discussion about having
depression vs bipolar vs drug-induced mania
o Dose related issues/advice: Any comment related to drug dosage;
Information about maximum dosage, what dosage is too high, or
drug overdose; any comment about taking the medicine exactly as
prescribed, taking it consistently and regularly; Information on
missed doses, i.e., what to do if a dose is missed; Also code for
comments about the drug having a different effect and/or being
used for a different reason at different doses, i.e., Seroquel is sleep
inducing at low doses, and sleep neutral at high doses
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o Generic/other drug equivalence: Recommendation or description of
a generic or other equivalents of the drug; may include dosing
equivalents, i.e., “10mg celexa = 5mg or less of lexapro”; and/or
comparison of similar drugs, i.e., contrasting effects of Lexapro
and another SSRI
o OTHER: Garbage can code for any segments that do not fit
elsewhere. Meds and pregnancy; meds and kids; I am new to meds
so don’t know what I should be feeling; street use or value of the
drug’ recycling or storage of meds; self-medicating with other
substances
o Poop out/Effects changed: Drug stopped working after a period of
time that it did work, or effects of the drug changed over time, i.e.,
“At first the drug helped keep me calm, but after taking it for a
while I found myself getting angry and aggressive”
 Other Drugs and Drug Combinations
o Don’t take this drug/combination: Recommend or advise to avoid a
specific drug or combination; User identifies combination of drugs
they used and states it was a poor combination or made things
worse, didn’t work for them, etc
o My drug combo/so many damn meds: Remark or description
regarding a person’s current drug combo, drug history, the
various drugs and combinations of drugs the person has tried over
the years, and past bad drug experiences; Note, if it is a
recommendation or caution, please use other codes; General idea
that they’ve tried everything, i.e., “I’ve taken every antidepressant
(or whatever) on the market,” tried other drugs that made their
problems even worse, tried other drugs that had too many side
effects, tried other drugs that were not effective; If a specific
comparison of a previous drug and the current drug, then code
under ‘other drug equivalence’
o Possible effects/ What to expect from other drug: Description of
possible effects to look out for or what a person can expect when
taking a drug or combination of drugs, i.e., lowered seizure
threshold from taking combo of antidepressant and multiple
anticonvulsants, or “Lamictal is often activating, Abilify is…”;
Code for effects or possible effects of any drug(s) other than
lexapro or seroquel
o Try this drug/combination: List or identification of a drug or a
combination of drugs that was or may be helpful for a person
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 Theories of Drug Action
o Targets/restores brain molecules/chemicals/neurotransmitters: Drugs
works by targeting or restoring chemicals in the brain; Includes
comments about the drug being “potent,” “selective,” “targeting
receptors,” etc
o Unsure about mechanism/Other: Not sure or not clear about the
mechanism of action of the drug/how the drug “works;” Or any
other theory of how the drug may work or have its effects, i.e.,
whether weight gain is caused by metabolic slowdown, stimulation
of appetite, both, or something else; Other general references to
“imbalance,” “chemical imbalance,” “messing with brain
chemicals,” etc.
PHARMACEUTICAL COMPANIES / FDA
 FDA approval status: Lists or clarifies FDA approval status for a drug and/or
indication, including whether uses are approved or off-label/ unapproved
 It’s a business: Remark that pharmaceutical companies are in the business of
selling drugs; May include a description of a pharmaceutical company gimmick
or way of doing business to maximize profits, i.e., launching a new drug when
another one is about to go off patent; May includes doctors’ role in prescribing
medicines as a business. Or pharma’s role in attempting to influence how doctors
prescribe drugs\
 Other pharma/regulatory/FDA issues: Any other comment or information related to
the pharmaceutical industry, regulatory industry or process, or other similar
issues
 Three percent my ass!: Drug information from pharmaceutical manufacturers or
on the drug label is limited, narrow in scope, is missing a particular effect, or
somehow inaccurately estimates the scope of frequency of a drug effect, i.e.,
“according to pharma sexual side effects are only a problem for me”
SUPPORT AND ADVICE
 Other general support: Any comment giving general support or advice.
Recommendation to keep a good/positive mindset when taking a drug. Comment
that a person feels validated about their own experience after reading similar
experiences of others on the website. Comment about the importance, helpfulness,
strength of the “community” of online users
 Seeking experiences/worried about effects: User is wondering if others have
experienced anything similar to what they have experience, and/or User is
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seeking others’ experiences with a drug, which may be specific (“does this sdrug
trigger hypomania?) or general (“what should I expect to happen when I take this
drug?”); User describes feeling worried or scared about taking the drug, usually
after having read about experiences of others on the websites, i.e., after reading
about weight gain or other side effects

APPENDIX F
Complete Log of Memo-Writing
Date

Case

Memo

Code

10/23/2009

Case
#27

We initially had two codes on
this segment: Side effects too
great and I hate this drug. I think
I'll make a general coding rule to
use the All in all, I'm positive
code and Side effects too great
code if they can be applied
BEFORE the more general A
miracle code and I hate this drug
code. I want to avoid applying 2
similar codes to the same
segment, and would prefer to
use the more specific code if it
fits before a more general code.

Not worth it
/ Side
effects too
great

This lexapro works too much like a
neuroleptic..i hate feeling out of
control, detached... I would rather be
depressed than totally anihilated !!!

10/24/2009

Case
#45

About being mis-informed or
uninformed about possible drug
effects?? Keep an eye to see if
this comes up more...

Doctor won't
listen / We
disagree / I
wasn't
informed

Nobody warns you about the apathy
when you start this drug, had I known
that I would no longer care about the
people and things I love, I would have
never started taking this drug.

12/1/09 update: This came up a
couple times in the agreement
sample. I added this as a
dimension of Doctor was wrong - which is now "Doctor was
wrong / We disagree / I wasn't
informed"
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Consumer Comment

Date

Case

Memo

Code

10/26/2009

Case
#65

Emotionally stable/calm/ normal
and Brain fog/Zombie (and/or
Lack of interest code) may be
two sides of the same coin. It's a
mellowing effect that for some
people is just the "right amount"
of mellowing to the point of
feeling "normal" or able to
handle stressful situations, and
for other people is "too much"
mellowing to the point of
becoming a zombie or spacey
(or to the point of apathy).

Emotionally
stable /
calm /
"normal"

Noticed being very mellow the day
after the 1st dose. The second day I
seemed a litte more myself, but at no
point felt "zombieish".

10/26/2009

Case
#77

I am wondering how best to
characterize consumers'
categorization of effects. Right
now I have Best Effect and
Worst Effect, but am not sure
how representative that is. It's
not as straight forward as
experts' categorization of
"severe" "serious" "less serious"
etc. This particular case seems
to be an example of an aspect of
the drug that is cool or good,
maybe not the Best Effect, but
SOMETHING nonetheless.

No / Limited
Side Effects

Plus, you can have a few drinks on
them with no ill effects! SIDE
EFFECTS. Not many,

10/27/2009

Case
#125

I think I'll really want to do some
analysis on this code to reflect
all the dimensions of doctor told
me to do this, I'm afraid to ask
my doctor or mention this to my
doctor (as in the present
example), how should I bring
this up to my doctor, etc. This
seems like a rich category.

Talking with
doc / Doc
explained /
Consult doc

My question is: I'm seeing my doctor
next week and am planning to tell her
how well things are working out. Do I
mention these side effects? I'm afraid
she may want to switch me to another
med. While it's only been three weeks
- I really think the Celexa is working.

10/27/2009

Case
#129

Coded as "other methods"
because this person is agreeing
with the previous post, which
said: "I'm betting that the AD
makes you hypomanic/manic,
and you reach for a cig to calm
you down."

Other
methods

You hit the nail on the head. Come to
think of it, it explains what happened
before and what is happening now.
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Consumer Comment

Date

Case

Memo

Code

10/27/2009

Case
#133

Unsure if "stupid" and "dopey"
are more similar to feeling "high"
or feeling confused/fuzzy/foggy,
or something else. Come back
to this...

Brain fog /
Zombie

Consumer Comment
Lexapro And Dopey Feeling Posted
by: Ginger Sun 28 September 2008
18:11:19 GMT +0000 I got a little
stupid on Lexapro, and it did
eventually go away.

Update: For now I will combine
Zombie and Dopey and
determine later if that's
appropriate
Update 12/7/09: I combined all
of these together into Cogntive
Slowing / Foggy/ Dopey
10/27/2009

Case
#133

Person must just accept the side
effect, deal with it, live with it,
etc.

Learn to live
with it

I am afraid the weight is here to stay
until I get off the Lex. I am going to try
a little harder in my exercise, but I'm
not a hard-core workout nut like I was
in college, so I will probably end up
just maintaining where I am.

10/28/2009

Case
#143

This whole thread is about
people sharing their weight gain
stories on Lexapro.

Weight gain

I guess I missed the part where
Lexapro causes weight gain I've been
steadily gaining weight the past four
years, but have only been on Lexapro
for about a year or so, maybe a year
and a half.

10/28/2009

Case
#147

Coded "Drug or Something
Else?" because previous poster
was suggesting the hair loss
was due to previous stress,
rather than the drug that the
person had only been on for 4
weeks. The current post is
agreeing that that may be the
case.

Drug or
Something
Else?

May was my standout month for
extreme stress this year. Oh and
February. And all summer. No wonder
my hair is thin!

10/29/2009

Case
#173

Perhaps create a code about
other people - family, friends,
doctor, etc - observing an effect
the drug is having on the
consumer.

Family/frien
d observed
an effect

My partner has noticed that I seem
somewhat spaced out and forgetful
(minor things like car keys, turning on
dishwasher, not hearing what
someone is saying to me for a
moment, etc).

12/1/09 Update: I collapsed
some of the family codes into
one general "Other family/friend
issues" which inclues the
dimension above.
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Date

Case

Memo

Code

Consumer Comment

10/29/2009

Case
#185

This comment in response to a
poster asking about what to
expect by taking her full dose of
Lexapro once a day rather than
split twice a day. Specifically
asking if there is a risk of mania.

Dose
related
issues /
advice

From Twice A Day To Once A Day
Posted by: Anna Thu 4 December
2008 14:28:33 GMT +0000 Anything's
possible when you are disturbing the
homeostasis... But honestly, I don't
think the risk is like, huge. Unless it
really hits your neurotransmitters like a
ton of bricks or something...

11/10/2009

Case
#96

I'm trying to distinguish "So
many damn meds" and "Other
drug equivalence." I am moving
comments like this one in which
there is a specific comparison of
or reference to a previous drug
and the current drug. More
general comments, like "I've
tried lots of meds..." will remain
under "so many damn meds."

Generic/oth
er drug
equivalence

I've been on lexapro for 3 years and
has been the only medication that has
really worked. I tried taking Zoloft and
it made my depression worse.

11/10/2009

Case
#239

Should this be coded as "Don't
take this combo" or as a
Contraindication? Maybe I need
to merge the two codes...

With other
medicines

By the way, if you start on SSRI
treatment, you should stop the 5HTP
since it may lead to 5HT-syndrome especially with Lexapro.

No or
limited
helpfulness
/ It's not my
wonder drug

And I did not find that it was working
all that well to begin with,

12/1/09 Update: This seems like
a clear contraindication now that
I read it again. But will need to
clearly distinguish or merge
these.
11/16/2009

Case
#123

Not sure whether to code No
beneficial effects or Ok, but not
great. I don't want 2 codes with
similar meaning for the same
segment.
12/1/09 Update: This same
question had come up a few
times in the agreement coding. I
merged No beneficial effects into
Ok, but not great, as well as
pulled out the Limited
Helpfulness cases from Poop
Out and merged them into Ok,
but not great.

11/27/2009

Case
#163

This comment is a response to
the previous post: "Lexapro left
me with my libido intact, but I
could not orgasm."
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Trouble
achieving
orgasm

That totally happened to me, too! It
freaked me out and then I
remembered... Oh, this is a side-effect.
It was weird.

Date

Case

11/28/2009

Case
#185

12/1/2009

Memo

Code

Consumer Comment

Not sure whether to code
Dependence/Withdrawal, or
Taper SLOWLY. Again, do not
need 2 codes with similar
meanings on 1 segment.

Dependenc
e/
Withdrawal

since you are cross-tapering from one
ssri to another, there shouldn't be a
problem in going relatively quickly. The
slower taper that is recommended with
ssris is more about if you are coming
off completely, to avoid withdrawal
effects.

Case
#115

We decided to use these codes
for consumer comments about
effects being "nothing intense,"
"mild," "insignificant" and other
words like "less severe" or
"severe"

Less
serious /
Less severe

SIDE EFFECTS. Nothing intense, but
I have noticed that I'm always hungry

12/4/2009

Case
#60

This would fit under the code I
originally had under Support and
Advice: Feeling validated. This
refers to a person feeling like
their experience is validated
after reading about others'
experiences online.

Other
general
support

I spend most of my spare time in bed
sleeping - I'm barely participating in
life. I seriously thought I had chronic
fatigue syndrome, but after reading
about other people's experiences, now
I suspect it's the Lexapro.

12/4/2009

Case
#86

Sometimes the experience of
the drug is defined by what
effects are ABSENT.

No / Limited
Side Effects

Never had any tiredness or spaciness
on it. I also did not experience serious
sexual side effects.

12/4/2009

Case
#124

I'm wondering if I will need a
code like "Clinical trials show...".
Or if I should just put this under
the citation code?

Academic
Journal /
"Research
shows..."

He said that there are clinical trials that
show that 80% of those who will
respond to it at all will show some
change in the first 2 weeks

I just wanted to add that I was in the
same boat and I couldn't take ONE
day! You're awfully brave.

12/13/09 Update: I've decided to
add this to the Citation code
"Academic Journal / Research
shows..."
12/8/2009

Case
#130

In reference to worsened anxiety
upon starting Lexapro

Symptoms
new /
worsened

12/8/2009

Case
#133

This would fall into a code like:
"Accepting / Dealing with *it*" as
a method of dealing with (or not
being able to deal with?) side
effects. Rather the person is
having to learn to just live with it.

Learn to live
with it
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Well, I have stayed in the vicinity of an
overall gain of 8-10 pounds. I did buy
some new pants. What else are you
going to do? I looked stupid in the
pants I had. I know I'll fit into them
when I get off this medication in
another 6 months, but I am just sort of
accepting it right now and dealing with
it.

Date

Case

12/8/2009

Case
#149

12/8/2009

12/9/2009

Memo

Code

Consumer Comment

Another comment about
"accepting" or "dealing
with/learning to live with" side
effects.

Learn to live
with it

I'm only on here venting about how I
am stressed and concerned about
weight gain, not saying I have quit yet.
I need some time to accept the side
effects.

Case
#156

I see this idea come up at times:
I don't plan on ever stopping this
drug / I will take this for a
lifetime, etc. I have been coding
these under "A miracle" and
possibly under "OTHER" at
times

A miracle /
saved my
life / I
recommend
(Lex/Ser
only)

I feel much less insane now, and don't
plan to stop taking it any time soon, I
haven't felt this serene in a long time.

Case
#134

I highlighted this in addition to
Dependence/Withdrawal
because of the comment
referring to "Looking back on the
drug experience..." now they can
see that their creativity had been
zapped.

Looking
back on
it.../Since I
stopped the
med...

I was having dinner and we had the
ketchup out, and Heinz has some
dumb commercial contest going on,
and I came up with a totally cool
commercial idea!! I wouldn't have been
able to think something like that up
when I was on the meds. But, at the
same time, I didn't notice that my
creativity was zapped while I was on
the meds.

12/13/09 Update: Decided to
add a code called "Looking back
on it.../Since I stopped the
med..." because this concept
continues to come up.
12/9/2009

Case
#472

Added Best/Fun Effect code
here because I wanted to mark
her comment "a benefit I had not
anticipated", and that comment
does not really fit anywhere else.

Best / Fun
Effect

A benefit I had not anticipated was
while taking Lexapro I no longer had
sleep paralysis.

12/9/2009

Case
#472

She says it HELPED her hot
flashes, so I will have to break
the improves from the worsens
hot flashes during analysis.

Hot flashes /
heat stroke

I also think it helped my hot flashes

12/9/2009

Case
#533

I did not code this My Drug
Combo (as I anticipate Kristina
will) because I thought Drug Or
Something Else? is more
specifically what this comment
refers to.

Drug or
Something
Else?
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hard time getting up in the morning . I
am also on bp meds and klonopin
which all cause drowsiness.

Date

Case

Memo

Code

12/9/2009

Case
#554

Ok, I am seeing that Taper
Slowly and
Dependence/Withdrawal are not
defined enough to clearly
differentiate them. I will have to
somehow merge them or
differentiate them (after we finish
agreement coding)

Taper
SLOWLY /
Low Starting
Dose

I will start tapering off of it after being
on it for a year. Take 200mg at
bedtime, now taking 100mg for a
month or two and going from there!

12/10/2009

Case
#573

After agreement coding, I think I
should merge Helps Me Sleep
with Tired/Excessive Sleeping and rename this new code
simply "Increased Sleep /
Sleepiness". As it stands now,
comments like this would be
difficult to classify as either
"Helps me" or "Excessive"

Extreme
sleepiness /
Tired

I did sleep for 14 hours straight

12/10/2009

Case
#591

Not sure if this belongs here, or
a code under Muscoloskeletal
and Neurological Effects

Brain fog /
Zombie

slurred speech, problems with walking
correctly/balance.

12/10/2009

Case
#613

This would have fallen within
Side Effect Trade-Off, however I
deleted that code prior to this
last round of agreement coding
because I had not seen it come
up often.

Other
methods

Now at 500mg the difficulty falling
asleep has returned and I'm back to
waking up sweaty with bad dreams
more often. But my daytime sedation
has gone down.

12/10/2009

Case
#613

This is in response to a concern
about taking a 300mg dose - i.e.,
whether that is too high, whether
they should start with something
lower, etc?

Dose
related
issues /
advice

Not just for the sake of being contrary,
I think the 'listen to your body'
approach can be appropriate in some
cases. NOTE: I am NOT saying it's ok
in ALL, or even MOST cases, just
SOME... especially with a med like
slurroquel where there's a huge dosing
range.

12/10/2009

Case
#613

I code these sorts of comments
with 'Waiting' because I interpret
this as the person is hoping
(read: waiting) to see what
happens next, i.e., whether the
weight will come off.

Ride out the
storm /
Eventually
goes away /
Waiting

I'm HOPING to experience rapid
weight loss as I taper down the
slurroquel.

12/10/2009

Case
#613

In response to a suggestion for
getting the "Anxiety and Phobia
Workbook"

Trying/Tried
alternative
treatment

I opted for Silver's suggestion of
Master your Panic, etc. Pretended that
I was ordering them for a client to
actually get me to get the books in the
house. Now would be a great time to
take them out!
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Consumer Comment

Date

Case

Memo

Code

12/11/2009

Case
#650

Nice example for illustrating how
the absence of an effect can be
as defining as the presence of
an effect.

No / Limited
Side Effects

I haven't gained any weight on it,
although that's more a matter of
avoiding a bad thing than saying a
good thing.

12/11/2009

Case
#675

This comment is in response to
a person asking if there is an
online Canadian pharmacy they
can get generic Seroquel?

Generic/oth
er drug
equivalence

Unfortunately we can't answer that
question. paypal are dicks about that
sort of thing, not that it's explicit in their
TOS or anything. Generic quetiapine
is available in other countries and if
you read
http://www.crazymeds.us/InternetPhar
macists.shtml you can find out on your
own.

12/11/2009

Case
#675

Not sure if I want to put these
comments about monitoring
blood levels for diabetes under
Dealing with Side Effects, or
under Medical Tests - Evidence
of Causality. It is a medical test,
but not having to do with
causality, but rather having to do
with Dealing with Side Effects.

Learn to live
with it

What's This About Seroquel And
Diabetes? Posted by: Jerod Poore Thu
14 August 2008 12:33:47 GMT +0000
There's like this blood test you can get
from a doctor. Just being on Seroquel
with a family history of diabetes is
enough to warrant it. Viola! Question
answered. Get one every six months
and you're set.

12/11/2009

Case
#675

Quote is from female with
menstruation irregularities.

Menstruatio
n Irregular

SEE QUOTE.

12/11/2009

Case
#675

Would code as "Learning to live
with it..."

Learn to live
with it

There's not much you can do about it.
It usually gets worse the longer you
take Seroquel.

12/11/2009

Case
#675

Talking about sensitivity to heat,
getting overheated, and terrible
sweats.

Hot flashes /
heat stroke

Am I The Only One Who Had This
Side Effect? Posted by: Jerod Poore
Mon 31 March 2008 14:07:04 GMT
+0000 Hardly. And t he reason jook
didn't spot it is because AstraZenca
decided to use doctorese to describe
it. Asthenia. Fatigue, malaise, night
sweats, hot flashes, and a mimicking
of arthritis. Up to 10% of people who
take Seroquel reported this during the
clinical trials!

12/11/2009

Case
#747

Code "Learning to live with it..."

Learn to live
with it

I've learned to live with this but I hope
no one else has to
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Consumer Comment

It's damn rare,

Date

Case

Memo

Code

Consumer Comment

12/11/2009

Case
#772

I should note that comments like
this have been coded under "so
many damn meds" and NOT
also under "limited or no
helpfulness." More specific
instances of a med not working
have been coded under the
latter. General references to
"none of the meds I've tried have
worked" or "I've tried 4 other
SSRI's and none of them worked
until I was prescribed Lexapro,"
etc are coded under "so many
damn meds"

My drug
combo / so
many damn
meds...

I had tried everything and it didn't work
(ambien, anything herbal, ativan) and
seroquel works!

12/12/2009

Case
#974

I interpret the "they" in this
comment as referring to doctors.

Other
doctorrelated
issues

being on my meds- which they finally
got right after 12 years- allowed me to
accomplish things that I never would
have thought I was able to do.

12/13/2009

Case
#1003

Here again the dilemma of
having to choose between
mental and physical health

No or
limited
helpfulness
/ It's not my
wonder drug

my gut is telling me to get off zyprexa
too, but i don't really know what my
alternatives are, and i do want to be
stabilized. it's a tough situation.

12/13/2009

Case
#1014

Sleep eating

12/17/2009

Case
#245

I highlighted because of the term
"adverse reactions" to describe
the effects. We've been coding
for "side effects", but not for
other terms that people may
use. Not sure if I need to return
to this and code them all under
"side effects" (to be sorted out
during analysis), add additional
terms for coding, or just ignore it
completely.
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Increase
appetite /
cravings

I would eat in my sleep and even if I
was awake, I literally could not feel full,
no matter how much I ate.

"Side Effect"

I guess I'm having too many adverse
reactions. Let's see.....nausea,
migraine , upset stomach, trembling ,
heart palpitations , dizzy , completely
lost appetite (can't eat at all) .

Date

Case

Memo

Code

Consumer Comment

12/17/2009

Case
#254

This person is definitely
weighing benefits vs costs, but
does not come to a decision. I
coded it as Side Effects Too
Great because she answers "no"
to her question about would she
have gone on Lexapro if she
knew about the weight gain.

Not worth it
/ Side
effects too
great

great for panic attacks . bad for weight
Thanks to Lexapro, I no longer have
anxiety attacks. they are still there, but
they don't come full blast. . However
and this is a big HOWEVER, I have
gained 35lbs on this med. I can't lose it
no matter what... Had I known about
this side effect would have gone on
Lexapro ? No.. . even though my life is
back... it's hard now because I am in a
size 16 and I am normally a size 10.. .
But which is better.. being anxiety free
and overweight? or skinny and panic
ridden? it's a hard question

12/30/2009

Case
#276

Relieved
withdrawal/discontinuation
symptoms caused by another
drug.

Alleviates
side effect
from
another
drug

Three days after stopping Zoloft I had
severe and constant dizziness,
increased blood pressure and heart
rate - so my DR thought I should try
going on something different as I
wasn't coping well going cold turkey.
Within an hour of starting Lexapro the
dizziness disappeared, my heart rate
dropped over 24 hours and I felt ok
again.

12/30/2009

Case
#278

Relieved side effects caused by
another drug.

Alleviates
side effect
from
another
drug

I tried lexapro to reduce the side
effects of effexor and hopefully have a
better mood elevation. It did solve the
sexual side effects

12/30/2009

Case
#280

Serotonin syndrome - I also
coded these effects individually.

Other Misc
Effects

After almost 5 weeks at a dose of
10mg I started to experience
symptoms of what seemed like, to me,
serotonin syndrome - agitation and
anxiety ; general tremor and tremor in
the jaw ; confusion ; headache ;
sweating etc. - so dropped my dose
down to 5mg and these effects
disappeared pretty quickly .

12/30/2009

Case
#283

Relieves side effects caused by
other drugs

Alleviates
side effect
from
another
drug

Have been on Lexapro two weeks,
best of Paxil, (gained weight/lost all
sex drive), Effexor, (severe headaches
and no sex drive), Wellbutrin, (gave
me a seizure second night), and now
Lexapro. So far better; sex drive
returning
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Date

Case

Memo

Code

Consumer Comment

12/30/2009

Case
#289

I am merging Flat feelings with
Feeling detached or unreal
because I think the emotional
numbness described here is a
central defining feature of each.
Feeling detached from their
emotions, from their lives, from
the world.

Numb /
Detached /
Lack of
energy or
interest

mainly consisted of a "detached"
feeling or what I would describe as
emotional numbness .

12/30/2009

Case
#296

Not really weight gain, but
"difficult to lose weight" - not
sure if I need an additional code
for this or just note it during
analysis.

Weight gain

Lexapro seems to make it more
difficult to take weight off than before

12/30/2009

Case
#300

Code: "Learn to live with it"

Learn to live
with it

I am able to squeeze in two sessions
of gym a week. I make a huge willpower effort to control my apetite. But
I have also accepted that I am not
going to be back to my weight of three
years ago before Lexapro. And,
frankly, I am not adding Wellbutrin for
weight loss. It makes me jittery.

12/30/2009

Case
#309

Should I combine Flat feelings
codes and Feeling detached or
unreal code? Are they kind of
similar?

12/30/2009

Case
#319

12/31/2009

1/1/2010

Numb /
Detached /
Lack of
energy or
interest

there is a feeling of being "detached"
from things that would normally
produce extreme sadness.

I don't have a code for shooting
pain / electrical zaps / brain zaps

Zaps /
Tingling

have some shooting pain in my head
that comes and goes.

Case
#1081

I am noticing here a difference in
language use: these mental and
mood changes are called
"symptoms" whereas effects
called "side effects" are more
often physical effects (with only
a few mental/mood changes,
including agitation, restlessness,
and nervousness). To me, it
implies that worsening
mood/mental changes may be
part of the original problem
rather than or more so than an
effect of the drug.

Talking with
doc / Doc
explained /
Consult doc

Call your doctor at once if you have
any new or worsening symptoms such
as:

Case
#333

Code: "Learned to live with it /
Learned to accept it"

Learn to live
with it

I have gained a bit of weight, but I dont
care. I am still pretty small just not
obsessed with being a size 0 anymore.
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Date

Case

Memo

Code

Consumer Comment

1/1/2010

Case
#348

Yes, this definitely illustrates
how Flat Feelings are the other
side of the Emotionally Stable
coin!

Numb /
Detached /
Lack of
energy or
interest

In a way, the medication has me on
such an even keel that it feels strange.
My reaction to things that would
normally upset me (and perhaps
should upset me) have been very
restrained. Pardon the simile, but I feel
like Spock on the old Star Trek series - very rationale and systematic, not at
all emotional. My therapist thought I
would not like being on Lexapro for
this very reason, but I guess it is
helping me work out issues at work in
a more productive way, and helping
me plan for a future career that is less
stress-inducing.

1/1/2010

Case
#349

Code: "Learn to live with it"

Learn to live
with it

I do have a slight ringing in my ears-that I think is from the Lexapro -- but Ill
deal with that -- anything is better than
the panic and anxiety I had before.

1/1/2010

Case
#382

I've come across a couple
comments about taking Lexapro
during pregnancy, including this
one that Lex was a safer choice
than another med. There was
another comment within Lexapro
about a woman who did stay on
Lex during pregnancy and
breastfeeding and all turned out
well. Obviously, these would not
be contraindications, but what
should I code them as?

Generic/oth
er drug
equivalence

Is not as effective as Paxil. Switched
from Paxil thinking Lexapro was safer
since I want to get pregnant.

1/2/2010

Case
#162

Code: Electrical tingling / shocks

Zaps /
Tingling

315

there has been this strange sensation
which I'm finding difficult to deal with.
It's in my arms mostly and feels like
there's a layer under my skin of
electrical pluses and when waking at
3 and 4 in the morning (still), I have
the desire to cut the skin and peel it
off, or cut the skin in a spiral round and
round the arm. It does go away
towards the end of the day (on most
days, but not today) and sometimes
it's around my head as well.

Date

Case

Memo

Code

Consumer Comment

1/2/2010

Case
#272

I've been coming across this
idea of "I'm new to drugs / this is
only my 1st (or 2nd) drug so I
don't know what I should be
feeling or I have nothing to
compare this experience to"

OTHER

I'm happy with the drug, but it was only
my second drug.

1/21/2010

Case
#172

Unsure how to categorize
"activating" as an effect.

Energy
increased /
Euphoria /
Mania

Lexapro (on its own) was activating for
me. My impression from lurking this
board for some time is that it is
activating for some others also.

Mar 2010 update: Coding this as
Energized / Euphoric because
activating is generally meant to
reflect a manic-type reaction.
1/24/2010

Case
#194

Code as "Side Effect Trade-Off"

Other
methods

Dear me. Someone who'd pick thin
over sexual function. Think about that
for a minute. One is an appearance
issue. (You didn't say fit. You said thin.
Difference.) The other one is a basic
human drive and arguably integral to
primary bond relationships. It's like
Fernando from SNL all over again. It's
better to look good than to feel good.

1/24/2010

Case
#194

Code as "Learning to deal with
it/ live with it"

Learn to live
with it

I don't, personally, feel it's "fair" that
the medication that seems to be the
most effective for me is also the one
that's nibbling at my kidneys. I'm
taking it because it's preferable to the
alternative. (I'm also far past the belief
that the world is fair, though, so maybe
a certain amount of cynicism helps
here.)

1/24/2010

Case
#195

This comment relates to the
general idea of weighing pros
and cons, which is why I coded it
here (taking from "there are no
absolutes here") rather than All
in All or Side Effects Too Great.
Neither of the latter exactly fit.
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YMMV

Not taking antidepressants carries its
own set of very real risks, up to and
including death of mom and child.
There are no absolutes here.

Date

Case

Memo

Code

Consumer Comment

1/24/2010

Case
#196

This is about mixing lexapro and
alcohol, but it's just the opposite
of a contraindication. He is
saying it's probably okay to mix
them and there should be no
interactions. I don't believe I
have a code that this would fall
under.

OTHER

Because so many people drink,
especially depressed people, that the
drug companies do shitloads of tests
mixing the two. There is no
interaction, no change in the effects of
either drug, no nothing. Of course
doctors should tell people not to drink,
but a beer or two every now and then
has yet to affect anyone I've observed
or who has written about taking an
SSRI.

1/24/2010

Case
#204

I've coded this for a couple
comments relating to the effects
of the drug being different from
when the person took it at a
previous point in time.

Poop Out /
Effects
Changed

It does seem like a strange
paradoxical reaction...perhaps your
nervous system is in a more sensitzed
state this time?

1/24/2010

Case
#207

Another more general comment
about weighing pros and cons.
Even more specifically here, the
relativeness of effects as
desireable or undersireable.

No or
limited
helpfulness
/ It's not my
wonder drug

I am not concerned, probably because
it hasn't gone on long enough to really
move from unpleasant but interesting
to outright irritating, but I rather wonder
how a person being treated for anxiety
is supposed to decide when not being
concerned is an undesirable sideeffect rather than a desired outcome.

1/24/2010

Case
#212

Learn to live with it/ deal with it

Learn to live
with it

Once I had the crown replaced I just
got used to that side effect as the
combo worked so well for my moods
for several years. I was on 300 mg
Wellbutrin and started at 10 mg
Lexapro and later raised to 20 mg. I
still have all my teeth and no long-term
damage that I'm aware of.

1/24/2010

Case
#232

Learn to live with; Also again this
idea of an effect as beneficial or
not is relative

Learn to live
with it

this is the one that still strikes me. It's
one I can live with and may even be a
beneficial effect depending on how
you think about it.

1/25/2010

Case
#233

A response to another user
stating that they expend more
calories than they take in, so
why do they continue to gain
weight? It goes against the laws
of science (according to this
user). The coded comment says
it would work that way but these
chemicals get in the way.

Unsure
about
mechansim
/ Other

Lexapro User And Weight Gain Posted
by: Cyeic Sun 16 December 2007
5:35:35 GMT +0000 It would be
thermodynamics, and a simple case of
weighing energy intake against energy
expenditure, if those pesky genes and
neurochemicals didn't get involved.
Look up "leptin" and associated
molecules.

317

Date

Case

1/26/2010

Case
#620

1/26/2010

Memo

Code

Consumer Comment

Relieves an adverse effect
caused by another drug.

Alleviates
side effect
from
another
drug

Now I have switched to Seroquel as I
have thinning bones from amenorrhea
and within a month my prolactin levels
have dropped from 3000 to 57 and my
periods have returned.

Case
#623

Maybe broaden the code "Going
back on meds" to also include
comments similar to "meds are
the solution for me"

Going back
on meds /
Meds may
be the
solution

Truth is, I function pretty well without
any of my meds, I just feel better with
them. I always need something for
sleep so while I'm taking something for
sleep I might as well take something
for everything else that ails me lol.

1/26/2010

Case
#624

"Tweaking"

Other
methods

Things are really not all too bad right
now when you look at how bad they
have been in the past! I just think
maybe my meds need to be tweaked a
bit...

1/26/2010

Case
#632

Use it PRN instead of daily

Other
methods

I had tried it once before back in
March and didn't like it because I was
taking it every night and made me into
a zombie during the day , but now I
take it only when feeling agitated at
night and once the zombification
wears off I feel a lot better.

1/26/2010

Case
#633

"Side effect trade-off"

Other
methods

when i take it on and off, i dont sleep
enough, so im totally exhausted
physically, then i take it and crash,
sleep too much.

1/26/2010

Case
#633

Though this comment is
referring to how to tweak a med
combo, rather than just a
statement of what the combo is.
I've come across several general
statements about med combos
or cocktails needing to be
tweaked...

My drug
combo / so
many damn
meds...

was just reading other post in the
treatments for bipolar section... and
read up on the topamax sheet - if that
is a sleepy kind of drug, maybe that +
lamictal would be good and i wouldnt
need the seroquel as often. plus, it
would keep the headaches (which i
think are more like cluster than
migraine) more in check.
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1/27/2010

Case
#638

Kind of similar to "Side Effect
Trade-Off", but not sure if that's
the best code here

Other
methods

After 4 years on seroquel I have been
having quite a bit of trouble getting my
sleep routine back into shape. The
thing is, the new medication that I am
on also has the initial side effect of
insomnia. I have been on that for 7 or
8 weeks now. I'm cool when it comes
to getting to sleep but I almost always
wake up at 3am and sometimes can't
get back to sleep until about 6am or
so.

1/27/2010

Case
#641

This is a general comment about
having to weigh side effects and
benefits

YMMV

Sometimes I adjust to the side effects,
other times the side effects win out.

1/27/2010

Case
#641

"Waiting" to see if the effects will
last...

Ride out the
storm /
Eventually
goes away /
Waiting

If you are at a point where it feels good
then pat yourself on the back and say
a prayer that it lasts. Sometimes there
is no rhyme or reason for the change.

1/27/2010

Case
#647

This is in response to a user
stating the seroquel they've
been on for 2 years is "bombing
out." The present comment is
advising that they plan what they
could do next.

Poop Out /
Effects
Changed

Q's Bombing Out? Posted by: seaview
Fri 2 January 2009 15:48:42 GMT
+0000 Yes. It may not hit, but better
plan what your next moves will be if it
does.

1/27/2010

Case
#647

Is the drug "bombing out" or is it
life stresses getting to me? (this
is the question the previous user
poses)

Drug or
Something
Else?

SEE QUOTE. Possibly. Possibly not.
(I'm dead helpful sometimes, me.) But
you know you've had a "fair bit to deal
with" recently, and you've moved, and
it's the time of year for festilities that
unbalance all of us in some way. All
adds to the mix.

1/27/2010

Case
#647

This refers to having or making
plans for ongoing well-being
and/or stability. Kind of reminds
me of users talking about
needing to tweak their cocktails,
or trying to think ahead or plan
ahead for what they anticipate
may be about to happen.

Making a
plan / Just
in case...

It's good that all your support eggs
aren't in one basket. That's a clumsy
way to put it, sorry - I guess I mean
that it's good that you have a GP and
meds and people acting as carers and
some maintenance / crisis plans.
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1/27/2010

Case
#647

Learn to live with it/deal with it

Learn to live
with it

a need to eat masses of carbohydrate.
Far more than my body could
genuinely need for day-to-day
functioning. I could easily add another
10 pounds in a week or so. I don't like
this side-effect, but I don't think too
much about it.

1/27/2010

Case
#649

Compare data to code here maybe needs to go in Making a
plan/Just in case.... I think that's
where I've put other comments
about keeping around
emergency meds

Making a
plan / Just
in case...

Plus, a lot of people don't really like
using AAP's as long term,
maintenance therapy, but see them as
best used only as short term,
emergency meds.

1/27/2010

Case
#659

Again, Making A Back-Up Plan
or Strategy

Making a
plan / Just
in case...

No, haven't tried Topa, but it is my
back up plan if I get the rash from
lamictal. See if he'll give it to you,
because it seems like any weight-gain
med may trigger an e/d episode.

1/27/2010

Case
#666

The comments by this user
seem suspicious to me - like this
info is just copied from a PI
sheet or some other source, and
a couple spelling/grammar
errors are thrown in to make it
appear authentic. Don't know...

Symptoms
reduced /
improved

it works at low doses as it is the most
sedating of the anti-pyyscotics so will
calm your anxiety and help to stabilise
your depression if your prone to
cycling.

1/27/2010

Case
#679

Having a back-up plan or
strategy

Making a
plan / Just
in case...

It's good that you have a plan and it
sounds like you have good
professionals too.

1/27/2010

Case
#682

Other methods to make it okay
to have a few drinks while on
seroquel

1/28/2010

Case
#686

Change to blood sugar / glucose
changes
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Other
methods

Alcohol Effects/ Libido On Seroquel
Posted by: therapeuticbrigg84 Sun 14
December 2008 22:13:15 GMT +0000
I guess you're right in that it takes
staying out late out of the equation, but
I don't think that one night a week of
staying out late is bad on this drug. as
I would end up taking it at a later time
maybe at 1am or 2am instead of my
regular 12 am drop- basically cuz I'm
pretty much a nightowl anyways.

Blood sugar
high /
Diabetes

And jooks right about the glocose
levels. Mine shot down when I woke
up from a seroquel saturated slumber.

Date

Case

1/28/2010

Case
#715

1/28/2010

Memo

Code

Consumer Comment

Relieves adverse effect caused
by another drug

Alleviates
side effect
from
another
drug

im currently suffering from lamictal
induced psychosis that wont go away
with zyprexa, clozapine (getting worse)
and bit better on seroquel and abilify

Case
#717

Previous user stated that their
doctor said 75mg of Seroquel
will not make them gain weight,
and was asking the forum if this
was true...

Trusting the
doctor ?

So maybe, maybe not. Seroquel is
definately one of the AAP associated
with weight gain , so perhapse your
doctor was trying to reasure you, or....

1/28/2010

Case
#717

General comment about the
user having to weigh benefits
and side effects

YMMV

Yes, seroquel has side effects, but all
medications do, you're not guarenteed
to get them - it seems you've been on
the medication for 5 years without
problems.

1/31/2010

Case
#532

I see this a lot - the "trade-off" this concept *could* fall under
the 'Limited Benefit' code.

Extreme
sleepiness /
Tired

Secondly, it makes me way too
sleepy... after an hour after I take the
medication I'm usually unable to move
about without tripping and falling. On
the flipside, without it I can't sleep, and
if I do sleep, it's like a 2 hour nap. Not
fun.

1/31/2010

Case
#538

I coded this as "limited benefit/ok
but not great" because this user
is weighing the benefits and
costs, but has not yet reached a
conclusion - other than the fact
that the drug isn't 'perfect'

No or
limited
helpfulness
/ It's not my
wonder drug

have been on 400mgs a day for a
month.dont know yet if the
benifits(less anxious,less easily
upset,moodswings lessen )is worth
the side effects.

1/31/2010

Case
#546

Not sure whether to code this
here or under "I'm done / I want
off". I put it here because there
is some element of weighing the
benefits and costs of the drug
here (as it DOES help them
sleep, but it may not be worth
the other effects).

No or
limited
helpfulness
/ It's not my
wonder drug

Seems to help alittle but really want to
get off this stuff - only thing is - it does
help me sleep.

2/1/2010

Case
#557

Another one where they know
they have to weigh pros and
cons, but did not reach a
conclusion within this review. I
put it here because it's an
acknowledgement of "limited
benefit" - in that the drug
partially solves their problem,
but causes other problems.

No or
limited
helpfulness
/ It's not my
wonder drug

So I ask myself: fat and happy or thin
and crazy? Hmmmmmm... I have
gained 30lbs since 12/06 and I know
that cannot ALL be my fault! It's kinda
bad when you have to choose
between your mental and physical
health. It is a tough choice to make.
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2/1/2010

Case
#563

weight gain isn't a "real" side
effect because it's just a given
effect for any antipsychotic

"Side Effect"

Long term use has not had any real
side effects except for the traditional
weight gain with an anti-psychotic.

2/1/2010

Case
#568

I see this over and over again being tired or fatigued, but also
liking this same effect for it's
help in sleeping. The same
effect is both good and bad
depending on what the user
needs at a certain time or in a
certain context. I need to be sure
to read through all the sleep
codes, and may need to merge
the "helps sleep" with the "tired"
code - as they are really the
same effect, just a different
interpretation given.

Extreme
sleepiness /
Tired

Fatigue (good for sleep though)

2/1/2010

Case
#570

This is almost another code for
sleeping: "extreme sleeping". It
doesn't quite fit within "helps me
sleep" and it's not "excessive
sleeping", but users most often
describe it as "extreme" sleeping

Extreme
sleepiness /
Tired

This pill feels very strong as it truly
knocks me out after taking at night. I
wonder if I could wake if the house
was on fire?!? SIDE EFFECTS
extreme sleeping within half hour at
night taking 300mg.

2/1/2010

Case
#584

I am coding any instance that a
person has, may have, or is
warning others of the risk of
diabetes. I decided to code this
way because I code 'expert'
sites based on warnings of side
effects, i.e., WebMD lists a
bunch of side effects and I code
them as side effects. I thought it
was only fair to treat consumer
sites the same way, so even if it
is not a personally experienced
effect, but something that they
list as a possible effect, I am
coding it as an effect.

Blood sugar
high /
Diabetes

I have heard there is a risk for
diabetes with seroquel and blood tests
should be required periodically

2/1/2010

Case
#590

Limited benefit because of the
"trade-off"

No or
limited
helpfulness
/ It's not my
wonder drug

Why does there always have to be a
trade-off with medications? You either
do well physically without, but suffer
mentally - or you take the meds, feel
well menatally, but pudge out! If these
med-researchers ever figure out the
metabolism/weight gain/endocrine
problems, they would hit the jack-pot!!!
GET IT RIGHT DOCS.

322

Consumer Comment
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Case

2/1/2010

Case
#768

2/2/2010

Memo

Code

Consumer Comment

For so many people, the same
effect is both good and bad at
the same time.

Numb /
Detached /
Lack of
energy or
interest

I was taking a lower dosage of
Seroquel for over a year before and
complained about the 'doziness.' I
didn't really care about day-to-day stuff
like mounting bills and housework, etc.
On the other hand, I didn't get anxiety
attacks either.

Case
#803

I'm taking this as an effect of the
drug - this user was able to cut
down on alcohol use as a result
of the seroquel working so well.

Other Misc
Effects

I have cut back on my alcohol use to a
much more acceptable level

2/2/2010

Case
#810

I coded this segment twice - as
'helps me sleep' and 'other'. The
'Other' is because it relieves an
adverse effect of another drug

Alleviates
side effect
from
another
drug

Seroquel has enabled me to take my
antidepressants, which cause
insomnia.

2/2/2010

Case
#811

Learn to live with it/deal with it

Learn to live
with it

I hope to find a cure for the eating
thing...if not, I'll just have to be heavy

2/2/2010

Case
#823

Relieves adverse effect of
another drug

Alleviates
side effect
from
another
drug

It always beats my insomnia, which is
caused by my Bipolar and other the
medications that I'm on.

2/2/2010

Case
#826

helps with IBS

Other Misc
Effects

It helps w/hypomanic, sleep , IBS

2/2/2010

Case
#862

This is a combo of appetite and
memory loss or sleep-walking "sleep eating". Good term to use
as a code or as a term to
describe users' experience.

Increase
appetite /
cravings

Thanks to the person who mentioned
the sleep eating! I began doing that
suddenly and did not know it was the
Seroquel

Memory
loss

Taking 600mg every night. Sometime
during the night I went into my
livingroom and somehow wrecked my
whole apt.! I woke up on the rug and
realized what I had done.

General Note, two terms
invented by users:
sleep eating and
extreme sleeping
2/2/2010

Case
#870

with sleep walking
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2/2/2010

Case
#872

Another case of weighing pros
and cons without reaching a real
conclusion, other than the drug
fixes some problems and causes
many others.

No or
limited
helpfulness
/ It's not my
wonder drug

He is closely monitored, but even with
that he is now experiencing health
problems that are a direct result of this
med. His triglicerides are off the chart
, blood-pressure is too low , sugar
high , and occasional chest pains .
Since we have been through most of
the available meds for his dissorders,
and he is relative stabile,it has been
decided that taking him off of the meds
will cause him to crash. I am in the
process of working with the doctors,
med and pcp, to decide what to do
before... I'm not sure what could
happen to him, but I was told his
situation is dangerous. I know it isn't
fair that there are not better meds out
there, or ones that the side affects
wouldn't kill you, so what is a mother
to do? Either way it seems to me that
my son is the looser; breakdownsuicide attempts or diabetes, heart
disease, or stroke. What would you
do?????

2/3/2010

Case
#1002

I am coding books as 'academic'
though I may need to go back
and pull these out into their own
category

Academic
Journal /
"Research
shows..."

have you ever read---The Looney Bin
Trip? By Kate Millet...good read, from
a very intellectual woman who didn't
like her lithium....but I am not antilithium,

2/3/2010

Case
#1055

User is stating that they want to
go from taking their
antipsychotic everyday as
maintenance treatment to an asneeded/PRN basis.

Dose
related
issues /
advice

let me taper off the risperidone and let
me try something else to stabilize my
mood, and just have the anti-psychotic
as a safety net.

2/3/2010

Case
#1055

Link to an MSN article about
risperidone being on the list of
the top 10 most dangerous
drugs

Internet

Wow, thanks dionysian. Definitely
helps. I emailed that link to the
psychiatrist too.

2/6/2010

Case
#977

Learn to live with it / deal with it

Learn to live
with it

He said he would be willing to work
with me on changing meds...but
recommended that I just deal with the
tremor , unless it gets worse.

2/8/2010

Case
#986

General comment about
weighing benefits vs negative
effects

No or
limited
helpfulness
/ It's not my
wonder drug

Perhaps list the effects of the medicine
you are taking. If the effects do not line
up with your goal or the negative
effects outweigh the positive then this
is a very good case for change.

324

Date

Case

Memo

Code

2/8/2010

Case
#986

PBS show on tv. I coded it here
because I also coded 'books'
here, and may separate them
out into 1 category later

Academic
Journal /
"Research
shows..."

PBS Frontline, Tuesday Jan8 The
Medicated Child Posted by: Inel just
saw it... it was very anti-climactic for
me. a little too soft-core.

2/8/2010

Case
#991

In this 'Other' category, I've
come across several times this
idea of "I wish, I wish, I wish..."

OTHER

Would'nt it be nice to be happy and
normal without having to swallow all of
this damn rat poison??!!!

2/8/2010

Case
#1013

Wants to quit meds, but stays on
them because of fear of what
might happen without them.... Is
that coded here, or as a
Dependence issue?

Drugs won't
work / I'm
done / I
don't need it

Wow i know exatly what you're talking
about. I haven't even been able to
make it to trying to go down on my
meds but i think about it all the time.
I'm just so afraid of my symptoms
returning. without meds, mine are
quite strong and this scares the
daylights out of me.

2/9/2010

Case
#1036

Not really 'drugs won't work,' but
a comment about the limited and
appropriate use of drugs...

Drugs won't
work / I'm
done / I
don't need it

People who are in severe psychotic
states or in states of self-injuring or
injuring others, or who are totally
unable to function often need to be
medicated. But the medication should
be short-term, at as low a dosage as
possible, with polypharmacy avoided
(no more than two drugs together),
and the patients should be titrated off
properly as soon as they are given the
proper modalities to support healing at
the root level of the condition, which
can be orthomolecular, energetic,
psychotherapeutic, probably several
things in combination--in a caring
environment that embraces nature.
However, our society is not set up in
such a way as to permit this.

2/9/2010

Case
#1040

"Side effect trade-off"

Other
methods

My doc added zonegran to the
zyprexa to try and mediate the weight
gain. Makes me very sleepy though.

2/10/2010

Case
#1085

"Warnings" - not "side effects" but I had no where else to code
this term

"Side Effect"

What warnings do you have for
Seroquel (Quetiapine)? The following
warnings are available for this
medication: May impair driving. Do
not drink alcohol. Obtain advice for
OTCs. May cause drowsiness.
Check with your doctor before
becoming pregnant.

325

Consumer Comment

Date

Case

Memo

Code

Consumer Comment

2/10/2010

Case
#1086

"used with or without other
medications"

OTHER

This medication is used with or without
other medications to treat certain
mental/mood conditions

2/11/2010

Case
#1083

I coded this here because of the
last 2 sentences.... which
comment on the lack of
transparency in both published
articles and the PI sheet. Jarod
here is trying to piece these
incomplete bits of info together

Three
percent my
ass!

I could find a study
http://www.ncbi.nlm.nih.gov/entrez/que
ry.fcgi?cmd=Retrieve&db=PubMed&lis
t_uids=14744167&dopt=Abstractindica
ting that Lexapro (escitalopram
oxalate) is good to prevent relapses of
major depressive disorder when
compared to a placebo. Close to
75% of the people taking Lexapro
(escitalopram oxalate) after 4-6
months were still not depressed, vs.
60% taking the wonder drug Placebo.
Unfortunately we don't get to see how
their MADRS scores were. I suspect
this was the fourth trial mentioned in
the PI sheet.

2/11/2010

Case
#1083

Relieved an adverse effect of
another drug

Alleviates
side effect
from
another
drug

I've found one reference to a single
case
studyhttp://www.ncbi.nlm.nih.gov/entre
z/query.fcgi?cmd=Retrieve&db=PubM
ed&list_uids=14660288&dopt=Abstrac
t where someone overcame the
sexual side effects of
Prozachttp://www.crazymeds.us/proza
c.html (fluoxetine hydrochloride) by
switching to Lexapro (escitalopram
oxalate).

2/12/2010

Case
#1084

Agitation

Other
reason /
diagnosis

If you're agitated, jumping out of your
skin and you just can't sleep, then
Seroquel (quetiapine fumarate) might
be just what you're looking for .

2/12/2010

Case
#1084

I need to look at the "zmobie"
codes, which I have put all under
"cognitive slowing, spacey,
dopey". Jarod equates zombie
with "flat feelings, lack of
interest". Perhaps I need to
merge these codes??

Numb /
Detached /
Lack of
energy or
interest

not giving a damn about anything
(a.k.a. the zombification effect).

2/12/2010

Case
#1084

Learn to live with it/deal with it

Learn to live
with it
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Except for the excessive sleepiness,
which could hang around for as long
as you take this med.

Date

Case

3/10/2010

Case
#1058

3/10/2010

Memo

Code

Consumer Comment

Finding a doc

Other
doctorrelated
issues

Re. docs, ask any docs (of any type)
that you trust to give you names of any
pdocs (psychiatrists) they've heard
particularly good stuff about (and/or
deal with bipolar a lot).

Case
#1058

Finding a doc

Other
doctorrelated
issues

Last change I had to make, I asked my
primary care doc, therapist, old doc
(she was going to work for the VA), my
husband's doc at the VA, our couples'
therapist at the VA . . . I heard the
same name from a couple of people I
really respected, tried that doc & am
really pleased with him. Of course, if I
hadn't been, it'd have been back out
there again. You have to have
someone you feel is competent & does
care (within the very limited time they
can give)

3/10/2010

Case
#1065

Med hoarding / disposing

Making a
plan / Just
in case...

I absolutely horde medication.
Prescriptions, over the counter meds,
herbs, vitamins, supplements,
tinctures, teas, expired, variously
acquired, frequently useful, but some
of which I can't even remember what
they do or how i came to posses them.
And all with this vague concept that I
might need them either for myself or
others, or, on bad days, because i
might at some point decide to
consume all of everything and see
what happens. but mostly i just can't
seem to make myself get rid of these
things.

3/10/2010

Case
#1069

Afraid of stopping or changing
meds

Looking
back on
it.../Since I
stopped the
med...

afraid to go off meds because of what
I've described elsewhere as the illness
I felt all the time once off them. As for
the headaches, I don't have them
anymore, but I don't know what would
happen if I tried anything new out. As
I've said elsewhere, Zyprexa has
sometimes been a weight gainer for
me, although there are other reasons
why I've put on weight in the past
year...but I can't let go of it because of
the year I lost of my life to all sorts of
other meds. And that started with evil
deathforce Seroquel.
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3/10/2010

Case
#1070

I am not sure where I am putting
these comments that
recommend someone get
regular tests for something:
either "medical tests" (but it's
really not Evidence of Causality)
or "I'm taking control" (because
they are monitoring drug effects)
or something else?

Check blood
levels

Also, if you take Seroquel, it's good to
have a fasting blood sugar check
every few months (a fingerstick at
least 2 hours after eating or drinking
anything except water.)

3/10/2010

Case
#1073

meds and pregnancy

OTHER

i'm on lithium and zyprexa. my doctor's
recommendation was to stay on both
throughout the pregnancy, and i'm
going to (i tried to get off the lithium
but it was a disaster).

3/11/2010

Case
#135

Comment about having to weigh
benefits and costs - though not
making a decision about them.

No or
limited
helpfulness
/ It's not my
wonder drug

3/11/2010

Case
#135

Brain zaps on Lexapro (while on
a stable dose)

Zaps /
Tingling

I've been on 20 mg Lexapro for a year
and a half at this point, perhaps
longer. I've also been on 200 mg of
generic Wellbutrin (100 mg taken twice
a day) for the better part of the year.
The zaps aren't comparable to the
ones I experienced during Effexor
withdrawal, but they're nonetheless
annoying. (I assume they have more
to do with Lexapro than with
Wellbutrin.) I've been having them for
3 days at this point, but I haven't been
missed a dose of my meds. (OK, I did
forget to take my stupid statin last
night, but that shouldn't be related,
right?)

3/11/2010

Case
#135

Comment about having to make
an assessment, but no decision
made...

No or
limited
helpfulness
/ It's not my
wonder drug

At the end of the trial period, you'll be
able to decide whether the benefits are
worth whatever side effects you might
develop. (There are some lucky
people who don't experience any side
effects to speak of.)
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If you do gain weight (which isn't
guaranteed in the first place), I think
it's important to consider how much
weight you actually gain vs. how well
the antidepressant is helping your
mood. It may still be worth it.
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3/11/2010

Case
#135

3/11/2010

Memo

Code

Consumer Comment

Learn to live with it

Learn to live
with it

Do Sexual Side Effects Ever Wear
Off? Posted by: Artemisia Mon 10
December 2007 15:52:53 GMT +0000
I'm one of those "zero, zilch, nada,
nothing, never" cases. Nothing works
even when I'm not on any meds...

Case
#964

Not so much the 'doctor' but the
'system' is wrong

Doctor won't
listen / We
disagree / I
wasn't
informed

The whole system needs to change. I
think if only I was taught to live with
specific symptoms. Like I have a fast
brain. No doubt about it- it's just fast.
They (medical community) wanted to
slow it down and I downed pills for it.
But I couldn't deal with a slower brainthat made me more crazy. But no one
saw that. If only I were taught how to
handle it going fast- taught how to
organize my fast thoughts. I had to
learn that stuff the hard way. I selftaught myself to handle my speech so
its understandable not fast and
jumping around topics. I may be
thinking that fast but I've learned how
to have appropriate conversations.

3/11/2010

Case
#964

Thinking of going back on meds

Going back
on meds /
Meds may
be the
solution

At times I wonder about going back on
Ritalin but only because my
organizational skills are nil. I can't
organize for the life of me and it
shows- my desk is always a mess as
is my whole therapy area where I treat
the kids. It is a constant struggle for
me to keep it all together.

3/11/2010

Case
#964

Related to "the system" - but not
jumping through hoops. I coded
this here because if this user
was complaining about "the
hospital" or "the system" I would
code it here. I may need to relabel this code to reflect any
comments related to 'the
system,' then.

Jumping
through
hoops /
Hospitals

hospitals didn't destroy my life- I still
went to college full time, I still held a
full time job (though it had flexible
hours to allow me the time off
sometimes)...I still had a very full life,
just with tiny interludes to get my head
straight. And to this day even though
I am shifting away from a pure medical
model, if I went nuts for some
reason...I still know that a hospital can
give me reprieve's.

3/11/2010

Case
#964

Thinking of going back on a
med; prevention

Making a
plan / Just
in case...

So this post is about PREVENTION
and not INTERVENTION. I want to
head off any bad things now before
anything happens and I think going
back on a mood stabilizer may help.
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3/12/2010

Case
#135

Helped IBS

Other Misc
Effects

I've been tentatively diagnosed with
IBS a couple of years ago (I was on
Effexor XR then). I've been oscillating
between constipation and diarrhea.
Switching to Lexapro actually made
my intestinal adventures less bad for a
while, but then they returned. They're
still not as bad as they were on Effexor
XR, though.

3/14/2010

Case
#1045

I think I've been coding any
"hospital experience" here just to
have them all in the same place.

Jumping
through
hoops /
Hospitals

i remember having one of those
experiences getting locked up (in beth
israel medical center on 17th and 1st)
and i was totally freaking out having a
panic attack thinking i was dying and
the psych doctor in his glasses and
white coat said that he could give a pill
that would help me and i told him to
fuck off, but then a couple hours later
at the request of some friends i gave in
and took it (it was xanax) and a couple
minutes later i felt totally fine. it was
pretty unnerving and quite a relief at
the same time.

3/14/2010

Case
#1066

I have come to put all comments
related to therapies other than
drugs here - so this now
includes positive comments
about other therapies, negative
comments/ disadvantages /
problems with other therapies,
and suggestions for other
therapies to seek out.

Trying/Tried
alternative
treatment

I want out. I don't want to do it
anymore. I'm sick of the heart-to-heart
chats, the raw disclosure, the drama
therapy, the art therapy, the group
therapy. I want to be left alone, but you
say that and they gently suggest you
write an "action plan" to schedule
"don't hurt self" into your unmonitored
evening. No one is close enough to
help, and those who are close are held
at arm's length because the idea of
being misunderstood by people I care
about so much is too painful to
contemplate experiencing. I think the
only treatment is self acceptance.
Getting there, however, is not always
achieved. What becomes of those
who fail?
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3/14/2010

Case
#1066

3/30/2010

Memo

Code

Consumer Comment

Making the decision to go back
on meds

Going back
on meds /
Meds may
be the
solution

For years I thought I could maintain on
my own, but when it became
impossible to do my boring desk job, it
was clear I needed help, and therapy
once a week isn't enough. I have an
appointment soon, thank goodness. I
want to get this ball rolling. I only see
my moods getting more violent as time
goes on. Maybe after I get some
stability, I'll be better able to attend to
the alternative methods that I don't
have the concentration to be diligent
about now. I quit Paxil cold
turkey...I'm sure I can quit again when
the time comes.

Case
#675

In response to a person who has
missed 2 days of Seroquel and
is suddenly very itchy all over.
Jerod proposes the itchiness is
caused by what he explains
here...

Alleviates
side effect
from
another
drug

You've increased the Lamictal since
you've been on Seroquel, right?
Seroquel's antihistamine qualities have
probably been suppressing Lamictal's
itchy side effect. Or Wellbutrin's. In any
event it took care of a side effect from
one or more of them.

4/2/2010

Case
#612

"Sedating" is difficult to code
because it's a neutral term.

4/4/2010

Case
#612

Not sure the best place to code
this. Kind of saying that the drug
didn't work for them, but may
work for you (hence, YMMV).
But it is an interesting example
of Drugs Only Have Effects that
Some Will Find Helpful and
Other Will Not.

4/4/2010

Case
#1064

Commenting on cognitive
decline over time on meds.
Another example of weighing
benefits and costs, but without
explicitly stating which
outweighs which - it's simply a
difficult trade-off.

Extreme
sleepiness /
Tired
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Seroquel is sedating. There's no way
around that.

YMMV

Lexapro. I hated the stuff, but the
reason I hated the stuff is the same
reason I'm going to suggest it. It
makes you not care as much. (At least
that's what it did for me.)

No or
limited
helpfulness
/ It's not my
wonder drug

When I read what I wrote even 10
years ago, I know I was smarter then.
But I also know I would not be alive
now had it not been for the drugs.

Date

Case

Memo

4/4/2010

Case
#1064

Again, the trade-off.
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Code

Consumer Comment

No or
limited
helpfulness
/ It's not my
wonder drug

While I'm grateful that I am no longer
as mad as I was, I know that I have
lost an edge. While it was dangerous
and painful at times, this edge gave
me the ability to use my madness as a
tool, a weapon and a shield in the ongoing struggles for Truth, Justice, Etc.
I am not as effective as an activist.

APPENDIX G
Resolutions to Inter-Coder Disagreements (Decision is in bold)
Case
Case #101
Case #101
Case #101
Case #101
Case #101
Case #105
Case #108
Case #109
Case #109
Case #109
Case #109
Case #112
Case #112
Case #112
Case #123
Case #123
Case #123
Case #123
Case #13
Case #13
Case #13
Case #134
Case #134
Case #134
Case #134
Case #134
Case #138
Case #138
Case #138
Case #138
Case #139
Case #139
Case #139
Case #139
Case #139
Case #151
Case #151
Case #160

Code
Evidence of Causality (Any comment)
Gastrointestinal and Urinary
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drug Issues (Any comment)
Other Effects
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Friends and Family (Any comment)
Evidence of Causality (Any comment)
Gastrointestinal and Urinary
Head or Face
Sexual changes
My Doctor (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Other Effects
My Drug Experience (Only for Lex & Ser)
Other Effects
Theories of Drug Action (Any comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
My Doctor (Any comment)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
My Drug Experience (Only for Lex & Ser)
Theories of Drug Action (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Weighing Benefits vs Side Effects/Cost (Any
comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Pharmaceutical Companies / FDA
Classification of Effects (Overlap with an Effect)
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1st coder
No
No
Yes
Yes
Yes
Yes

2nd coder
Yes
Yes
No
No
No
No

No
No
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
No
Yes
Yes
No
No
No
No
No
No

Yes
Yes
No
No
No
Yes
No
No
Yes
No
No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes

No
Yes
No
No
No
No
Yes
Yes
Yes

Yes
No
Yes
Yes
Yes
Yes
No
No
No

No

Yes

No
No

Yes
Yes

Case
Case #160
Case #163
Case #163
Case #164
Case #169
Case #169
Case #169
Case #169
Case #169
Case #174
Case #174
Case #174
Case #176
Case #176
Case #178
Case #178
Case #179
Case #179
Case #179
Case #179
Case #179
Case #180
Case #180
Case #180
Case #184
Case #184
Case #185
Case #185
Case #185
Case #187
Case #187
Case #187
Case #191
Case #191
Case #191
Case #191
Case #197
Case #215
Case #215
Case #215

Code
My Drug Experience (Only for Lex & Ser)
Classification of Effects (Overlap with an Effect)
Other Effects
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Doctor (Any comment)
Other Drug Issues (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
Friends and Family (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Doctor (Any comment)
Friends and Family (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
Other Drugs and Drug Combinations (Any comment)
Classification of Effects (Overlap with an Effect)
Contraindications (Only for Lex & Ser)
Theories of Drug Action (Any comment)
Classification of Effects (Overlap with an Effect)
My Doctor (Any comment)
Theories of Drug Action (Any comment)
Evidence of Causality (Any comment)
Muscoloskeletal and Neurological
Other Effects
Weighing Benefits vs Side Effects/Cost (Any
comment)
Support and Advice (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drug Issues (Any comment)
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1st coder
No
Yes
Yes
No

2nd coder
Yes
No
No
Yes

No
Yes
No
Yes
No
Yes
No
Yes

Yes
No
Yes
No
Yes
No
Yes
No

Yes

No

No
No
No

Yes
Yes
Yes

Yes
No
No
Yes
No
No
Yes
No
No
No
No
Yes
No
No
No
No
No
No
No
No

No
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No

Yes
Yes

No
No

Yes
Yes

Case
Case #216
Case #218
Case #218
Case #22
Case #22
Case #239
Case #239
Case #239
Case #239
Case #243
Case #243
Case #243
Case #243
Case #244
Case #244
Case #244
Case #244
Case #252
Case #252
Case #253
Case #253
Case #253
Case #253
Case #256
Case #256
Case #259
Case #259
Case #259
Case #27
Case #270
Case #270
Case #270
Case #270
Case #270
Case #271
Case #271
Case #271
Case #277
Case #277

Code
Classification of Effects (Overlap with an Effect)
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Classification of Effects (Overlap with an Effect)
Gastrointestinal and Urinary
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
Mental or mood changes
My Doctor (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
My Drug Experience (Only for Lex & Ser)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
Mental or mood changes
Classification of Effects (Overlap with an Effect)
Mental or mood changes
Support and Advice (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Effects
Weighing Benefits vs Side Effects/Cost (Any
comment)
Mental or mood changes
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Gastrointestinal and Urinary
Other Effects
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1st coder
No
No
Yes
No
Yes
No
Yes
No
No
Yes

2nd coder
Yes
Yes
No
Yes
No
Yes
No
Yes
Yes
No

No
No
Yes

Yes
Yes
No

No
Yes
No
Yes

Yes
No
Yes
No

No
Yes
No
Yes
No
Yes

Yes
No
Yes
No
Yes
No

No
No
No

Yes
Yes
Yes

No
No
Yes

Yes
Yes
No

Yes
Yes
Yes
No
No
No
No

No
No
No
Yes
Yes
Yes
Yes

No
Yes
No

Yes
No
Yes

Case
Case #279
Case #279
Case #288
Case #288
Case #288
Case #288
Case #292
Case #292
Case #292
Case #292
Case #293
Case #293
Case #293
Case #297
Case #299
Case #299
Case #303
Case #303
Case #303
Case #307
Case #308
Case #313
Case #313
Case #313
Case #315
Case #315
Case #315
Case #334
Case #34
Case #34
Case #34
Case #34
Case #342
Case #346
Case #346
Case #352
Case #352
Case #352
Case #352

Code
Classification of Effects (Overlap with an Effect)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
My Drug Experience (Only for Lex & Ser)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Friends and Family (Any comment)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Classification of Effects (Overlap with an Effect)
Support and Advice (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Other Effects
Other Effects
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Other Effects
Classification of Effects (Overlap with an Effect)
Muscoloskeletal and Neurological
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Support and Advice (Any comment)
Classification of Effects (Overlap with an Effect)
Sleep changes
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Support and Advice (Any comment)
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1st coder
Yes
Yes

2nd coder
No
No

No
Yes
No
No

Yes
No
Yes
Yes

No
Yes
No
No
No
No
No

Yes
No
Yes
Yes
Yes
Yes
Yes

No
No
No
No
Yes
No
No
No

Yes
Yes
Yes
Yes
No
Yes
Yes
Yes

No

Yes

Yes
No
No

No
Yes
Yes

Yes
Yes
No
No
No
Yes
No
No
Yes
Yes

No
No
Yes
Yes
Yes
No
Yes
Yes
No
No

No
No
No
No

Yes
Yes
Yes
Yes

Case
Case #357
Case #357
Case #357
Case #357
Case #357
Case #362
Case #362
Case #362
Case #363
Case #363
Case #363
Case #363
Case #363
Case #364
Case #364
Case #364
Case #373
Case #374
Case #374
Case #374
Case #377
Case #385
Case #385
Case #388
Case #390
Case #393
Case #393
Case #393
Case #393
Case #394
Case #396
Case #396
Case #397
Case #397
Case #400
Case #400
Case #400
Case #401
Case #401
Case #401

Code
Classification of Effects (Overlap with an Effect)
Mental or mood changes
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Drug Experience (Only for Lex & Ser)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
Head or Face
Other Drug Issues (Any comment)
Other Effects
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
Friends and Family (Any comment)
Other Drug Issues (Any comment)
Friends and Family (Any comment)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Effects
My Doctor (Any comment)
Finances / The System (Any comment)
Theories of Drug Action (Any comment)
Classification of Effects (Overlap with an Effect)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
Other Effects
Sleep changes
Support and Advice (Any comment)
Classification of Effects (Overlap with an Effect)
Friends and Family (Any comment)
Other Effects
Other Drug Issues (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
My Doctor (Any comment)
Other Drugs and Drug Combinations (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Classification of Effects (Overlap with an Effect)
My Drug Experience (Only for Lex & Ser)
Weighing Benefits vs Side Effects/Cost (Any
comment)
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1st coder
No
Yes
No
No
No

2nd coder
Yes
No
Yes
Yes
Yes

No
No
Yes
No
Yes
No
No
Yes

Yes
Yes
No
Yes
No
Yes
Yes
No

No
No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
Yes

No
No
Yes
No
No
No
No
No
Yes
No
No
No
Yes
Yes
No

Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
No
Yes

No
No
No

Yes
Yes
Yes

No
No
Yes

Yes
Yes
No

Case
Case #413
Case #413
Case #415
Case #416
Case #416
Case #43
Case #43
Case #43
Case #436
Case #445
Case #447
Case #59
Case #6
Case #7
Case #7
Case #80
Case #80
Case #80
Case #80
Case #80
Case #83
Case #83
Case #87
Case #87
Case #88
Case #89
Case #91
Case #91
Case #99
Case #99
Case #99

Code
Other Effects
Sexual changes
Classification of Effects (Overlap with an Effect)
Classification of Effects (Overlap with an Effect)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Classification of Effects (Overlap with an Effect)
Classification of Effects (Overlap with an Effect)
Friends and Family (Any comment)
Other Drug Issues (Any comment)
Evidence of Causality (Any comment)
Other Drug Issues (Any comment)
Support and Advice (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Doctor (Any comment)
Nose Throat Chest
Skin
Sleep changes
Muscoloskeletal and Neurological
Other Effects
My Doctor (Any comment)
Other Drugs and Drug Combinations (Any comment)
Evidence of Causality (Any comment)
My Drug Experience (Only for Lex & Ser)
Other Drug Issues (Any comment)
Weighing Benefits vs Side Effects/Cost (Any
comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Drug Experience (Only for Lex & Ser)
Support and Advice (Any comment)
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1st coder
No
Yes
No
No
No
No
Yes
Yes
No
No
No
Yes
No
No
No
Yes

2nd coder
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
No
Yes
Yes
Yes
No

No
No
No
No
Yes
No
No
Yes
No
Yes
No
Yes

Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
No
Yes
No

Yes

No

Yes
No

No
Yes

Part II of Inter-Coder Agreement Resolutions
Case
Case #1001
Case #1001
Case #1002
Case #1002
Case #1002
Case #1003
Case #1003
Case #1005
Case #1005
Case #1005
Case #1014
Case #1014
Case #1020
Case #1020
Case #1020
Case #1020
Case #1021
Case #1021
Case #1028
Case #1028
Case #1028
Case #1028
Case #1031
Case #1037
Case #1037
Case #1037
Case #1043
Case #1047
Case #1056
Case #1056
Case #1056
Case #1056
Case #1060
Case #1060
Case #1060

Code
Evidence of Causality (Any comment)
Other Drug Issues (Any comment)
Citations and Links (Any comment)
Evidence of Causality (Any comment)
Support and Advice (Any comment)
Assessing the Overall Experience
Evidence of Causality (Any comment)
Evidence of Causality (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Pharmaceutical Companies / FDA
Citations and Links (Any comment)
Evidence of Causality (Any comment)
Assessing the Overall Experience
Evidence of Causality (Any comment)
Friends and Family (Any comment)
Support and Advice (Any comment)
Other Drug Issues (Any comment)
Support and Advice (Any comment)
Citations and Links (Any comment)
Contraindications (Only for Lex & Ser)
Pharmaceutical Companies / FDA
Support and Advice (Any comment)
Support and Advice (Any comment)
Assessing the Overall Experience
Evidence of Causality (Any comment)
Theories of Drug Action (Any comment)
Classification of Effects (Overlap with an Effect)
My Doctor (Any comment)
Citations and Links (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Friends and Family (Any comment)
Other Drug Issues (Any comment)
Citations and Links (Any comment)
Evidence of Causality (Any comment)
My Doctor (Any comment)
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1st coder
Yes
No
Yes
No
No
Yes
No
Yes
No
Yes
No
No
Yes
No
No
No
Yes
No
No
Yes
Yes
No
No
Yes
No
No
No
No
No
No

2nd coder
No
Yes
No
Yes
Yes
No
Yes
No
Yes
No
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
No
No
Yes

No
No
Yes
Yes
No

Case
Case #1060
Case #1072
Case #1072
Case #1079
Case #1079
Case #1079
Case #1079
Case #456
Case #456
Case #470
Case #470
Case #472
Case #472
Case #472
Case #472
Case #487
Case #511
Case #511
Case #511
Case #511
Case #516
Case #516
Case #519
Case #533
Case #533
Case #537
Case #537
Case #537
Case #537
Case #537
Case #545
Case #545
Case #547
Case #547
Case #547
Case #548

Code
Support and Advice (Any comment)
Other Drug Issues (Any comment)
Support and Advice (Any comment)
Muscoloskeletal and Neurological
Other Drug Issues (Any comment)
Other Effects
Support and Advice (Any comment)
Friends and Family (Any comment)
Other Effects
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Effects
Classification of Effects (Overlap with an Effect)
Friends and Family (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drug Issues (Any comment)
Support and Advice (Any comment)
Assessing the Overall Experience
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Mental or mood changes
Nose Throat Chest
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Other Drug Issues (Any comment)
My Doctor (Any comment)
Other Drugs and Drug Combinations (Any comment)
Assessing the Overall Experience
Discontinuing / Missed Doses (Only for Lex & Ser)
Muscoloskeletal and Neurological
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Effects
Head or Face
Other Effects
Assessing the Overall Experience
Evidence of Causality (Any comment)
Other Drug Issues (Any comment)
Other Effects
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1st coder
No
Yes
No
No
No
No
No
No
Yes
No
Yes
Yes
No
Yes
No
No
Yes
No

2nd coder
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
No
Yes
Yes
No
Yes

Yes
No
Yes

No
Yes
No

No
No
No
No
No
No
Yes
Yes
No
Yes
No
Yes
No
Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
No
Yes
No
No

Case
Case #548
Case #554
Case #555
Case #555
Case #560
Case #560
Case #560
Case #565
Case #565
Case #567
Case #573
Case #573
Case #581
Case #586
Case #586
Case #591
Case #591
Case #591
Case #599
Case #599
Case #599
Case #604
Case #604
Case #613
Case #613
Case #613
Case #617
Case #617
Case #617
Case #617
Case #617
Case #617
Case #617
Case #617
Case #621
Case #621

Code
Skin
Other Drug Issues (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drugs and Drug Combinations (Any comment)
Mental or mood changes
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Mental or mood changes
Muscoloskeletal and Neurological
Assessing the Overall Experience
Appetite and Weight
Other Effects
Friends and Family (Any comment)
Muscoloskeletal and Neurological
Support and Advice (Any comment)
Other Drugs and Drug Combinations (Any comment)
Other Effects
Support and Advice (Any comment)
Assessing the Overall Experience
Other Effects
Citations and Links (Any comment)
Pharmaceutical Companies / FDA
Skin
Appetite and Weight
Citations and Links (Any comment)
Classification of Effects (Overlap with an Effect)
Head or Face
Other Drug Issues (Any comment)
Other Drugs and Drug Combinations (Any comment)
Skin
Sleep changes
Evidence of Causality (Any comment)
Other Effects
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1st coder
No
No
No

2nd coder
Yes
Yes
Yes

No
No
Yes
No
No
Yes

Yes
Yes
No
Yes
Yes
No

Yes
Yes
No
No
No
Yes
No
No
No
No
No
No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No

No
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
No
No
No
No
No
Yes
No
No
Yes
Yes

Case
Case #626
Case #626
Case #626
Case #629
Case #629
Case #629
Case #629
Case #642
Case #642
Case #642
Case #642
Case #642
Case #642
Case #643
Case #646
Case #646
Case #646
Case #646
Case #650
Case #650
Case #650
Case #650
Case #654
Case #654
Case #654
Case #655
Case #655
Case #655
Case #655
Case #675
Case #675
Case #675
Case #675
Case #675
Case #675
Case #681

Code
Assessing the Overall Experience
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Support and Advice (Any comment)
Appetite and Weight
Evidence of Causality (Any comment)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Assessing the Overall Experience
Discontinuing / Missed Doses (Only for Lex & Ser)
Evidence of Causality (Any comment)
Mental or mood changes
Other Effects
Support and Advice (Any comment)
Sleep changes
Evidence of Causality (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Pharmaceutical Companies / FDA
Support and Advice (Any comment)
Classification of Effects (Overlap with an Effect)
Discontinuing / Missed Doses (Only for Lex & Ser)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Effects
Head or Face
Other Drugs and Drug Combinations (Any comment)
Support and Advice (Any comment)
Assessing the Overall Experience
Classification of Effects (Overlap with an Effect)
Discontinuing / Missed Doses (Only for Lex & Ser)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Appetite and Weight
Assessing the Overall Experience
Classification of Effects (Overlap with an Effect)
Mental or mood changes
Muscoloskeletal and Neurological
Support and Advice (Any comment)
Classification of Effects (Overlap with an Effect)
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1st coder
Yes
No

2nd coder
No
Yes

No
No
No
No
No
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
No
No
Yes
No
Yes
Yes
No
No
Yes
No
Yes
No
No
Yes
Yes
Yes
No
No
No

Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
Yes
No
No
Yes
Yes
No
Yes
No
Yes
Yes
No
No
No
Yes
Yes
Yes

Case
Case #681
Case #683
Case #683
Case #683
Case #687
Case #687
Case #687
Case #695
Case #695
Case #696
Case #701
Case #701
Case #701
Case #704
Case #704
Case #716
Case #716
Case #718
Case #719
Case #719
Case #719
Case #720
Case #720
Case #720
Case #723
Case #723
Case #725
Case #725
Case #747
Case #747
Case #747
Case #747
Case #747
Case #752

Code
Mental or mood changes
Dealing with side effects / Finding optimum
effectiveness (Any comment)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Assessing the Overall Experience
Evidence of Causality (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Contraindications (Only for Lex & Ser)
Appetite and Weight
Other Drugs and Drug Combinations (Any comment)
Sleep changes
Other Drug Issues (Any comment)
Support and Advice (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Pharmaceutical Companies / FDA
Evidence of Causality (Any comment)
Evidence of Causality (Any comment)
Friends and Family (Any comment)
Other Effects
Assessing the Overall Experience
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Doctor (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Other Drug Issues (Any comment)
Mental or mood changes
Other Effects
Assessing the Overall Experience
Classification of Effects (Overlap with an Effect)
Discontinuing / Missed Doses (Only for Lex & Ser)
Muscoloskeletal and Neurological
Other Drug Issues (Any comment)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
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1st coder
No
No

2nd coder
Yes
Yes

No
Yes
Yes
No
Yes
Yes
No

Yes
No
No
Yes
No
No
Yes

No
No
No
No
Yes
No
No

Yes
Yes
Yes
Yes
No
Yes
Yes

Yes
No
Yes
Yes
No
Yes
Yes
No
No

No
Yes
No
No
Yes
No
No
Yes
Yes

No
Yes
No
No
Yes
No
No
Yes
No

Yes
No
Yes
Yes
No
Yes
Yes
No
Yes

Case
Case #761
Case #761
Case #761
Case #772
Case #772
Case #772
Case #773
Case #777
Case #777
Case #777
Case #777
Case #779
Case #779
Case #779
Case #779
Case #779
Case #779
Case #780
Case #780
Case #784
Case #784
Case #784
Case #786
Case #786
Case #786
Case #786
Case #799
Case #799
Case #799
Case #812
Case #814
Case #828
Case #832
Case #832
Case #832
Case #832

Code
Friends and Family (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drugs and Drug Combinations (Any comment)
My Diagnosis / Reason for Use (Only for Lex & Ser)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Other Effects
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Head or Face
Nose Throat Chest
Other Drug Issues (Any comment)
Appetite and Weight
Discontinuing / Missed Doses (Only for Lex & Ser)
Evidence of Causality (Any comment)
Friends and Family (Any comment)
My Doctor (Any comment)
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Assessing the Overall Experience
My Doctor (Any comment)
Other Drug Issues (Any comment)
Assessing the Overall Experience
Friends and Family (Any comment)
My Doctor (Any comment)
Support and Advice (Any comment)
Evidence of Causality (Any comment)
My Doctor (Any comment)
Other Effects
My Diagnosis / Reason for Use (Only for Lex & Ser)
Mental or mood changes
Other Drug Issues (Any comment)
Classification of Effects (Overlap with an Effect)
Discontinuing / Missed Doses (Only for Lex & Ser)
My Diagnosis / Reason for Use (Only for Lex & Ser)
Other Drug Issues (Any comment)
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1st coder
No
No
No
Yes
No
Yes
Yes
No

2nd coder
Yes
Yes
Yes
No
Yes
No
No
Yes

No
No
No
No
No
Yes
No
No
Yes
No
Yes

Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
No

Yes
No
No
No
No
No
Yes
No
No
Yes
Yes
No
No
No
No
Yes
Yes

No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
No

Case
Case #832
Case #832
Case #854
Case #854
Case #854
Case #854
Case #854
Case #855
Case #855
Case #855
Case #855
Case #855
Case #866
Case #866
Case #866
Case #880
Case #880
Case #880
Case #880
Case #888
Case #888
Case #895
Case #895
Case #898
Case #906
Case #906
Case #921
Case #938
Case #967
Case #974
Case #974
Case #974
Case #974
Case #975
Case #992
Case #992

Code
Other Drugs and Drug Combinations (Any comment)
Other Effects
Assessing the Overall Experience
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Discontinuing / Missed Doses (Only for Lex & Ser)
Lab Tests
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Friends and Family (Any comment)
Head or Face
Other Effects
Sleep changes
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
Support and Advice (Any comment)
Classification of Effects (Overlap with an Effect)
Mental or mood changes
My Doctor (Any comment)
Nose Throat Chest
Mental or mood changes
My Doctor (Any comment)
Appetite and Weight
Other Effects
Classification of Effects (Overlap with an Effect)
Mental or mood changes
Sleep changes
Assessing the Overall Experience
Classification of Effects (Overlap with an Effect)
Friends and Family (Any comment)
Assessing the Overall Experience
My Doctor (Any comment)
Other Drugs and Drug Combinations (Any comment)
Support and Advice (Any comment)
Finances / The System (Any comment)
Appetite and Weight
Assessing the Overall Experience
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1st coder
No
Yes
No
Yes
No

2nd coder
Yes
No
Yes
No
Yes

No
Yes
No

Yes
No
Yes

No
No
No
Yes
No
No
No
No
Yes
Yes
No
Yes
No
No
Yes
No
No
No
No
Yes
No
Yes
Yes
No
No
No
No
Yes

Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
Yes
Yes
Yes
No

Case
Case #992
Case #992
Case #992
Case #997
Case #997
Case #997
Case #997

Code
Classification of Effects (Overlap with an Effect)
Dealing with side effects / Finding optimum
effectiveness (Any comment)
Theories of Drug Action (Any comment)
Classification of Effects (Overlap with an Effect)
Evidence of Causality (Any comment)
Other Drug Issues (Any comment)
Pharmaceutical Companies / FDA
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1st coder
No
Yes

2nd coder
Yes
No

Yes
No
Yes
No
Yes

No
Yes
No
Yes
No

APPENDIX H
WikiScanner Search Results for Pharmaceutical Company Edits from 2002-2007
Astra Zeneca: Total edits: 949
Edits related to medications or pharmaceutical companies: 23 (2.4%)
Wikipedia entries edited and a description of edits made


“Astra Zeneca”: 6 edits
o Updated name of CEO, Vice President position title, web address, and similar



“Fed Food, Drug, and Cosmetic Act”: 3 edits
o Added and edited statements about the history of the Act



“FDA”: 1 edit
o Added entry to searchable category “pharmacology”



“Good Manufacturing Practice”: 4 edits
o Added and deleted sections about enforcement and purpose of guidelines



“Omeprazole”: 1 edit
o Deleted sentence: “Faced with the loss of patent protection and competition from generic
manufacturers, AstraZeneca developed, launched, and heavily marketed [[esomeprazole]]
(Nexium), a single [[enantiomer]] form of omeprazole”

o Added summaries of several studies where Nexium outperforms Prilosec


“Quetiapine”: 6 edits
o Edited 2 mistakes about dosages; edited language regarding approved
indications
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o Deleted sentence and reference for: “a known risk that teenagers taking the drug
‘may be more likely to think about harming or killing themselves or to plan or try to do so’”



“Risperidone”: 1 edit
o Deleted sentence: “Risperidone is now the most commonly prescribed [[antipsychotic]]
medication in the [[United States]]”




Note: Risperidone is made by Janssen

“Thalidomide”: 1 edit
o Changed quotations around a phrase to parentheses

Eli Lilly: Total edits: 832
Edits related to medications or pharmaceutical companies: 38 (4.6%)
Wikipedia entries edited and a description of edits made


“Dimethoxy-4-iodoamphetamine”: 1 edit
o Described used of DOI in research



“Cocaine”: 1 edit
o Deleted word “potent” before “SSRI” regarding Venlafaxine as a treatment
for cocaine addiction



“Drotrecogin alfa”: 4 edits
o Deleted word “deceptive” before “marketing campaign” regarding Lilly’s
promotion of drug; Changed indication to state that a second opinion is not
necessary
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o Added sentence, “PROWESS was terminated early for a statistically significant positive
efficacy signal - unethical to continue trial - as this would have meant exposing severe sepsis
patients to possibly receiving placebo.”

o Deleted 6 contraindications, including for pregnancy, breast feeding, and
patients under age 18


“Eli Lilly and Company”: 13 edits
o Corrected revenue figures from $12.6 billion to $13.9b
o Added names of drugs to a list of Lilly’s products; minor edits to title of
former president Bush who was a board member



“Erectile Dysfunction”: 2 edits
o Added link to the Cialis home page



“G D Searle and Company”: 1 edit
o Deleted statement that former CEO Donald Rumsfeld “could be the most
prominent [[douchebag]] in the U.S.”



“Insulin/ Insulin analog”: 6 edits
o Edited mode of production; corrected spelling of “lilly” and “lispro” (a drug)



“Lilly Research Laboratories”: 1 edit
o Created page for above entry; added 1 introductory sentence



“Novo Nordisk”: 1 edit
o Deleted “the first” regarding NovoLog being “the first rapid acting insulin
analogue”



“Olanzapine”: 1 edit
o Corrected registered name of drug
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“Pemetrexed”: 1 edit
o Added that drug is “clinically developed by Indianapolis based drug maker, Eli Lilly &
Company”



“Pfizer”: 2 edits
o Grammatical clean-up



“Potassium bromide”: 3 edits
o Added information about use for seizures in dogs



Talk:Fluoxetine: 1 contribution
o

Added paragraph: “I have been taking fluoxetine and had very little in the way of side
effects - just a small amount of nausea at the start. It has been very successful in treating my
depression so far and I'm feeling good for the first time in ages. I just wanted to add this as
I'm sure there are others who it has helped and as mentioned above they don't tend to speak
out. I think that an explanation in part of why there is such a broad range of reactions to drugs
like these is the limited understanding of the basis of the disease. In my opinion what we
know as depression could have many causes each presenting with similar symptoms
explaining why some treatments only work for some individuals.”

GlaxoSmithKline: Total edits: 1,148
Edits related to medications or pharmaceutical companies: 31 (2.7%)
Wikipedia entries edited and a description of edits made


“Celecoxib”: 2 edits
o Corrected grammar
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“Fluticasone”: 4 edits
o Edited grammar and links



“GlaxoSmithKline”: 15 edits
o Added paragraph that starts: “For many years now GSK has been a leading
contributor to a multinational govenment and industry alliance to rid the world of
lymphatic filariasis (elephantiasis)….” and added new subheading called “Good

Works”
o Minor edits to headquarters and locations; updated revenues (an increase)
and number of employees (an increase); added links to GSK site for
corporate governance, global locations and merger history


“Lamotrigine”: 2 edits
o Added and then deleted link to generic drug manufacturer



“Lapatinib”: 1 edit
o Corrected name of drug



“Motilin”: 1 edit
o Elaborated on description of the hormone



“Neuropathy”: 1 edit
o Added word “central” to nervous system disorder



“Resistin”: 3 edits
o Minor edits to existing references for clinical studies



Talk:GlaxoSmithKline: 1 edit
o Added statement that GSK still makes Ribena

351



Talk:Reverse transcriptase inhibitor: 1 edit
o Created talk page with: “Understanding RTI provide a novel platform for
the developing of anti-HIV medication. This is one area that
GlaxoSmithKline needs to be commended.”
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